

EXHIBIT 44

1 UNITED STATES DISTRICT COURT
2 FOR THE NORTHERN DISTRICT OF OHIO
3 EASTERN DIVISION
4

5 -----)
6 IN RE: NATIONAL PRESCRIPTION)
7 OPIATE LITIGATION) Case No. 1:17-MD-2804
8 -----) Hon. Dan A. Polster
9 APPLIES TO ALL CASES)
10 -----)

11
12 HIGHLY CONFIDENTIAL
13 SUBJECT TO FURTHER CONFIDENTIALITY REVIEW
14

15 The videotaped deposition of WILLIAM
16 RATLIFF, called for examination, taken pursuant to the
17 Federal Rules of Civil Procedure of the United States
18 District Courts pertaining to the taking of
19 depositions, taken before JULIANA F. ZAJICEK, a
20 Registered Professional Reporter and a Certified
21 Shorthand Reporter, at the Hilton Garden Inn, 8910
22 Hatfield Drive, Indianapolis, Indiana, on December
23 19, 2018, at 9:36 a.m.
24

Page 2	Page 4
<p>1 APPEARANCES: 2 ON BEHALF OF THE PLAINTIFFS: 3 KELLER ROHRBACK L.L.P. 4 1201 Third Avenue, Suite 3200 5 Seattle, Washington 98101-3052 6 206-623-1900 7 BY: DEAN KAWAMOTO, ESQ. 8 dkawamoto@kellerrohrback.com; 9 DAVID J. KO, ESQ. 10 dko@kellerrohrback.com 11 12 ON BEHALF OF THE STATE OF TENNESSEE PLAINTIFFS: 13 BRANSTETTER, STRANCH & JENNINGS, PLLC 14 The Freedom Center 15 223 Rosa L. Parks Avenue, Suite 200 16 Nashville, Tennessee 37203 17 615-254-8801 18 BY: TRICIA HERZFELD, ESQ. 19 triciah@bsjfirm.com 20 21 ON BEHALF OF AMERISOURCEBERGEN CORPORATION and 22 AMERISOURCEBERGEN DRUG CORPORATION: 23 JACKSON KELLY PLLC 24 500 Lee Street East, Suite 1600 25 Charleston, West Virginia 25301-3202 26 304-284-4138 27 BY: JON L. ANDERSON, ESQ. (Telephonically) 28 jlanderson@JacksonKelly.com 29 30 ON BEHALF OF MALLINCKRODT LLC and SPECGX LLC: 31 ROPES & GRAY LLP 32 Prudential Tower 33 800 Boylston Street 34 Boston, Massachusetts 02199-3600 35 617-951-7910 36 BY: ANDREW O'CONNOR, ESQ. 37 andrew.o'connor@ropesgray.com; 38 ELISSA REIDY, ESQ. 39 elissa.reidy@ropesgray.com</p>	<p>1 ALSO PRESENT: 2 DONALD LOHMAN, ESQ. 3 VP Legal, Mallinckrodt. 4 5 6 7 THE VIDEOGRAPHER: 8 MR. MICHAEL NEWELL, 9 Golkow Litigation Services. 10 11 12 13 14 15 REPORTED BY: JULIANA F. ZAJICEK, CSR 84-2604 16 17 18 19 20 21 22 23 24</p>
Page 3	Page 5
<p>1 APPEARANCES: (Continued) 2 ON BEHALF OF CARDINAL HEALTH, INC.: 3 WILLIAMS & CONNOLLY LLP 4 725 Twelfth Street, N.W. 5 Washington, D.C. 20005 6 202-434-5000 7 BY: KATELYN ADAMS, ESQ. (Telephonically) 8 kadams@wc.com 9 10 ON BEHALF OF McKESSON CORPORATION: 11 COVINGTON & BURLING, LLP 12 One City Center 13 850 Tenth Street, NW 14 Washington, D.C. 20001 15 202-662-5531 16 BY: EMILY L. KVESELIS, ESQ. 17 ekveselis@cov.com 18 19 ON BEHALF OF ENDO HEALTH SOLUTIONS INC., ENDO 20 PHARMACEUTICALS INC., PAR PHARMACEUTICAL COMPANIES, 21 INC.: 22 23 ARNOLD & PORTER KAYE SCHOLER LLP 24 777 South Figueroa Street, 44th Floor 25 Los Angeles, California 90017-5844 26 213-243-4238 27 BY: TIFFANY M. IKEDA, ESQ. (Telephonically) 28 tiffany.ikeda@arnoldporter.com 29 30 ON BEHALF OF WALMART INC.: 31 32 JONES DAY 33 2727 North Harwood Street 34 Dallas, Texas 75201-1515 35 214-220-3939 36 BY: LAURA JANE DURFEE, ESQ. 37 ldurfee@jonesday.com</p>	<p>1 INDEX 2 3 WITNESS: PAGE: 4 WILLIAM RATLIFF 5 EXAM BY MR. KAWAMOTO..... 14 6 EXAM BY MS. HERZFELD..... 335 7 EXAM BY MR. O'CONNOR..... 453 8 FURTHER EXAM BY MR. KAWAMOTO..... 458 9 10 ***** 11 12 EXHIBITS 13 MALLINCKRODT-RATLIFF EXHIBIT MARKED FOR ID 14 No. 001 Excerpt from the National Drug 28 15 Threat Assessment from 2011 16 17 No. 002 E-mail from Ratliff to Harper, 39 18 3/22/11, Subject: H.D. Smith; 19 MNK-51-0000269884 20 21 No. 003 Mallinckrodt PowerPoint 66 22 presentation: Overview 23 Presentation for New Employee 24 Orientation, Updated 11/04/08; 25 MNK-T1 0000388159 - 187 26 27 No. 004 Mallinckrodt PowerPoint: Overview 73 28 Presentation for Product and 29 Patient Safety Group, Update 30 11/04/08; MNK-T1 0000420207 - 227 31 No. 005 E-mail from Kimberly France to 77 32 Kate Muhlenkamp, 9/2/08, Subject: 33 Action Plan, w/attachment; MNK-T1</p>

Highly Confidential - Subject to Further Confidentiality Review

Page 6			Page 8		
1	E X H I B I T S (Continued)		1	E X H I B I T S (Continued)	
2	MALLINCKRODT-RATLIFF EXHIBIT	MARKED FOR ID	2	MALLINCKRODT-RATLIFF EXHIBIT	MARKED FOR ID
3	No. 006 Mallinckrodt PowerPoint, 86		3	No. 020 E-mail from Karen Harper to Ratliff and Spaulding, 11/2/2010, 214	
4	Controlled Substance Suspicious Order Monitoring Program, Introductory Training for Field Sales, June 5, 2008; MNK-T1 0000277066 - 075		4	Subject: Draft DEA St. Louis Meeting Notes, w/attachment; MNK-T1 0000421973 - 975	
5			5		
6	No. 007 E-mail chain, top one from Karen Harper to Bill Ratliff, 12/13/2007, Subject: FW: Please read important information; MNK-T1 0004211219 - 226	110	6	No. 021 E-mail chain, top one from Donald Lohman to Barbara Boockholdt, among others, Subject: Meeting Agenda, w/attachment; MNK-T1 0000471744 - 750	221
7			7		
8			8		
9	No. 008 E-mail chain, top one from Karen Harper to Bill Ratliff, 2/29/2008, Subject: FW: DEA Suspicious Order Monitoring Update; MNK-T1 0007146630 - 633	126	9	No. 022 PowerPoint presentation: DEA & Regulations Training, October 20th & 21st; MNK-T1 0002950399	237
10			10		
11	No. 009 E-mail chain, top one from Jim Rausch to Bill Ratliff, among others, 4/1/08, Subject: RE: Suspicious Order Monitoring; MNK-T1 0000268860	137	11	No. 023 E-mail from Karen Harper to John Adams, among others, 6/6/08, Subject: Suspicious Order Monitoring Notes from Bulk Narcotics Sales Meeting Presentation; MNK-T1 0000419956 - 957	238
12			12		
13	No. 010 E-mail chain, top one from Karen Harper to Bill Ratliff, 3/3/2008, Subject: DEA Compliance Monthly Highlights, February 2008; MNK-T1 0001308810 - 811	147	13	No. 024 E-mail chain, top one from Karen Harper to Jim Rausch, George Saffold, 6/9/10, Subject: RE: Suspicious Order Monitoring Program; MNK-T1 0000264412 - 413	242
14			14		
15	No. 011 E-mail from Karen Harper to Bill Ratliff, among others, 4/10/2008, Subject: Draft Procedure: Mallinckrodt Controlled Substance Suspicious Order Monitoring, w/attachments; MNK-T1 0000273902 - 909	156	15	No. 025 Global Controlled Substance Compliance Procedure, Revision Date: 01/04/11; MNK-T1 0000307322 - 324	247
16			16		
17	No. 012 E-mail from Karen Harper to Bill Ratliff, 6/3/2008, Subject: DEA Compliance Monthly Report - May, 2008; MNK-T1 0002908468 - 469	171	17	No. 026 Pharmacy Information Sheet, 10/11/11; MNK-T1 0000570903 - 905	251
18			18	No. 027 Pharmacy Information Sheet, Date: 10/11/11; MNK-T1 0000571105 - 111	256
19			19		
20			20	No. 028 Handwritten notes by Bill Ratliff; MNK-T1 0000386469 - 472	261
21			21		
22			22		
23			23		
24			24		
Page 7			Page 9		
1	E X H I B I T S (Continued)		1	E X H I B I T S (Continued)	
2	MALLINCKRODT-RATLIFF EXHIBIT	MARKED FOR ID	2	MALLINCKRODT-RATLIFF EXHIBIT	MARKED FOR ID
3	No. 013 Interoffice Correspondence from Karen Harper to JoAnne Levy, Subject: Controlled Substance Compliance Monthly Report, Date: January 6, 2009; MNK-T1 0000502031 - 032	174	3	No. 029 Covidien PowerPoint entitled "EXALGO Utilization," by Julie Milford; MNK-T1-002694677	265
4			4		
5			5	No. 030 E-mail chain, to one from Bill Ratliff to Karen Harper, 5/20/08, Subject: Fw: Sunrise Wholesale; MNK-T1 0000290601 - 603	271
6			6		
7	No. 014 E-mail chain, top one from Karen Harper to Bill Ratliff, 5/18/11, Subject: RE: Hydromorphone; MNK-T1 0000283602 - 603	180	7		
8			8	No. 031 E-mail chain, top one from Karen Harper to Bill Ratliff, 5/20/08, Subject: FW: Sunrise Wholesale; MAL-MI 000015271 - 273	276
9	No. 015 E-mail from Karen Harper to Kerry Hamilton and Bill Ratliff, 11/2/10, Subject: Explanation of Mallinckrodt Chargeback System; MNK-T1 0000387492	186	9		
10			10	No. 032 E-mail chain, top one from Bill Ratliff to Cathy Stewart, among others, 5/24/08, Subject: Re: Intermediate Credit Update on Sunrise Pharmaceutical; MNK-T1 0000290580 - 582	278
11	No. 016 E-mail chain, top one from Bill Ratliff to Karen Harper, 7/21/10, Subject: RE: Dea Dialog 7/20/10 - Suspicious Order Monitoring Harvard Drug License Suspension; MNK-T1 0000561571 - 575	190	11		
12			12		
13			13	No. 033 E-mail chain, top one from Cathy Stewart to Bill Ratliff and Karen Harper, 5/20/08, Subject: FW: Sunrise Wholesale; MNK-T1 0003028219 - 220	283
14			14		
15	No. 017 PowerPoint presentation, Mallinckrodt Controlled Substance Suspicious Order Monitoring Program, Presentation for Marketing Group, March 21, 2011; MNK-T1 0000496098 - 124	194	15		
16			16	No. 034 E-mail chain, top one from Karen Harper to Bill Ratliff, 11/14/08, Subject: FW: Oxy 15 mg & 30 mg @ Sunrise; MNK-T1 0000307120 - 121	288
17	No. 018 E-mail chain, top one from Bill Ratliff to Karen Harper, 5/2/2008, Subject: FW: Suspicious Order Monitoring Miscellaneous Update; MNK-T1 0000419903 - 904	199	17		
18			18	No. 035 E-mail chain, top one from Victor Borelli to Bill Ratliff, 7/27/09, Subject: RE: Pete Kleissle, Oxy Investigation; MNK-T1 0000307203 - 207	294
19			19		
20	No. 019 E-mail chain, top one from Eileen Spaulding to Karen Harper, 8/1/2008, Subject: RE: DEA Meeting Proposal; MNK-T1 0000274608 - 609	210	20	No. 036 E-mail chain, top one from Victor Borelli to Bill Ratliff, among others, 8/4/09, Subject: RE: Florida medication coming into Tennessee; MNK-T1 0000562325 - 329	300
21			21		
22			22		
23			23		
24			24		

Page 10	Page 12
<p>1 E X H I B I T S (Continued)</p> <p>2 MALLINCKRODT-RATLIFF EXHIBIT MARKED FOR ID</p> <p>3 No. 037 E-mail chain, top one is from Lisa 308 Lundergan to Cathy Stewart, among 4 others, 8/11/09, Subject: RE: Sunrise Customer Chargebacks, 5 w/attachment; MNK-T1 0000456333 - 335</p> <p>6 No. 038 E-mail chain, top one from Cathy 310 7 Stewart to Charity Aranda and Karen Harper, 8/17/09, Subject: 8 FW: Sunrise Chargeback Summary, w/attachment; 9 MNK-T1 0000290041 - 053</p> <p>10 No. 039 Controlled Substance Compliance 319 11 Suspicious Order Monitoring, Customer Audit Checklist, date 12 completed: 08/18/09; MNK-T1 0000307243 - 245</p> <p>13 No. 040 Excerpt of chargeback data re 323 14 Sunrise Wholesale Inc.; MNK-T1 0000264291</p> <p>15 No. 041 Administrative Memorandum of 330 16 Agreement between the US DOJ, DEA and Mallinckrodt, 7/2017</p> <p>17 No. 042 Spreadsheet; MNK_TNSTA05224016 - 347 18 029</p> <p>19 No. 043 Pharmacy Information Sheet, 356 10/17/11, Jabos Pharmacy; MNK_TNSTA01665655 - 656</p> <p>20 No. 044 Pharmacy Information Sheet, 366 21 10/17/11, Rippetoe, Inc.; MNK_TNSTA01666082 - 083</p> <p>22 No. 045 Pharmacy Information Sheet, 370 23 10/17/11, East Tennessee Discount 24 Drug; MNK_TNSTA01665081 - 082</p>	<p>1 E X H I B I T S (Continued)</p> <p>2 MALLINCKRODT-RATLIFF EXHIBIT MARKED FOR ID</p> <p>3 No. 055 Spreadsheet, chargeback data, TN 429 oxy 15 through June 2012;</p> <p>4 MNK_TNSTA0534773</p> <p>5 No. 056 Spreadsheet, chargeback data, TN 444 oxy 30 through June 2012;</p> <p>6 MNK_TNSTA0534773</p> <p>7 No. 057 Memorandum from Howard Davis to 458 Karen Harper, 11/2/10, Subject: 8 Suspicious Order Monitoring Program No. C/S Comp 3.0; MNK-T1 9 0000269399 - 400</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>
Page 11	Page 13
<p>1 E X H I B I T S (Continued)</p> <p>2 MALLINCKRODT-RATLIFF EXHIBIT MARKED FOR ID</p> <p>3 No. 046 Pharmacy Information Sheet, 374 2/26/12, East Tennessee Discount 4 Drug; MAL-NY00004465</p> <p>5 No. 047 E-mail from Karen Harper to 377 6 Christine Inman, 10/20/11, Subject: AmerisourceBergen General SOM Notes and Individual Pharmacy 7 Comments, w/attachment; MNK_TNSTA05124366 - 373</p> <p>8 No. 048 Covidien Controlled Substance 381 9 Compliance/Suspicious Order Monitoring Distributor Customer 10 Audit Checklist, Audit Date: 02/01/12; MNK_TNSTA05346757 - 764</p> <p>11 No. 049 Spreadsheet, ABC Top 40 and Multi 405 12 Dist Tab; MNK_TNSTA05323795 - 802</p> <p>13 No. 050 E-mail from Bill Ratliff to Donald 411 14 Walker, among others, 12/5/11, Subject: Additional Pharmacies; MNK_TNSTA05310282</p> <p>15 No. 051 E-mail from Donald Walker to Bill 413 16 Ratliff, 12/12/11, Subject: Additional Pharmacies, 17 w/attachment; MNK_TNSTA05324116 - 117</p> <p>18 No. 052 Pharmacy Information Sheet, 417 19 3/20/12, Bradley Drug Co.; MAL-NY00004333</p> <p>20 No. 053 Consent Order by the Tennessee 424 21 Department of Health re Dr. Michael Rhodes, 7/21/09</p> <p>22 No. 054 Spreadsheet, May 2012 Top Oxy 30 426 23 Pharms; MNK_TNSTA05348540</p> <p>24</p>	<p>1 THE VIDEOGRAPHER: We are now on the record. My</p> <p>2 name is Michael Newell. I am a videographer for</p> <p>3 Golkow Litigation Services.</p> <p>4 Today's date is December 19th, 2018. The</p> <p>5 time is 9:36 a.m.</p> <p>6 This video deposition is being held in</p> <p>7 Indianapolis, Indiana, in the matter of National</p> <p>8 Prescription Opiate Litigation.</p> <p>9 The deponent today is Floyd Ratliff.</p> <p>10 Counsel will be noted for the stenographic</p> <p>11 record.</p> <p>12 The court reporter is Juliana Zajicek and</p> <p>13 will now swear in the witness.</p> <p>14 (WHEREUPON, the witness was duly</p> <p>15 sworn.)</p> <p>16 MR. KAWAMOTO: Dean Kawamoto, Keller Rohrback,</p> <p>17 on behalf of the Plaintiffs.</p> <p>18 MR. KO: Good morning. David Ko, Keller</p> <p>19 Rohrback, also on behalf of the Plaintiffs.</p> <p>20 MS. HERZFELD: Tricia Herzfeld, Branstetter,</p> <p>21 Stranch & Jennings, on behalf of the Tennessee</p> <p>22 Plaintiffs.</p> <p>23 MS. KVESELIS: Emily Kveselis, Covington &</p> <p>24 Burling, for McKesson.</p>

Page 14

1 MS. DURFEE: Laura Jane Durfee, Jones Day, for
2 Walmart.
3 MR. LOHMAN: John Lohman in-house with
4 Mallinckrodt.
5 MS. REIDY: Elissa Reidy of Ropes & Gray for
6 Mallinckrodt, LLC and SpecGX.
7 MR. O'CONNOR: Andrew O'Connor of Ropes & Gray,
8 Mallinckrodt, LLC, SpecGX and Floyd Ratliff.
9 MR. KAWAMOTO: Do you want any of the telephonic
10 appearances or -- okay.
11 WILLIAM RATLIFF,
12 called as a witness herein, having been first duly
13 sworn, was examined and testified as follows:
14 EXAMINATION
15 BY MR. KAWAMOTO:
16 Q. Good morning, Mr. Ratliff. Thank you for
17 being here.
18 A. Good morning.
19 Q. Have you ever been deposed before?
20 A. Yes.
21 Q. And can you briefly describe the matter
22 you were deposed in?
23 A. It was a matter when I was with the FBI.
24 It was at the US Department of Justice. It concerned

Page 15

1 an investigation. I was one of the -- the writers for
2 the final report.
3 Q. And did this case involve -- or did this
4 matter involve narcotics?
5 A. It did not.
6 Q. So -- well, how -- how long ago was that?
7 A. Approximately 1996.
8 Q. Okay. So some time ago.
9 In terms of the rules for the deposition
10 then, sir, just to help things go more smoothly, it is
11 very important for us to not speak -- speak over each
12 other. If I ask a question and you don't understand
13 what the question is, please let me know and I will do
14 my best to rephrase it. When you answer, you need to
15 answer audibly, so nodding your head isn't going to
16 work. And if you want to take a break, let me know.
17 If there is a question pending, I think it probably
18 makes sense for you to answer the question, but then I
19 will -- we'll accommodate whatever breaks you need.
20 Does that sound agreeable?
21 A. Understood.
22 Q. Okay. So with respect to this
23 deposition -- well, actually, let me take a step back.
24 You used to work for the Federal Bureau of

Page 16

1 Investigation. Have you ever testified in court
2 before?
3 A. Many times.
4 Q. Okay. And can you generally describe the
5 cases that you testified in?
6 A. I testified in all matters that were
7 investigated by the FBI. I was a special agent for
8 approximately 14-and-a-half years where I investigated
9 cases, and those cases involved bank robberies and
10 extortions, drug cases. I was cross-trained with the
11 DEA in the early '80s. Just...
12 Q. And for the drug cases, did any of them
13 involve prescription opioids?
14 A. No.
15 Q. Now, you indicated that you cross-trained
16 with the DEA. What -- what do you mean by that?
17 A. In 19 -- this is going back a long way --
18 '82 -- '81, '82, '83, the FBI had received joint
19 jurisdiction with the Department -- or the Drug
20 Enforcement Administration to assist them with the
21 overwhelming drug crisis in the United States at that
22 time. So they -- the FBI selected certain agents to
23 be trained to assist the DEA or to work their own
24 cases within the FBI but in coordination with the DEA.

Page 17

1 Q. So you're familiar with the Controlled
2 Substances Act?
3 A. I am.
4 Q. Okay. With respect to this deposition,
5 how did you prepare for it?
6 A. I spoke with counsel from Ropes & Gray.
7 Q. And do you recall roughly how many times
8 you spoke with counsel?
9 A. Two times.
10 Q. And were those in-person meetings or
11 telephonic?
12 A. They were. I'm sorry. They were.
13 Q. And roughly when did these meetings occur?
14 A. One was yesterday and one was several
15 months back.
16 Q. And how long did these meetings last,
17 approximately?
18 A. Four or five hours.
19 Q. So four or five hours per meeting?
20 A. Yes.
21 Q. And I'm going to ask you a question about
22 documents. I'm not asking you to describe the
23 documents -- I'm not asking you to describe the
24 substance of the documents for me, but why don't we

<p style="text-align: right;">Page 18</p> <p>1 start with: Did you review any documents during these</p> <p>2 meetings?</p> <p>3 A. Yes.</p> <p>4 Q. And did any of these documents refresh</p> <p>5 your recollection?</p> <p>6 A. Yes.</p> <p>7 Q. Okay. Do you know if these documents have</p> <p>8 been produced in this case?</p> <p>9 A. No.</p> <p>10 MR. KAWAMOTO: And so I'm -- I'll make a general</p> <p>11 request of counsel to provide any documents that --</p> <p>12 that he reviewed.</p> <p>13 MR. O'CONNOR: I can say for the record they</p> <p>14 have all been produced.</p> <p>15 BY MR. KAWAMOTO:</p> <p>16 Q. Do you have any documents in your personal</p> <p>17 possession relating to your work at Mallinckrodt?</p> <p>18 A. No.</p> <p>19 Q. Did you have a company phone?</p> <p>20 A. I did.</p> <p>21 Q. Did you ever send any text messages</p> <p>22 related to your work at Mallinckrodt?</p> <p>23 A. I'm not certain that I did. I -- I'm not</p> <p>24 very technical. As far as I know I carried a</p>	<p style="text-align: right;">Page 20</p> <p>1 Q. And what was your position with them right</p> <p>2 before you joined Mallinckrodt?</p> <p>3 A. When I retired, I was special agent in</p> <p>4 charge of the FBI in Albany, New York. We covered</p> <p>5 Vermont, all counties out to the Finger Lakes and just</p> <p>6 north of New York City was our territory.</p> <p>7 Q. Did you ever work for the National Drug</p> <p>8 Intelligence Center?</p> <p>9 A. I did.</p> <p>10 Q. And when was that from?</p> <p>11 A. I'm trying to associate this with other</p> <p>12 movement in my career to give you an accurate date.</p> <p>13 Q. Sure.</p> <p>14 A. I would say 1996 and 1997.</p> <p>15 Q. And what position did you hold with them?</p> <p>16 A. I was the deputy director.</p> <p>17 Q. And what were your job responsibilities as</p> <p>18 deputy director?</p> <p>19 A. It was basically to -- to manage the</p> <p>20 entire operation. There was a director, but those</p> <p>21 specific duties fall to the deputy director.</p> <p>22 Q. Are you familiar with the "national drug</p> <p>23 threat assessment"?</p> <p>24 A. I've heard that term, but I've been</p>
<p style="text-align: right;">Page 19</p> <p>1 BlackBerry. Is that a text?</p> <p>2 Q. I think they are somewhat different, but</p> <p>3 I -- I take it from your answer you are not a heavy</p> <p>4 texter?</p> <p>5 A. Correct.</p> <p>6 Q. Fair enough.</p> <p>7 During your time at Mallinckrodt, were you</p> <p>8 ever interviewed by any regulators or law enforcement</p> <p>9 personnel?</p> <p>10 A. I spoke with law enforcement personnel</p> <p>11 often but I was never interviewed in that sense.</p> <p>12 Q. And you've never been deposed while</p> <p>13 employed by Mallinckrodt?</p> <p>14 A. I have not.</p> <p>15 Q. And how long did you work for Mallinckrodt</p> <p>16 for?</p> <p>17 A. Approximately -- it was September of 2000</p> <p>18 until June of 2012.</p> <p>19 Q. And what did you do after you left your</p> <p>20 job at Mallinckrodt?</p> <p>21 A. Played golf.</p> <p>22 Q. Now, prior to joining Mallinckrodt, you</p> <p>23 were with the FBI?</p> <p>24 A. That's correct.</p>	<p style="text-align: right;">Page 21</p> <p>1 retired for six-and-a-half years and I seldom think</p> <p>2 about any of this, so. And that would have been in</p> <p>3 the 1990s, 20 years ago, so I'm not certain how to</p> <p>4 answer the question other than I believe I've heard</p> <p>5 that term.</p> <p>6 Q. What was the job or what was the function</p> <p>7 of the National Drug Intelligence Center?</p> <p>8 A. We employed our own analysts and analysts</p> <p>9 from the FBI, the DEA, and most government agencies</p> <p>10 with, I had like to describe it with three initials.</p> <p>11 We were funded through the Department of Justice and</p> <p>12 also through the Central Intelligence Agency. And our</p> <p>13 job was to gather information from agencies that</p> <p>14 didn't have specific drug law enforcement type of</p> <p>15 jurisdiction.</p> <p>16 So, for instance, the Coast Guard might do</p> <p>17 an interdiction and they might have a lot of</p> <p>18 information that never gets to the Drug Enforcement</p> <p>19 Administration or to the FBI or to the proper agency.</p> <p>20 So the National Drug Intelligence Center employed all</p> <p>21 of these different agencies so we could coordinate</p> <p>22 that information, make reports, and put it back out to</p> <p>23 the inf- -- to the agencies that would most benefit</p> <p>24 from that information.</p>

Page 22

1 Q. And is it your understanding that one of
2 the functions of the National Drug Intelligence Center
3 was to put out this report entitled "The National Drug
4 Threat Assessment"?

5 A. That's -- I'm certain that's where I heard
6 that term, but it's been many years.

7 Q. Do you ever recall working on a drug
8 threat assessment for the -- the NDIC?

9 A. Not personally.

10 Q. Would you agree that there is an opioid
11 crisis facing this country?

12 MR. O'CONNOR: Objection.

13 BY THE WITNESS:

14 A. I would.

15 BY MR. KAWAMOTO:

16 Q. And roughly when did it start?

17 A. I don't recall the exact timing.

18 Q. If you had to estimate, though, what --
19 what -- roughly when would you put the date, pre 2000,
20 2012, if you had to ballpark it?

21 A. I would rather not guess.

22 Q. Were you concerned about the opioid
23 epidemic while you were employed at Mallinckrodt?

24 A. Yes.

Page 23

1 Q. And you joined Mallinckrodt in 2000, is
2 that correct?

3 A. Correct, um-hum.

4 Q. Did you ever hear the term "opioid
5 epidemic user" discussed while you were employed at
6 Mallinckrodt?

7 A. Yes. The -- what you need to understand,
8 if I might add some additional information, I worked
9 as the Security Manager for Mallinckrodt until they
10 were purchased by Tyco, Tyco International, and then
11 it became Tyco Healthcare, then I became the Director
12 of Security, director, not manager, but Director of
13 Security for Tyco Healthcare. That eventually was
14 spun off into Covidien and I was the Chief Security
15 Officer for Covidien worldwide.

16 Q. And so was it in the context of your work
17 as the Director of Security for Tyco that you heard
18 this term or you used this term -- or I'm sorry -- you
19 heard this term discussed?

20 MR. O'CONNOR: Objection.

21 BY THE WITNESS:

22 A. I just can't recall exactly when I heard
23 the term. Did I hear that term, yes.

24 BY MR. KAWAMOTO:

Page 24

1 Q. And what are the causes of this opioid
2 crisis?

3 A. It would be abuse of narcotics.

4 Q. Would you agree that overprescription by
5 doctors is a cause?

6 A. Yes.

7 Q. Would you agree that the over distribution
8 by pharmaceuticals is a cause?

9 MR. O'CONNOR: Objection.

10 BY THE WITNESS:

11 A. Yes.

12 BY MR. KAWAMOTO:

13 Q. Do you know what a pill mill is?

14 A. I do.

15 Q. What is it?

16 A. It's -- it's one that produces an excess
17 of narcotics for the street.

18 Q. And when you say "produces an excess of
19 narcotics for the street," are you -- are you
20 referring to a manufacturer of narcotics?

21 A. No.

22 Q. So what -- what do you mean when you say
23 it produces -- a pill mill "produces an excess of
24 narcotics for the street"?

Page 25

1 A. A manufacturer receives a quota from the
2 Drug Enforcement Administration. They have an
3 overview of what pain medications are needed to be
4 distributed through distributors throughout the
5 United States. They have the big picture. The
6 manufacturers only have a small portion of the picture
7 because they were granted quota, normally not the
8 entire amount they request, but they were granted a
9 certain amount of quota by the Drug Enforcement
10 Administration.

11 MR. KO: By the way, I believe everyone's
12 real-time is down.

13 MR. KAWAMOTO: Do you want to take a quick ten
14 second break?

15 THE VIDEOGRAPHER: We are going off the record
16 at 9:52.

17 (WHEREUPON, a recess was had
18 from 9:52 to 9:55 a.m.)

19 THE VIDEOGRAPHER: We are back on the record at
20 9:55.

21 BY MR. KAWAMOTO:

22 Q. So, Mr. Ratliff, before we went off the
23 record, we were discussing pill mills.

24 Are pill mills essentially pharmacies?

<p style="text-align: right;">Page 26</p> <p>1 MS. DURFEE: Objection.</p> <p>2 BY THE WITNESS:</p> <p>3 A. There is no way for me to answer that. I</p> <p>4 don't know that.</p> <p>5 BY MR. KAWAMOTO:</p> <p>6 Q. Okay. Well, what -- I think we</p> <p>7 established that in your view a pill mill is not a</p> <p>8 manufacturer, so what -- what is a pill mill?</p> <p>9 A. They are putting licit pills into the</p> <p>10 illicit market.</p> <p>11 Q. And can you give me an example of a pill</p> <p>12 mill?</p> <p>13 A. Well, there are countries, Mexico would be</p> <p>14 one, China would be another, that introduce pills into</p> <p>15 the United States at a -- at a large rate. So those</p> <p>16 would be pill mills.</p> <p>17 Q. And so your understanding of the term</p> <p>18 "pill mill" is -- is that it would include China, for</p> <p>19 example?</p> <p>20 A. Yes.</p> <p>21 Q. Could a local retail pharmacy be a pill</p> <p>22 mill?</p> <p>23 A. Yes.</p> <p>24 MS. DURFEE: Objection.</p>	<p style="text-align: right;">Page 28</p> <p>1 deaths from that illicit product that was in the</p> <p>2 market.</p> <p>3 Q. And by illicit distribution of narcotics,</p> <p>4 does that include prescription opioids?</p> <p>5 MR. O'CONNOR: Objection.</p> <p>6 BY THE WITNESS:</p> <p>7 A. Yes.</p> <p>8 BY MR. KAWAMOTO:</p> <p>9 Q. In fact, weren't the majority of illicit</p> <p>10 narcotics that were being distributed prescription</p> <p>11 opioids?</p> <p>12 MR. O'CONNOR: Objection.</p> <p>13 BY THE WITNESS:</p> <p>14 A. I don't know that.</p> <p>15 MR. KAWAMOTO: I'd like to mark as exhibit --</p> <p>16 So this is going to be marked as</p> <p>17 Exhibit 1, and I'm not quite sure what the best way to</p> <p>18 get this to the other side of the table is, so if I</p> <p>19 give it to you can you sort of circulate it.</p> <p>20 (WHEREUPON, a certain document was</p> <p>21 marked Mallinckrodt-Ratliff</p> <p>22 Deposition Exhibit No. 001, for</p> <p>23 identification, as of 12/19/2018.)</p> <p>24 BY MR. KAWAMOTO:</p>
<p style="text-align: right;">Page 27</p> <p>1 BY MR. KAWAMOTO:</p> <p>2 Q. Did you ever encounter such pill mills</p> <p>3 while working for Mallinckrodt?</p> <p>4 A. I did.</p> <p>5 Q. Do you believe pill mills contributed to</p> <p>6 the opioid crisis?</p> <p>7 A. I do.</p> <p>8 Q. And were you concerned about them while</p> <p>9 you were employed at Mallinckrodt?</p> <p>10 A. Yes.</p> <p>11 Q. And did you believe it was -- strike that.</p> <p>12 Do you believe Mallinckrodt had an</p> <p>13 obligation to prevent its products from reaching pill</p> <p>14 mills?</p> <p>15 MR. O'CONNOR: Objection.</p> <p>16 BY THE WITNESS:</p> <p>17 A. Yes.</p> <p>18 BY MR. KAWAMOTO:</p> <p>19 Q. And do you recall when you first became</p> <p>20 concerned about pill mills?</p> <p>21 A. I can't give you a specific date or year.</p> <p>22 There were -- there was a lot of information on the</p> <p>23 news about the illicit, not licit, but illicit</p> <p>24 distribution of narcotics and that it was causing</p>	<p style="text-align: right;">Page 29</p> <p>1 Q. So, Mr. Ratliff, I've handed you what's</p> <p>2 Exhibit 1. It's an excerpt from the National Drug</p> <p>3 Threat Assessment from 2011. I put it up on the Elmo</p> <p>4 for your convenience.</p> <p>5 A. Okay.</p> <p>6 Q. You'll note that it's put out by the US</p> <p>7 Department of Justice and it is the National Drug</p> <p>8 Intelligence Center is actually the institution that's</p> <p>9 responsible for it.</p> <p>10 Directing your attention to the top of</p> <p>11 Page 37, and I'll high right this, this wording for</p> <p>12 you.</p> <p>13 Can you please read what I have just</p> <p>14 highlighted?</p> <p>15 A. "The abuse of CPDs constitutes a problem</p> <p>16 second only to the abuse of marijuana in scope and</p> <p>17 pervasiveness in the United States; the problem is</p> <p>18 particularly acute among adolescents."</p> <p>19 Q. Would you agree with that statement?</p> <p>20 MR. O'CONNOR: Objection.</p> <p>21 BY THE WITNESS:</p> <p>22 A. Based on their assessment, yes.</p> <p>23 BY MR. KAWAMOTO:</p> <p>24 Q. Well, do you have any reason to believe</p>

<p style="text-align: right;">Page 30</p> <p>1 that the assessment is inaccurate?</p> <p>2 A. No.</p> <p>3 Q. That's all with that one.</p> <p>4 A. Okay.</p> <p>5 Q. So is it fair to say that the opioid</p> <p>6 crisis is largely driven by prescription opioids?</p> <p>7 MR. O'CONNOR: Objection.</p> <p>8 BY THE WITNESS:</p> <p>9 A. I would say yes.</p> <p>10 BY MR. KAWAMOTO:</p> <p>11 Q. Are you aware of the term "migration" with</p> <p>12 respect to -- strike that.</p> <p>13 Are you familiar with the use of the term</p> <p>14 "migration" in the context of opioid products?</p> <p>15 A. No, not that I recall.</p> <p>16 Q. Did you have particular concerns with</p> <p>17 opioid products going to Florida and from there making</p> <p>18 their way -- making their way to other parts of the</p> <p>19 country?</p> <p>20 MR. O'CONNOR: Objection.</p> <p>21 BY THE WITNESS:</p> <p>22 A. Yes.</p> <p>23 BY MR. KAWAMOTO:</p> <p>24 Q. What were those concerns?</p>	<p style="text-align: right;">Page 32</p> <p>1 but I know they've had a great deal of -- of problems.</p> <p>2 Q. So it would be fair to characterize West</p> <p>3 Virginia as a hot spot as we are using that term,</p> <p>4 would it not?</p> <p>5 MR. O'CONNOR: Objection.</p> <p>6 BY THE WITNESS:</p> <p>7 A. Yes.</p> <p>8 BY MR. KAWAMOTO:</p> <p>9 Q. What about Georgia?</p> <p>10 A. I don't know specifically that Georgia was</p> <p>11 a hot spot.</p> <p>12 Q. What about Tennessee?</p> <p>13 A. Just for the record, I've been retired</p> <p>14 six-and-a-half years and most of the information you</p> <p>15 are asking is much longer ago than that and I'm --</p> <p>16 I'll do my very best, but I haven't really thought</p> <p>17 about any of this since I retired. So I'm going to do</p> <p>18 my very best to answer those questions, but you are</p> <p>19 asking questions about long ago for me.</p> <p>20 Q. No, I understand that, and I appreciate</p> <p>21 your best efforts.</p> <p>22 A. I'm doing the best I can.</p> <p>23 Q. Sir, thank you.</p> <p>24 A. At the time I -- there were a number of</p>
<p style="text-align: right;">Page 31</p> <p>1 A. There came a time that we began to look at</p> <p>2 our customer's customer. We manufactured oxycodone.</p> <p>3 We sold that to distributors and distributors sold</p> <p>4 that to their customers. And there came a time when</p> <p>5 we started looking at our customer's customer. So I</p> <p>6 actually went to Florida and reviewed a number of</p> <p>7 pharmacies to see if they were legitimate pharmacies</p> <p>8 in my opinion or if they were, I guess what you would</p> <p>9 call a pill mill.</p> <p>10 Q. And why go to Florida to do that?</p> <p>11 A. Because that was, I think, according to</p> <p>12 DEA one of the hot spots. There were others in the</p> <p>13 United States that we also looked at, but Florida was</p> <p>14 one that DEA was particularly concerned about.</p> <p>15 Q. And do you recall what some of the other</p> <p>16 hot spots were?</p> <p>17 A. I do. New Jersey would be one, Las Vegas,</p> <p>18 Nevada would be another, as an example.</p> <p>19 Q. What about Kentucky?</p> <p>20 A. I'm certain we've discussed Kentucky in</p> <p>21 those terms.</p> <p>22 Q. And what about West Virginia?</p> <p>23 A. I'm not certain if that was a term we used</p> <p>24 or a state we looked at while I was still employed,</p>	<p style="text-align: right;">Page 33</p> <p>1 states that were having issues, I believe, but it was</p> <p>2 Florida was where DEA really wanted us to focus our</p> <p>3 efforts at that time.</p> <p>4 Q. And in just going back briefly to the</p> <p>5 issue of hot spots, do you -- do you recall</p> <p>6 conversations about Tennessee?</p> <p>7 MR. O'CONNOR: Objection.</p> <p>8 BY THE WITNESS:</p> <p>9 A. Not specifically.</p> <p>10 BY MR. KAWAMOTO:</p> <p>11 Q. What about Ohio?</p> <p>12 MR. O'CONNOR: Objection.</p> <p>13 BY THE WITNESS:</p> <p>14 A. Not specifically.</p> <p>15 BY MR. KAWAMOTO:</p> <p>16 Q. Now, with respect to Florida, what were</p> <p>17 your concerns about Florida?</p> <p>18 A. We were getting information that a number</p> <p>19 of the pharmacies, these would be the customers of our</p> <p>20 customer, were purchasing large amounts of oxycodone</p> <p>21 30s, 30-milligram tablets.</p> <p>22 Q. And was the concern that this would --</p> <p>23 this would -- these products were essentially being</p> <p>24 diverted?</p>

Page 34

1 MR. O'CONNOR: Objection.
2 BY THE WITNESS:
3 A. We didn't know that at the time. The --
4 the effort was to go and obtain additional information
5 so we can make an assessment of those pharmacies. You
6 know, one, for example, may be next to a Veterans
7 Administration hospital and maybe they had a reason
8 for purchasing large amounts, others may be putting
9 them back into the illicit market. So we needed
10 additional information to make an assessment whether
11 or not that we would continue to supply our
12 distributor. The distributor had a responsibility to
13 know their customers. They have the same exact
14 responsibility that a manufacturer has to develop a
15 program to prevent diversion. So they are supposed to
16 have security people just like myself that would go to
17 those pharmacies and review them.
18 So to obtain additional information, I
19 went to Florida and I obtained cooperation from two of
20 our forensic auditors from Covidien that didn't work
21 for Mallinckrodt to go to the east side of the state,
22 they were both fluent in Spanish, to review these
23 high -- they were high dosage pharmacies to see were
24 they good, solid pharmacies or were they very small

Page 35

1 pharmacies with no other products in their -- on their
2 shelves and signs that indicated Mallinckrodt products
3 sold for cash only. So we went to Florida and we made
4 that review and then we made recommendations, not only
5 to DEA, that we were not going to provide product to
6 our distributors to go to those but that they should
7 also review our results because we, you know, stopped
8 selling to our distributor. And the distributor's
9 responsibility then was to -- to go to that pharmacy
10 and make an assessment also. And if they had
11 information that we didn't have, they could always
12 come forward.
13 Q. And you indicated that you went to Florida
14 to make an assessment of these pharmacies and
15 essentially determine if they were pill mills or not,
16 is that fair?
17 MR. O'CONNOR: Objection.
18 BY THE WITNESS:
19 A. That's fair.
20 BY MR. KAWAMOTO:
21 Q. And what were the results of that
22 assessment? Did you identify pill mills in Florida?
23 A. I did.
24 Q. In your opinion, were there a higher

Page 36

1 number of pill mills in Florida than -- well, strike
2 that.
3 Based on your experience and in your
4 opinion were there a higher number of pill mills in
5 Florida than in other states?
6 MR. O'CONNOR: Objection.
7 BY THE WITNESS:
8 A. I don't -- I would have no way to assess
9 that.
10 BY MR. KAWAMOTO:
11 Q. Would it be fair to say you identified a
12 large number of pill mills in Florida?
13 MR. O'CONNOR: Objection.
14 BY THE WITNESS:
15 A. I would say yes.
16 BY MR. KAWAMOTO:
17 Q. And would you agree that the pills that
18 ended up with these pill mills in Florida -- well,
19 strike that.
20 The pills that went to these pill mills in
21 Florida didn't always stay in Florida, did they?
22 MR. O'CONNOR: Objection.
23 BY THE WITNESS:
24 A. I'd have no way to know that.

Page 37

1 BY MR. KAWAMOTO:
2 Q. Do you recall ever being informed or
3 contacted by law enforcement in other states
4 indicating that they had -- they had possession of
5 Mallinckrodt product from the illicit market and it
6 appears that that product came from Florida?
7 A. I believe that we received information
8 from Tennessee. They requested assistance on
9 identifying the actual numbers the -- that are
10 contained on the bottles and that we provided that
11 information, and that's -- it's been a long time ago,
12 and I believe that was the case.
13 Q. So that would be an example of pills
14 traveling from Florida to Tennessee in the illicit
15 market, is that fair?
16 A. Fair.
17 Q. And there is nothing to prevent a pill
18 that originally is shipped to Florida from being
19 transported to Kentucky, is there?
20 A. No.
21 Q. And were you aware that there were people
22 coming into Florida from out of state for the express
23 purpose of obtaining opioid products?
24 MR. O'CONNOR: Objection.

<p style="text-align: right;">Page 38</p> <p>1 BY THE WITNESS:</p> <p>2 A. DEA -- I spoke with DEA frequently, Pete</p> <p>3 Kleisele, and that information would have been gleaned</p> <p>4 from conversations with Pete.</p> <p>5 BY MR. KAWAMOTO:</p> <p>6 Q. And so DEA indicated to you that they were</p> <p>7 concerned that people were coming from out of state</p> <p>8 into Florida to obtain opioid products?</p> <p>9 MR. O'CONNOR: Objection.</p> <p>10 BY THE WITNESS:</p> <p>11 A. That's correct. And we also provided --</p> <p>12 they are -- there is no oxy in the tablet, they are</p> <p>13 placebos, would be the term, to law enforcement DEA so</p> <p>14 they could have an undercover operation in Florida.</p> <p>15 So we did know about that, and they couldn't</p> <p>16 redistribute product that they took in without the</p> <p>17 Attorney General personally approving that. So we</p> <p>18 provided placebos to them to assist them with their</p> <p>19 investigation.</p> <p>20 BY MR. KAWAMOTO:</p> <p>21 Q. And do you know where those placebos</p> <p>22 ultimately ended up? Do you know if they stayed in</p> <p>23 Florida or if they were distributed up and down the</p> <p>24 Eastern Seaboard?</p>	<p style="text-align: right;">Page 40</p> <p>1 it's got my name from and to Karen.</p> <p>2 And I remember basically what the e-mail</p> <p>3 says, because they came to Mallinckrodt, to my office,</p> <p>4 on occasion asking for assistance in how to</p> <p>5 investigate the pharmacies, and so we -- we gave them</p> <p>6 whatever we could in assistance, so.</p> <p>7 Q. And H.D. Smith was a Mallinckrodt</p> <p>8 customer?</p> <p>9 A. Yes.</p> <p>10 Q. Now, do you see on the e-mail where it</p> <p>11 says: "H.D. Smith has suspended all sales of oxy 30s</p> <p>12 into Florida for the immediate future"?</p> <p>13 A. Correct.</p> <p>14 Q. Do you have an understanding of why they</p> <p>15 did that?</p> <p>16 A. The owner -- I mean, this is from a -- you</p> <p>17 have to remember how many years ago this has been.</p> <p>18 I'm going to give you my best recollection of that</p> <p>19 conversation.</p> <p>20 Q. That -- that would be appreciated.</p> <p>21 A. So the owner said: There are problems in</p> <p>22 Florida. You guys go down there and see what's going</p> <p>23 on. And so he said: And stop the sales until we</p> <p>24 figure it out.</p>
<p style="text-align: right;">Page 39</p> <p>1 A. They were --</p> <p>2 MR. O'CONNOR: Objection.</p> <p>3 BY THE WITNESS:</p> <p>4 A. Well, I don't know specifically where they</p> <p>5 ended up. DEA requests assistance, but they never</p> <p>6 come back and say, These are the results of your</p> <p>7 assistance.</p> <p>8 MR. KAWAMOTO: So I'd like to mark this as</p> <p>9 Exhibit 2, if I could.</p> <p>10 (WHEREUPON, a certain document was</p> <p>11 marked Mallinckrodt-Ratliff</p> <p>12 Deposition Exhibit No. 002, for</p> <p>13 identification, as of 12/19/2018.)</p> <p>14 BY MR. KAWAMOTO:</p> <p>15 Q. So, Mr. Ratliff, I've handed you an</p> <p>16 exhibit. It is Bates numbered MNK-T 269884. It is at</p> <p>17 the very bottom.</p> <p>18 And could you review that Exhibit and let</p> <p>19 me know when you are ready?</p> <p>20 A. Okay.</p> <p>21 Q. So this is an e-mail that you sent to</p> <p>22 Karen Harper on March 22nd, 2011.</p> <p>23 Do you recall sending this e-mail?</p> <p>24 A. Not particularly, but I sent it because</p>	<p style="text-align: right;">Page 41</p> <p>1 Q. And when you say, the owner said: You</p> <p>2 guys go down there, was he referring to his people or</p> <p>3 was he referring to Mallinckrodt or both?</p> <p>4 A. He had no authority over us. He was</p> <p>5 talking about his people.</p> <p>6 Q. Okay. And do you see further on in the</p> <p>7 e-mail, it says: "He went on to explain, as he told</p> <p>8 us, that they do not sell to pain management clinics."</p> <p>9 A. Okay.</p> <p>10 Q. Do you understand what the concern was</p> <p>11 with pain management clinics?</p> <p>12 MR. O'CONNOR: Objection.</p> <p>13 BY THE WITNESS:</p> <p>14 A. Pain management clinics. We -- we</p> <p>15 produced or manufactured oxycodone 5s, 15s and 30s.</p> <p>16 The pain management clinics tended to prescribe the</p> <p>17 oxycodone 30s, which is the highest dose at that time</p> <p>18 that we manufactured. So there is no way for us to</p> <p>19 know if they are treating legitimate pain from</p> <p>20 their -- their customers, but, I mean, that's</p> <p>21 certainly an issue because of the volume that they</p> <p>22 were selling.</p> <p>23 Q. And so you had a concern that the pain</p> <p>24 management clinics may have been overprescribing, is</p>

<p style="text-align: right;">Page 42</p> <p>1 that fair?</p> <p>2 MR. O'CONNOR: Objection.</p> <p>3 BY THE WITNESS:</p> <p>4 A. I don't know that I knew that at the time,</p> <p>5 but they were purchasing large amounts from their</p> <p>6 customers. Let me restate this.</p> <p>7 There the -- our customers, the</p> <p>8 distributors, were selling to these pharmacies and</p> <p>9 that the doctors were writing scripts to those</p> <p>10 pharmacies for their patients. So it was far removed</p> <p>11 from us. So for me to tell you today that -- that I</p> <p>12 knew specifically this was going on, there is no way I</p> <p>13 could do that.</p> <p>14 BY MR. KAWAMOTO:</p> <p>15 Q. Well, I understand that, but this e-mail</p> <p>16 indicates that you had -- well, this -- this e-mail</p> <p>17 indicates that the distributor had a concern with pain</p> <p>18 management clinics.</p> <p>19 And it sounds like you shared that</p> <p>20 concern, is that fair?</p> <p>21 MR. O'CONNOR: Objection.</p> <p>22 BY THE WITNESS:</p> <p>23 A. I'm trying to see where I agreed. I --</p> <p>24 BY MR. KAWAMOTO:</p>	<p style="text-align: right;">Page 44</p> <p>1 in here in this e-mail -- or e-mail that I agree with</p> <p>2 that. You know, did we have a concern, I think it was</p> <p>3 on the news about pain management clinics, and so I</p> <p>4 didn't live in a bubble. So there certainly -- you</p> <p>5 know, if you believe the news, that there was a</p> <p>6 problem with pain management doctors.</p> <p>7 Q. And when you completed your review of your</p> <p>8 customers' customers, that confirmed that there was a</p> <p>9 problem with pain management doctors, isn't that</p> <p>10 correct?</p> <p>11 A. That is correct.</p> <p>12 MR. O'CONNOR: Objection.</p> <p>13 THE WITNESS: Sorry.</p> <p>14 BY MR. KAWAMOTO:</p> <p>15 Q. Do you recall when you first started</p> <p>16 reviewing your customers' customers?</p> <p>17 A. I would be guessing if I said a specific</p> <p>18 time. I -- I just -- I hate to guess.</p> <p>19 Q. What prompted you to start looking at your</p> <p>20 customers' customers?</p> <p>21 A. DEA was concerned that everyone -- they</p> <p>22 wanted everyone to be involved in the suspicious order</p> <p>23 monitoring program specifically and to delve into</p> <p>24 their customer's customer. That was -- came out of a</p>
<p style="text-align: right;">Page 43</p> <p>1 Q. Well, let me rephrase the question.</p> <p>2 Did you -- while employed at Mallinckrodt,</p> <p>3 did you share a concern regarding pain management</p> <p>4 clinics and the prescription of oxy 30s?</p> <p>5 MR. O'CONNOR: Objection.</p> <p>6 BY THE WITNESS:</p> <p>7 A. At a point when we started to review our</p> <p>8 customers' customers.</p> <p>9 BY MR. KAWAMOTO:</p> <p>10 Q. And at the very bottom of the e-mail, do</p> <p>11 you see the sentence that says: "He concluded that if</p> <p>12 the pharmacies were filling too many scripts for pain</p> <p>13 management doctors or were uncooperative that they</p> <p>14 would no longer sell to that pharmacy"?</p> <p>15 A. Yes.</p> <p>16 Q. Did you agree with that conclusion?</p> <p>17 A. That was their conclusion. I was</p> <p>18 reporting what they were telling me.</p> <p>19 Q. But do you think that conclusion was a</p> <p>20 reasonable one for them to be making?</p> <p>21 A. As I previously stated, at the time I</p> <p>22 hadn't had an opportunity to review our customers'</p> <p>23 customers and then the downstream with the pharmacies</p> <p>24 and their patients. So to say -- I don't see anywhere</p>	<p style="text-align: right;">Page 45</p> <p>1 conference that DEA held, if I were guessing, I would</p> <p>2 say '09. It may have been a different time. I just</p> <p>3 don't want to misspeak. That's --</p> <p>4 Q. No, I understand that, sir.</p> <p>5 A. I'm trying to give you the best, and it's</p> <p>6 been a long time.</p> <p>7 Q. Now, the -- your customers, the</p> <p>8 distributors, were also supposed to be vetting their</p> <p>9 customers, is that fair?</p> <p>10 A. That's fair.</p> <p>11 MR. O'CONNOR: Objection.</p> <p>12 BY MR. KAWAMOTO:</p> <p>13 Q. Did you ever have concerns with the</p> <p>14 vetting process that your customers were using to vet</p> <p>15 their customers?</p> <p>16 MS. KVESELIS: Object to form.</p> <p>17 BY MR. KAWAMOTO:</p> <p>18 Q. You can answer.</p> <p>19 A. Yes.</p> <p>20 Q. That -- the objection is preserved for the</p> <p>21 record.</p> <p>22 A. Um-hum, yes.</p> <p>23 Q. And can you describe those concerns?</p> <p>24 MS. KVESELIS: Object to form.</p>

<p style="text-align: right;">Page 46</p> <p>1 BY THE WITNESS:</p> <p>2 A. We weren't sure that they were going to</p> <p>3 their customers and doing an audit, so we came up with</p> <p>4 a form that required a lot of information from those</p> <p>5 pharmacies that purchased large amounts of our</p> <p>6 products, and there were a number of questions on</p> <p>7 there that would help us, it would give us more</p> <p>8 information, additional information, and would -- it</p> <p>9 would allow us to make an assessment then, too, of the</p> <p>10 distributor if they were following up with those</p> <p>11 pharmacies if there were any concerns.</p> <p>12 BY MR. KAWAMOTO:</p> <p>13 Q. And do you recall any of the distribute --</p> <p>14 strike that.</p> <p>15 Do you recall any of the distributors that</p> <p>16 you had concerns about?</p> <p>17 MR. O'CONNOR: Objection.</p> <p>18 MS. KVESELIS: Object to form.</p> <p>19 BY THE WITNESS:</p> <p>20 A. Our job was to ensure our customers were</p> <p>21 in compliance. So if we had concerns about one of</p> <p>22 their customers or more than one of their customers,</p> <p>23 we would bring that to their attention. And it was</p> <p>24 the intent that they understood exactly what we</p>	<p style="text-align: right;">Page 48</p> <p>1 Q. And what distributor was this that we are</p> <p>2 talking about?</p> <p>3 A. AmerisourceBergen.</p> <p>4 Q. Do you recall a distributor named</p> <p>5 "Sunrise"?</p> <p>6 A. Yes.</p> <p>7 Q. And what do you recall about that</p> <p>8 distributor?</p> <p>9 A. That they had hired a DEA either agent or</p> <p>10 compliance analyst to assist them with their -- their</p> <p>11 entry into the market. And at some point our people,</p> <p>12 not myself, went to Sunrise to review the operation</p> <p>13 and make a determination if they were a legitimate</p> <p>14 enterprise.</p> <p>15 Q. And do you recall that Sunrise voluntarily</p> <p>16 surrendered its license to the DEA?</p> <p>17 MR. O'CONNOR: Objection.</p> <p>18 BY THE WITNESS:</p> <p>19 A. I don't recall that specifically, but I</p> <p>20 believe that's correct.</p> <p>21 BY MR. KAWAMOTO:</p> <p>22 Q. Do you recall anything about Masters</p> <p>23 Pharmaceuticals?</p> <p>24 MR. O'CONNOR: Objection.</p>
<p style="text-align: right;">Page 47</p> <p>1 expected as a manufacturer.</p> <p>2 BY MR. KAWAMOTO:</p> <p>3 Q. And do you recall any specific</p> <p>4 distributors, though, that you had concerns about</p> <p>5 their compliance?</p> <p>6 MR. O'CONNOR: Objection.</p> <p>7 BY MR. KAWAMOTO:</p> <p>8 Q. Do any -- do any names stand out for you?</p> <p>9 MR. O'CONNOR: Objection.</p> <p>10 BY THE WITNESS:</p> <p>11 A. There was one that was dilatory. We gave</p> <p>12 them specific deadlines, like 30 days, provide this</p> <p>13 information back to Mallinckrodt so we could make an</p> <p>14 assessment in 30 days. They didn't always make those</p> <p>15 deadlines. That doesn't necessarily mean that they</p> <p>16 were out of compliance or had ill intent. It meant</p> <p>17 that they didn't provide the information. So we would</p> <p>18 have to go back to them and say, We need this</p> <p>19 information to make an assessment.</p> <p>20 Q. And would --</p> <p>21 A. On one occasion we brought that to</p> <p>22 management's -- the management of that distributor's</p> <p>23 attention. And they, to the best of my knowledge, you</p> <p>24 know, fixed the -- the matter right away.</p>	<p style="text-align: right;">Page 49</p> <p>1 BY THE WITNESS:</p> <p>2 A. I know that I was involved in an audit of</p> <p>3 Masters.</p> <p>4 BY MR. KAWAMOTO:</p> <p>5 Q. And what do you recall about that audit?</p> <p>6 A. Almost nothing. It's been so long ago,</p> <p>7 and what happens is that the different audits, they</p> <p>8 just kind of all meld together, and at my age I'm --</p> <p>9 I'm having more difficulty remembering things that are</p> <p>10 ten years old or -- or longer, so.</p> <p>11 Q. Do you know if Masters had its license</p> <p>12 revoked by the DEA?</p> <p>13 A. I believe that to be the case. I know we</p> <p>14 made -- we sent information to DEA after the audit. I</p> <p>15 do remember that. But we had two audits within a day</p> <p>16 or so of each -- of those audits, and that's why I'm</p> <p>17 somewhat confused if it's Masters or one of the other</p> <p>18 distributors.</p> <p>19 Q. And do you recall what information you</p> <p>20 sent to DEA about Masters Pharmaceuticals?</p> <p>21 A. No.</p> <p>22 Q. What about Harvard, do you recall them as</p> <p>23 a distributor?</p> <p>24 A. I never have been to Harvard. I've heard</p>

<p style="text-align: right;">Page 50</p> <p>1 that name, but that's all I know.</p> <p>2 Q. And what about KeySource?</p> <p>3 MR. O'CONNOR: Objection.</p> <p>4 BY THE WITNESS:</p> <p>5 A. I think KeySource, again, I'm almost</p> <p>6 guessing, but I believe it's in Cincinnati and was one</p> <p>7 of the ones that we audited during that two-day</p> <p>8 period.</p> <p>9 BY MR. KAWAMOTO:</p> <p>10 Q. And do you recall if they lost their</p> <p>11 license to the DEA for Schedule II narcotics?</p> <p>12 A. Again, I'd be guessing. I don't know, but</p> <p>13 I believe they may have. This has been, you know,</p> <p>14 long ago.</p> <p>15 Q. Now, you indicated that you were the</p> <p>16 secure -- that you were the security director for</p> <p>17 Mallinckrodt, is that -- is that right?</p> <p>18 A. I was the security manager for</p> <p>19 Mallinckrodt. I was the security director when it</p> <p>20 became Tyco Healthcare.</p> <p>21 Q. And so were you promoted into that</p> <p>22 position?</p> <p>23 A. I was.</p> <p>24 Q. And roughly when did you become the</p>	<p style="text-align: right;">Page 52</p> <p>1 off from -- from Tyco International.</p> <p>2 Q. And with respect to opioid products, what</p> <p>3 were your responsibilities, for the opioid products?</p> <p>4 A. To prevent diversion, to ensure that in</p> <p>5 the manufacturing sites that there were programs in</p> <p>6 place.</p> <p>7 Q. And could you define diversion for me?</p> <p>8 What's your understanding of that term?</p> <p>9 A. Diversion is taking a licit product, a</p> <p>10 legitimate product and taking it away in an illi- --</p> <p>11 in an illicit way for one's own personal use or for</p> <p>12 sale.</p> <p>13 Q. So would the overprescription by a doctor</p> <p>14 constitute diversion in your opinion?</p> <p>15 MR. O'CONNOR: Objection.</p> <p>16 BY THE WITNESS:</p> <p>17 A. There is no way for me to -- to without</p> <p>18 additional information about a specific doctor to make</p> <p>19 that generalization.</p> <p>20 BY MR. KAWAMOTO:</p> <p>21 Q. But if a doctor is prescribing opioids for</p> <p>22 non-medically valid reasons, that would be an example</p> <p>23 of diversion?</p> <p>24 A. That's a hypothetical, it seems. I don't</p>
<p style="text-align: right;">Page 51</p> <p>1 security director for Tyco? And I understand that</p> <p>2 that -- this happened a while ago, so, you know, I'm</p> <p>3 not --</p> <p>4 A. I'm trying to remember.</p> <p>5 Q. -- I understand that --</p> <p>6 A. It is difficult to...</p> <p>7 Q. -- yeah, you may not be exact.</p> <p>8 A. I would say sometime in 2001. Is that --</p> <p>9 and I may be wrong. I may be off a year. I think</p> <p>10 it's --</p> <p>11 Q. Sure. But the early 2000s, is that right?</p> <p>12 A. Yes, that would be fair.</p> <p>13 Q. What were your responsibilities as</p> <p>14 security director for Mallinckrodt? I'm sorry.</p> <p>15 What were your responsibilities as</p> <p>16 security director for Tyco?</p> <p>17 A. We had facilities all over. We were</p> <p>18 responsible for the pharmaceutical section, for</p> <p>19 surgical instruments, for surgical materials. That's</p> <p>20 not a good way to say that. It's surgical supplies.</p> <p>21 And there was additionally one other division that had</p> <p>22 to do with breathing apparatus for people that needed</p> <p>23 oxygen. That was sold off fairly early. So we -- we</p> <p>24 maintained those three divisions until Covidien spun</p>	<p style="text-align: right;">Page 53</p> <p>1 know how I could answer that without specifics.</p> <p>2 Q. Well, what specifics would you need?</p> <p>3 A. I -- I'd need to know what type of</p> <p>4 patients he sees and does he write the same script 90</p> <p>5 tablets of 30-milligram for every patient he sees.</p> <p>6 Now, would that be a -- something that I would want to</p> <p>7 know, yes. So if that's the case, but still without</p> <p>8 additional information, it's really difficult for me</p> <p>9 to make that assessment.</p> <p>10 Q. But in the example you gave, the 90</p> <p>11 tablets of 30 of oxy 30 for every patient he sees, in</p> <p>12 your -- in your view that would be an example of</p> <p>13 diversion?</p> <p>14 MR. O'CONNOR: Objection.</p> <p>15 BY THE WITNESS:</p> <p>16 A. No. It would be suspicious, but I can't</p> <p>17 make the assessment literally without having specifics</p> <p>18 about his customers. Would it be suspicious, yes.</p> <p>19 BY MR. KAWAMOTO:</p> <p>20 Q. So it could be diversion?</p> <p>21 A. It's possible.</p> <p>22 Q. And the pill mills, the distribution of</p> <p>23 Mallinckrodt products by pill mills, that would be</p> <p>24 another example of diversion, would it not?</p>

<p style="text-align: right;">Page 54</p> <p>1 MR. O'CONNOR: Objection.</p> <p>2 BY THE WITNESS:</p> <p>3 A. It would.</p> <p>4 BY MR. KAWAMOTO:</p> <p>5 Q. And so when you say your re -- one of your</p> <p>6 responsibilities was to prevent diversion, it was to</p> <p>7 prevent the pill mills from getting your product?</p> <p>8 MR. O'CONNOR: Objection.</p> <p>9 BY MR. KAWAMOTO:</p> <p>10 Q. Fair?</p> <p>11 A. No, not fair.</p> <p>12 We are the manufacturer. The distributor</p> <p>13 has a responsibility to know who their customers are</p> <p>14 and where those pills are going. So do -- do we have</p> <p>15 a responsibility to monitor our distributors, yes.</p> <p>16 And we were auditing those distributors just as you've</p> <p>17 discussed with Masters and the other one that you</p> <p>18 said. So we were monitoring those people to make a</p> <p>19 determination if they were doing due diligence on</p> <p>20 their employees, but you can't take that information</p> <p>21 and bring it all of the way back to the manufacturer.</p> <p>22 You have to go back through DEA in the quota that they</p> <p>23 allot to each of the manufacturers. We were not by</p> <p>24 any stretch the only manufacturer of oxy. There is</p>	<p style="text-align: right;">Page 56</p> <p>1 Let me just say one other thing. We asked</p> <p>2 DEA for assistance time and time again. They were --</p> <p>3 they were silent. They gave us -- they said it's your</p> <p>4 responsibility. Yeah, but could you just give us a</p> <p>5 hint about what you would like to see. And they just</p> <p>6 couldn't seem to come up with anything. They said</p> <p>7 it's not their responsibility. To me it is their</p> <p>8 responsibility. They are the regulatory agency and</p> <p>9 they are trying to say, no, this is all our</p> <p>10 customers -- all of the registrants' issues, and they</p> <p>11 should have been at least somewhat helpful and they</p> <p>12 weren't.</p> <p>13 Q. But at some point in time they did</p> <p>14 indicate to you that you should know your customers's</p> <p>15 customer, right?</p> <p>16 A. Exactly, yes, they did.</p> <p>17 Q. And at that point would you agree that you</p> <p>18 had an obligation to know your customer's customer?</p> <p>19 MR. O'CONNOR: Objection.</p> <p>20 BY THE WITNESS:</p> <p>21 A. At that time we started identifying our</p> <p>22 customers' customers.</p> <p>23 BY MR. KAWAMOTO:</p> <p>24 Q. Because DEA indicated that you had that</p>
<p style="text-align: right;">Page 55</p> <p>1 OxyContin, oxycodone, other products manufactured. So</p> <p>2 you're trying to make a leap that's not necessarily in</p> <p>3 my opinion appropriate.</p> <p>4 Q. But you had a responsibility to know your</p> <p>5 customers' customers, did you not?</p> <p>6 MR. O'CONNOR: Objection.</p> <p>7 BY THE WITNESS:</p> <p>8 A. At a certain point in time we were told we</p> <p>9 should know our customer's customer, and that came</p> <p>10 secondhand out of a meeting in DEA. At that time we</p> <p>11 didn't know how we would even make that determination,</p> <p>12 how we would even determine who our customers'</p> <p>13 customers were. And at -- at some point we made</p> <p>14 the -- we developed information that we had a system</p> <p>15 called chargebacks, and if you want me to explain</p> <p>16 that, I can't, but I know that we had a system so we</p> <p>17 had information on our distributors' customers.</p> <p>18 Once we had that information, that's when</p> <p>19 we started with the forms, sending those out to the</p> <p>20 distributors trying to determine if they had done due</p> <p>21 diligence with all of their customers. They weren't</p> <p>22 our customers. They were our customers' customers.</p> <p>23 So we didn't have that responsibility from ad</p> <p>24 infinitum. It was at a certain point.</p>	<p style="text-align: right;">Page 57</p> <p>1 responsibility, yes?</p> <p>2 MR. O'CONNOR: Objection.</p> <p>3 BY THE WITNESS:</p> <p>4 A. They didn't ever say, You have that</p> <p>5 responsibility. It came from a conference in DC</p> <p>6 with -- with the compliance group and that term at</p> <p>7 some point came up. And so it drifted back through</p> <p>8 the grapevine, for lack of a better way to say it,</p> <p>9 that they were talking about having their -- their</p> <p>10 registrants know their customer's customer.</p> <p>11 And basically at that time we had never</p> <p>12 heard that term. DEA had never come to us personally</p> <p>13 and said, You need to know your customer's customer.</p> <p>14 So -- and by the time DEA actually told us that, it</p> <p>15 was late in -- in 2011. It was the same date they had</p> <p>16 the -- the earthquake in Washington, D.C. And we felt</p> <p>17 it. Because they said, You need to know your</p> <p>18 customer's customer.</p> <p>19 And the very next week I was on a plane to</p> <p>20 Florida because they said, You need to do this. That</p> <p>21 was really the first time they ever told us that we</p> <p>22 needed to do that. We had a good program, we did the</p> <p>23 very best we could to prevent diversion, and once they</p> <p>24 said, You need to do this, we did it. We did it</p>

<p style="text-align: right;">Page 58</p> <p>1 immediately.</p> <p>2 And for -- furthermore, not only did we do</p> <p>3 that, we started cancelling a lot of these. We were</p> <p>4 going back to our distributors and telling them, We</p> <p>5 are not going to -- to sell products to you that you</p> <p>6 sell to these particular pharmacies. And so it</p> <p>7 worked.</p> <p>8 BY MR. KAWAMOTO:</p> <p>9 Q. So you indicated that, I think you just</p> <p>10 said: "We were going back to our distributors and</p> <p>11 telling them that we are not going to sell products to</p> <p>12 you that sell" -- "that you sell to these particular</p> <p>13 pharmacies"?</p> <p>14 MR. O'CONNOR: Objection.</p> <p>15 BY THE WITNESS:</p> <p>16 A. That's correct.</p> <p>17 BY MR. KAWAMOTO:</p> <p>18 Q. So shouldn't the distributors have done</p> <p>19 that on their own?</p> <p>20 MS. KVESELIS: Object to the form.</p> <p>21 MR. O'CONNOR: Objection.</p> <p>22 BY THE WITNESS:</p> <p>23 A. Yeah, yes.</p> <p>24 BY MR. KAWAMOTO:</p>	<p style="text-align: right;">Page 60</p> <p>1 of those pharmacies because we felt very strongly that</p> <p>2 they were selling products they shouldn't of.</p> <p>3 Q. And do you recall what -- what the case</p> <p>4 was that you testified on behalf of the DEA in?</p> <p>5 A. Gulf Coast Pharmacy, I believe. That's</p> <p>6 been a long time also.</p> <p>7 Q. And you say you visited a total of 30</p> <p>8 pharmacies, is that right?</p> <p>9 MR. O'CONNOR: Objection.</p> <p>10 BY MR. KAWAMOTO:</p> <p>11 Q. To the best of your recollection?</p> <p>12 A. Not by --</p> <p>13 Q. But you and -- you and --</p> <p>14 A. There were two.</p> <p>15 Q. -- two other forensic officers from --</p> <p>16 A. From Covidien, not from Mallinckrodt, but</p> <p>17 from the corporation.</p> <p>18 Q. Okay.</p> <p>19 A. They did the -- the others, and I can't</p> <p>20 recall exactly what the -- the separation was, but we</p> <p>21 covered all of those 30 pharmacies.</p> <p>22 Q. And with respect to those 30 pharmacies,</p> <p>23 do you have a rough estimate from how many you decided</p> <p>24 should not be receiving Mallinckrodt products?</p>
<p style="text-align: right;">Page 59</p> <p>1 Q. And do you recall how many distributors</p> <p>2 you went to to tell them: We are no longer going to</p> <p>3 essentially -- well, strike that.</p> <p>4 Do you recall how many distributors you</p> <p>5 went to and told them, You need to cut off these</p> <p>6 customers?</p> <p>7 A. We took --</p> <p>8 MS. KVESELIS: Object to form.</p> <p>9 BY THE WITNESS:</p> <p>10 A. We took the top three, McKesson, Cardinal,</p> <p>11 and AmerisourceBergen, and we looked at their top ten</p> <p>12 pharmacies in Florida. So that was -- there was --</p> <p>13 were a total of 30 pharmacies. They were the ones</p> <p>14 that purchased the most of the oxycodone 30s through</p> <p>15 their distributors. And so when we identified</p> <p>16 those -- and as I said, when DEA told us that, the</p> <p>17 very next -- next week I was in Florida. And I had --</p> <p>18 I caused two of our forensic auditors to cover the</p> <p>19 east side of the state, because they had Spanish</p> <p>20 speaking ability, and I covered the west side of the</p> <p>21 state. And I went into a number of these pharmacies</p> <p>22 to try to determine exactly what DEA had said, know</p> <p>23 your customer's customer. In fact, I had testified in</p> <p>24 the Fort Myers, Florida on behalf of DEA against one</p>	<p style="text-align: right;">Page 61</p> <p>1 A. I don't know. Some of them were</p> <p>2 absolutely legitimate pharmacies. You walk in and</p> <p>3 they look like a Walgreens. And they have all of the</p> <p>4 products out there. You talk to the pharmacist and</p> <p>5 she is very aware of issues in Florida and, you know,</p> <p>6 they would tell me what they were doing to prevent.</p> <p>7 They looked at the -- the scripts written by the</p> <p>8 doctors to make sure that they were consistent, and</p> <p>9 sometimes they would contact the doctors. Others were</p> <p>10 literally pill mills where they -- they had to buzz</p> <p>11 you in at the door and they had stanchions and they</p> <p>12 had a sign "Mallinckrodt Cash Only." To me that's a</p> <p>13 pill mill.</p> <p>14 Q. Is it fair to say it's not that difficult</p> <p>15 to identify a pill mill if someone has your</p> <p>16 experience?</p> <p>17 MR. O'CONNOR: Objection.</p> <p>18 BY THE WITNESS:</p> <p>19 A. I don't think that's fair. There are so</p> <p>20 many variables. You -- you know, for me, you know, I</p> <p>21 spent years in law enforcement. I can look at a</p> <p>22 situation much differently than one that's never been</p> <p>23 in law enforcement. I mean, I look at the people that</p> <p>24 are in and around the pharmacy and if they look like</p>

<p style="text-align: right;">Page 62</p> <p>1 they are legitimate pain patients, are -- you know, 2 are there some elderly people on walkers, are there -- 3 you just need information to be able to make that 4 assessment. You can't make a blanket assessment, 5 especially without a, in my opinion, a law enforcement 6 background. 7 BY MR. KAWAMOTO: 8 Q. And so when you visit a pharmacy to 9 evaluate whether it's a pill mill or not, can you list 10 for me the things that you look for? 11 A. One of the things you look for, like I 12 stated before, is do you have to be buzzed into the 13 pharmacy. So they look at you and they have to push a 14 buzzer to let you in. Very little product on the 15 shelf. A sign such as "Mallinckrodt products left 16 side, cash only, no insurance." 17 Q. And these would -- these would all be 18 indicators that it's a pill mill? 19 A. Absolutely. 20 Q. And what else? 21 A. No product on the shelf, just strictly 22 filling prescriptions in large numbers of -- of oxy 30 23 going into that and being prescribed. So that's 24 certainly information that you -- you would want</p>	<p style="text-align: right;">Page 64</p> <p>1 the parking lot, and do they see me and recognize a 2 law enforcement person or a former law enforcement 3 person who is watching them. So if they got up and 4 ran, that's a sign. 5 BY MR. KAWAMOTO: 6 Q. Do you look for out of plate license -- 7 I'm sorry. 8 Do you look for out-of-state license 9 plates? 10 A. Yes. 11 Q. Why? 12 A. Well, I'll give you a specific. In 13 Las Vegas there were out-of-state license plates all 14 over, a very large pharmacy, people in the -- in the 15 room, there were slot machines, they were dozing off, 16 appeared to -- again, with my law enforcement 17 experience, they appeared to be on some kind of 18 narcotic. And when they are selling large amounts 19 of -- of that product to people from out of state, you 20 know, that's a sign. 21 MR. O'CONNOR: Counsel, we have been going about 22 an hour. Should we take a break? 23 MR. KAWAMOTO: Sure. Why don't -- why don't we 24 take a break then.</p>
<p style="text-align: right;">Page 63</p> <p>1 more -- to make a proper assessment you need as much 2 information as possible. But those are things that I 3 would look for when trying to make an assessment. 4 Q. Do you also look at the clientele of the 5 pill mill? 6 A. No. 7 MR. O'CONNOR: Objection. 8 BY THE WITNESS: 9 A. There is no way to do that. 10 BY MR. KAWAMOTO: 11 Q. But you can see who is going in and out of 12 the pharmacy? 13 A. I can, yeah, physically see who is coming 14 and going depending on the length of time. That would 15 be, as I said before, do they have elderly people, do 16 they have walkers, are they all young people. 17 Q. And if they are all young people, is that 18 a warning sign? 19 A. Well -- 20 MR. O'CONNOR: Objection. 21 BY THE WITNESS: 22 A. -- there are additional warning signs. Do 23 they have what we call meth mouth, which is bad teeth, 24 are they sitting down or kneeling down besides cars in</p>	<p style="text-align: right;">Page 65</p> <p>1 THE VIDEOGRAPHER: We are going off the record 2 at 10:41. 3 (WHEREUPON, a recess was had 4 from 10:41 to 10:53 a.m.) 5 THE VIDEOGRAPHER: We are back on the record at 6 10:53. 7 BY MR. KAWAMOTO: 8 Q. So, Mr. Ratliff, as you've noted on 9 several occasions, I am asking you questions about 10 events that have occurred, you know, some years in the 11 past, and I understand that. So I think what it makes 12 sense to do is I'm going to start showing you 13 documents that I think will help refresh your memory. 14 You should review as much of the document 15 as you need to be comfortable, but as some of these 16 are, you know, several pages, I will probably -- well, 17 I will direct you to certain portions that I am 18 interested in. And, you know, as I said, you 19 should -- you should review as much of the document as 20 you feel is appropriate. 21 So why don't we start with what I believe 22 is going to be Exhibit 3. And I think the -- let's 23 see. 24 (WHEREUPON, a certain document was</p>

<p style="text-align: right;">Page 66</p> <p>1 marked Mallinckrodt-Ratliff 2 Deposition Exhibit No. 003, for 3 identification, as of 12/19/2018.) 4 BY MR. KAWAMOTO: 5 Q. And so I've handed you a document that's 6 Bates numbered 388159, and it's a Mallinckrodt -- 7 Mallinckrodt PowerPoint presentation. It's an 8 Overview Presentation for New Employee Orientation. 9 Do you recall this PowerPoint? 10 A. Yes. 11 Q. And what do you recall about it? Well, 12 strike that. 13 Who did -- did you deliver this 14 PowerPoint? Did you -- is this your PowerPoint 15 presentation? 16 MR. O'CONNOR: Objection. 17 BY THE WITNESS: 18 A. Normally it was delivered by Karen Harper. 19 BY MR. KAWAMOTO: 20 Q. But you were involved in preparing it, 21 were you not? 22 A. Yes. 23 Q. And so it's several pages. I would like 24 to focus your attention on the two org charts that are</p>	<p style="text-align: right;">Page 68</p> <p>1 BY THE WITNESS: 2 A. Normally e-mails, occasional conversations 3 on the phone, occasional in-person meetings. 4 BY MR. KAWAMOTO: 5 Q. And who is Jim O'Connor? 6 A. He is a securities supervisor in 7 St. Louis. 8 Q. And it's -- do you see where it says 9 "Security Officers"? 10 A. Yes. 11 Q. Who are those or what are those? 12 A. They are -- there were 14 officers that 13 were all trained and duly -- in the law enforcement 14 academy, former police officers, and they were charged 15 with securing our facility there in St. Louis where we 16 manufactured products. 17 Q. And so we are talking physical security, 18 is that correct? 19 A. Yes. 20 Q. And then there are a number of people that 21 are reporting to Jim O'Connor that are security 22 monitors. 23 Do you see that? 24 A. Yes.</p>
<p style="text-align: right;">Page 67</p> <p>1 on Pages 3 and 4 of the PowerPoint. 2 A. Okay. 3 Q. So the first is the power -- is an org 4 chart for the Security Group Organization. 5 A. Yes. 6 Q. Is that your organization? Or is that -- 7 is that the organization you were working in, the 8 department you were -- you were working in? 9 MR. O'CONNOR: Objection. 10 BY THE WITNESS: 11 A. Yes. 12 BY MR. KAWAMOTO: 13 Q. And then if you put this up there, you'll 14 see your name Corporate Security Director for 15 Covidien? 16 A. Um-hum. 17 Q. Who is John Griffin? 18 A. Deputy legal counsel for Covidien. 19 Q. And did you report directly to him? 20 A. I did. 21 Q. And how -- what was the nature of your 22 communication? Did you provide monthly reports, or 23 how did you communicate? 24 MR. O'CONNOR: Objection.</p>	<p style="text-align: right;">Page 69</p> <p>1 Q. What is a security monitor? 2 A. Each building where narcotics are 3 manufactured has a monitor. So anyone -- anyone 4 coming or going has to open their lunch box, their -- 5 they have to show them their coat, they have to 6 basically take their hat off, pockets, pull their 7 pockets out, everything, to ensure they are not 8 diverting product. 9 Q. Okay. And then if you turn the page over, 10 it's going to be another org chart. It's a Controlled 11 Substance Compliance Group Organization. 12 A. Um-hum. 13 Q. So who is Karen Harper? 14 A. Karen Harper is the DEA compliance 15 manager. 16 Q. And what did she do? 17 A. She was responsible for quota for all of 18 the employees that controlled the quota in the 19 manufacturing. Also she was responsible for 20 communicating with DEA, any discrepancies or -- she 21 just -- she had a -- a wide range of responsibilities. 22 Q. And who was responsible for the suspicious 23 order monitoring program? 24 A. Karen.</p>

Page 70

1 Q. Were you involved in that as well?

2 A. I assisted her, yes.

3 Q. And what were your responsibilities with

4 respect to the SOM program?

5 A. Well, to assist as necessary.

6 Q. So did you have sort of defined tasks that

7 you were responsible for or was it primarily whatever

8 Karen asked you to help her with?

9 MR. O'CONNOR: Objection.

10 BY THE WITNESS:

11 A. Primarily whatever Karen asked me to

12 assist her with. Occasionally I did, I went to audits

13 when I was available, and I helped coordinate contact

14 with DEA, the local DEA in St. Louis, so.

15 BY MR. KAWAMOTO:

16 Q. Were you involved in reviewing the

17 policies that -- well, strike that.

18 Were you involved in reviewing or revising

19 suspicious order monitoring -- suspicious order

20 monitoring program policies?

21 A. Karen Harper wrote the program, but I

22 assisted in the process.

23 Q. And who is JoAnne Levy or JoAnne Levy?

24 A. VP of pharmaceutical logistics.

Page 71

1 Q. And what -- what did she do, what were her

2 responsibilities?

3 A. That's outside my purview.

4 Q. So I take it you didn't work directly with

5 her?

6 A. No.

7 Q. What about Eileen Spaulding, what did she

8 do?

9 A. She worked for Karen Harper in Hobart,

10 New York.

11 Q. And was Hobart your primary -- well, I'm

12 sorry. Strike that.

13 What was the -- what did the -- what

14 function did the Hobart facility fulfill?

15 MR. O'CONNOR: Objection.

16 BY THE WITNESS:

17 A. They took the raw product and made tablet

18 form and other products. So it wasn't all just

19 tablets.

20 BY MR. KAWAMOTO:

21 Q. And do you know who Carrie Johnson was?

22 A. Not necessarily.

23 Q. What about Mar- -- what about Mary Lewis?

24 A. Mary Lewis worked in St. Louis and worked

Page 72

1 for Karen and she also worked at Webster Groves. We

2 had a facility there with our -- they were developing

3 new products and so forth, so she helped with the

4 coordination there.

5 Q. And I'm sorry. What was -- what function

6 did the Webster Groves facility play?

7 A. They were research and development.

8 Q. And do you know who Lee Nelson is?

9 A. I did. He is now deceased.

10 Q. What were his responsibilities?

11 A. He monitored quota.

12 Q. And what about Wender -- Wendy Slaby or

13 Slaby?

14 A. She worked for Karen.

15 Q. And what about Christine Greg -- I'm

16 sorry -- Christine -- Christie Kegg?

17 A. She worked for Karen.

18 Q. But other than working for Karen, you

19 don't know what their responsibilities were?

20 A. I don't.

21 Q. And I take it you didn't work with either

22 one of them?

23 A. Well, they were in close proximity to my

24 office, but I didn't work specifically or -- with

Page 73

1 them.

2 Q. You can put that aside.

3 Okay. So I'm going to give you another

4 PowerPoint marked Exhibit 4.

5 (WHEREUPON, a certain document was

6 marked Mallinckrodt-Ratliff

7 Deposition Exhibit No. 004, for

8 identification, as of 12/19/2018.)

9 BY MR. KAWAMOTO:

10 Q. And for this PowerPoint I'd like to direct

11 your attention to Page 4 of it which has another

12 organizational chart.

13 A. Okay.

14 Q. Now, Mallinckrodt had a suspicious order

15 monitoring program, did it not?

16 A. Yes.

17 Q. And it was required to have this program

18 by the applicable law and DEA regulations, is that

19 correct?

20 MR. O'CONNOR: Objection.

21 BY THE WITNESS:

22 A. Yes.

23 BY MR. KAWAMOTO:

24 Q. Can you look at this org chart and

Page 74

1 identify for me all of the people that you believe
2 were involved in that suspicious order monitoring
3 program?
4 A. Could you be more specific?
5 Q. Well, there is a suspicious order
6 monitoring program, and I'm -- I would like to figure
7 out what employees were involved in implementing
8 that -- well, either designing or implementing that
9 program?
10 MR. O'CONNOR: Objection.
11 BY THE WITNESS:
12 A. Well, I would say Karen Harper
13 specifically, but everyone on this page had some
14 responsibility. They were our logistics, they were
15 our transportation, moving product from one place to
16 another. So they are all responsible to prevent
17 diversion.
18 BY MR. KAWAMOTO:
19 Q. Well, so, do you see Michael Pheneu?
20 A. I do.
21 Q. What were his diversion control
22 responsibilities?
23 MR. O'CONNOR: Objection.
24 BY THE WITNESS:

Page 75

1 A. He didn't work for me. I know who Michael
2 is. I know he controlled transportation of products.
3 Beyond that, I really don't know what his
4 responsibilities are.
5 BY MR. KAWAMOTO:
6 Q. Well, how about Jim Rausch, do you see his
7 name? He is underneath Michael.
8 A. You are asking me questions about long ago
9 and employees that weren't employed by me or I didn't
10 work with on a daily basis or even sometimes didn't
11 see for long periods of time.
12 Q. Well, why don't we do this --
13 A. These were headquarters in Hazelwood and I
14 was at the St. Louis plant. The times I was at
15 Hazelwood was -- they were brief and it was for a
16 specific meeting.
17 Q. So what individuals on this org chart did
18 you work with the in the context of the suspicious
19 order monitoring program?
20 A. Karen Harper.
21 Q. Anyone else?
22 A. And her team. I mean, they were right
23 around the corner from my office. So if there was
24 some questions, I could talk to them, but normally I

Page 76

1 did everything through Karen.
2 Q. So do you -- you don't recall ever working
3 with Jim Rausch?
4 A. If you are asking have I ever been in a
5 meeting with Jim Rausch, probably.
6 Q. Or communicated with him via e-mail?
7 A. Probably, but I can't tell you
8 specifically all of these years later if that's a
9 fact.
10 Q. What about Cathy Stewart, do you recall
11 working with her?
12 A. I know Cathy Stewart because her husband
13 is a security officer.
14 Q. But other than through her husband, do you
15 recall working with Cathy Stewart in the context of
16 the suspicious order monitoring program?
17 A. Not specifically.
18 If you have documents that you can refresh
19 my memory, I'd be happy to review them.
20 Q. Okay. Well, yeah, why don't -- why don't
21 we do that then.
22 MR. KAWAMOTO: I'd like to mark this as exhibit,
23 I believe it's five.
24 (WHEREUPON, a certain document was

Page 77

1 marked Mallinckrodt-Ratliff
2 Deposition Exhibit No. 005, for
3 identification, as of 12/19/2018.)
4 BY MR. KAWAMOTO:
5 Q. So, this is an e-mail and an attachment
6 with the Bates No. 448772, and the title of the
7 attachment is the: "Oxycodone Extended Release
8 RiskMAC" -- "RiskMAP Action Plan."
9 A. Okay.
10 Q. Are you familiar with this RiskMAP action
11 plan?
12 A. I don't recall it.
13 Q. If you could turn to Page 3 of the
14 attachment. It says "Supplay" -- "Supply Chain &
15 Security."
16 And do you see your name identified for a
17 number of these -- of these rows?
18 A. Yes.
19 Q. So the first row is: "Provide
20 notification to DEA of any confirmed diversion."
21 A. Um-hum.
22 Q. Can you explain what -- what does that
23 mean?
24 A. If we have a diversion, they should tell

<p style="text-align: right;">Page 78</p> <p>1 me.</p> <p>2 Q. And I'm sorry. Who should tell you?</p> <p>3 A. The person that discovers the diversion or</p> <p>4 whoever is in charge of that particular event.</p> <p>5 Q. And then you would then report that to</p> <p>6 DEA?</p> <p>7 A. Unless there was an investigation that was</p> <p>8 necessary, and then we would perform an investigation</p> <p>9 to try to determine what happened in that specific</p> <p>10 incident, and then we would report it to DEA.</p> <p>11 Q. Do you recall any specific incidents of</p> <p>12 diversion while you were the security director?</p> <p>13 A. I'm certain there were some diversions,</p> <p>14 but specifically, no. I know that -- that DEA -- or</p> <p>15 not DEA -- Hobart had several diversions. And I know</p> <p>16 they worked closely with DEA and the state police on</p> <p>17 those. I wasn't responsible for Hobart. They had a</p> <p>18 security manager there, but he would report all of</p> <p>19 that to me so I would be aware of it.</p> <p>20 Q. And the incident -- the incidents that you</p> <p>21 are describing, are they examples -- are they</p> <p>22 essentially examples of theft, someone walks off from</p> <p>23 the facility with -- with bottles of pills?</p> <p>24 A. Normally not bottles. It would be -- it</p>	<p style="text-align: right;">Page 80</p> <p>1 told.</p> <p>2 Q. Now, it says: "Investigate abnormal</p> <p>3 orders."</p> <p>4 What is an abnormal order?</p> <p>5 A. From time to time Karen would be advised</p> <p>6 that a customer had ordered a large amount, much more</p> <p>7 than they had ever ordered in the past, so they would</p> <p>8 automatically give that to Karen to do an</p> <p>9 investigation to say, do you have any idea what's</p> <p>10 going on with this customer, so.</p> <p>11 Q. Are you familiar with the term "peculiar</p> <p>12 order"?</p> <p>13 A. Yes.</p> <p>14 Q. Okay. What --</p> <p>15 A. Peculiar means it was excessive.</p> <p>16 Q. And is there a difference between an</p> <p>17 abnormal order and a peculiar order or are they the</p> <p>18 same?</p> <p>19 MR. O'CONNOR: Objection.</p> <p>20 BY THE WITNESS:</p> <p>21 A. Not in my mind. They are the same.</p> <p>22 BY MR. KAWAMOTO:</p> <p>23 Q. What about a suspicious order?</p> <p>24 MR. O'CONNOR: Objection.</p>
<p style="text-align: right;">Page 79</p> <p>1 would be a few pills, normally.</p> <p>2 Q. The third row says: "Investigate" --</p> <p>3 "Investigate abnormal orders." And it identifies</p> <p>4 Karen Harper and you as the point people.</p> <p>5 What did that entail?</p> <p>6 MR. O'CONNOR: Objection.</p> <p>7 BY THE WITNESS:</p> <p>8 A. That entailed Karen at least advising me</p> <p>9 about it, and she normally handled all of those</p> <p>10 matters. She worked -- there was a time she worked</p> <p>11 for me and then there was a time she apparently worked</p> <p>12 for JoAnne Levy and others, so.</p> <p>13 BY MR. KAWAMOTO:</p> <p>14 Q. And roughly when did she work for you</p> <p>15 from, if you can recall?</p> <p>16 A. I can't recall. I just know that she that</p> <p>17 did work for me from -- for a period of time. That's</p> <p>18 the best I can do.</p> <p>19 Q. And then was she promoted?</p> <p>20 A. They just realigned responsibilities.</p> <p>21 Q. Do you know why they did that?</p> <p>22 A. At the time JoAnne Levy wanted the DEA</p> <p>23 compliance group under the logistics. She thought it</p> <p>24 better fit than with security. That's what I was</p>	<p style="text-align: right;">Page 81</p> <p>1 BY THE WITNESS:</p> <p>2 A. I'm not sure how to define it at this</p> <p>3 point. It's a -- I just -- I don't know that there is</p> <p>4 a difference in those terms.</p> <p>5 BY MR. KAWAMOTO:</p> <p>6 Q. So an abnormal order -- I guess what I'm</p> <p>7 trying to understand is was there a difference with</p> <p>8 respect to Mallinckrodt's terminology between an</p> <p>9 abnormal order and a suspicious order?</p> <p>10 MR. O'CONNOR: Objection.</p> <p>11 BY THE WITNESS:</p> <p>12 A. Not in my mind.</p> <p>13 BY MR. KAWAMOTO:</p> <p>14 Q. Now, can you turn to Page 5 of this</p> <p>15 attachment.</p> <p>16 A. Okay.</p> <p>17 Q. It says "Pharmacovigilance, Surveillance &</p> <p>18 Epidemiology."</p> <p>19 A. Say that again.</p> <p>20 Q. It says "Pharmacovigilance, Surveillance &</p> <p>21 Epidemiology."</p> <p>22 Do you see that?</p> <p>23 A. I do.</p> <p>24 Q. Okay. And the first row references:</p>

<p style="text-align: right;">Page 82</p> <p>1 "Receive, capture, and monitor adverse events." 2 Do you know what an adverse event is? 3 A. Not necessarily. 4 Q. So I take it it wasn't -- you didn't -- 5 you didn't ever identify or report an adverse event? 6 MR. O'CONNOR: Objection. 7 BY THE WITNESS: 8 A. This has been a long time ago. If you had 9 asked me contemporaneous when this was written or -- I 10 would have probably had an answer. Today I would be 11 guessing if I said what that means. You are showing 12 me documents that are -- you know, I haven't thought 13 about in all of these years. And this is the first 14 time I've seen this document today since I probably 15 worked there six-and-a-half years ago or probably 16 years before that. 17 BY MR. KAWAMOTO: 18 Q. Well, and so my question is, as you sit 19 here today, do you have any recollection of what's an 20 adverse -- what an adverse event means? 21 A. No. 22 Q. Okay. Did you ever work with Maria 23 Chianti -- Chianta? 24 A. That name is not familiar. You know, if</p>	<p style="text-align: right;">Page 84</p> <p>1 every line of this document. 2 Q. And then turning to Page 5, I'm just 3 trying to understand what interaction, if any, you had 4 with this group of people and the work they were 5 doing. 6 So this is now "Pharmacovigilance, 7 Surveillance & Epidemiology." 8 Do you see that? 9 A. Okay. 10 Q. Are you familiar with the AERS database, 11 that's A-E-R-S? 12 A. No. Not today I am not, so. 13 Q. And are you familiar with a RiskMAP 14 report? 15 A. It just doesn't ring a bell. 16 Q. Okay. What about one of the rows is: 17 "Monitor longitudinal patient data for patterns of 18 abuse." 19 Was that something you were ever involved 20 in? 21 A. Please repeat. 22 Q. One of the rows indicates: "Monitor 23 longitudinal patient data for patterns of abuse." 24 Was that ever a task that you were</p>
<p style="text-align: right;">Page 83</p> <p>1 you have a document that identifies me working with 2 her, you could show it to me, and I'd be happy to talk 3 about it, but right now I could -- I have no idea who 4 she is. 5 Q. Well, sir, your name appears in this 6 document. Did you -- did you review it? 7 A. Probably at that time I reviewed it. But 8 it's been a great deal of time removed since I would 9 have done this, and maybe I would have reviewed it one 10 time. 11 Q. Well, going back to the supply chain and 12 security, are -- are these tasks and responsibilities 13 accurate? 14 MR. O'CONNOR: Objection. 15 BY THE WITNESS: 16 A. Are you talking about everything written 17 here? 18 BY MR. KAWAMOTO: 19 Q. No. I'm talking about the ones that 20 reference you. 21 A. Without going through every line of 22 everything, I would think that if it's written like 23 this, it would probably be accurate, but I can't make 24 that statement today because, you know, I haven't read</p>	<p style="text-align: right;">Page 85</p> <p>1 involved in? 2 A. I don't think so. 3 Q. The next task is: "Issue 15-day alert 4 report involving Oxycodone ER regardless of the 5 outcome the following: All medication errors 6 involving breaking, chewing, crushing, accidental 7 overdoses, adverse events in children under 18." 8 Is that a responsibility that you were 9 ever involved in or a task that you were ever involved 10 in? 11 A. No. 12 Are these employees of Mallinckrodt? 13 Q. To be honest, sir, I don't know. I'm just 14 reading them off of this. 15 A. Yeah, well, the reason is I don't know who 16 these people are and I don't know that I have ever 17 heard their names. So I was just wondering if you are 18 asking me questions about people that weren't even 19 with Mallinckrodt, so. 20 Q. Well, and you don't have -- so you don't 21 have any familiarity with the RiskMAP action plan? 22 A. To the best of my knowledge, no. 23 Q. So you don't know if this was prepared 24 specific -- strike that.</p>

<p style="text-align: right;">Page 86</p> <p>1 You don't know if this was prepared</p> <p>2 specifically for oxycodone or whether this was</p> <p>3 prepared for all of their products?</p> <p>4 A. I have no way -- no way to know that.</p> <p>5 Q. The e-mail is from Kimberly France to Kate</p> <p>6 Muhlenkamp.</p> <p>7 Do you know who Kimberly France is?</p> <p>8 A. No.</p> <p>9 Q. What about Kate Muhlenkamp?</p> <p>10 A. I don't. I don't think so.</p> <p>11 MR. KAWAMOTO: So this is Exhibit 6. Thank you.</p> <p>12 (WHEREUPON, a certain document was</p> <p>13 marked Mallinckrodt-Ratliff</p> <p>14 Deposition Exhibit No. 006, for</p> <p>15 identification, as of 12/19/2018.)</p> <p>16 BY MR. KAWAMOTO:</p> <p>17 Q. So, Mr. Ratliff, I have handed you</p> <p>18 Exhibit 6, which is another PowerPoint. It is Bates</p> <p>19 No. 277066.</p> <p>20 A. Um-hum, yes.</p> <p>21 Q. And it is the: "Mallinckrodt Controlled</p> <p>22 Substance Suspicious Order Monitoring Program,</p> <p>23 Introductory Training for Field Sales."</p> <p>24 Are you familiar with this PowerPoint?</p>	<p style="text-align: right;">Page 88</p> <p>1 Order Monitoring Procedure Team."</p> <p>2 Do you see that?</p> <p>3 A. Yes.</p> <p>4 Q. And it identifies you as a member of this</p> <p>5 team. Is that accurate?</p> <p>6 A. Yes.</p> <p>7 Q. Okay. And so -- well, strike that.</p> <p>8 Do you recall when this team was formed?</p> <p>9 A. I don't recall the team specifically. My</p> <p>10 name was used in instances such as this because I</p> <p>11 should be involved if there is a problem. So, was I</p> <p>12 on the team, probably. Did they meet, I couldn't tell</p> <p>13 you that today at all.</p> <p>14 Q. Well, do you recall being involved in a</p> <p>15 suspicious order monitoring team while you were at</p> <p>16 Mallinckrodt?</p> <p>17 A. No.</p> <p>18 Q. So you don't recall -- well, you've</p> <p>19 indicated that you didn't work directly with JoAnne</p> <p>20 Levy.</p> <p>21 Do you recall working with John Adams?</p> <p>22 A. I don't know who he is.</p> <p>23 Q. Okay. And we've -- you don't know who</p> <p>24 Kimberly France is. You know Karen Harper.</p>
<p style="text-align: right;">Page 87</p> <p>1 A. This is 2008, ten years ago. I know that</p> <p>2 we had PowerPoints such as this. I can't recall this</p> <p>3 specifically.</p> <p>4 Q. But would you have helped prepare this</p> <p>5 type of a PowerPoint?</p> <p>6 MR. O'CONNOR: Objection.</p> <p>7 BY THE WITNESS:</p> <p>8 A. If I can't remember it, I can't tell you</p> <p>9 if I helped prepare it. I don't -- it doesn't seem --</p> <p>10 I don't know. I don't think so, but...</p> <p>11 BY MR. KAWAMOTO:</p> <p>12 Q. Would you have ever delivered this type of</p> <p>13 a PowerPoint?</p> <p>14 A. Normally not.</p> <p>15 MR. O'CONNOR: Objection.</p> <p>16 THE WITNESS: Sorry.</p> <p>17 BY THE WITNESS:</p> <p>18 A. Normally not.</p> <p>19 BY MR. KAWAMOTO:</p> <p>20 Q. So directing your attention to Page 3.</p> <p>21 A. What page?</p> <p>22 Q. Page 3 of the PowerPoint.</p> <p>23 A. Okay.</p> <p>24 Q. So it says: "Mallinckrodt Suspicious</p>	<p style="text-align: right;">Page 89</p> <p>1 A. I do.</p> <p>2 Q. You don't know Michael Pheney, is that --</p> <p>3 A. I do know who Michael Pheney is.</p> <p>4 Q. Okay. But you don't recall working with</p> <p>5 him?</p> <p>6 A. He was not a direct report to me. Did we</p> <p>7 know one another, yes.</p> <p>8 Q. Well, my question is a little more</p> <p>9 specific, sir. I'm talking about in the context of</p> <p>10 the suspicious order monitoring program for</p> <p>11 Mallinckrodt, do you recall working with Mr. Pheney?</p> <p>12 A. I can say with some reasonable memory that</p> <p>13 there may have been occasions where he and I discussed</p> <p>14 something about transportation, so, but this is I</p> <p>15 think eight -- about eight years ago -- or ten years</p> <p>16 ago.</p> <p>17 Q. And we've already -- I think we've already</p> <p>18 gone over Mr. Rausch. And you don't recall working</p> <p>19 with him in the context of the SOM program, is that</p> <p>20 fair?</p> <p>21 A. I know who he is.</p> <p>22 Q. Okay. Cathy Stewart you only know because</p> <p>23 her husband was a security officer, is that right?</p> <p>24 MR. O'CONNOR: Objection.</p>

<p style="text-align: right;">Page 90</p> <p>1 BY THE WITNESS:</p> <p>2 A. I know that Cathy and Karen had</p> <p>3 interaction.</p> <p>4 BY MR. KAWAMOTO:</p> <p>5 Q. And did those interactions involve you,</p> <p>6 though?</p> <p>7 A. Normally not.</p> <p>8 Q. What about Susan Marlatt?</p> <p>9 A. I can't remember her at all.</p> <p>10 Q. And for the team advisors, do you know</p> <p>11 what role they played -- well, strike that.</p> <p>12 Do you recall ever interacting with Jerry</p> <p>13 Moss in the context of this SOM program?</p> <p>14 A. I don't recall that today.</p> <p>15 Q. What about Jason Jones?</p> <p>16 A. I don't know who that is.</p> <p>17 Q. Jeff Burd?</p> <p>18 A. It means nothing.</p> <p>19 Q. Bob Lesnak?</p> <p>20 A. I don't know that I ever worked directly</p> <p>21 with him. I mean, I'd say no because I just can't</p> <p>22 recall.</p> <p>23 Q. Okay. And we've covered Eileen Spaulding,</p> <p>24 right?</p>	<p style="text-align: right;">Page 92</p> <p>1 A. Yes.</p> <p>2 Q. Okay. So according to this PowerPoint,</p> <p>3 DEA regulations "require registrants to design and</p> <p>4 operate a suspicious order identification system."</p> <p>5 Do you agree with this?</p> <p>6 A. Yes.</p> <p>7 Q. And it "requires that registrants report</p> <p>8 suspicious orders to DEA when discovered through</p> <p>9 monitoring."</p> <p>10 Do you agree with that?</p> <p>11 A. I would, yes.</p> <p>12 Q. The "registrant is reminded that their</p> <p>13 responsibility does not end merely with the filing of</p> <p>14 a suspicious order report."</p> <p>15 Do you agree with that?</p> <p>16 A. I do.</p> <p>17 Q. And what -- what do you interpret that to</p> <p>18 mean, that the responsibility does not end merely with</p> <p>19 the filing of a suspicious order report?</p> <p>20 A. It means if there is an investigation</p> <p>21 needed that we conduct the investigation and we</p> <p>22 provide follow-up information.</p> <p>23 Q. So put another way, it is not sufficient</p> <p>24 to simply identify a suspicious order and then ship</p>
<p style="text-align: right;">Page 91</p> <p>1 A. I know who Eileen is. She worked for</p> <p>2 Karen at Hobart.</p> <p>3 Q. So we've got a suspicious order monitoring</p> <p>4 team, but you don't recall whether they had any</p> <p>5 meetings and you don't recall participating in any</p> <p>6 meetings, is that correct?</p> <p>7 MR. O'CONNOR: Objection; form.</p> <p>8 BY THE WITNESS:</p> <p>9 A. I'm saying it was ten years ago and I</p> <p>10 don't recall. That's what I'm saying.</p> <p>11 BY MR. KAWAMOTO:</p> <p>12 Q. But I understand that, sir.</p> <p>13 A. So, so to try to indicate that I never --</p> <p>14 I don't know if I attended meetings or not because I</p> <p>15 don't specifically remember this.</p> <p>16 Q. So, well, do you have any memory of what</p> <p>17 this team was supposed to do?</p> <p>18 A. I have no memory of this at all. There</p> <p>19 were a number of things I was involved in and would</p> <p>20 have met in and so forth ten years ago, but I don't</p> <p>21 recall it. That's the best I can do.</p> <p>22 Q. Okay. So if you turn over the page, it is</p> <p>23 "DEA Policy on Suspicious Orders."</p> <p>24 Do you see that?</p>	<p style="text-align: right;">Page 93</p> <p>1 the order, is that fair?</p> <p>2 MR. O'CONNOR: Objection.</p> <p>3 BY THE WITNESS:</p> <p>4 A. There is a difference in what you are</p> <p>5 saying. You are saying -- repeat what you were</p> <p>6 asking, please.</p> <p>7 BY MR. KAWAMOTO:</p> <p>8 Q. So one of the consequences of this</p> <p>9 requirement is that it would not be adequate to simply</p> <p>10 identify a suspicious order to the DEA and then ship</p> <p>11 that order, is that cor- -- is that fair?</p> <p>12 MR. O'CONNOR: Objection.</p> <p>13 BY THE WITNESS:</p> <p>14 A. If you go on, it says a "registrant must</p> <p>15 conduct an independent analysis of suspicious orders</p> <p>16 prior to completing a sale to determine whether the</p> <p>17 controlled substances are likely to be diverted."</p> <p>18 So to me if you go there, that's -- yes,</p> <p>19 it's true.</p> <p>20 BY MR. KAWAMOTO:</p> <p>21 Q. Okay. And when it says "conduct an</p> <p>22 independent analysis of suspicious orders," what does</p> <p>23 it mean to conduct an independent analysis?</p> <p>24 A. I know that these came to Karen and that</p>

<p style="text-align: right;">Page 94</p> <p>1 there were certain things that she would do. She</p> <p>2 would do certain checks, she would check with DEA, but</p> <p>3 she would also go on the internet and look at the --</p> <p>4 she had the ability to look at the building and to see</p> <p>5 if it was a real site, especially with new orders.</p> <p>6 There were a number of things that she could do to</p> <p>7 fulfill that.</p> <p>8 Q. And did you assist her in this independent</p> <p>9 analysis of suspicious orders?</p> <p>10 A. On occasion.</p> <p>11 Q. And what type of assistance did you</p> <p>12 provide?</p> <p>13 A. Going on the internet and looking up to</p> <p>14 see if it was a legitimate building, that how long had</p> <p>15 they been there and if they owned it or if they</p> <p>16 rented, and if it appeared that they had the, you</p> <p>17 know, the requisite storage facilities and so forth.</p> <p>18 There were other things. I just don't remember what</p> <p>19 they all were, so.</p> <p>20 Q. And Mallinckrodt had these obligations by</p> <p>21 virtue of the fact that it was a registrant under the</p> <p>22 Controlled Substances Act, is that correct?</p> <p>23 MR. O'CONNOR: Objection.</p> <p>24 BY THE WITNESS:</p>	<p style="text-align: right;">Page 96</p> <p>1 one, you know, one product or whatever. So it makes</p> <p>2 it look like a huge number if you look at everyone</p> <p>3 that is registered to do anything, but there are a lot</p> <p>4 of people registered with DEA that don't manufacture</p> <p>5 narcotics. There aren't that many is what I'm saying.</p> <p>6 BY MR. KAWAMOTO:</p> <p>7 Q. And when you say "there aren't that many,"</p> <p>8 what you are saying is there are not -- there are not</p> <p>9 that many registrants, that you think this number</p> <p>10 is --</p> <p>11 A. I'm saying that manufacture pain medicine,</p> <p>12 pain pills, pain products. And I may be wrong. But I</p> <p>13 think that's -- I'm surprised by that number, how</p> <p>14 about that.</p> <p>15 Q. But it's certainly fair to say that DEA</p> <p>16 was re -- was relying on Mallinckrodt to do its part</p> <p>17 to monitor suspicious orders?</p> <p>18 MR. O'CONNOR: Objection.</p> <p>19 BY THE WITNESS:</p> <p>20 A. That's correct.</p> <p>21 BY MR. KAWAMOTO:</p> <p>22 Q. And then if you flip the page to Page 5.</p> <p>23 A. Okay.</p> <p>24 Q. The first bullet point is: "Failure to</p>
<p style="text-align: right;">Page 95</p> <p>1 A. Correct.</p> <p>2 BY MR. KAWAMOTO:</p> <p>3 Q. Now, the bottom bullet point is: "There</p> <p>4 are currently 1,288,992 DEA registrants, DEA must rely</p> <p>5 on the States and individual registrants to monitor."</p> <p>6 Would you agree with that statement?</p> <p>7 A. It was my understanding that they had more</p> <p>8 responsibility than just telling the registrants it's</p> <p>9 their responsibility, especially in '08, so. I don't</p> <p>10 know who wrote this and I'm not -- I just don't know</p> <p>11 who wrote it, so. Am I absolutely clear and believe</p> <p>12 that, not necessarily.</p> <p>13 Q. Well, if there are over a million DEA</p> <p>14 registrants, don't they -- doesn't DEA have to rely on</p> <p>15 these registrants to do their monitoring?</p> <p>16 MR. O'CONNOR: Objection.</p> <p>17 BY MR. KAWAMOTO:</p> <p>18 Q. How else would the system work if that --</p> <p>19 if that wasn't the case?</p> <p>20 MR. O'CONNOR: Objection.</p> <p>21 BY THE WITNESS:</p> <p>22 A. We all have a program in place to do that.</p> <p>23 So the answer is do they rely on us, yes. Some of</p> <p>24 these registrants are little tiny things that have</p>	<p style="text-align: right;">Page 97</p> <p>1 maintain effective div" -- "effective controls against</p> <p>2 diversion is inconsistent with the public interest."</p> <p>3 In other -- in other words, this is simply</p> <p>4 that Mallinckrodt has a duty to maintain effective</p> <p>5 controls against diversion, is that another way of</p> <p>6 saying this?</p> <p>7 MR. O'CONNOR: Objection.</p> <p>8 BY THE WITNESS:</p> <p>9 A. Yes.</p> <p>10 BY MR. KAWAMOTO:</p> <p>11 Q. Now, there is a letter that seems to be</p> <p>12 placed on the side.</p> <p>13 Do you see that? Or it is a picture of a</p> <p>14 letter. Do you see that?</p> <p>15 A. I see there is a letter there.</p> <p>16 Q. Okay. And if you can make out the date,</p> <p>17 it's December 27, 2007?</p> <p>18 A. Yeah, I can't see that good.</p> <p>19 Q. Okay. Is this the 2007 Rannazzisi letter?</p> <p>20 MR. O'CONNOR: Objection.</p> <p>21 BY THE WITNESS:</p> <p>22 A. I have my bifocals and I have my reading</p> <p>23 glasses and I just can't see well enough to verify</p> <p>24 what you were saying.</p>

<p style="text-align: right;">Page 98</p> <p>1 BY MR. KAWAMOTO:</p> <p>2 Q. Fair enough.</p> <p>3 Do you recall Mr. Rannazzisi sending out a</p> <p>4 letter to registrants in 2007?</p> <p>5 A. I don't recall it specifically, no.</p> <p>6 Q. Okay. What about sending out a letter in</p> <p>7 2006?</p> <p>8 A. It's just too long ago.</p> <p>9 Q. Okay. So Page 6 is: "Recent DEA Actions</p> <p>10 Involving Distributors."</p> <p>11 Do you see that?</p> <p>12 A. Yes.</p> <p>13 Q. Did Mallinckrodt follow these DEA actions</p> <p>14 involving their distributors?</p> <p>15 MR. O'CONNOR: Objection.</p> <p>16 BY THE WITNESS:</p> <p>17 A. Yes.</p> <p>18 BY MR. KAWAMOTO:</p> <p>19 Q. Why?</p> <p>20 A. DEA, if they suspended a license, then</p> <p>21 they wouldn't be licensed to have our product.</p> <p>22 Q. Was Mallinckrodt concerned internally</p> <p>23 about the DEA actions involving distributors?</p> <p>24 MR. O'CONNOR: Objection.</p>	<p style="text-align: right;">Page 100</p> <p>1 BY MR. KAWAMOTO:</p> <p>2 Q. Well, underneath the heading it says:</p> <p>3 "DEA suspends licenses of distributors for not</p> <p>4 maintaining effective controls against diversion of</p> <p>5 controlled substances."</p> <p>6 Do you see that?</p> <p>7 A. I see that.</p> <p>8 Q. And do you recall what the DEA's concerns</p> <p>9 were with respect to the failure to maintain effective</p> <p>10 controls for these institutions?</p> <p>11 A. No.</p> <p>12 Q. So, can you turn to Page 8 of this</p> <p>13 PowerPoint?</p> <p>14 A. I can.</p> <p>15 Q. And it says: "Revise Controlled Substance</p> <p>16 Suspicious Order Monitoring Procedure Highlights."</p> <p>17 Do you see that?</p> <p>18 A. Okay.</p> <p>19 Q. Can you review that list for me and let me</p> <p>20 know when you are done?</p> <p>21 A. Okay.</p> <p>22 Q. Is this an accurate description of your</p> <p>23 suspicious order monitoring procedure?</p> <p>24 A. Yes.</p>
<p style="text-align: right;">Page 99</p> <p>1 BY THE WITNESS:</p> <p>2 A. Our customers are the distributors. They</p> <p>3 send it to their distribution centers. So be clear</p> <p>4 about what you are talking about. A distribution</p> <p>5 center is not -- I mean, it's our customer's</p> <p>6 distribution center. So did AmerisourceBergen -- we</p> <p>7 did audits of -- of some of these, I can recall.</p> <p>8 BY MR. KAWAMOTO:</p> <p>9 Q. Well, did the DEA actions involving the</p> <p>10 distributors raise any concerns at Mallinckrodt</p> <p>11 regarding either your SOM -- well, regarding your SOM</p> <p>12 program?</p> <p>13 MR. O'CONNOR: Objection.</p> <p>14 BY THE WITNESS:</p> <p>15 A. No. And the reason is these distributors</p> <p>16 had multiple distribution centers. If they closed</p> <p>17 one, that -- they didn't close all of the distribution</p> <p>18 centers. They closed one. And it may be for whatever</p> <p>19 reason, that they did an audit, they had product</p> <p>20 mis -- you know, inappropriately stored, or it could</p> <p>21 be a number of things. I don't know. But I think</p> <p>22 what you are talking about are distribution centers</p> <p>23 that they utilized to store their product when it went</p> <p>24 out to their customers in those areas.</p>	<p style="text-align: right;">Page 101</p> <p>1 MR. O'CONNOR: Objection.</p> <p>2 BY MR. KAWAMOTO:</p> <p>3 Q. And when was this procedure in effect</p> <p>4 from?</p> <p>5 A. Say again.</p> <p>6 Q. When was this procedure in effect from,</p> <p>7 what time period did it cover, roughly?</p> <p>8 A. Based on the PowerPoint, it would be</p> <p>9 June 5th of 2008.</p> <p>10 Q. And do you know how far back it went?</p> <p>11 A. I don't know.</p> <p>12 Q. Do you recall it changing at some point in</p> <p>13 the future?</p> <p>14 A. I don't recall.</p> <p>15 Q. Now, it says: "Security and DEA</p> <p>16 Compliance will work closely with the Business in</p> <p>17 reviewing peculiar orders and escalation to suspicious</p> <p>18 order status."</p> <p>19 Do you see that?</p> <p>20 A. Yes.</p> <p>21 Q. And security would be you, is that right?</p> <p>22 A. Correct.</p> <p>23 Q. What does it mean for security and DEA</p> <p>24 compliance to work closely with the business? Who is</p>

<p style="text-align: right;">Page 102</p> <p>1 the business?</p> <p>2 A. DEA compliance managed this. If there was</p> <p>3 an issue, she would bring it to my attention, if she</p> <p>4 needed additional assistance or guidance. Who she</p> <p>5 dealt with at this time, I can't remember ten years</p> <p>6 ago. I just -- I can't remember.</p> <p>7 Q. Okay. Though it says security and DEA</p> <p>8 Compliance, so both of you will work closely with the</p> <p>9 business, and so I'm asking from your standpoint as</p> <p>10 the security person --</p> <p>11 A. Yes.</p> <p>12 Q. -- you know, what -- what -- how did you</p> <p>13 work with the business in reviewing peculiar orders</p> <p>14 and the escalation of suspicious orders?</p> <p>15 A. Now, all of this listed above that would</p> <p>16 come to Karen Harper, and if she had an issue with it</p> <p>17 and couldn't resolve it, she would bring it to me.</p> <p>18 Does that help.</p> <p>19 Q. Okay. But my question relates to the</p> <p>20 bottom of the page. And I'm asking, you know, what is</p> <p>21 your understanding of how you were going to work with</p> <p>22 the business in reviewing peculiar orders and the</p> <p>23 escalation to suspicious order status?</p> <p>24 MR. O'CONNOR: Objection.</p>	<p style="text-align: right;">Page 104</p> <p>1 peculiar orders?</p> <p>2 A. There were times that Karen Harper would</p> <p>3 bring something in that she couldn't resolve, and I</p> <p>4 know that I would help her at that time, but I can't</p> <p>5 be more specific than that. I just -- I just know</p> <p>6 that we worked together on things like this.</p> <p>7 Q. Do you recall any instances in which --</p> <p>8 when Harper shared concerns from business managers</p> <p>9 with you regarding suspicious orders?</p> <p>10 MR. O'CONNOR: Objection.</p> <p>11 BY THE WITNESS:</p> <p>12 A. I don't recall.</p> <p>13 BY MR. KAWAMOTO:</p> <p>14 Q. So turning to Page 9.</p> <p>15 A. Okay.</p> <p>16 Q. It is a "Revised Controlled Substance</p> <p>17 Suspicious Order Customer Checklist."</p> <p>18 A. Um-hum.</p> <p>19 Q. Do you have any recollection of a customer</p> <p>20 checklist?</p> <p>21 A. I do.</p> <p>22 Q. And what was -- what was -- who designed</p> <p>23 that checklist?</p> <p>24 A. Karen.</p>
<p style="text-align: right;">Page 103</p> <p>1 BY THE WITNESS:</p> <p>2 A. I simply can't recall.</p> <p>3 BY MR. KAWAMOTO:</p> <p>4 Q. Okay. Now, the second part of that</p> <p>5 phrase, "reviewing peculiar orders and escalation to</p> <p>6 suspicious order status," what -- what does -- what do</p> <p>7 you interpret that to mean?</p> <p>8 A. It has been ten years. I don't recall. I</p> <p>9 just don't remember.</p> <p>10 Q. So one of the items above, it says: "An</p> <p>11 algorithm is customized by customer category, class of</p> <p>12 trade."</p> <p>13 Do you see that?</p> <p>14 A. I see it.</p> <p>15 Q. And do you have any recollection of a --</p> <p>16 of an algorithm being used?</p> <p>17 A. We used algorithms at one point to -- if</p> <p>18 anyone was -- had ordered more of a particular product</p> <p>19 and we sent that to DEA. So, I remember that.</p> <p>20 Q. But you don't recall anything about the</p> <p>21 algorithm, what its components were or anything like</p> <p>22 that?</p> <p>23 A. Ten years, I don't recall.</p> <p>24 Q. Do you recall being asked to review</p>	<p style="text-align: right;">Page 105</p> <p>1 Q. Did you have any input into it?</p> <p>2 A. Karen is pretty -- pretty capable of doing</p> <p>3 things like this. Did I approve it or did I look at</p> <p>4 it, I'm certain that I probably looked at it at some</p> <p>5 point, but did I make additions or deletions, it's</p> <p>6 way -- way too long ago. I don't recall.</p> <p>7 Q. Okay. And underneath it says: "To be</p> <p>8 completed by Field Sales."</p> <p>9 A. Um-hum.</p> <p>10 Q. And it says: "Know your customer is the</p> <p>11 goal."</p> <p>12 Is that accurate?</p> <p>13 A. I would say yes.</p> <p>14 Q. So as of the date -- date of this</p> <p>15 PowerPoint, which is June 5th, 2008, your</p> <p>16 understanding is that there was an obligation for</p> <p>17 Mallinckrodt to know its customer, is that -- is that</p> <p>18 accurate?</p> <p>19 MR. O'CONNOR: Objection.</p> <p>20 BY THE WITNESS:</p> <p>21 A. What we did is we developed a form to give</p> <p>22 us additional information to do that, and that's what</p> <p>23 that form did, it required all kinds of things to be</p> <p>24 filled out to give us additional information, and that</p>

<p style="text-align: right;">Page 106</p> <p>1 was, I think assisted us to know who our customers'</p> <p>2 customers were.</p> <p>3 BY MR. KAWAMOTO:</p> <p>4 Q. And part of this form is a description of</p> <p>5 the neighborhood, requires an on-site visit, physical</p> <p>6 description of a facility or photos, and it includes a</p> <p>7 list of indicators.</p> <p>8 So, are those statements accurate with</p> <p>9 respect to what the information that was being</p> <p>10 collected by this customer checklist?</p> <p>11 MR. O'CONNOR: Objection.</p> <p>12 BY THE WITNESS:</p> <p>13 A. To the best of my memory, yeah.</p> <p>14 BY MR. KAWAMOTO:</p> <p>15 Q. And to be clear, this was an obligation</p> <p>16 that Mallinckrodt believed it had based on the</p> <p>17 applicable law, correct, this wasn't a voluntary</p> <p>18 endeavor?</p> <p>19 MR. O'CONNOR: Objection.</p> <p>20 BY THE WITNESS:</p> <p>21 A. You are wrong. It was a voluntary</p> <p>22 endeavor to know more about those customers, to create</p> <p>23 a better program to comply with the law. So we did</p> <p>24 this -- DEA didn't say, make a form and do this. We</p>	<p style="text-align: right;">Page 108</p> <p>1 factor. We had everything up and you'd like to know</p> <p>2 where it is. Is it a -- is it a legitimate building,</p> <p>3 is it in a hospital complex or in a -- it depends on</p> <p>4 where it is. If it's something that doesn't appear to</p> <p>5 be a legitimate business, that would be of concern to</p> <p>6 us. If it's down an alley in the back of a store,</p> <p>7 that would be a concern for us.</p> <p>8 Q. And the line that says: "Requires on-site</p> <p>9 visit, inside and out," what is that in reference to?</p> <p>10 A. It is to the salespeople signing them up.</p> <p>11 Q. So prior to signing up a -- prior to</p> <p>12 signing up a customer, the salesperson was required to</p> <p>13 conduct an on-site visit?</p> <p>14 MR. O'CONNOR: Objection.</p> <p>15 BY THE WITNESS:</p> <p>16 A. Say that again.</p> <p>17 BY MR. KAWAMOTO:</p> <p>18 Q. Prior to signing someone up, the</p> <p>19 salesperson was required to conduct an on-site visit?</p> <p>20 MR. O'CONNOR: Objection.</p> <p>21 BY THE WITNESS:</p> <p>22 A. Apparently.</p> <p>23 BY MR. KAWAMOTO:</p> <p>24 Q. And the last line is: "Includes a list of</p>
<p style="text-align: right;">Page 107</p> <p>1 did this on our own based on what Karen believed would</p> <p>2 be helpful, so.</p> <p>3 BY MR. KAWAMOTO:</p> <p>4 Q. And what she believed was necessary to</p> <p>5 comply with your requirement or your obligation to</p> <p>6 maintain effective controls against diversion,</p> <p>7 correct?</p> <p>8 A. We were constantly trying to improve.</p> <p>9 Q. And in 2008, one of the ways you</p> <p>10 believed -- well, strike that.</p> <p>11 In 2008, one of the -- one of the factors</p> <p>12 that you believed would help you improve would be</p> <p>13 knowing your customer's customer, is that right?</p> <p>14 A. Yes.</p> <p>15 MR. O'CONNOR: Objection.</p> <p>16 THE WITNESS: Sorry.</p> <p>17 BY MR. KAWAMOTO:</p> <p>18 Q. And why is it important to know the</p> <p>19 description of the neighborhood? I'm still on -- on</p> <p>20 Slide 9 on Page 9.</p> <p>21 A. It is an additional factor.</p> <p>22 Q. But of what significance, why -- why does</p> <p>23 it help you in your analysis?</p> <p>24 A. It is just an -- it is just an additional</p>	<p style="text-align: right;">Page 109</p> <p>1 indicators (watch outs) that require further review by</p> <p>2 Security Director."</p> <p>3 Security director is you, is that right?</p> <p>4 A. Yes.</p> <p>5 Q. Okay. And so what is a list of indicators</p> <p>6 that require further review?</p> <p>7 A. If they sent this to me, I would look at</p> <p>8 it not only from a security director point of view but</p> <p>9 a law enforcement point of view. And we had customers</p> <p>10 in the northeast that didn't appear to be pharmacies</p> <p>11 at all and yet they were trying to buy our product and</p> <p>12 somehow had gotten a registration. So we wanted to</p> <p>13 see exactly where and what the business was. So there</p> <p>14 are a lot of factors that you -- you look at, and</p> <p>15 that's exactly what this is.</p> <p>16 Q. Okay. And you reference pharmacies. So</p> <p>17 we are talking about your customer's customer at this</p> <p>18 point, correct?</p> <p>19 MR. O'CONNOR: Objection.</p> <p>20 BY THE WITNESS:</p> <p>21 A. Our -- the distributors sold to</p> <p>22 pharmacies.</p> <p>23 BY MR. KAWAMOTO:</p> <p>24 Q. And part -- and what these -- what these</p>

<p style="text-align: right;">Page 110</p> <p>1 bullet points are referencing, though, is it's an 2 on-site visit to the pharmacy? 3 A. We were trying to -- 4 MR. O'CONNOR: Objection. 5 BY MR. KAWAMOTO: 6 Q. You can answer. 7 A. We were trying to identify our customers' 8 customers to be more in tune with the program, to 9 improve our program. 10 Q. Okay. Thank you. You can put that aside. 11 MR. KAWAMOTO: So this is now going to be 12 Exhibit 7. 13 (WHEREUPON, a certain document was 14 marked Mallinckrodt-Ratliff 15 Deposition Exhibit No. 007, for 16 identification, as of 12/19/2018.) 17 BY MR. KAWAMOTO: 18 Q. So this is an e-mail marked Bates 19 No. 4211219, and at the very top is an e-mail from 20 Karen Harper to you. 21 Do you recall receiving this e-mail? 22 A. No. 23 Q. But you don't have any doubt that you, in 24 fact, did receive it?</p>	<p style="text-align: right;">Page 112</p> <p>1 trying to make sure we are on the same page. 2 Q. Okay. Well, why -- why don't you review 3 the attachment and then -- 4 A. Okay. But you're not -- 5 Q. -- I'll have questions to you about that? 6 A. You are not saying I ever received it, you 7 are just asking me to review it now? 8 Q. Yes. I'm saying that -- I'm saying that 9 regardless of whether you received it or not, I -- I 10 would like to ask you some questions about this 11 attachment. 12 A. Okay. I've read it. 13 Q. Okay. So I guess my first question to you 14 is prior to -- prior to today, do you recall ever 15 reviewing this letter? 16 A. No. 17 Q. Do you recall ever discussing this letter 18 with anyone? 19 A. Not to my knowledge. 20 Q. Okay. 21 A. This is '06, 2006. 22 Q. Yes. 23 A. Yeah, I don't recall that. 24 Q. Okay. Do you know who Joseph T.</p>
<p style="text-align: right;">Page 111</p> <p>1 A. I don't have any doubt that this was sent. 2 You asked me if I had any -- if I recalled receiving 3 it in 2007, and I don't. 4 Q. Okay. And I'm going to -- my questions 5 primarily relate to the attachment. 6 A. Okay. Are you saying I received this? 7 Q. Yes. This -- the e-mail and the 8 attachment were forwarded to you on December 2007. 9 That's what the top e-mail indicates. And my 10 questions are going to primarily relate to this 11 attachment. 12 A. I'm still having a difficult time figuring 13 out where it says that this was sent to me. 14 Q. Well, the -- the very top e-mail -- 15 A. Yes. 16 Q. -- it's from Karen Harper and then "to", 17 it is to Bill Ratliff. 18 Do you see that? 19 A. Yes. 20 Q. Okay. And it's forwarding an e-mail with 21 an attachment. 22 A. Well, to be clear, E-9 and A-14 are our 23 policies. They have nothing to do with the letters 24 and the things you said are attached. So I'm just</p>	<p style="text-align: right;">Page 113</p> <p>1 Rannazzisi is? 2 A. Yes, I do. 3 Q. Do you know him? 4 A. No. 5 Q. Do you respect his views? 6 A. Not necessarily. 7 Q. Why not? 8 A. I've watched him on 60 Minutes and he was 9 in charge at that time but nes- -- didn't take any 10 necessary action to assist the registrants, and he 11 points fingers at everyone but himself, to be honest. 12 Q. So this letter starts at the beginning: 13 "This letter is being sent to every 14 commercial entity in the United States registered with 15 the Drug Enforcement Administration to distribute 16 controlled substances." 17 So, that would include Mallinckrodt, would 18 it -- would it not? 19 A. If they say "every registrant," the answer 20 is yes. 21 Q. Okay. Now, do you see in the middle of 22 Page 2, and actually let me put this up on the Elmo if 23 it helps you. 24 Okay. So, do you see the sentence that I</p>

<p style="text-align: right;">Page 114</p> <p>1 am highlighting?</p> <p>2 A. Yes.</p> <p>3 Q. Okay. So: "The DEA regulations require</p> <p>4 all distributors to report suspicious orders of</p> <p>5 controlled substances."</p> <p>6 And then underneath it there is the -- it</p> <p>7 is the cite to the reg -- to the regulations. And</p> <p>8 then it says -- can you read that for me, what I'm --</p> <p>9 what I just highlighted?</p> <p>10 A. "The registrant shall design and operate a</p> <p>11 system to disclose to the registrant suspicious orders</p> <p>12 of controlled substances. The registrant shall inform</p> <p>13 the Field Division Office of the Administration in his</p> <p>14 area of suspicious orders when discovered by the</p> <p>15 registrant. Suspicious orders include orders of</p> <p>16 unusual size, orders deviate substantially from a</p> <p>17 normal pattern, and orders of unusual frequency."</p> <p>18 Q. And this obligation applies to</p> <p>19 Mallinckrodt, correct?</p> <p>20 A. It does. It's a statute.</p> <p>21 Q. And do you recall when -- when the statute</p> <p>22 was enacted?</p> <p>23 MR. O'CONNOR: Objection.</p> <p>24 BY THE WITNESS:</p>	<p style="text-align: right;">Page 116</p> <p>1 right underneath or right next to No. 1?</p> <p>2 A. "Ordering excessive quantities of a</p> <p>3 limited variety of controlled substances (e.g.,</p> <p>4 ordering only phentermine, hydrocodone, and</p> <p>5 Alprazolam) while ordering few, if any, other drugs."</p> <p>6 Q. And would you agree that that is a</p> <p>7 circumstance that would raise cause for concern?</p> <p>8 A. I read it.</p> <p>9 Q. Is that a red flag, sir?</p> <p>10 A. I read it, but I don't know what you --</p> <p>11 without additional information, I don't know. I've --</p> <p>12 I've never seen this document before and you are</p> <p>13 asking me to read it into the record and then you are</p> <p>14 asking me questions about is that a red flag and I</p> <p>15 just don't have enough information to say is it or</p> <p>16 isn't it. So, you know, I'm not even sure what two of</p> <p>17 the drugs are.</p> <p>18 Q. Well, let me put it another way.</p> <p>19 The DEA is saying that "ordering excessive</p> <p>20 quantities of a limited variety of controlled</p> <p>21 substances," and then it gives examples of controlled</p> <p>22 substances, "while ordering few, if any, other drugs"</p> <p>23 is a red flag.</p> <p>24 Do you agree with that?</p>
<p style="text-align: right;">Page 115</p> <p>1 A. I have no clue. Title 21 has many, many</p> <p>2 statutes, but it also has many revisions and they are</p> <p>3 all listed in the front of Title 21. So without</p> <p>4 having that information, there would be no information</p> <p>5 for me to know that.</p> <p>6 Q. But whenever the effective date of this</p> <p>7 regulation is, it applies to all registrants,</p> <p>8 including Mallinckrodt, correct?</p> <p>9 A. Yes.</p> <p>10 Q. Okay. And then can you read this section</p> <p>11 right underneath it?</p> <p>12 A. "It bears emphasis that the foregoing</p> <p>13 reporting requirement is in addition to, and not in</p> <p>14 lieu of, the general requirement under Title 21" --</p> <p>15 "under 21 U.S.C. 823(e) that a distributor maintain</p> <p>16 effective controls against diversion."</p> <p>17 Q. And you would agree that also applies to</p> <p>18 Mallinckrodt?</p> <p>19 A. It does.</p> <p>20 Q. Then on Page 3, it shows circumstances</p> <p>21 that may be indicative of diversion.</p> <p>22 Do you see that?</p> <p>23 A. I do.</p> <p>24 Q. And can you read the first one? It's</p>	<p style="text-align: right;">Page 117</p> <p>1 MR. O'CONNOR: Objection.</p> <p>2 BY THE WITNESS:</p> <p>3 A. If that's what they are saying, that's</p> <p>4 what they believe.</p> <p>5 BY MR. KAWAMOTO:</p> <p>6 Q. And I'm asking you, sir, what do you</p> <p>7 believe?</p> <p>8 A. I just don't know. I don't -- as I said,</p> <p>9 I don't know what the other products are. I look at</p> <p>10 it in a different way. If they were ordering few of</p> <p>11 these and a lot of -- of oxycodone, that would be a</p> <p>12 red flag, but that doesn't seem to be their -- their</p> <p>13 point, so.</p> <p>14 Q. Well, but if -- if I -- if you were to</p> <p>15 change this statement to say: "Ordering excessive</p> <p>16 quantities of a limited variety of controlled</p> <p>17 substances (e.g. oxycodone) while ordering few, if</p> <p>18 any, other drugs," would you agree with that</p> <p>19 statement?</p> <p>20 A. Yes.</p> <p>21 Q. Then can you read No. 2 for me?</p> <p>22 A. "Ordering a limited variety of controlled</p> <p>23 substances in quantities disproportionate to the</p> <p>24 quantity of non-controlled medications ordered."</p>

<p style="text-align: right;">Page 118</p> <p>1 Q. Do you agree with that statement?</p> <p>2 A. I do.</p> <p>3 Q. Okay. What about No. 3, can you please</p> <p>4 read that?</p> <p>5 A. "Ordering excessive quantities of a</p> <p>6 limited variety of controlled substances in</p> <p>7 combination with excessive quantities of lifestyle</p> <p>8 drugs."</p> <p>9 Q. And do you agree with that statement?</p> <p>10 A. I don't know what those are, so I'm not</p> <p>11 going to say "yes" or "no."</p> <p>12 Q. Well, when you say you don't know what</p> <p>13 those are, you don't know what -- I take it you know</p> <p>14 what controlled substances means. Are you -- are you</p> <p>15 referring to the lifestyle drugs?</p> <p>16 A. Well, what are lifestyle drugs? What does</p> <p>17 that mean?</p> <p>18 Q. Okay. Well, moving on to point 4 then.</p> <p>19 A. Okay.</p> <p>20 Q. Can you read that?</p> <p>21 A. "Ordering the same controlled</p> <p>22 substance" -- "substance from multiple distributors."</p> <p>23 Q. Do you agree that that is a red flag?</p> <p>24 A. There is no way that we would know that.</p>	<p style="text-align: right;">Page 120</p> <p>1 insurance payments for controlled substances made via</p> <p>2 the internet. There is no way in the world we would</p> <p>3 know that. And there is a privacy issue there. "Does</p> <p>4 the pharmacy charge reasonable prices?" How would we</p> <p>5 know if it charges reasonable prices for their area?</p> <p>6 "Does a pharmacy offer to sell controlled substances</p> <p>7 without a prescription?" How would we know that?</p> <p>8 So, if you want me to agree with this, we</p> <p>9 are going to have to get very specific on every line</p> <p>10 and what it means so I'm correct when I answer your</p> <p>11 question.</p> <p>12 Q. Okay. So why don't we try that then.</p> <p>13 Starting with No. 1: "What percentage of</p> <p>14 the pharmacy's business does dispensing controlled</p> <p>15 substances constitute?"</p> <p>16 Would you agree that that's a -- that's</p> <p>17 something Mal- -- would you agree that that's</p> <p>18 something that is -- well, strike that.</p> <p>19 Would you agree that that's a red flag?</p> <p>20 MR. O'CONNOR: Objection.</p> <p>21 BY THE WITNESS:</p> <p>22 A. I would agree that this is part of our</p> <p>23 form that we sent so we would be able to delve into</p> <p>24 that information to determine how much controlled</p>
<p style="text-align: right;">Page 119</p> <p>1 Q. Well, I understand that, but if you had</p> <p>2 that information, would that be a red flag to you?</p> <p>3 A. So that's a hypothetical. If we happen to</p> <p>4 have that information somehow, would that be a red</p> <p>5 flag, in that hypothetical, yes.</p> <p>6 Q. Okay.</p> <p>7 A. But we would have no way to make that</p> <p>8 determination.</p> <p>9 Q. And then underneath that there is a list</p> <p>10 of -- well, can you review the list underneath that?</p> <p>11 It is another numeric list of one through ten.</p> <p>12 A. I've finished with No. 10.</p> <p>13 Q. Okay. Are there any factors on this list</p> <p>14 of ten that you do not agree are a red flag?</p> <p>15 MR. O'CONNOR: Objection.</p> <p>16 BY THE WITNESS:</p> <p>17 A. If we had the information, enough</p> <p>18 information to make that assessment, those would be</p> <p>19 red flags, but you've gone from a manufacturer to a</p> <p>20 distributor to a pharmacy to a doctor. So what you</p> <p>21 are saying is, do I agree if I had all of that</p> <p>22 information, but we are -- you have to remember, we</p> <p>23 were the manufacturer and we don't always have -- we</p> <p>24 can't always mine down to, does a pharmacy accept</p>	<p style="text-align: right;">Page 121</p> <p>1 substance versus non-controlled substances a pharmacy</p> <p>2 orders. So we believe that would be a red flag.</p> <p>3 That's why we asked the pharmacies at that question.</p> <p>4 BY MR. KAWAMOTO:</p> <p>5 Q. And I take it No. 2: "Is the pharmacy</p> <p>6 complying with the laws of every state in which it is</p> <p>7 dispensing controlled substances?"</p> <p>8 Clearly if it were not, that would be a</p> <p>9 red flag, is that correct?</p> <p>10 MR. O'CONNOR: Objection.</p> <p>11 BY THE WITNESS:</p> <p>12 A. There is no way we would have that</p> <p>13 information, and so to -- you are asking me things</p> <p>14 that there is no way that I would know. So DEA should</p> <p>15 know that, but Mallinckrodt wouldn't necessarily know</p> <p>16 that, especially if the pharmacy is doing something</p> <p>17 nefarious. So would it be a red flag if -- if one</p> <p>18 knew that? Well, yes, but how would one know that?</p> <p>19 So you are putting me in a position to answer</p> <p>20 questions there is no way I would know.</p> <p>21 BY MR. KAWAMOTO:</p> <p>22 Q. Well, for No. 3, it says: "Is the</p> <p>23 pharmacy soliciting buyers of controlled substances</p> <p>24 via the internet or is the pharmacy associated with an</p>

<p style="text-align: right;">Page 122</p> <p>1 internet site that solicits orders for controlled 2 substances?"</p> <p>3 I mean, that -- that would seem to be one 4 where you could both ask the pharmacy and go on the 5 internet, right?</p> <p>6 MR. O'CONNOR: Objection. 7 BY THE WITNESS:</p> <p>8 A. Well, I don't know that you could find 9 that out over the internet or how you could do that. 10 I just don't know. And I've told you before I am not 11 very technical. So soliciting buyers via the 12 internet, I'm not certain how we would know that. 13 BY MR. KAWAMOTO:</p> <p>14 Q. Well, you could ask -- you could ask the 15 pharmacy if they engage in that practice, though, 16 right?</p> <p>17 A. Right. 18 Q. Would it be worth it to ask them? 19 MR. O'CONNOR: Objection. 20 BY THE WITNESS:</p> <p>21 A. It would. I don't know if that's on our 22 form or not. I just don't know that. 23 BY MR. KAWAMOTO:</p> <p>24 Q. Okay. Well, so let me take a step back</p>	<p style="text-align: right;">Page 124</p> <p>1 investigating this and making these determinations. 2 So we took it upon ourselves voluntarily to go into 3 these situations and get as much information as we 4 could through this form we developed, so. 5 BY MR. KAWAMOTO:</p> <p>6 Q. And these are the types of questions, 7 though, that distributors should be asking of their 8 customers, is that correct? 9 MR. O'CONNOR: Objection. 10 MS. KVESELIS: Object. 11 BY THE WITNESS:</p> <p>12 A. The distributor, possibly, but not the 13 manufacturer. We did it voluntarily to get as much 14 information as possible and to better, you know, hone 15 our program so we could make those decisions in 16 concert with the distributor, too. 17 BY MR. KAWAMOTO:</p> <p>18 Q. And you did it because you believed it 19 would result in more effective diversion controls, is 20 that correct? 21 MR. O'CONNOR: Objection. 22 BY THE WITNESS:</p> <p>23 A. That's correct. 24 THE WITNESS: Sorry.</p>
<p style="text-align: right;">Page 123</p> <p>1 then. 2 For these -- these ten items, these are 3 all things that presumably the pharmacy would know, is 4 that correct? 5 MS. DURFEE: Objection; form. 6 BY THE WITNESS:</p> <p>7 A. The pharmacy should know if they are being 8 nefarious, I would think, if they are doing things 9 that are outside their, you know, filling 10 prescriptions. Are there scripts written for those 11 prescriptions? I mean, they are -- does the pharmacy 12 often sell controlled substances without a 13 prescription? I'm not certain that the pharmacy would 14 tell you that if you asked them, so. 15 BY MR. KAWAMOTO:</p> <p>16 Q. Sure. They might not tell you that, but 17 they can certainly provide -- some of these other 18 categories they could provide that information, is 19 that correct? 20 MS. DURFEE: Objection to form. 21 BY THE WITNESS:</p> <p>22 A. They could certainly provide that to their 23 distributor because the distributor is the person who 24 should know all of this. They should be the ones</p>	<p style="text-align: right;">Page 125</p> <p>1 BY THE WITNESS: 2 A. Are we through with that? 3 BY MR. KAWAMOTO:</p> <p>4 Q. Yes, we are done with that. 5 A. Okay. 6 MR. O'CONNOR: Counsel, I think it has been 7 about an hour, maybe time for lunch? 8 MR. KAWAMOTO: Sure. What -- about what time is 9 it? 10 MS. REIDY: 12:07. 11 MR. KAWAMOTO: Yeah, why don't we -- how long a 12 break do you want? Do you want to do -- 13 MR. O'CONNOR: We can go off the record here. 14 MR. KAWAMOTO: Yeah. 15 THE VIDEOGRAPHER: We are going off the record 16 at 12:07. 17 (WHEREUPON, a recess was had 18 from 12:07 to 12:49 p.m.) 19 THE VIDEOGRAPHER: We are back on the record at 20 12:49. 21 MR. KAWAMOTO: Okay. I'd like to mark this as 22 Exhibit 8. 23 (WHEREUPON, a certain document was 24 marked Mallinckrodt-Ratliff</p>

<p style="text-align: right;">Page 126</p> <p>1 Deposition Exhibit No. 008, for 2 identification, as of 12/19/2018.) 3 MR. O'CONNOR: Is there more than one? Are 4 there more copies? 5 MR. KAWAMOTO: Yes, they should be behind. 6 THE WITNESS: Here we go. 7 (WHEREUPON, there was a short 8 interruption.) 9 BY MR. KAWAMOTO: 10 Q. Okay. So this is another e-mail and 11 attachment. The e-mail is Bates numbered 7146630. 12 And my questions are going to relate to 13 the attachment. 14 A. Okay. 15 Q. Okay. So first in terms of establishing 16 the -- the e-mail chain, the very top e-mail is an 17 e-mail from Karen Harper to you, Mr. Ratliff. It's a 18 2/29/2008. 19 Do you see that, sir? 20 A. I do. 21 Q. Okay. And it attaches -- it attaches a 22 letter from the DEA dated December 27, 2007. 23 Do you have any recollection of receiving 24 this letter?</p>	<p style="text-align: right;">Page 128</p> <p>1 DEA's interpretation of a requirement that registrants 2 are required to follow with respect to the size of an 3 order? 4 MR. O'CONNOR: Objection. 5 BY MR. KAWAMOTO: 6 Q. Is that correct? 7 A. Yes. 8 Q. And turning to the back of the letter -- 9 A. Okay. 10 Q. -- the very top paragraph. 11 Could you read that top paragraph, it is 12 the first few sentences? 13 A. "Registrants that rely on rigid formulas 14 to define whether an order is suspicious may be 15 failing to detect suspicious orders. For example, a 16 system that identifies orders as suspicious only if 17 the total amount of a controlled substance ordered 18 during one month exceeds the amount ordered the 19 previous month by a certain percentage or more is 20 insufficient." 21 Q. Do you agree with that statement, sir? 22 A. I agree that DEA is telling us that. 23 Q. And substantively, though, do you agree 24 that reliance on a rigid formula to define whether an</p>
<p style="text-align: right;">Page 127</p> <p>1 A. In 2007... 2 I don't recall this specific letter, but 3 since it's attached and it appears to have come to me, 4 I'm certain that I received it at some point. 5 Q. Okay. Do you recall ever discussing this 6 letter with anyone? 7 A. And the government letters such as this 8 are called boilerplate. They send them out every once 9 in a while just to remind the registrants and/or -- 10 and it comes into the government also, they do the 11 same thing, to remind people of the rules and 12 regulations. 13 Q. And so I've -- if you could read the 14 portion of the letter towards the bottom that I'm 15 going to highlight for ease of reference? 16 A. On the front page? 17 Q. Ah, yes, on the front page. 18 A. What you have highlighted, okay. 19 Q. Yes, it starts with "the size". 20 A. "The size of an order alone, whether or 21 not it deviates from a normal pattern, is enough to 22 trigger the registrant's responsibility to report the 23 order as suspicious." 24 Q. And so you would agree that this is the</p>	<p style="text-align: right;">Page 129</p> <p>1 order is suspicious may -- may be failing to detect 2 suspicious orders, do you agree with that as a matter 3 of substance, sir? 4 A. Not necessarily. The reason I say that is 5 there -- most all of the registrants that we dealt 6 with, and Karen Harper dealt with them, used an 7 algorithm to identify suspicious orders, in that they 8 were -- they deviated from the norm. They sent that 9 to DEA. There came a time that Pete Kleissle called 10 me and said, That's no longer effective. We know 11 you've been sending us those. Please cease and 12 desist, don't do that, you know, look at your program 13 and do something different. And that's what started 14 the total reinforcement or the looking at the program 15 and trying to make it the -- the model of the 16 industry. 17 Q. And I -- I understand that DEA is telling 18 you that in this letter, but in terms of the substance 19 of their concern, do you agree -- well, strike that. 20 Would you agree that DEA's concern that 21 reliance on rigid formulas to define whether an order 22 is suspicious may be failing to detect suspicious 23 orders is a valid concern? 24 MR. O'CONNOR: Objection.</p>

Page 130

1 BY THE WITNESS:
 2 A. I don't know that I agree with that.
 3 BY MR. KAWAMOTO:
 4 Q. So you -- you think it would be fine to
 5 rely on a rigid formula?
 6 A. At the time we relied on a rigid formula
 7 because there were times we had more information than
 8 DEA. A particular registrant, DEA had pulled their
 9 registration. So another distributor came in and
 10 wanted to order additional product. We knew that. So
 11 to say just because it deviates it's suspicious isn't
 12 always the case.
 13 Q. Well, but isn't DEA saying something
 14 separate, they are saying that if you are using a
 15 rigid formula to define whether an order is suspicious
 16 without taking a broader view or looking at more data,
 17 you may be failing to detect suspicious orders,
 18 isn't -- isn't that what DEA is saying in that -- in
 19 that first two -- the first couple of sentences?
 20 MR. O'CONNOR: Objection.
 21 BY THE WITNESS:
 22 A. They are saying this system fails placed
 23 by a pharmacy if the pharmacy -- see, you're -- we are
 24 still confusing the manufacturer from the distributor

Page 131

1 to the pharmacy, so. So what you did is you stopped
 2 short of reading the rest of the facts that talk about
 3 this is -- "This system fails to identify orders
 4 placed by a pharmacy if the pharmacy placed unusually
 5 large orders from the beginning of its relationship
 6 with the distributor." And you are trying to say, Oh,
 7 well, this refers to the manufacturer also when it
 8 doesn't say that.
 9 BY MR. KAWAMOTO:
 10 Q. And so your interpretation of this letter,
 11 then, is that there is nothing wrong with a
 12 manufacturer relying on a rigid formula?
 13 A. Again, I'm going to say not necessarily
 14 that I agree with that statement because I think it's
 15 too rigid. What I'm saying is this is with regard to
 16 a distributor in pharmacies and you are trying to --
 17 to put that on everyone that's a registrant, and I
 18 just think that's far reaching.
 19 Q. Well, but the -- the -- the first page of
 20 the letter says, it says; "This letter is being
 21 sent" -- this is at the very top. "This letter is
 22 being sent to every entity in the United States
 23 registered with the Drug Enforcement Administration to
 24 manufacture or distribute controlled substances."

Page 132

1 So this is going to every registrant --
 2 A. It is.
 3 Q. -- both manufacturers and distributors?
 4 A. Exactly.
 5 Q. And the statement above relating to rigid
 6 formulas, my question to you is: For a manufacturer
 7 like Mallinckrodt, is it okay for the manufacturer to
 8 rely on rigid formulas in light of this DEA letter?
 9 MR. O'CONNOR: Objection.
 10 BY THE WITNESS:
 11 A. I don't know if I have an opinion about
 12 it.
 13 BY MR. KAWAMOTO:
 14 Q. You were director of security, sir. You
 15 don't have any opinion --
 16 A. No.
 17 Q. -- as to whether or not rigid formulas are
 18 appropriate with respect to detecting --
 19 A. No.
 20 Q. -- suspicious orders?
 21 A. Rigid formulas were used by almost all
 22 manufacturing registrants for years. So were they
 23 always wrong, is that what you are saying, they have
 24 always been wrong? What we are saying is we got a

Page 133

1 great deal of information from that. And from that we
 2 were able to determine if it's suspicious. What we
 3 were telling DEA is this is a deviation by those rigid
 4 numbers from what they've ordered in the past. It was
 5 my belief that they would use that information in
 6 deciding who they would audit or not audit. So when
 7 they are coming out and telling us this, they are
 8 saying that now it's your responsibility to -- don't
 9 just send us this anymore because it's really not
 10 helping. So that's the time when we changed and did
 11 what DEA required. They are saying, Don't send us
 12 rigid numbers any more. But what I'm saying is, I
 13 don't agree with the fact that those were wrong.
 14 Q. But you would -- you would agree that as
 15 of the date of this letter, which is December 2007, it
 16 was no longer appropriate to rely on a rigid formula
 17 in light of DEA's letter?
 18 MR. O'CONNOR: Objection.
 19 BY MR. KAWAMOTO:
 20 Q. Is that correct?
 21 A. Well, if we go back -- see, you're --
 22 you're only taking part of that paragraph, and I just
 23 have fault with that. They -- it talks about
 24 pharmacies. So it's saying, if you read -- if the --

<p style="text-align: right;">Page 134</p> <p>1 the distributors, which is different than the 2 manufacturers, if they use rigid numbers in doing 3 this, they may be missing this. So it's not saying 4 just because all registrants received it doesn't 5 necessarily mean that they are talking to the 6 manufacturers. 7 Q. Okay. And my question to you then, sir, 8 is: As a manufacturer, when you read this letter, and 9 you read that paragraph, and is it okay if you are a 10 manufacturer to rely on a rigid formula for 11 identifying suspicious orders? 12 MR. O'CONNOR: Objection. 13 BY MR. KAWAMOTO: 14 Q. I understand that distributors may be 15 doing something different or they may be differently 16 situated, but with respect to a manufacturer, is it 17 okay for a manufacturer like Mallinckrodt to rely on a 18 rigid formula to define whether an order is 19 suspicious? 20 MR. O'CONNOR: Objection. 21 BY THE WITNESS: 22 A. I'll just restate what I said. We 23 believed giving those numbers to DEA would allow them 24 to audit if they thought -- because they have</p>	<p style="text-align: right;">Page 136</p> <p>1 said, Okay. And I called Karen in and I said, Pete 2 said don't send those, these monthly letters anymore. 3 So at that point DEA is saying to a 4 manufacturer, Yeah, we don't -- we don't want you to 5 do that anymore. So that is our -- when we knew that, 6 that's when our program started to change. We started 7 to fine -- to define knowing our customers's customer 8 and we developed that form that gave all of this 9 information from those pharmacies so we could make 10 better decisions. So we were trying to help DEA in 11 every way, but to say I'm basing that -- if I would 12 have read this at the time, I would have said, Well, 13 they are talking about pharmacies, not manufacturers. 14 Q. So your interpretation of this letter, I 15 understand that you had a phone conversation with Pete 16 Kleissle, but your interpretation of this letter and 17 this paragraph is that this applies to distributors 18 and not manufacturers, is that correct? 19 A. As I read it today, that's what I -- 20 that's how I interpret it. But you have to remember 21 this is -- well, it's only ten years ago, over ten 22 years ago. 23 Q. But you don't have any reason to believe 24 as you sit here today that you would have had a</p>
<p style="text-align: right;">Page 135</p> <p>1 additional information. They have information from 2 other -- other registrants. Maybe that distributor 3 was buying from five different manufacturers. So, we 4 don't know that. We were providing those numbers to 5 them in an -- in an effort to alert them that this is 6 a little out of the ordinary. And to say that's just 7 absolutely wrong is just not right. 8 BY MR. KAWAMOTO: 9 Q. Well, I'm -- I'm not saying that's 10 absolutely wrong, sir. I'm asking a slightly 11 different question, which is going forward from 2007 12 onward -- I'm sorry -- going forward from December 13 2007 onward, was it acceptable to rely on a rigid 14 formula? I'm not asking you about rigid formulas 15 prior to December of 2007. I'm saying, after the date 16 of this letter, would it be appropriate for a 17 manufacturer to rely on a rigid formula in determining 18 whether an order is suspicious? 19 MR. O'CONNOR: Objection. 20 BY THE WITNESS: 21 A. I received a telephone call from Pete 22 Kleissle at some time, and I don't think it was -- I 23 think it was after this where he said, Yeah, don't do 24 that anymore, don't said those. So at that point I</p>	<p style="text-align: right;">Page 137</p> <p>1 different interpretation of this letter ten years ago? 2 A. Ten years ago I thought we had a great 3 program in place, so. 4 Q. And what do you believe now, sir? 5 A. I think our program has improved. 6 Q. So you can put that aside. 7 A. Okay. 8 MR. KAWAMOTO: Okay. So this is now Exhibit 9. 9 (WHEREUPON, a certain document was 10 marked Mallinckrodt-Ratliff 11 Deposition Exhibit No. 009, for 12 identification, as of 12/19/2018.) 13 BY MR. KAWAMOTO: 14 Q. So this is an e-mail chain from Karen 15 Harper to you with the Bates No. 268860, and the 16 bottom e-mail is an e-mail from you, Mr. Ratliff, to a 17 number of people, cc'ing Karen Harper. 18 A. Okay. 19 Q. So can you review the bottom e-mail, 20 please? 21 A. I can. 22 Okay. 23 Q. Okay. So, sir, can you read the top 24 paragraph of your e-mail?</p>

<p style="text-align: right;">Page 138</p> <p>1 A. I can.</p> <p>2 "Jim," I guess it's to Jim Rausch, "Pete</p> <p>3 Kleissle, DEA Diversion Group Supervisor, St. Louis,</p> <p>4 just called regarding several letters he has received</p> <p>5 from you detailing suspicious orders" -- "suspicious</p> <p>6 orders. He advised that he needs more information, in</p> <p>7 that, if it is suspicious why are we filling the</p> <p>8 order. I explained that we use a calculation based</p> <p>9 on" -- "upon an amount previously order. He stated,</p> <p>10 'If you think it is suspicious, don't fill it.' I</p> <p>11 will go into more detail on Friday."</p> <p>12 Q. Okay. Thank you.</p> <p>13 So that is an e-mail that you sent to Jim</p> <p>14 Rausch, Michael Pheney and Cathy Stewart.</p> <p>15 A. Um-hum.</p> <p>16 Q. Does this refresh your recollection as to</p> <p>17 what Jim Rausch -- the role Jim Rausch was playing in</p> <p>18 the suspicious order monitoring program?</p> <p>19 A. Yes. Jim works with Pheney and he is --</p> <p>20 they obviously are the ones that are gathering the</p> <p>21 information, I guess, upon what orders are being sent.</p> <p>22 You have to remember, he didn't work for me, so I</p> <p>23 don't have a specific knowledge of what he did.</p> <p>24 Q. I understand that.</p>	<p style="text-align: right;">Page 140</p> <p>1 A. So that -- that e-mail sentence suggests</p> <p>2 that the suspicious -- that you were supposed -- you</p> <p>3 were -- well, strike that.</p> <p>4 That line suggests that you were sending</p> <p>5 out suspicious or you were filling suspicious orders</p> <p>6 after notifying the DEA of those orders, is that</p> <p>7 correct?</p> <p>8 MR. O'CONNOR: Objection.</p> <p>9 BY THE WITNESS:</p> <p>10 A. No, it is not correct. What he is saying</p> <p>11 is, I need more information. So what we've used is</p> <p>12 that algorithm that we believed was helping them. So</p> <p>13 he is saying, Don't do that anymore, but he is not</p> <p>14 saying, Oh, yeah, you are sending me this information</p> <p>15 and it's suspicious. We were providing the</p> <p>16 information to them to assist them. So to say that</p> <p>17 any of those were suspicious, we don't really -- we</p> <p>18 just know they didn't fit within the algorithm.</p> <p>19 BY MR. KAWAMOTO:</p> <p>20 Q. But he also says: "He advised that he</p> <p>21 needs more information that if it is suspicious, why</p> <p>22 are we filling the order."</p> <p>23 So doesn't that last phrase, "if it is</p> <p>24 suspicious why are we filling the order," suggest that</p>
<p style="text-align: right;">Page 139</p> <p>1 A. Okay. But this is what I was speaking of</p> <p>2 before when Pete called me and said, Don't do that</p> <p>3 anymore.</p> <p>4 Q. And what you are referring to is Pete</p> <p>5 called you and said don't send him any more letters,</p> <p>6 is that correct?</p> <p>7 A. Yes.</p> <p>8 Q. And what -- what were the letters that Jim</p> <p>9 was sending to Pete?</p> <p>10 A. They were a -- I can't tell you</p> <p>11 specifically, but they had to do with the orders, and</p> <p>12 I don't know what their calculations were, I don't</p> <p>13 know anything about that. I just know that they</p> <p>14 filled out letters and sent them based on an algorithm</p> <p>15 that had been developed and was being used.</p> <p>16 Q. Okay. And do you see this -- this</p> <p>17 sentence that I'm highlighting? Could you repeat</p> <p>18 that, please?</p> <p>19 A. Several letters he has received from me</p> <p>20 detailing suspicious orders. "He advised that he</p> <p>21 needs more information, in that, if it is suspicious</p> <p>22 why are we filling the order," is that what you are</p> <p>23 asking?</p> <p>24 Q. Yes.</p>	<p style="text-align: right;">Page 141</p> <p>1 you were filling suspicious orders?</p> <p>2 A. Well, the rest of that conversation with</p> <p>3 Pete -- sorry, I didn't mean to talk over you. Please</p> <p>4 repeat yourself.</p> <p>5 Q. Doesn't that phrase "if it is suspicious</p> <p>6 why are we filling the order," doesn't that suggest</p> <p>7 that you were filling suspicious orders and he is</p> <p>8 asking you why?</p> <p>9 MR. O'CONNOR: Objection.</p> <p>10 BY THE WITNESS:</p> <p>11 A. That's not what he is -- that is not what</p> <p>12 he related to me. He is just saying, Don't do that</p> <p>13 anymore. If you -- if it's the algorithm, if it</p> <p>14 doesn't fit, we don't have enough based on what you</p> <p>15 are sending us based on your algorithm. And I'll give</p> <p>16 you more information on Friday about what's going on,</p> <p>17 so.</p> <p>18 BY MR. KAWAMOTO:</p> <p>19 Q. And so that -- that phrase then is</p> <p>20 inaccurate?</p> <p>21 A. I would say it's poorly worded on my part.</p> <p>22 Q. And when he says: "He stated, 'If you</p> <p>23 think it is suspicious, don't fill it,'" why would</p> <p>24 he -- why would he say that -- why would he say that</p>

<p style="text-align: right;">Page 142</p> <p>1 to you? And you have that in quotes, sir.</p> <p>2 A. Um-hum.</p> <p>3 MR. O'CONNOR: Objection.</p> <p>4 BY MR. KAWAMOTO:</p> <p>5 Q. Why would he say that to you if he didn't</p> <p>6 have a concern that you were filling suspicious</p> <p>7 orders?</p> <p>8 MR. O'CONNOR: Objection.</p> <p>9 BY THE WITNESS:</p> <p>10 A. I don't believe that Pete believed we were</p> <p>11 filling suspicious orders. If he had believed that,</p> <p>12 he and his team would have been at Mallinckrodt going</p> <p>13 through all of our records. He was just explaining to</p> <p>14 me in a very emphatic way to change what you are</p> <p>15 doing. And that came out of headquarters. And so did</p> <p>16 he say that, yes.</p> <p>17 BY MR. KAWAMOTO:</p> <p>18 Q. And what did he want you to do -- well,</p> <p>19 strike that.</p> <p>20 What were you doing that he had concerns</p> <p>21 about?</p> <p>22 MR. O'CONNOR: Objection.</p> <p>23 BY THE WITNESS:</p> <p>24 A. We were using an algorithm, as all of the</p>	<p style="text-align: right;">Page 144</p> <p>1 know that.</p> <p>2 Q. Sure. But he was clearly running them at</p> <p>3 a minimum on some, correct?</p> <p>4 A. At a minimum on some, but I would think it</p> <p>5 was -- the algorithm affected all of the customers.</p> <p>6 Q. Okay. So I understand that you are not</p> <p>7 sure whether it was all of them or some of them, but I</p> <p>8 guess my point is, regardless of whether it was all of</p> <p>9 the orders or some of the orders, he was running an</p> <p>10 algorithm on these orders and that -- that algorithm</p> <p>11 presumably identified various orders.</p> <p>12 Is that your understanding?</p> <p>13 MR. O'CONNOR: Objection.</p> <p>14 BY THE WITNESS:</p> <p>15 A. Yes, if they were -- if they were out</p> <p>16 of -- if they were higher than they had been, if it</p> <p>17 had increased at a certain time, there is a method to</p> <p>18 all of that. I don't profess to know what it is, but</p> <p>19 I know we were doing that, and he was being very</p> <p>20 specific about this, about us stopping with the --</p> <p>21 with the algorithms.</p> <p>22 BY MR. KAWAMOTO:</p> <p>23 Q. Okay. So presumably after April</p> <p>24 of 2008 -- well, strike that.</p>
<p style="text-align: right;">Page 143</p> <p>1 other registrants were, and he is saying don't use</p> <p>2 that.</p> <p>3 BY MR. KAWAMOTO:</p> <p>4 Q. And what did he want you to do instead</p> <p>5 then?</p> <p>6 A. Provide him more information.</p> <p>7 Q. So I want to make sure I understand what</p> <p>8 you mean by you say you were using an algorithm.</p> <p>9 A. Um-hum.</p> <p>10 Q. So you were applying a formula to a</p> <p>11 group -- well, do you know if this algorithm was</p> <p>12 applied to all of the orders for your opioid products</p> <p>13 or only some?</p> <p>14 MR. O'CONNOR: Objection.</p> <p>15 BY THE WITNESS:</p> <p>16 A. I don't know that. Jim Rausch would be a</p> <p>17 better source for that. He is the one that filled out</p> <p>18 the letters based on the orders that they received,</p> <p>19 so.</p> <p>20 BY MR. KAWAMOTO:</p> <p>21 Q. So Jim is running an algorithm on some</p> <p>22 population of orders?</p> <p>23 A. You're putting words. I -- I don't know</p> <p>24 if he was running it on all of the -- I just don't</p>	<p style="text-align: right;">Page 145</p> <p>1 I take it you responded to his direction</p> <p>2 by stopping use of the algorithm, is that correct?</p> <p>3 MR. O'CONNOR: Objection.</p> <p>4 BY THE WITNESS:</p> <p>5 A. I think that's what I did with this</p> <p>6 e-mail.</p> <p>7 BY MR. KAWAMOTO:</p> <p>8 Q. Okay. And so what took its place?</p> <p>9 Instead of using an algorithm to identify suspicious</p> <p>10 orders, how did you identify them?</p> <p>11 A. Well, you'd have to ask Karen Harper. We</p> <p>12 started a new program. I can't tell you the exact</p> <p>13 date that we started sending out those forms to</p> <p>14 identify all of our -- all of the other information.</p> <p>15 I just don't know the answer to that.</p> <p>16 Q. And you reference in the second paragraph</p> <p>17 "Frank Sapienza"?</p> <p>18 A. Yes.</p> <p>19 Q. Who is he?</p> <p>20 A. He was with DEA.</p> <p>21 Q. And the reference is, you have a call</p> <p>22 planned with Frank Sapienza on Friday "to strengthen</p> <p>23 our suspicious order monitoring system" -- I'm</p> <p>24 sorry -- "our suspicious order identification system."</p>

<p style="text-align: right;">Page 146</p> <p>1 Do you recall anything about that call</p> <p>2 with Frank?</p> <p>3 A. I don't.</p> <p>4 Q. Do you have any recollection of how you</p> <p>5 were going to strengthen your suspicious order</p> <p>6 identification system?</p> <p>7 A. Not at this point I don't.</p> <p>8 Q. Who would have been in charge of that</p> <p>9 program -- of that project?</p> <p>10 A. Karen Harper.</p> <p>11 Q. Do you have any recollection of your</p> <p>12 involvement in that project as you sit here today?</p> <p>13 A. I'm sure I assisted, but I can't tell you</p> <p>14 that -- Karen is very informed and knows everything</p> <p>15 there is about DEA compliance, so she would have taken</p> <p>16 this on as a responsibility to write a program. Did I</p> <p>17 read it, did I look at it, did I make recommendations,</p> <p>18 at this point I can't tell you, you know. Would that</p> <p>19 be normal, yes.</p> <p>20 Q. Okay. And when you say you will go into</p> <p>21 more detail on Friday, that's in the top paragraph, do</p> <p>22 you recall what any of those details were?</p> <p>23 A. I can't remember the conversation.</p> <p>24 Q. So all you recall right -- all you recall</p>	<p style="text-align: right;">Page 148</p> <p>1 Highlights, February 2008."</p> <p>2 Do you see that, sir?</p> <p>3 A. I do.</p> <p>4 Q. Okay. Do you recall receiving -- do you</p> <p>5 re -- well, strike that.</p> <p>6 Were these e-mails that Karen sent out</p> <p>7 every month?</p> <p>8 MR. O'CONNOR: Objection.</p> <p>9 BY THE WITNESS:</p> <p>10 A. Well, it says: "DEA Compliance Monthly</p> <p>11 Highlights," so there is an assumption to be made, but</p> <p>12 you have to remember this is over ten years ago. So</p> <p>13 do I remember receiving this, I see my name on it, and</p> <p>14 that's about all I can tell you about that. It's over</p> <p>15 ten years.</p> <p>16 BY MR. KAWAMOTO:</p> <p>17 Q. And you are the only one that's receiving</p> <p>18 this e-mail. So why -- why is she sending this to</p> <p>19 you?</p> <p>20 A. She may have worked for me at the time. I</p> <p>21 don't know.</p> <p>22 Q. Now, do you see the section marked</p> <p>23 "Suspicious Order Monitoring"?</p> <p>24 A. Uh-huh, I do.</p>
<p style="text-align: right;">Page 147</p> <p>1 based on this e-mail today is that you received a call</p> <p>2 from Pete Kleis- -- from --</p> <p>3 A. Pete Kleissle.</p> <p>4 Q. -- from Pete Kleissle, and as a result you</p> <p>5 directed Jim to stop sending him letters and</p> <p>6 Mallinckrodt stopped using the algorithm.</p> <p>7 Is that accurate?</p> <p>8 MR. O'CONNOR: Objection.</p> <p>9 BY THE WITNESS:</p> <p>10 A. I think that's accurate.</p> <p>11 MR. KAWAMOTO: I believe we are up to</p> <p>12 Exhibit 10.</p> <p>13 (WHEREUPON, a certain document was</p> <p>14 marked Mallinckrodt-Ratliff</p> <p>15 Deposition Exhibit No. 010, for</p> <p>16 identification, as of 12/19/2018.)</p> <p>17 BY MR. KAWAMOTO:</p> <p>18 Q. So this is an e-mail from Karen Harper to</p> <p>19 you --</p> <p>20 A. Okay.</p> <p>21 Q. -- dated March 3rd, 2008. It has got</p> <p>22 Bates No. 1308810.</p> <p>23 And the title of this e-mail -- the title</p> <p>24 of this e-mail is: "DEA Compliance Monthly</p>	<p style="text-align: right;">Page 149</p> <p>1 Q. And I guess the second line of that says:</p> <p>2 "Further, the need for a comprehensive</p> <p>3 review and upgrade of our Suspicious Order Monitoring</p> <p>4 program has received elevated priority. A conference</p> <p>5 call on the matter with Corporate Logistics is</p> <p>6 scheduled for tomorrow."</p> <p>7 Do you -- do you see that?</p> <p>8 A. No. Where is it?</p> <p>9 Q. Let me -- let me highlight it for you.</p> <p>10 A. Okay. So you are saying: "Further, the</p> <p>11 need for a comprehensive review and upgrade of our</p> <p>12 Suspicious Order Monitoring program has received</p> <p>13 elevated priority. A conference call on the matter</p> <p>14 will" -- "with Corporate Logistics is scheduled for</p> <p>15 tomorrow."</p> <p>16 I see that.</p> <p>17 Q. Okay. Do you -- is this -- do you agree</p> <p>18 with this statement? Meaning in March of 2008, do you</p> <p>19 recall there being -- do you recall the need for a</p> <p>20 comprehensive review and upgrade of your suspicious</p> <p>21 order monitoring program and do you recall it</p> <p>22 receiving elevated priority?</p> <p>23 MR. O'CONNOR: Objection.</p> <p>24 BY THE WITNESS:</p>

Page 150

1 A. We constantly tried to upgrade our program
 2 to be the best for any manufacturer.
 3 So when I read this, it does not surprise
 4 me that it's written in that way, and I think we were
 5 always striving to -- to have a better program, so, if
 6 that answers your question.
 7 BY MR. KAWAMOTO:
 8 Q. But this references a comprehensive review
 9 and upgrade and it notes that that has received
 10 elevated priority.
 11 A. I don't know what that means.
 12 Q. So that would -- that would suggest
 13 something other than sort of routine improvement,
 14 would it not?
 15 A. I will repeat, this has been way over ten
 16 years, and for me to look at that and make a decision
 17 on what that meant or who did it and when they did it
 18 is really kind of -- I just can't tell you that. I'm
 19 saying we were constantly trying to upgrade our
 20 program to be in compliance. So, if we needed to have
 21 a -- a better program or more up -- yeah, I think we
 22 could all -- always say we can improve, so. But you
 23 are asking questions here, you know, we are going on
 24 11 years here, so. I have been retired

Page 151

1 six-and-a-half. I -- I mean, I know you want me to
 2 say certain things but I just can't, so.
 3 Q. Well, sir, I don't want you to say
 4 anything. I'm just interested in what your
 5 recollection is and that's why we are going through
 6 these records.
 7 A. Okay. Well, that's my recollection.
 8 Thank you.
 9 Q. Okay. And do you have any recollection of
 10 what triggered this comprehensive review and upgrade?
 11 A. Well, I don't know. So, was it the 3/3 --
 12 April 1st, no.
 13 Q. Okay. And the reference to "received
 14 elevated priority," do you know --
 15 A. I have no idea. I have no idea in the
 16 world. I don't know who the elevated priority would
 17 have come from or anything about it.
 18 Q. Well, you indicated that Karen Harper at
 19 this time may have been working for you, is that
 20 right?
 21 A. Well, I said may have been working for me.
 22 So I don't remember. She worked for me for a time.
 23 Q. But you don't recall any particular
 24 urgency in early 2008 regarding the upgrade and review

Page 152

1 of your SOM program?
 2 A. You can ask me this for ten times. I'm
 3 going to tell you I don't recall this because of the
 4 length of time that's passed. I've been out of the
 5 company for six-and-a-half years. I'm doing my best
 6 to cooperate, but if I don't remember, I don't
 7 remember.
 8 Q. Well, and the purpose of these documents
 9 is to see if they can refresh your recollection.
 10 A. And I'm saying they don't.
 11 Q. So, do you recall any concerns that
 12 Mallinckrodt had in this time period, so early 2008,
 13 regarding its SOM program?
 14 MR. O'CONNOR: Objection.
 15 BY THE WITNESS:
 16 A. We wanted to have the best program
 17 possible.
 18 BY MR. KAWAMOTO:
 19 Q. Well, I understand that, sir.
 20 A. We were constantly trying to upgrade the
 21 program and make it -- and obtain additional
 22 information so we could assist. You know, there was a
 23 time we thought that our distributors were doing their
 24 due diligence. We reviewed -- they sent us all of

Page 153

1 their -- their programs in written form and they
 2 looked really nice. But unless you drilled down be --
 3 beyond that, you don't really know if they are, you
 4 know, doing what they should be doing, their due
 5 diligence. So that's when we started to develop the
 6 form that we are asking our salespeople to go out on
 7 all of our customers and give us this information so
 8 we can make the best decision possible so we are
 9 ensuring that we are not sending out anything that's
 10 suspicious.
 11 Q. And my question to you is slightly
 12 different, which is do you recall any concerns at this
 13 time period, which would be March of 2008?
 14 MR. O'CONNOR: Objection.
 15 BY THE WITNESS:
 16 A. I don't.
 17 THE WITNESS: Sorry.
 18 MR. O'CONNOR: That's okay.
 19 BY MR. KAWAMOTO:
 20 Q. Now, sir, you've repeatedly referenced
 21 that you were continuing to improve your program.
 22 What's the basis for that statement?
 23 A. That's the form that we developed to ask
 24 questions about the -- not -- not only the -- the --

Page 154

1 from the distributors but from their customers. So we
2 as a manufacturer sold to distributors, and in many
3 conversations with DEA we were looking at, Okay. Now
4 we are going to have to go to the customer, our
5 customer, the distributor, to their customers to
6 determine if they are actually doing what the
7 distributor -- distributor should be doing in
8 reviewing. So, yes, we were doing that. We were --
9 yeah, we were constantly trying to upgrade that to
10 make sure we had enough information to make decisions
11 like that.
12 Q. And when did that occur?
13 A. I can't tell you. I don't know.
14 Q. Other than knowing your customer's
15 customer, what other steps did you take to improve and
16 upgrade your program, which you said you were doing
17 constantly?
18 A. I mean, that's knowing our customer's
19 customer was the thrust of that -- that program at the
20 time.
21 Q. So that was -- that was the improvement,
22 sir?
23 A. To the best of my knowledge.
24 Q. And so when Karen is in March of 2008

Page 155

1 talking to -- talking about improving the program,
2 your recollection is the component -- what she was --
3 well, strike that.
4 Your recollection is that that improvement
5 was knowing your customer's customer, is that correct?
6 MR. O'CONNOR: Objection.
7 BY THE WITNESS:
8 A. I can't tell you at this time sitting here
9 exactly when the form was developed or when we started
10 doing that. I just can't tell you that. I just -- I
11 have no memory of exactly when that happened.
12 BY MR. KAWAMOTO:
13 Q. Okay.
14 A. But I know that we started to do that.
15 And the exact date, I can't -- I just can't tell you.
16 I don't know.
17 Q. And what do you recall about the form? I
18 mean, this is -- we've repeatedly discussed this form.
19 What do you -- what do you recall about the form? Who
20 did it go to, what did it ask for, what type of
21 information was it trying to seek?
22 MR. O'CONNOR: Objection.
23 BY THE WITNESS:
24 A. I mean, I'd love to see the form and I

Page 156

1 could explain it to you. Do you have the form?
2 BY MR. KAWAMOTO:
3 Q. We have -- well, we've seen several forms.
4 They appear to be drafts. So, to be honest, I'm
5 not -- I'm not sure.
6 A. Well, we had -- we had a -- I'm sorry.
7 Q. So as you sit here now, and we'll go
8 through additional documents --
9 A. Okay.
10 Q. -- but what is it you recall about this
11 form?
12 A. That it stated the name, it stated the
13 proportion of controlled substance to non-controlled
14 substances, the number of cash customers as opposed to
15 insurance customers or whatever, and I know it talked
16 in terms of the two highest prescribing doctors. You
17 have to remember, over ten years old, I just -- I
18 mean, that's just really a vague recollection, so.
19 I'm doing my best to help you.
20 MR. KAWAMOTO: Here we go.
21 (WHEREUPON, a certain document was
22 marked Mallinckrodt-Ratliff
23 Deposition Exhibit No. 011, for
24 identification, as of 12/19/2018.)

Page 157

1 BY MR. KAWAMOTO:
2 Q. So this is an e-mail with several
3 attachments, and why don't we start with the e-mail.
4 So if you could review that and let me know when you
5 are ready.
6 A. Okay. I have read that.
7 Q. Okay. So this is an e-mail from Karen
8 Harper to you, Michael Pheney, Jim Rausch, Cathy
9 Stewart, and Kimberly France.
10 A. Um-hum.
11 Q. And it is dated April 10th, 2008. It's
12 Bates number is 273902.
13 And do you recall receiving this e-mail?
14 A. May name is on it, so I must have received
15 it, but I don't recall receiving it.
16 Q. Okay. Now, in this Karen is raising
17 various questions regarding improvements to the
18 suspicious order checklist.
19 Is that accurate?
20 A. That's what it says.
21 Q. Okay. And what -- what do you recall
22 about what the suspicious order checklist was?
23 A. I don't really recall it at all.
24 Q. Okay. Well, so why don't we look at some

<p style="text-align: right;">Page 158</p> <p>1 of the attachments then, because I believe one of them</p> <p>2 is a -- a checklist.</p> <p>3 A. Okay.</p> <p>4 Q. Actually, two of them are checklists.</p> <p>5 A. Okay.</p> <p>6 Q. So the "Controlled Substance Order</p> <p>7 Checklist," that's the first attachment.</p> <p>8 Do you see that?</p> <p>9 A. I do.</p> <p>10 Q. And just so I understand how this</p> <p>11 checklist was used, this would be completed by the</p> <p>12 customer service representative. So this wasn't --</p> <p>13 this wasn't part of the effort to know your customer's</p> <p>14 customer, was it?</p> <p>15 A. I think it was part of the overall --</p> <p>16 excuse me -- suspicious order monitoring program. Did</p> <p>17 I ever see these, no. Was I aware that there was a</p> <p>18 checklist, probably at that time, but I think it was</p> <p>19 part and parcel to the -- to the suspicious order</p> <p>20 monitoring program. They were trying to bring</p> <p>21 everybody in on the same page.</p> <p>22 Q. The next attachment is an overview of</p> <p>23 something called "The Integrichain Pilot Program."</p> <p>24 Do you see that?</p>	<p style="text-align: right;">Page 160</p> <p>1 how we have an obligation to do that. It's -- I don't</p> <p>2 know what "The Integrichain Pilot Program" is or who</p> <p>3 wrote the document. And sometimes they use -- they</p> <p>4 use words and phrases that aren't necessarily in -- in</p> <p>5 keeping with a manufacturer. So they are saying,</p> <p>6 whatever this program is that we should be doing that,</p> <p>7 and we had some -- we had people at some point that</p> <p>8 came in and tried to -- tried to provide information</p> <p>9 that it was their -- their project, their pet project.</p> <p>10 So am I saying that we were -- no, I don't think so.</p> <p>11 I don't think that's the job of a manufacturer at all.</p> <p>12 Our job is to prevent diversion. But as a growing --</p> <p>13 that's somebody's special project and they decided</p> <p>14 that we should have this obligation. So do I agree</p> <p>15 with that, no.</p> <p>16 BY MR. KAWAMOTO:</p> <p>17 Q. Well, so what part of the obligation do</p> <p>18 you not agree with, because it says Covidien -- I</p> <p>19 mean, "As a growing leader in the pain management</p> <p>20 category, Covidien has a social and business</p> <p>21 obligation to prevent abuse."</p> <p>22 Do you agree that there is an obligation</p> <p>23 to prevent abuse if you are a manufacturer?</p> <p>24 MR. O'CONNOR: Objection.</p>
<p style="text-align: right;">Page 159</p> <p>1 A. I do see that.</p> <p>2 Q. Do you recall anything about The</p> <p>3 Integrichain Pilot Program?</p> <p>4 A. No.</p> <p>5 Q. The very top paragraph, right underneath</p> <p>6 Background, could you read that for me, please?</p> <p>7 A. "As a growing leader in the pain</p> <p>8 management category, Covidien has a social and</p> <p>9 business obligation to prevent abuse, diversion and</p> <p>10 theft of its" -- "and theft of its" whatever. There</p> <p>11 is something wrong there. "Detailed data, through</p> <p>12 surveillance and pharmacovigilance, is an important</p> <p>13 resource for the company."</p> <p>14 Q. So recognizing that there appears to be a</p> <p>15 word missing, other than that, would you generally</p> <p>16 agree with that statement?</p> <p>17 A. I don't know what pharmacovigilance is.</p> <p>18 Q. Well, how about the sentence: "As a</p> <p>19 growing leader in the pain management category,</p> <p>20 Covidien has a social and business obligation to</p> <p>21 prevent abuse, diversion and theft" of something?</p> <p>22 MR. O'CONNOR: Objection.</p> <p>23 BY THE WITNESS:</p> <p>24 A. As a manufacturer, I think -- I don't know</p>	<p style="text-align: right;">Page 161</p> <p>1 BY THE WITNESS:</p> <p>2 A. We have an obligation to prevent</p> <p>3 diversion, but there is no way as a manufacturer we</p> <p>4 are going to be able to prevent abuse. If down the</p> <p>5 line, I'll give you an example, it's in a prison,</p> <p>6 there is never a perfect system. You are always going</p> <p>7 to get drugs into a prison. Even -- even the most</p> <p>8 hardened prisoners -- prisons get contraband into that</p> <p>9 prison. So what you are saying is we have a -- an</p> <p>10 obligation to prevent abuse. The doctor has an</p> <p>11 obligation. The pharmacist has an obligation. But</p> <p>12 the manufacturer, I don't believe so.</p> <p>13 BY MR. KAWAMOTO:</p> <p>14 Q. Okay. So the manufacturer in your opinion</p> <p>15 does not have any obligation to prevent abuse?</p> <p>16 A. It's our responsibility to prevent</p> <p>17 diversion.</p> <p>18 Q. What's the difference between diver- --</p> <p>19 diversion and abuse?</p> <p>20 A. Well, abuse would be someone going into a</p> <p>21 pharmacy with a script from a -- a doctor who writes</p> <p>22 them for a certain amount of money and going out and</p> <p>23 either selling those drugs or taking them, and that's</p> <p>24 abuse. So is it our responsibility to prevent that,</p>

<p style="text-align: right;">Page 162</p> <p>1 no. There is no way we could do that, so.</p> <p>2 Q. Now, what you described, sir, is someone</p> <p>3 coming in with a script that they paid a doctor to</p> <p>4 obtain and then having it filled and then either</p> <p>5 taking the pills themselves or selling the pills.</p> <p>6 Isn't that what occurs at a pill mill?</p> <p>7 A. At a what?</p> <p>8 MR. O'CONNOR: Objection.</p> <p>9 BY MR. KAWAMOTO:</p> <p>10 Q. Isn't that what occurs at a pill mill,</p> <p>11 isn't that what happens with pill mills, people come</p> <p>12 in with scripts that are probably not legitimate, they</p> <p>13 obtain -- they obtain products and then those opioid</p> <p>14 products make their way into the illicit market?</p> <p>15 MR. O'CONNOR: Objection.</p> <p>16 BY MR. KAWAMOTO:</p> <p>17 Q. Isn't that the problem with the pill mill,</p> <p>18 sir?</p> <p>19 A. Yes.</p> <p>20 Q. Okay. And you do have an obligation, your</p> <p>21 diversion obligation is to prevent your products from</p> <p>22 ending up in pill mills?</p> <p>23 MR. O'CONNOR: Objection.</p> <p>24 BY THE WITNESS:</p>	<p style="text-align: right;">Page 164</p> <p>1 Q. Well, sir, to be honest, it is not clear</p> <p>2 who did write this.</p> <p>3 A. Okay.</p> <p>4 Q. What I've got is the attachment to the</p> <p>5 e-mail.</p> <p>6 A. So -- okay. So we don't have any idea who</p> <p>7 wrote it, if it was a pet project, if someone brought</p> <p>8 it in at a time, you don't know that?</p> <p>9 Q. Well, procedurally speaking, there is a --</p> <p>10 there are limits to how many of your questions I can</p> <p>11 answer, but --</p> <p>12 A. Okay.</p> <p>13 Q. -- I'm comfortable saying I don't know who</p> <p>14 wrote this.</p> <p>15 A. Thank you.</p> <p>16 Q. And hence why I'm asking you about it.</p> <p>17 A. I appreciate it because I don't know who</p> <p>18 wrote it earlier.</p> <p>19 Okay. "Covidien currently monitors</p> <p>20 diversion of our product through transactional data</p> <p>21 via electronic exchange and audit services from</p> <p>22 manufacturer to direct customer. Although these</p> <p>23 systems meet current standards for monitoring</p> <p>24 diversion, we are limited by our inability to track</p>
<p style="text-align: right;">Page 163</p> <p>1 A. Our obligation is to determine if our</p> <p>2 distributor has a program in place to do exactly that.</p> <p>3 So what we found out was they weren't fulfilling their</p> <p>4 obligation in every instance. So then we went further</p> <p>5 to go out and determine who those customers were to</p> <p>6 see if they were providing licit or illicit pills in</p> <p>7 the market. So the first responsibility is to the</p> <p>8 distributor. So we took it upon ourselves to go out</p> <p>9 and find out who those customers, our customers'</p> <p>10 customers are to try to prevent that, so.</p> <p>11 BY MR. KAWAMOTO:</p> <p>12 Q. But if you determined that a customer's</p> <p>13 customer was a pill mill, then you had an obligation</p> <p>14 to cut them -- to direct the distributor to cut them</p> <p>15 off, did you not?</p> <p>16 MR. O'CONNOR: Objection.</p> <p>17 BY THE WITNESS:</p> <p>18 A. Absolute -- absolutely. And we did that</p> <p>19 many times.</p> <p>20 BY MR. KAWAMOTO:</p> <p>21 Q. And then can you read the highlighted</p> <p>22 section in the paragraph underneath "Compliance Need:</p> <p>23 Simultaneous Abuse and Diversion Monitoring," please?</p> <p>24 A. Could you tell me who wrote this?</p>	<p style="text-align: right;">Page 165</p> <p>1 resources simultaneously through a comprehensive</p> <p>2 monitoring system that utilize" -- "utilizes all sales</p> <p>3 and supply chain data. This is occurring at a time</p> <p>4 when prescription drug abuse, misuse, and diversion</p> <p>5 are increasing, which we anticipate will prompt the</p> <p>6 enactment of stricter monitoring requirements."</p> <p>7 Q. So focusing on that last sentence that you</p> <p>8 just read --</p> <p>9 A. Okay.</p> <p>10 Q. -- "This is occurring at a time when</p> <p>11 prescription drug abuse, misuse, and diversion are</p> <p>12 increasing, which we anticipate will prompt the</p> <p>13 enactment of stricter monitoring requirements," is</p> <p>14 that an accurate statement in your opinion? And the</p> <p>15 date of this e-mail and presumably this attachment is</p> <p>16 going to be April of 2008.</p> <p>17 A. So ten-and-a half years ago. So I don't</p> <p>18 know that. And I don't know who wrote the document.</p> <p>19 I don't know what their -- their ability to have this</p> <p>20 information would be, and I just don't know that I can</p> <p>21 say with any specificity that -- that this is</p> <p>22 accurate. I just -- you know, I don't know.</p> <p>23 Q. Well, is it fair to say that over your</p> <p>24 time at Mallinckrodt, which spanned from 2000 to 2012,</p>

<p style="text-align: right;">Page 166</p> <p>1 there was an increase in drug abuse, misuse and 2 diversion, is that accurate? 3 MR. O'CONNOR: Objection. 4 BY THE WITNESS: 5 A. I think it's probably accurate. 6 BY MR. KAWAMOTO: 7 Q. And did that prompt the enactment -- 8 enactment of stricter monitoring requirements, sir? 9 MR. O'CONNOR: Objection. 10 BY THE WITNESS: 11 A. DEA never gave us any advice on what we 12 should do or not do other than not to send anymore 13 letters with the algorithm, okay. But they never 14 said, You need to do this or that. At one point they 15 said, It would be nice if you know your customer's 16 customer. And that came, as I said, not directly, but 17 it came through a sidebar from DEA. 18 So, did -- did we do everything within our 19 power to start identifying those customers' customers, 20 yes. We were doing our very best to identify those 21 people. But did the DEA ever say in writing, until 22 much later when we had the earthquake meeting at the 23 end of '11 when they said, You need to know your 24 customer's customer. Before that it had been kind of,</p>	<p style="text-align: right;">Page 168</p> <p>1 A. Okay. 2 BY MR. KAWAMOTO: 3 Q. So is -- is this the form that you were 4 referencing with respect to -- to the form to help you 5 know your customer's customer? 6 A. It's familiar. So I -- you know, it very 7 well could be that form. 8 Q. And would you have been involved in 9 developing this form? 10 A. I don't think so. 11 Q. Do you recall ever reviewing this form 12 when it was filled out? 13 A. Yes. 14 Q. And what did you review it for? What was 15 the purpose of your review? 16 A. We needed additional information on -- on 17 registrants to see if we felt that they were 18 legitimate. 19 Q. And can you walk me through how this, how 20 the information in this form would have helped you 21 determine whether a -- well, strike that. 22 A. Do you have a -- where I can see the whole 23 thing? I -- it's cut off at the bottom. 24 Q. Yeah, it's -- it is in the back of your --</p>
<p style="text-align: right;">Page 167</p> <p>1 It would be nice if you knew that, but they would 2 never give us any instruction on what they meant. 3 BY MR. KAWAMOTO: 4 Q. Do you know if this pilot program was ever 5 implemented, this Integrichain Pilot Program? 6 A. I have no clue. I don't know who wrote 7 it, I don't know -- I just don't know. You would 8 think there would be something on here that would 9 identify the writer. 10 Q. Are you familiar with 852 sales data? 11 A. No. I don't know what that means. 12 Q. What about 867 sales data? 13 A. Is there someplace I can look at this? I 14 don't -- I don't -- 15 Q. No, it's -- it's not going to be present 16 here. I'm just asking if you are familiar with it? 17 A. I'm not familiar with the sales data. 18 Q. Now, after the Integrichain overview, 19 there is this "New Customer Checklist." 20 A. Okay. 21 Q. Now, you'll -- do you recall that we were 22 discussing a form, you know, probably ten minutes ago? 23 MR. O'CONNOR: Objection. 24 BY THE WITNESS:</p>	<p style="text-align: right;">Page 169</p> <p>1 it is towards the end of -- 2 A. That's this? 3 MR. O'CONNOR: Can we have the Bates number? 4 MR. KAWAMOTO: Yeah. It's Bates No. 273907, so 5 it should be as part of that document. 6 BY THE WITNESS: 7 A. Thank you. 8 BY MR. KAWAMOTO: 9 Q. Sure. 10 A. Yeah, this isn't the form. This is not 11 the one I was talking about. 12 Q. Understood. 13 Would you -- do you recall ever reviewing 14 this particular form, though, when it was filled out? 15 A. No. 16 Q. Now, the next attachment, and it is Bates 17 No. 273908, it's a "Controlled Substance Suspicious 18 Monitoring" and it is a "DEA Compliance Procedure." 19 This appears to be on a standardized form. 20 Is that -- is that accurate? 21 A. Yes. 22 Q. Okay. And the originator is Karen Harper. 23 What -- what is this form, what is its 24 function?</p>

<p style="text-align: right;">Page 170</p> <p>1 MR. O'CONNOR: Objection.</p> <p>2 BY MR. KAWAMOTO:</p> <p>3 Q. Let me put that another way.</p> <p>4 How did -- how did Mallinckrodt use these</p> <p>5 types of forms internally? Is this a formal policy</p> <p>6 document or -- I'm trying to understand what I'm</p> <p>7 looking at?</p> <p>8 MR. O'CONNOR: Objection.</p> <p>9 BY THE WITNESS:</p> <p>10 A. I know I've seen these and seen more than</p> <p>11 one of them. How it was implemented, I'd -- I'd be</p> <p>12 guessing, so.</p> <p>13 BY MR. KAWAMOTO:</p> <p>14 Q. Now, on the back page it has</p> <p>15 responsibilities and then it identifies various</p> <p>16 departments.</p> <p>17 Do you see that?</p> <p>18 A. Yes.</p> <p>19 Q. Okay. So you've got the "Customer Data</p> <p>20 Integrity Group. Perform Dun & Bradstreet information</p> <p>21 check on new controlled" -- well, actually, strike</p> <p>22 that.</p> <p>23 Can you review this and let me know if you</p> <p>24 recall this process ever being implemented?</p>	<p style="text-align: right;">Page 172</p> <p>1 A. Okay. I have read the "Regulatory</p> <p>2 Interpretations." What other?</p> <p>3 Q. Okay. The one up top saying "Suspicious</p> <p>4 Order Mentoring."</p> <p>5 A. Okay.</p> <p>6 Q. Okay. So it says under Suspicious Order</p> <p>7 Mentoring, I think that means monitoring: "The team</p> <p>8 continues work and three meetings were held in May."</p> <p>9 Is the -- is the reference to the team the</p> <p>10 SOM team?</p> <p>11 A. I -- yeah, I don't know.</p> <p>12 Q. Okay. And I take it you don't recall</p> <p>13 anything about meetings being held in May on</p> <p>14 suspicious order monitoring or mentoring?</p> <p>15 A. No.</p> <p>16 Q. Okay. Now, the next sentence references</p> <p>17 a: "Procedure that is in Draft 3 Revision and a</p> <p>18 subcommittee which has become work on which algorithms</p> <p>19 will be used to screen orders of unusual quantity,</p> <p>20 frequency and pattern."</p> <p>21 A. Okay.</p> <p>22 Q. So, do you have any recollection of a</p> <p>23 subcommittee?</p> <p>24 A. No.</p>
<p style="text-align: right;">Page 171</p> <p>1 A. After all of these years, I just can't</p> <p>2 remember it.</p> <p>3 Q. You can't remember it.</p> <p>4 A. I mean, I just can't remember.</p> <p>5 Q. Now, with respect to security director,</p> <p>6 that would have been you, is that correct?</p> <p>7 A. Yes.</p> <p>8 Q. Do you recall if -- if this was an</p> <p>9 accurate description of your -- of your role in 2008?</p> <p>10 MR. O'CONNOR: Objection.</p> <p>11 BY THE WITNESS:</p> <p>12 A. Again, I can't recall. I just don't know.</p> <p>13 (WHEREUPON, a certain document was</p> <p>14 marked Mallinckrodt-Ratliff</p> <p>15 Deposition Exhibit No. 012, for</p> <p>16 identification, as of 12/19/2018.)</p> <p>17 BY MR. KAWAMOTO:</p> <p>18 Q. So this is an e-mail from Karen Harper to</p> <p>19 you. It is entitled "DEA Compliance Monthly Report,</p> <p>20 May 2008," and it has a Bates number of 2908468. And</p> <p>21 I only want to ask you about two things, the</p> <p>22 regulatory interpretations and the suspicious order --</p> <p>23 well, it says "Suspicious Order Mentoring." I suspect</p> <p>24 that may be a typo.</p>	<p style="text-align: right;">Page 173</p> <p>1 Q. Now, the -- the -- this is dated June</p> <p>2 of 2008 and it's referencing work on algorithms which</p> <p>3 will be used to screen orders of unusual quantity,</p> <p>4 frequency and pattern.</p> <p>5 So if you will recall in April of 2008 you</p> <p>6 had a conversation with Pete Kleissle.</p> <p>7 Do you recall that?</p> <p>8 A. Yes.</p> <p>9 Q. And the upshot of that conversation is</p> <p>10 that you were to stop -- well, Jim Rausch was to stop</p> <p>11 sending him letters and using that algorithm?</p> <p>12 MR. O'CONNOR: Objection.</p> <p>13 BY THE WITNESS:</p> <p>14 A. He said, Don't send us letters using the</p> <p>15 algorithms.</p> <p>16 BY MR. KAWAMOTO:</p> <p>17 Q. Okay.</p> <p>18 A. That doesn't mean that the algorithms</p> <p>19 aren't effective, because that's what they are saying</p> <p>20 here, I think, that they are -- the algorithms have</p> <p>21 some benefit to us, so that's what I get from reading</p> <p>22 it. But do I recall it, no.</p> <p>23 Q. And so do you have any recollection of</p> <p>24 whether the algorithm was changed or modified over</p>

<p style="text-align: right;">Page 174</p> <p>1 time?</p> <p>2 A. I don't.</p> <p>3 Q. And actually, you don't -- you don't</p> <p>4 recall whether the algorithm was still being used</p> <p>5 after April of 2008?</p> <p>6 A. I don't. I know that they weren't sending</p> <p>7 letters to DEA with it.</p> <p>8 Q. Going to "Regulatory Interpretations" --</p> <p>9 A. Okay.</p> <p>10 Q. -- it says -- can you read that first</p> <p>11 sentence?</p> <p>12 A. "As newly appointed Dosage Customer</p> <p>13 Service Manager, Cathy Stewart requested several</p> <p>14 regulatory interpretations pertaining to DEA 222 over</p> <p>15 shipment and States versus Federal controlled</p> <p>16 substance laws."</p> <p>17 Q. Do you know what that is in reference to?</p> <p>18 A. No.</p> <p>19 Is that all from this?</p> <p>20 Q. That's all for that.</p> <p>21 A. Thank you.</p> <p>22 (WHEREUPON, a certain document was</p> <p>23 marked Mallinckrodt-Ratliff</p> <p>24 Deposition Exhibit No. 013, for</p>	<p style="text-align: right;">Page 176</p> <p>1 A. I don't.</p> <p>2 Q. Okay. Were you -- do you recall ever</p> <p>3 becoming aware of a significant gap in the program?</p> <p>4 A. No.</p> <p>5 Q. The second line from the bottom, it says,</p> <p>6 "Further, HDMA endorses an electronic order monitoring</p> <p>7 system and we need to determine status (has pilot</p> <p>8 program been run?)"</p> <p>9 Well, do you know what HDMA is?</p> <p>10 A. I don't.</p> <p>11 Q. Okay. And do you know -- do you have any</p> <p>12 recollection of an electronic order monitoring system?</p> <p>13 A. At this time I don't. I just don't.</p> <p>14 Q. And the last sentence says: "More work on</p> <p>15 suspicious order monitoring program will be on the</p> <p>16 agenda for January."</p> <p>17 A. Okay.</p> <p>18 Q. So based on the document, sir, it appears</p> <p>19 that Mallinckrodt was working on its suspicious order</p> <p>20 monitoring program since early 2008 until early 2009.</p> <p>21 Is that accurate?</p> <p>22 A. We were constantly refining, reviewing,</p> <p>23 and improving the suspicious order monitoring program.</p> <p>24 So if that's what you are saying, yes.</p>
<p style="text-align: right;">Page 175</p> <p>1 identification, as of 12/19/2018.)</p> <p>2 BY MR. KAWAMOTO:</p> <p>3 Q. So the questions I have for you, sir,</p> <p>4 relate to the back page under "Ongoing Projects," and</p> <p>5 in particular it is the second bullet point.</p> <p>6 A. The second bullet?</p> <p>7 Q. Yes. The one that I'll -- I'll highlight</p> <p>8 it here.</p> <p>9 Do you see that highlighted section, sir?</p> <p>10 A. I do.</p> <p>11 Q. Now, the first sentence references "HDMA</p> <p>12 Industry Guidance."</p> <p>13 Do you know what that -- what is HDMA</p> <p>14 Industry Guidance?</p> <p>15 A. No.</p> <p>16 Q. It also references: "One significant gap</p> <p>17 will be worked wherein HDMA suggests that the customer</p> <p>18 (as opposed to shipper's sales rep) fills out the</p> <p>19 information gathering document regarding business</p> <p>20 background, customer base, state and federal license,</p> <p>21 and signs and notarizes the statement."</p> <p>22 Do you see that statement?</p> <p>23 A. I do.</p> <p>24 Q. Do you know what that is in reference to?</p>	<p style="text-align: right;">Page 177</p> <p>1 Q. But do you have any recollection of when</p> <p>2 the enhanced or new suspicious order monitoring</p> <p>3 program was implemented?</p> <p>4 A. I believe it was always in a stage of -- I</p> <p>5 mean, it was always being used as it was being</p> <p>6 reviewed and improved is my recollection.</p> <p>7 Q. But you don't -- you are not aware or</p> <p>8 familiar with any of the details of that SOM program</p> <p>9 as you sit here today?</p> <p>10 A. Say that one more time, please.</p> <p>11 Q. You are not aware or familiar with any of</p> <p>12 the details of that SOM program as you sit here today?</p> <p>13 MR. O'CONNOR: Objection.</p> <p>14 BY THE WITNESS:</p> <p>15 A. Was I aware of the suspicious order</p> <p>16 monitoring program, is that what you are asking?</p> <p>17 BY MR. KAWAMOTO:</p> <p>18 Q. No. I'm asking -- I'm asking about the</p> <p>19 specifics of its implementation.</p> <p>20 Do you know whether there was an algorithm</p> <p>21 in effect? Do you know when the customer checklist</p> <p>22 was rolled out?</p> <p>23 MR. O'CONNOR: Objection.</p> <p>24 BY MR. KAWAMOTO:</p>

<p style="text-align: right;">Page 178</p> <p>1 Q. I take it -- I mean, you don't -- you</p> <p>2 don't recall any of those details?</p> <p>3 A. I don't.</p> <p>4 MR. O'CONNOR: Objection.</p> <p>5 BY MR. KAWAMOTO:</p> <p>6 Q. So your basis for saying that there was</p> <p>7 always some type of program in effect is what? Is it</p> <p>8 your general recollection or --</p> <p>9 A. Karen.</p> <p>10 Q. -- why would you say that?</p> <p>11 A. Karen would come in from time to time and</p> <p>12 say, We are going to do this. And I'd go, Okay. She</p> <p>13 was right next -- in the office right next to me. And</p> <p>14 so was -- did that mean did I know at the time, maybe.</p> <p>15 This is only -- we are getting only nine years ago.</p> <p>16 What I'm saying is would I have known at the time what</p> <p>17 was going on, yes. But what you are asking me is to</p> <p>18 review things that I haven't thought about in all of</p> <p>19 those years and today is the first time I'm looking at</p> <p>20 this in nine years, ten years, eleven years and asking</p> <p>21 me to recall those details. And I apologize. I</p> <p>22 can't. I just -- my memory is not good enough to go</p> <p>23 back and look at this and say, Yep, that's what -- I</p> <p>24 just don't remember that.</p>	<p style="text-align: right;">Page 180</p> <p>1 BY THE WITNESS:</p> <p>2 A. That's exactly the case, and she would</p> <p>3 have made a presentation to him. She would have done</p> <p>4 a PowerPoint and the whole thing.</p> <p>5 BY MR. KAWAMOTO:</p> <p>6 Q. But there is -- there is -- to the best of</p> <p>7 your knowledge, there is no archive that has, you</p> <p>8 know, this -- on this date this program was in fact --</p> <p>9 was in effect?</p> <p>10 A. I don't know that. I just don't know that</p> <p>11 there was a specific date and we said, Okay. Now we</p> <p>12 are rolling it out today. And so there was nothing</p> <p>13 before or nothing -- no, that didn't happen. It was a</p> <p>14 gradual -- I mean, she worked on this all of the time,</p> <p>15 trying to put it together, so.</p> <p>16 (WHEREUPON, a certain document was</p> <p>17 marked Mallinckrodt-Ratliff</p> <p>18 Deposition Exhibit No. 014, for</p> <p>19 identification, as of 12/19/2018.)</p> <p>20 THE WITNESS: Sorry.</p> <p>21 BY MR. KAWAMOTO:</p> <p>22 Q. So this is an e-mail chain between you and</p> <p>23 Karen Harper.</p> <p>24 A. Okay.</p>
<p style="text-align: right;">Page 179</p> <p>1 Q. So if I wanted to determine what this --</p> <p>2 what's this -- what suspicious order monitoring</p> <p>3 program was in effect, say, in July of 2008, where</p> <p>4 would I go -- how would I do that?</p> <p>5 A. I would talk to Karen Harper.</p> <p>6 Q. Okay. Is there any formal document that</p> <p>7 you are aware of that would tell me, you know, this is</p> <p>8 a --</p> <p>9 A. If we have a specific date that said,</p> <p>10 Okay. Now the program is in place, I don't know. I</p> <p>11 don't think so. I think it was a -- a gradual</p> <p>12 implementation.</p> <p>13 And I apologize for talking over you.</p> <p>14 Q. That's okay.</p> <p>15 A. I'll try not to do that.</p> <p>16 Q. So if you got a new president of specialty</p> <p>17 generics and he wanted to know -- he comes in in</p> <p>18 August of 2008 and he wants to know what your SOM</p> <p>19 program is, I take it he would have gone to Karen</p> <p>20 Harper, is that how he would have learned about it</p> <p>21 or --</p> <p>22 A. Sure.</p> <p>23 MR. O'CONNOR: Objection.</p> <p>24 THE WITNESS: I'm sorry.</p>	<p style="text-align: right;">Page 181</p> <p>1 Q. And its Bates number is 283602.</p> <p>2 And you'll note that at the top there is a</p> <p>3 discussion of, you know, flooring installation, and I</p> <p>4 don't have any questions about that.</p> <p>5 A. Thank you.</p> <p>6 Q. But I do have questions about the e-mail</p> <p>7 below that and then the e-mail below that. So if you</p> <p>8 can review that and the e-mail on the back of the</p> <p>9 page. Let me know when you are done.</p> <p>10 A. Okay.</p> <p>11 Q. Okay. And so this e-mail, the very bottom</p> <p>12 e-mail, can you please read that? It is not very</p> <p>13 long.</p> <p>14 A. "I agree with David and Kyle Wright" --</p> <p>15 Q. Oh, no, I'm sorry. I meant the full</p> <p>16 e-mail on 283603, so the back of the page.</p> <p>17 A. "Yesterday, I had a lengthy chat with Matt</p> <p>18 Harbaugh and David Silver. We spoke briefly about the</p> <p>19 suspicious order monitoring program and its</p> <p>20 importance. David made the comment, that if a</p> <p>21 distributor was ordering oxycodone and hydrocodone, a</p> <p>22 good test of their legitimacy was to determine if they</p> <p>23 were buying hydromorphone. Interesting thought.</p> <p>24 Let's discuss."</p>

<p>Page 182</p> <p>1 Q. So what -- what is -- can you explain 2 what's being -- well, strike that. 3 Who is Matt Harbaugh and who is David 4 Silver or who are? 5 A. David Silver was a VP. Matt Harbaugh, I 6 don't -- I remember the name, but I don't know what 7 his position was. 8 Q. And David Silver was a VP at Mallinckrodt? 9 A. Yes. He was at headquarters in -- in 10 Hazelwood. 11 Q. And you are discussing -- you're -- well, 12 what -- what are you discussing in this e-mail? 13 A. David was a computer wizard, a savant 14 almost. He -- he just could do just about anything 15 with facts and figures, and that's my memory of what 16 he was doing with the company. 17 So he made the comment that: "If a 18 distributor was ordering oxycodone and hydrocodone, a 19 good test of their legitimacy was to determine if they 20 were buying hydromorphone. Interesting thought. 21 Let's discuss." 22 Q. And why would that have been a good test 23 of their legitimacy? 24 A. I have no clue. I know that sounds</p> <p>Page 183</p> <p>1 terrible, but I -- I can't remember even in 2011, is 2 what it says. So we are back to only seven years ago. 3 You know, if I were guessing, it's a pain medication. 4 Q. Hydromorphone -- hydromorphone is a pain 5 medication? 6 A. Yes. 7 Q. So all three of those are pain 8 medications, aren't they? 9 A. Correct. 10 Q. Okay. Well, why don't -- 11 A. There is not much else I could tell you. 12 Q. Why don't we look at the e-mail above that 13 from Karen Harper to you. 14 A. Okay. 15 Okay. 16 Q. So based on this e-mail, Karen agrees or I 17 guess endorses the idea of looking at drug combination 18 purchase patterns? 19 A. Yes. 20 Q. Why -- why -- why would looking at drug 21 combination purchase patterns be helpful? 22 A. You know, to -- to determine the 23 legitimacy of the pharmacy. I mean, they are using -- 24 they are looking for other tools to use, and that's</p>	<p>Page 184</p> <p>1 what I get from that. 2 Q. Well, and how -- how would -- how would 3 looking at the drug combination purchase pattern help 4 you determine the legitimacy of the pharmacy? Is 5 it -- is it if they are only purchasing oxycodone, 6 that's a red flag, is that what this is about? 7 A. I don't know that. 8 Q. Now, then, your e-mail above is: "Thanks, 9 I believe David was" -- "David was thinking more in 10 line with pain relievers that are not as addictive, as 11 opposed to only ordering those that are." 12 Do you have -- do you have any 13 recollection of what you meant by that statement? 14 A. No. 15 Q. Do you recall at a time in the context of 16 your "know your customer's customer push" that you 17 started looking at drug combination purchase patterns? 18 MR. O'CONNOR: Objection. 19 BY THE WITNESS: 20 A. I don't remember that. 21 BY MR. KAWAMOTO: 22 Q. Would you agree, though, that if you had 23 a -- if you found out that a pharmacy was only 24 purchasing oxycodone from a distributor, that would be</p> <p>Page 185</p> <p>1 a cause of concern for you? 2 MR. O'CONNOR: Objection. 3 BY THE WITNESS: 4 A. I would say yes. 5 MR. O'CONNOR: We have been going a little over 6 an hour. Maybe a five-minute break? 7 MR. KAWAMOTO: Sure, that's fine. 8 THE WITNESS: I mean -- 9 MR. KAWAMOTO: Well -- 10 THE WITNESS: I don't have a problem. 11 MR. O'CONNOR: Actually, yeah, I'd like to take 12 a break. 13 THE WITNESS: Okay. 14 MR. KAWAMOTO: Fine. 15 THE VIDEOGRAPHER: Going off the record at 2:03. 16 (WHEREUPON, a recess was had 17 from 2:03 to 2:21 p.m.) 18 THE VIDEOGRAPHER: We are back on the record at 19 2:21. 20 BY MR. KAWAMOTO: 21 Q. So, I have another e-mail for you, 22 Mr. Ratliff. It is an e-mail from Karen Harper to a 23 woman named Kerry Hamilton at DOJ, cc'ing you, and the 24 Bates number is 387492.</p>
---	--

<p style="text-align: right;">Page 186</p> <p>1 (WHEREUPON, a certain document was 2 marked Mallinckrodt-Ratliff 3 Deposition Exhibit No. 015, for 4 identification, as of 12/19/2018.) 5 BY THE WITNESS: 6 A. Okay. 7 BY MR. KAWAMOTO: 8 Q. Okay. First, do you -- well, this is an 9 e-mail from Karen Harper to Ms. Hamilton and cc'ing 10 you and it is dated 11/2010. 11 The top -- the first sentence of the 12 e-mail references "information that Mallinckrodt 13 presented yesterday to DEA offices in St. Louis and 14 Albany, New York." 15 Do you have any recollection of those 16 meetings? 17 A. I know Kerry Hamilton is with DEA. She is 18 a compliance person. 19 Q. And do you recall speaking to her? 20 A. I've spoken to Kerry more than once -- 21 Q. Okay. 22 A. -- in meetings at the DEA office there in 23 St. Louis. 24 Q. And do you recall meeting with her</p>	<p style="text-align: right;">Page 188</p> <p>1 description accurate or do you -- do you believe it's 2 not accurate? 3 MR. O'CONNOR: Objection. 4 BY THE WITNESS: 5 A. If Karen -- if Karen Harper wrote it, I 6 would think it's accurate. 7 BY MR. KAWAMOTO: 8 Q. Okay. And then the highlighted -- could 9 you please read the highlighted sections of the 10 e-mail? 11 A. "When submitting chargebacks, distributors 12 must provide Mallinckrodt with specific detailed 13 information indicating how much product was sold to 14 each end user pharmacy." Also, "Based on this 15 chargeback data, Mallinckrodt" -- "Mallinckrodt has 16 some information regarding pharmacy buying practices." 17 Is that where you stopped? 18 Q. And do you believe that that is consistent 19 with your understanding about Mallinckrodt's 20 chargeback data? 21 A. If Karen Harper wrote it, that's accurate. 22 Q. Okay. And then the last sentence, let me 23 highlight that. 24 Okay. Can you please read that sentence?</p>
<p style="text-align: right;">Page 187</p> <p>1 regarding chargeback data? 2 A. I know we met, but I can't tell you that 3 it was about this or this was -- well, what I'm 4 looking at, this relates to DEA offices, if this was 5 done via conference or -- or how New York and DEA 6 St. Louis would be done yesterday is the only problem 7 I'm having. 8 Q. Sure. So it may have been a conference 9 call, but regardless of -- 10 A. It could have been. 11 Q. -- whether it was either a telephonic 12 meeting or an actual meeting, is that -- 13 A. Yeah. Yeah, I don't remember it 14 specifically. 15 Q. What is your understanding of 16 Mallinckrodt's chargeback data? 17 A. That it is very confusing. And I know 18 it's written out here, but it's -- it's more confusing 19 than this, in my opinion. I've never really 20 understood, you know, when they pay it and how it 21 works, if they are given credit. I just don't know 22 that answer, so. 23 Q. So do you see the -- the portions that 24 I've highlighted -- well, first, is this general</p>	<p style="text-align: right;">Page 189</p> <p>1 A. "That said, Mallinckrodt assumes that most 2 transactions would result in a chargeback request." 3 Q. And you have no reason to disagree with 4 Ms. Harper on this, do you? 5 A. I don't know if that's -- I don't have any 6 reason to disagree. 7 Q. Okay. How was chargeback data being used 8 in the context of knowing your customer's customer, 9 sir? 10 MR. O'CONNOR: Objection. 11 BY THE WITNESS: 12 A. I mean, at some point we were using it, 13 so. Can I tell you exactly when it started and how it 14 was used, I know that we used a form, not the one you 15 showed me before, but a form to -- to glean as much 16 information as we could from pharmacies prior to the 17 chargeback information being available to us. 18 BY MR. KAWAMOTO: 19 Q. And this e-mail indicates that by at least 20 11/2010, Mallinckrodt was using the chargeback data? 21 A. Yes. 22 Q. And from a diversion control standpoint, 23 what did the chargeback data help you do, what 24 information did it provide?</p>

<p style="text-align: right;">Page 190</p> <p>1 MR. O'CONNOR: Objection.</p> <p>2 BY THE WITNESS:</p> <p>3 A. It identified the distributor's customers.</p> <p>4 BY MR. KAWAMOTO:</p> <p>5 Q. And it also indicated how much they were</p> <p>6 purchasing from that distributor, correct? Meaning it</p> <p>7 wasn't just -- it not only identified the customer, it</p> <p>8 also identified the volume of product?</p> <p>9 MS. KVESELIS: Objection to form.</p> <p>10 MR. O'CONNOR: Objection.</p> <p>11 BY THE WITNESS:</p> <p>12 A. I assume that's the case. I shouldn't</p> <p>13 assume, but...</p> <p>14 MR. KAWAMOTO: Actually, can I take a 20 second</p> <p>15 break? I just need to grab an exhibit.</p> <p>16 THE VIDEOGRAPHER: Going off the record at 2:28.</p> <p>17 (WHEREUPON, a recess was had</p> <p>18 from 2:28 to 2:29 p.m.)</p> <p>19 THE VIDEOGRAPHER: We are back on the record at</p> <p>20 2:29.</p> <p>21 (WHEREUPON, a certain document was</p> <p>22 marked Mallinckrodt-Ratliff</p> <p>23 Deposition Exhibit No. 016, for</p> <p>24 identification, as of 12/19/2018.)</p>	<p style="text-align: right;">Page 192</p> <p>1 Q. Do you recall being present at that</p> <p>2 meeting?</p> <p>3 A. No.</p> <p>4 Q. Okay. Then can you read that sentence</p> <p>5 starting from "within" that I've highlighted on my</p> <p>6 copy of the document?</p> <p>7 A. "Within that session, DEA announced a 'new</p> <p>8 direction' initiative whereby enforcement action will</p> <p>9 be aimed at all entities within the supply chain,</p> <p>10 including manufacturing registrants."</p> <p>11 Should I go on?</p> <p>12 Q. Yes.</p> <p>13 A. Okay. "The expectation is becoming that</p> <p>14 suppliers have not only an obligation to know their</p> <p>15 customers but an additional responsibility to know</p> <p>16 their customers. DEA now has information that</p> <p>17 indicates, as enforcement activity directed at pain</p> <p>18 clinics in Florida as it relates to the diversion of</p> <p>19 oxycodone 15 and 30-milligram is escalated, the pain</p> <p>20 clinics are reestablishing their businesses in</p> <p>21 Georgia, Ohio and Texas."</p> <p>22 Q. Okay. Thank you.</p> <p>23 So is it fair to say that as of July 2010,</p> <p>24 the DEA was indicating that it believed you should</p>
<p style="text-align: right;">Page 191</p> <p>1 BY MR. KAWAMOTO:</p> <p>2 Q. Mr. Ratliff, I understand that this e-mail</p> <p>3 is fairly lengthy, so I'm going to question you on the</p> <p>4 first three pages. So Bates range 571 to 573, if that</p> <p>5 helps your review.</p> <p>6 A. Where did you want me to stop?</p> <p>7 Q. Well, why don't we look at the e-mail that</p> <p>8 spans Pages 572 to 573.</p> <p>9 A. On Harvard Drug?</p> <p>10 Q. Yes.</p> <p>11 A. Okay.</p> <p>12 Q. Okay. And so the e-mail -- the e-mail is</p> <p>13 about Mallinckrodt customer Harvard Drug.</p> <p>14 Do you recall anything about that</p> <p>15 customer?</p> <p>16 MR. O'CONNOR: Objection.</p> <p>17 BY THE WITNESS:</p> <p>18 A. I know that -- that we did an audit at</p> <p>19 some point, but I wasn't involved.</p> <p>20 BY MR. KAWAMOTO:</p> <p>21 Q. Okay. Now, the e-mail also references an</p> <p>22 impromptu meeting following a site visit on July 21st,</p> <p>23 2010.</p> <p>24 A. Okay.</p>	<p style="text-align: right;">Page 193</p> <p>1 know your customer's customer?</p> <p>2 MR. O'CONNOR: Objection.</p> <p>3 BY THE WITNESS:</p> <p>4 A. Yes.</p> <p>5 BY MR. KAWAMOTO:</p> <p>6 Q. And do you recall anything about pain --</p> <p>7 being informed that pain clinics were reestablishing</p> <p>8 their businesses in Georgia, Ohio and Texas?</p> <p>9 A. I don't recall that specifically.</p> <p>10 Q. And then turning the page, could you</p> <p>11 please read the -- what I have highlighted under</p> <p>12 Action Plan?</p> <p>13 A. "The team believes the suspicious order</p> <p>14 monitoring program can be further enhanced by</p> <p>15 analyzing chargeback data for indirect customers and</p> <p>16 direct sales information available within existing</p> <p>17 systems."</p> <p>18 Q. Okay. And the reference to the "team,"</p> <p>19 was that the suspicious order monitoring team?</p> <p>20 A. I believe that's what she was referring</p> <p>21 to.</p> <p>22 Q. Okay. And so in re -- in response to</p> <p>23 DEA's -- in response to DEA's direction that</p> <p>24 Mallinckrodt and other manufacturers need to start</p>

<p style="text-align: right;">Page 194</p> <p>1 knowing their customer's customer, Mallinckrodt's 2 response, and I'm not saying this is a complete 3 response, but a part of Mallinckrodt's response was to 4 start relying on chargeback data. 5 Is that accurate? 6 A. I think so. 7 Q. Okay. Thank you. 8 A. Is that all on that document? 9 Q. Yes, that's all on that document. 10 (WHEREUPON, a certain document was 11 marked Mallinckrodt-Ratliff 12 Deposition Exhibit No. 017, for 13 identification, as of 12/19/2018.) 14 BY MR. KAWAMOTO: 15 Q. So this is a PowerPoint, Bates numbered 16 496098, and I'm only going to ask you about certain 17 pages, but looking at the cover page, it is the 18 Mallinckrodt Controlled Substance Suspicious Order 19 Monitoring Program, Presentation for Marketing Group, 20 March 21st, 2011. 21 Do you have any recollection of this 22 PowerPoint? 23 A. No. 24 Q. Okay. Would this PowerPoint have been put</p>	<p style="text-align: right;">Page 196</p> <p>1 A. I would think just to inform them of 2 what's going on with Harvard and Sunrise. 3 Q. And with respect to Sunrise, it says: 4 "License voluntarily surrendered." 5 What does that mean to you? 6 A. That DEA asked for it and they gave it to 7 them without having to suspend them themselves. 8 Q. Which means that after they voluntarily 9 surrender their license, that -- that is a -- I guess 10 a permanent status, isn't it? 11 MR. O'CONNOR: Objection. 12 BY THE WITNESS: 13 A. I don't know that. I don't know that 14 they -- once they -- it could be a -- a matter of the 15 way they stored their material and if they came back, 16 I'm just giving you a hypothetical, if they -- they 17 remedied that, then they could reapply. So I don't 18 know if it's permanent. That's why I'm saying I don't 19 know. 20 BY MR. KAWAMOTO: 21 Q. But if it were for failure to maintain 22 effective diversion controls, that voluntarily -- 23 that -- I'm sorry -- that voluntary surrender would 24 likely be permanent, would it not?</p>
<p style="text-align: right;">Page 195</p> <p>1 together by the compliance department? 2 A. I would think, yes. 3 Q. And it is a presentation for the marketing 4 group. Do you know why that they -- why the 5 compliance department or why -- well, strike that. 6 Do you know why the marketing group would 7 be receiving a presentation on Mallinckrodt's 8 suspicious order monitoring program? 9 A. I would believe it's to make sure 10 everybody is on the same page with the suspicious 11 order monitoring program. 12 Q. And directing your attention to, I believe 13 it's Page 14 of this PowerPoint. 14 A. Okay. 15 Q. And it has information relating to Harvard 16 Drugs and Sunrise Distributors. 17 A. Okay. 18 Q. Do you see that? 19 Do you know why this information would be 20 conveyed to the marketing department -- well, strike 21 that. 22 What is -- what is the -- what is the 23 substance of the information in this PowerPoint 24 regarding Harvard Drug and Sunrise Distributors?</p>	<p style="text-align: right;">Page 197</p> <p>1 MR. O'CONNOR: Objection. 2 BY THE WITNESS: 3 A. I don't know that. 4 BY MR. KAWAMOTO: 5 Q. To your knowledge, did Sunrise ever get 6 its license back? 7 A. I don't know that. 8 Q. Directing your attention to Page 15. 9 A. Okay. 10 Q. Can you please read -- could you please 11 read the statements under the DEA St. Louis 12 Conversation? 13 A. "Mallinckrodt was named as a supplier of 14 Harvard at a DEA training session in Washington, D.C. 15 Pain clinic undercover operations reveal a 'cattle 16 call' scenario. Mallinckrodt is viewed as the kingpin 17 within the drug cartel. DEA is implementing a 'new 18 direction' initiative aimed at manufacturing [sic] of 19 oxycodone. DEA expectation has evolved to require 20 that manufacturers know their customers' customers." 21 Q. Okay. So much of that is consistent with 22 the e-mail that we -- that we viewed previously? 23 A. Yes. 24 Q. Do you ever recall being informed that</p>

<p style="text-align: right;">Page 198</p> <p>1 Mallinckrodt was viewed as the kingpin within the drug 2 cartel with reference to Harvard? 3 A. Yes. 4 Q. And what do you recall about that 5 discussion or conversation? 6 A. We were outraged about it. It's just 7 simply not true, and to -- to use terms like that in a 8 conference with DEA compliance personnel is disgusting 9 in my opinion. Being from a Federal agency, we would 10 never do that in a wide open forum and make some 11 outlandish statement like that. 12 Q. And to be clear, the entity that was 13 making the statement, though, was the Drug Enforcement 14 Administration, is that correct? 15 A. Yeah. It doesn't make them right. It 16 just makes them the Drug Enforcement Administration. 17 Q. And what's meant by "plain" -- "pain 18 clinic undercover operations reveal a cattle call 19 scenario"? 20 Do you know what that means? 21 MR. O'CONNOR: Objection. 22 BY THE WITNESS: 23 A. I really don't. 24 BY MR. KAWAMOTO:</p>	<p style="text-align: right;">Page 200</p> <p>1 Discussion Group? 2 A. It's a group of manufacturers that get 3 together and compare notes. They can't talk about 4 quota or manufacture, but they can talk about things 5 like the suspicious order monitoring program, DEA 6 letters and -- and different things like that. They 7 can talk about all kinds of stuff. They just have to 8 be careful about not discussing their quota issues and 9 so forth with other registrants. 10 Q. And can you read this highlighted section 11 for me, please? 12 A. "One member of industry indicated they 13 have received advice from DEA that the suspicious 14 order monitoring program should allow DEA registrants 15 to 'know their customer' and compare that activity to 16 a bank's obligation to report \$10,000 transactions to 17 law enforcement for detection of money laundering 18 while having the ability to detect multiple 19 transactions at 9,999." 20 Q. Okay. And can you also read what's 21 underneath it? 22 A. "Other suggestions included: On-site 23 visits for all controlled substance customers, close 24 scrutiny of" -- "scrutiny of small, independent</p>
<p style="text-align: right;">Page 199</p> <p>1 Q. Okay. 2 A. Are we still on the same document? 3 Q. No. We are done with that document. 4 A. Okay. Thank you. 5 (WHEREUPON, a certain document was 6 marked Mallinckrodt-Ratliff 7 Deposition Exhibit No. 018, for 8 identification, as of 12/19/2018.) 9 BY MR. KAWAMOTO: 10 Q. Yeah, so this is an e-mail chain between 11 you and Karen Harper among other people. It's Bates 12 number is 419903. 13 A. Okay. 14 Q. So directing your attention to the bottom 15 e-mail from Karen Harper to you and others. 16 A. Okay. 17 Q. It states: "On 4/23/08, I attended a 18 meeting of the Midwest Controlled Substance Discussion 19 Group in Chicago. Among the agenda items was 20 suspicious order monitoring." 21 Do you recall whether you attended that 22 meeting as well? 23 A. I never attended these meetings ever. 24 Q. What was the Midwest Controlled Substance</p>	<p style="text-align: right;">Page 201</p> <p>1 pharmacies, close scrutiny of pain management 2 clinics." 3 Q. And so those suggestions, particularly the 4 "close scrutiny of small independent pharmacies" and 5 the "close scrutiny of pain management clinics," that 6 would be consistent with knowing your customer's 7 customer, would it not? 8 A. It would be, but the people that attended 9 this meeting can also be distributors. They don't 10 have to just be manufacturers. They are in the 11 industry, so. 12 Q. But as a -- as a general -- I mean, well, 13 from your standpoint in terms of the enhancements that 14 Mallinckrodt is seeking to make to its suspicious 15 order monitoring program, that -- those types of 16 enhancements, the close scrutiny of small independent 17 pharmacies and close scrutiny of pain management 18 clinics, were things that Mallinckrodt was 19 undertaking, is that correct? 20 MR. O'CONNOR: Objection. 21 BY THE WITNESS: 22 A. Well, if you read this, it says: "On-site 23 visits for all controlled substance customers." 24 I mean, what you are saying is "all" and</p>

<p style="text-align: right;">Page 202</p> <p>1 that's a -- I just can't agree with that. There are 2 pharmacies all over the United States that are as 3 legitimate as can be and then they order through their 4 parent or directly from one of our distributors. So 5 to say we have to go to all of those... 6 "Close scrutiny of small, independent 7 pharmacies." So -- "Close scrutiny of pain management 8 clinics." 9 So what you are saying is the manufacturer 10 bypasses the distributor and goes directly to all pain 11 management clinics; close scrutiny of small, 12 independent pharmacies. I'm not sure you understand 13 what that means. 14 Q. Well, I don't know that -- I'm not sure 15 that that is what that's saying. I think what it's 16 saying is: On-site visits of all controlled substance 17 customers, and you've indicated that that's -- 18 A. Those are suggestions. 19 Q. -- that that may not be feasible. 20 But close scrutiny of small, independent 21 pharmacies, that -- that is something that a 22 manufacturer could do, could it not, and isn't that 23 what Mallinckrodt was doing? 24 A. These are --</p>	<p style="text-align: right;">Page 204</p> <p>1 Mallinckrodt agreed with, did it not? 2 A. I don't know that. 3 Q. Isn't that -- 4 A. These are -- 5 Q. Well -- 6 A. These are other suggestions included, but 7 you are saying we agreed to that. I have no reason to 8 think that we agreed to that. 9 Q. Well, isn't that part of knowing your 10 customer's customer though? 11 A. I don't think so. I mean, how do we know 12 that the close scrutiny of small, independent 13 pharmacies, that they even buy from one of our 14 distributors. You understand that there are many, 15 many distributors and there are many manufacturers and 16 they a lot of times don't buy our product, they buy 17 someone else's. 18 Q. But looking at your customer's customer, 19 meaning those customers of the customer of 20 Mallinckrodt, looking at that universe, it would make 21 sense to scrutinize small, independent pharmacies, 22 would it not? 23 MR. O'CONNOR: Objection. 24 BY THE WITNESS:</p>
<p style="text-align: right;">Page 203</p> <p>1 MR. O'CONNOR: Objection. 2 BY THE WITNESS: 3 A. -- suggestions -- 4 BY MR. KAWAMOTO: 5 Q. No, I understand that. 6 A. -- that you can include to -- I mean, it 7 is not a direct -- and you have to remember who is 8 meeting. These are manufacturers and distributors 9 meeting, and within that they are saying this is what 10 we are kind of hearing from DEA that, you know, in a 11 perfect world, because when you talk about the bank's 12 obligations and then the -- their ability -- you know, 13 9,999, that's a structuring violation. I used to have 14 a bank fraud squad and I got those every week, but 15 that didn't mean that those people were crooks. That 16 meant that they had either taken or deposited that 17 much money. So you have to at least -- do you see 18 what I'm saying? It's -- it's not an absolute. That 19 program is meant to determine if someone is abusing, 20 they're -- they're money laundering or selling or 21 drugs or some other illicit product, so. 22 Q. But the suggestions for close scrutiny of 23 small, independent pharmacies and close scrutiny of 24 pain management clinics, those were suggestions that</p>	<p style="text-align: right;">Page 205</p> <p>1 A. I don't know. I just -- I don't think so 2 because the thing I have a real hang-up with on-site 3 visits of all controlled substance. That's the first 4 recommendation. That's incredible, "all." You just 5 can't do that. And then close scrutiny of small, 6 independent pharmacies, have you -- well, I'm not 7 going to ask you a question. 8 In Florida there are literally hundreds 9 and hundreds of small, independent pharmacies, and 10 I've been in some of those. And while in there, they 11 say, Well, we deliver or We have a better price or We 12 can get this for a customer or They ordered this in 13 addition to that. So there is no way I could say they 14 are doing something nefarious because they are a 15 small, independent pharmacy, but to go to every single 16 one in Florida alone is just -- it's beyond how that 17 would be within anyone's capability, so. 18 Q. But if you had a way to screen the small, 19 independent pharmacies and prioritize certain ones, 20 then it would make sense to focus on those, would it 21 not? 22 MR. O'CONNOR: Objection. 23 BY THE WITNESS: 24 A. Some of those people don't get chargebacks</p>

<p style="text-align: right;">Page 206</p> <p>1 because they don't buy enough product, so they 2 wouldn't be visible to us at all. 3 BY MR. KAWAMOTO: 4 Q. But some of them would be in the 5 chargeback system, correct? 6 MR. O'CONNOR: Objection. 7 BY THE WITNESS: 8 A. I don't know that. 9 BY MR. KAWAMOTO: 10 Q. And what about pain management clinics, I 11 mean, that was -- that was an area that Mallinckrodt 12 scrutinized, did it not? 13 A. We looked at the pharmacies, not the 14 doctors. So pain -- pain management clinics, that -- 15 they write the script to the pharmacy. So now you've 16 removed it one more time. You have the -- you have 17 the manufacturer, the distributor, you have then the 18 distributor's customer would be the clinic, and then 19 beyond the clinic you have the doctor that writes the 20 script. So now you don't just know your customer's 21 customer because the distributor doesn't know the 22 customers, the doctors. 23 Q. But in certain instances don't pain 24 management clinics dispense opioid products strictly</p>	<p style="text-align: right;">Page 208</p> <p>1 affiliated with the pain management clinic or the pain 2 management clinic opened up a pharmacy, then you would 3 look at them as well, correct? 4 MR. O'CONNOR: Objection. 5 BY THE WITNESS: 6 A. Please repeat that. I'm -- you are losing 7 me on that. 8 BY MR. KAWAMOTO: 9 Q. Did you ever encounter a situation where a 10 pain management clinic had a pharmaceutical license 11 that was giving out drugs to its patients? 12 A. No. You are asking me personally, right? 13 No. 14 Q. Or in your experience working for 15 Mallinckrodt as the director of security? 16 A. I never saw it. I'm not saying it didn't 17 happen. I just never saw it, so. 18 Q. Now, the paragraph above where it says: 19 "Advice from DEA that sus" -- "that the Suspicious 20 Order Monitoring program should allow DEA registrants 21 to 'know their customer' and compare that activity to 22 a bank's obligation to report \$10,000 transactions to 23 law enforcement," that is a capability that the 24 chargeback data would have provided to you, is that</p>
<p style="text-align: right;">Page 207</p> <p>1 in Florida? 2 A. I don't know that. I just don't know 3 that. The ones that I looked at were writing scripts 4 to the pharmacy and that's where we, you know, we were 5 looking at the pharmacy, was it legitimate, if you get 6 15 scripts and they are all 90 pills for 30-milligrams 7 and not everybody has the same pain threshold or 8 issues. 9 Q. And when you say, "The ones that I looked 10 at were writing scripts," those -- did you -- those 11 were the pain management clinics that you looked at? 12 A. No. 13 MR. O'CONNOR: Objection. 14 BY MR. KAWAMOTO: 15 Q. Then what -- what's the reference to 16 "ones," what were you looking at? 17 A. We were looking at the pharmacies. The 18 pharmacies -- the pain management, those are the 19 doctors. So the doctors are writing a script to the 20 pharmacy for the patient. 21 Q. Okay. And so you didn't look at the pain 22 management clinics, you just looked at the pharmacies? 23 A. Yes. 24 Q. And to the degree the pharmacy was</p>	<p style="text-align: right;">Page 209</p> <p>1 correct? 2 MR. O'CONNOR: Objection. 3 BY THE WITNESS: 4 A. The \$10,000 transaction is the law. 5 BY MR. KAWAMOTO: 6 Q. No, I'm aware of that. 7 A. Okay. 8 Q. But if you were to translate that, for 9 example, on a certain threshold of pills, that is 10 something that chargeback data could have given you 11 insight into? 12 MR. O'CONNOR: Objection. 13 BY THE WITNESS: 14 A. This information is coming from a member, 15 one -- an attendee at this conference. So, I don't 16 know how -- you know, how valid that information is 17 without -- I don't know that was, I don't know what 18 their background is or how they would know. I don't 19 know that I can agree. Do we know our -- should we 20 know our customer's customer, after DEA told us, yes. 21 So I can tell you that's the case. But I don't know 22 how all of this other is even -- even important. 23 As I told you before, having a bank fraud 24 squad, I got this information every single week as the</p>

<p style="text-align: right;">Page 210</p> <p>1 supervisor, and a lot of times it was -- it wasn't</p> <p>2 consistent. There was no pattern to it. So what we</p> <p>3 were looking for is a pattern. So to say this --</p> <p>4 Q. Okay. Well, putting -- okay. Putting</p> <p>5 aside this e-mail, sir --</p> <p>6 A. Say again.</p> <p>7 Q. Putting aside this e-mail.</p> <p>8 A. Okay.</p> <p>9 Q. So putting this e-mail aside.</p> <p>10 A. Okay.</p> <p>11 Q. The volume of oxy co -- of oxy 30s that</p> <p>12 your customer's customer was obtaining from its</p> <p>13 distributor, that was relevant information that</p> <p>14 Mallinckrodt would pay attention to, would it not?</p> <p>15 A. Yes.</p> <p>16 Q. Okay.</p> <p>17 (WHEREUPON, a certain document was</p> <p>18 marked Mallinckrodt-Ratliff</p> <p>19 Deposition Exhibit No. 019, for</p> <p>20 identification, as of 12/19/2018.)</p> <p>21 BY MR. KAWAMOTO:</p> <p>22 Q. So this is an e-mail chain with Bates</p> <p>23 No. 274608, and the bottom e-mail includes you, the</p> <p>24 top e-mail does not. But the bottom e-mail includes</p>	<p style="text-align: right;">Page 212</p> <p>1 about a meeting in that timeframe?</p> <p>2 A. I remember I met Michael Morley. He was</p> <p>3 with the DEA. I met him on more than one occasion, I</p> <p>4 believe. Do I remember this particular meeting, no.</p> <p>5 Q. And who is Michael Morley?</p> <p>6 A. He was a -- he was in the Wash -- it is in</p> <p>7 Virginia. We call it the Washington, D.C. DEA</p> <p>8 headquarters. It is actually in Virginia, right</p> <p>9 across the river, and he was one of their -- I believe</p> <p>10 he was a supervisor, but he was also a lab-type person</p> <p>11 and then he went into the supervisory position and</p> <p>12 then back. He transferred out of headquarters and</p> <p>13 went to Texas, back in the labs, so. I do know who he</p> <p>14 is. And I have met with him, but I just don't</p> <p>15 remember being there with all of these people.</p> <p>16 Q. Okay. And do you recall anything about</p> <p>17 the suspicious order monitoring initiative that was</p> <p>18 the subject of a presentation by Mallinckrodt?</p> <p>19 A. The problem is I don't remember</p> <p>20 specifically about this meeting, and I really don't</p> <p>21 remember all of these people, so I'm not certain I was</p> <p>22 there. You do understand I traveled quite a lot, so.</p> <p>23 If I was available for a meeting, I would go.</p> <p>24 Q. How often did you have meetings at --</p>
<p style="text-align: right;">Page 211</p> <p>1 a -- an agenda or a rough agenda for a DEA meeting in</p> <p>2 Washington, D.C.</p> <p>3 Do you see that, sir?</p> <p>4 A. Say that again. I was reading.</p> <p>5 Q. The bottom e-mail from Karen Harper to</p> <p>6 JoAnne Levy, cc'ing various people, including you --</p> <p>7 A. Okay.</p> <p>8 Q. -- contains an agenda for a meeting with</p> <p>9 DEA in Washington, D.C.</p> <p>10 Do you see that?</p> <p>11 A. I do.</p> <p>12 Q. Okay. And for Mallinckrodt attendees, you</p> <p>13 are listed as an attendee.</p> <p>14 Do you see that?</p> <p>15 A. Yes.</p> <p>16 Q. Okay. And do you also see under</p> <p>17 Presentation by Mallinckrodt to include, it says:</p> <p>18 "Suspicious Order Monitoring Initiative."</p> <p>19 Do you see that?</p> <p>20 A. Yes.</p> <p>21 Q. Do you recall attending a meeting in</p> <p>22 August at DEA offices in Washington, D.C.?</p> <p>23 A. Not specifically.</p> <p>24 Q. Well, do you generally recall anything</p>	<p style="text-align: right;">Page 213</p> <p>1 well, the DEA headquarters are in Arlington, Virginia?</p> <p>2 A. Yes.</p> <p>3 Q. How often would you have meetings at DEA</p> <p>4 headquarters?</p> <p>5 A. I would say once or twice a year.</p> <p>6 Q. Now, the fact the attendees include</p> <p>7 Charles Bramlage, president of Pharmaceutical</p> <p>8 Products, right?</p> <p>9 A. That's what it says.</p> <p>10 Q. And it includes the vice president JoAnne</p> <p>11 Levy?</p> <p>12 A. Um-hum.</p> <p>13 Q. I mean, this would -- the attendance list</p> <p>14 would suggest this was an import -- important meeting,</p> <p>15 would it not?</p> <p>16 MR. O'CONNOR: Objection.</p> <p>17 BY THE WITNESS:</p> <p>18 A. Okay. It is a draft e-mail to Michael</p> <p>19 Morley and it's suggestion -- suggesting these people</p> <p>20 should attend. So, if I was available, I probably</p> <p>21 would have attended, but I can't tell you today that I</p> <p>22 attended at all. It's a draft. These are who they</p> <p>23 are recommending go to this meeting.</p> <p>24 BY MR. KAWAMOTO:</p>

Page 214

1 Q. Do you know who Patricia Woz -- Woznick
2 was?
3 A. I've seen the name before, but I don't
4 know who she is really. Have I met her sometime in
5 the past, this is in '08, so it's ten years old, so,
6 yeah, I don't know that I know her.
7 Q. So if I wanted to find out more about this
8 meeting, who would I talk to?
9 A. I would talk to the writer. It would be
10 Karen Harper.
11 Q. That would be Karen Harper?
12 A. Yeah.
13 Q. Okay.
14 A. I'm not saying I didn't attend. I'm
15 saying I don't recall attending, and I don't recall
16 attending with all of these people anyway. Okay.
17 Q. Okay.
18 (WHEREUPON, a certain document was
19 marked Mallinckrodt-Ratliff
20 Deposition Exhibit No. 020, for
21 identification, as of 12/19/2018.)
22 BY MR. KAWAMOTO:
23 Q. So this is an e-mail from Karen Harper to
24 you and Eileen Spaulding. Its Bates number is 421973,

Page 215

1 and the attachment is meeting notes from a meeting at
2 DEA St. Louis in November of 2010.
3 Do you see that, sir?
4 A. I do.
5 Q. Now, if you look at the attachment which
6 are the meeting notes.
7 A. Okay.
8 Q. It says: "Representing Mallinckrodt." It
9 identifies you and Karen Harper.
10 A. Um-hum.
11 Q. Do you have any recollection of this
12 meeting, sir?
13 A. I actually do.
14 Q. Okay. What do you recall about it?
15 A. That we met with them to provide them
16 details of our program and how it was evolving and
17 changing into what we thought was an exceptional
18 program and would be a leader in the industry.
19 Q. Okay. Now, the second paragraph down from
20 "General Feedback From St. Louis."
21 Okay. So can you read that highlighted
22 paragraph for me, please?
23 A. "Further, DPM advised that, nationally,
24 the DEA has been holding conferences to realign their

Page 216

1 resources focusing on inspection/investigations of
2 manufacturing registrants since DEA has been
3 ineffective at stopping the illicit sales of oxycodone
4 15 and 30-milligram tablets. Additionally, the
5 Mal" -- "that Mallinckrodt has been mentioned
6 specifically at DEA conferences in Washington, D.C.
7 given that Mallinckrodt is the dominant manufacturer
8 of generic oxycodone 30-milligrams."
9 Q. Do you recall that conversation from that
10 meeting, sir?
11 A. I more recall the paragraph above it. So
12 that's what I took away from the meeting, that it was,
13 you know, one of the best programs he had seen. He
14 couldn't approve it, but he thought it was a --
15 certainly -- and that's what I looked at. That's what
16 I brought back from that meeting, if that's what you
17 are asking.
18 Q. Well, what is -- who is the DPM?
19 A. He is the diversion program manager. That
20 would be Scott Collier.
21 Do you see above where they -- they put
22 "Diversion Program Manager (DPM)" above --
23 Q. Yes.
24 A. -- DEA attendees?

Page 217

1 So he is the one that's saying the best
2 suspicious order monitoring process he has seen to
3 date and what he expected from a Mallin- -- from
4 Mallinckrodt as an industry leader, that's exactly
5 what I took away from that meeting. And I was proud
6 of it, because we had developed and continued to
7 strive to put the very best program we could together
8 to ensure that we prevented diversion, so.
9 Q. And you believe that DEA would be in a
10 position to know whether a program was good or not,
11 right?
12 A. Yes, I think so, certainly someone at his
13 level. That's a high level.
14 Q. Okay. But do you have -- you don't have
15 any recollection of DEA indicating that they had been
16 ineffective at stopping illicit sales of oxy 15 and
17 30-milligram tablets?
18 A. That may have come up, but that was kind
19 of a common knowledge that they were having a
20 difficult time. It's what I alluded to earlier this
21 morning that we thought they were using this to do
22 audits, and when we did -- sent them the letters and
23 so forth, it turns out they weren't doing that at all.
24 So we were a little surprised, but we -- I mean,

<p style="text-align: right;">Page 218</p> <p>1 that's all I have to say.</p> <p>2 Q. So did Mallinckrodt pay -- start paying</p> <p>3 particular attention to oxy 15 and oxy 30 shipments as</p> <p>4 a result of these concerns?</p> <p>5 A. We did all along. It wasn't just because</p> <p>6 of these concerns. We were always concerned about</p> <p>7 those shipments.</p> <p>8 Q. You were always concerned about the</p> <p>9 shipment of oxy 15 and oxy 30?</p> <p>10 A. Yes.</p> <p>11 Q. Now, do you see the bottom paragraph that</p> <p>12 says: "DEA had positive comments about Mallinckrodt</p> <p>13 retaining Howard Davis"?</p> <p>14 A. Um-hum.</p> <p>15 Q. Who is Howard Davis?</p> <p>16 A. Howard Davis was a -- I believe he was a</p> <p>17 diversion program manager in Atlanta, and so we were</p> <p>18 trying to get a better understanding of what was</p> <p>19 required by DEA. So he retired. He came to</p> <p>20 St. Louis, we hired him as a consultant. So he -- he</p> <p>21 was supposed to look at our program and say, We can do</p> <p>22 this or We can do that. He was just taking our</p> <p>23 program that was already written and maybe changing a</p> <p>24 word here or there, but it was our program. It had</p>	<p style="text-align: right;">Page 220</p> <p>1 better, you try to use every resource that you can,</p> <p>2 and so that was a resource that we thought might be</p> <p>3 able to help us. And DEA recommended him. Pete</p> <p>4 Kleissle recommended the guy. He said he was</p> <p>5 wonderful, so, okay.</p> <p>6 Q. And he was a DPM, right?</p> <p>7 A. I believe so.</p> <p>8 Q. So he was the same level as Scott Collier?</p> <p>9 A. That's my memory, but he may have been the</p> <p>10 same level as Pete Kleissle, but I believe he was a</p> <p>11 DPM.</p> <p>12 Q. Okay. So he had a very high level of</p> <p>13 expertise, did he not?</p> <p>14 MR. O'CONNOR: Objection.</p> <p>15 BY THE WITNESS:</p> <p>16 A. That was my hope.</p> <p>17 BY MR. KAWAMOTO:</p> <p>18 Q. And you ultimately recommended him to</p> <p>19 another manufacturer in St. Louis?</p> <p>20 A. I did.</p> <p>21 Are we through with that document?</p> <p>22 Q. Yes.</p> <p>23 (WHEREUPON, a certain document was</p> <p>24 marked Mallinckrodt-Ratliff</p>
<p style="text-align: right;">Page 219</p> <p>1 already been done. And he worked on it for several</p> <p>2 weeks. And I was disappointed to say the least. I</p> <p>3 thought that having someone at that elevated position</p> <p>4 would ensure we had the very best program possible for</p> <p>5 an industry leader, and that's what we were, and we</p> <p>6 were always striving to have the very best program</p> <p>7 possible. So we hired him and he was with us for a</p> <p>8 short time. I recommended him to go with another</p> <p>9 registrant there in St. Louis. And I know that he</p> <p>10 eventually went over there and did work for them also.</p> <p>11 Q. And I'm sorry. You indicated that you</p> <p>12 were disappointed in him?</p> <p>13 A. I was hoping that he would have some magic</p> <p>14 bullet, that he would come in and say, Oh, this is</p> <p>15 what we are looking at, but he didn't have that. He</p> <p>16 took the program we had already written and was</p> <p>17 basically copying it over and -- and polishing it a</p> <p>18 little bit, but it really didn't change the substance</p> <p>19 of that particular -- the program we had already</p> <p>20 written, so.</p> <p>21 Q. And so you were looking for him to</p> <p>22 substantively change the program or -- I'm not clear</p> <p>23 on exactly why you were disappointed in him?</p> <p>24 A. Well, when you are always attempting to do</p>	<p style="text-align: right;">Page 221</p> <p>1 Deposition Exhibit No. 021, for</p> <p>2 identification, as of 12/19/2018.)</p> <p>3 BY THE WITNESS:</p> <p>4 A. Which one do you want me to read?</p> <p>5 BY MR. KAWAMOTO:</p> <p>6 Q. Let's see. Actually, why don't we focus</p> <p>7 on the attachment. So that's -- this document is</p> <p>8 Bates No. 471744 and the attachment is Bates</p> <p>9 No. 471750.</p> <p>10 A. Okay.</p> <p>11 Q. So this is an agenda from an August 23rd,</p> <p>12 2011, meeting between you and the DEA at DEA</p> <p>13 headquarters.</p> <p>14 A. Okay.</p> <p>15 Q. And do you see under Expected Attendees</p> <p>16 that you are listed as an expected attendee?</p> <p>17 A. Um-hum.</p> <p>18 Q. Do you recall attending this meeting?</p> <p>19 A. I absolutely do.</p> <p>20 Q. Okay.</p> <p>21 A. That was the day they had the earthquake</p> <p>22 in Washington, D.C.</p> <p>23 Q. And what do you recall about this meeting?</p> <p>24 A. That they were very specific about knowing</p>

Page 222

1 our customer's customer, and they talked about some of
2 our distributors in detail, and we provided a lot of
3 information to them about what we were doing. And
4 they went, That's well and good, but you really need
5 to do this. And so when I left, this -- this is the
6 meeting I told you the following week I was in
7 Florida, this is what predicated that trip to Florida
8 was this specific -- this very meeting.
9 Q. Now, prior to this meeting, though, you
10 had received indications that DEA expected you to know
11 your customer's customer, had you not?
12 A. Yes.
13 MR. O'CONNOR: Objection.
14 THE WITNESS: I'm sorry.
15 BY MR. KAWAMOTO:
16 Q. Do you recall any of the distributors that
17 were specifically discussed at this meeting?
18 A. I do.
19 Q. And who were they?
20 A. The -- they call it the big three.
21 Q. And so that would be?
22 A. McKesson, Cardinal and AmerisourceBergen.
23 Q. And did the DEA have concerns about these
24 distributors?

Page 223

1 MR. O'CONNOR: Objection.
2 MS. KVESELIS: Object to form.
3 BY THE WITNESS:
4 A. They wanted to ensure that we looked at
5 their customers.
6 BY MR. KAWAMOTO:
7 Q. And you say that -- I believe you said
8 that the DEA provided specific information about these
9 distributors. Is that accurate or did I misunderstand
10 you?
11 MR. O'CONNOR: Objection.
12 BY THE WITNESS:
13 A. They named some of the people saying, If
14 it were me, I would look at these, their customers.
15 BY MR. KAWAMOTO:
16 Q. And did they identify the -- or strike
17 that.
18 Did they identify specific customers'
19 customers that you should be looking at?
20 A. No.
21 Q. They just indicated that if they were you,
22 they would scrutinize the customers' customers of
23 these three -- these big three distributors?
24 A. Right, because they are --

Page 224

1 MR. O'CONNOR: Objection.
2 BY THE WITNESS:
3 A. Right, because they are large and they --
4 they buy or they purchase large amounts of product and
5 distribute them, so, you know, that's why they were --
6 that's -- that's my opinion.
7 BY MR. KAWAMOTO:
8 Q. And you indicated that when you went to
9 Florida, you and two other forensic analysts looked at
10 30 pharmacies, is that accurate?
11 A. Yes.
12 Q. Did that list of 30 pharmacies come from
13 this meeting or did you generate that independently?
14 MR. O'CONNOR: Objection.
15 BY THE WITNESS:
16 A. We used the -- the information that we
17 possessed to look at the customers of these -- these
18 three major distributors. So we took the top ten
19 purchasers, that would be their customers, for each
20 one of those and then we divided those up into
21 territory and made assignments based on doing all 30
22 of those in a short period of time.
23 BY MR. KAWAMOTO:
24 Q. Now, when you say you used the information

Page 225

1 that we possessed, are you referring to the chargeback
2 information, is that correct?
3 A. Yes.
4 Q. Do you know how long Mallinckrodt has been
5 collecting chargeback information for?
6 MR. O'CONNOR: Objection.
7 BY THE WITNESS:
8 A. No, no clue.
9 BY MR. KAWAMOTO:
10 Q. Do you know if they had it in 2000?
11 MR. O'CONNOR: Objection.
12 BY THE WITNESS:
13 A. I didn't know about chargebacks until I
14 had been employed there a long time, so. I didn't
15 know.
16 BY MR. KAWAMOTO:
17 Q. But assuming this chargeback information
18 was available, you could have done this analysis
19 earlier?
20 MR. O'CONNOR: Objection.
21 BY MR. KAWAMOTO:
22 Q. It theoretically would have been possible?
23 MR. O'CONNOR: Objection.
24 BY THE WITNESS:

<p style="text-align: right;">Page 226</p> <p>1 A. Theoretically, if it was available and if 2 we knew it was available. The issue is that's 3 confidential customer data that if our -- our 4 competitors knew what we were selling to certain 5 customers, that would be valuable to them, and so that 6 was unknown to us for a long time because they were 7 protecting confidential information on our -- on our 8 customers. So -- 9 Q. And to be clear -- 10 A. -- and I understood that, so. 11 Sorry. 12 Q. To be clear, when you say "they were 13 protecting confidential information," they were 14 protecting confidential information within the 15 company; in other words, they were protecting 16 confidential information from you and Karen Harper, is 17 that what you are saying? 18 MR. O'CONNOR: Objection. 19 BY THE WITNESS: 20 A. They restricted access to that information 21 to all but need-to-know people within that department. 22 So, did they restrict it from Karen and I, one of 23 hundreds and hundreds of employees that didn't have 24 access to that information. So based on that, yes.</p>	<p style="text-align: right;">Page 228</p> <p>1 highly confidential, so. So I think we -- we used it 2 at some point well before the 2011. I know we were 3 using it before that, so. 4 Q. So, I mean -- so, are we talking about 5 2008, 2009 -- 6 A. Yeah, I -- 7 Q. -- roughly when? 8 MR. O'CONNOR: Objection. 9 BY MR. KAWAMOTO: 10 Q. I mean, clearly 2011, you had access to it 11 before 2011? 12 A. Um-hum. 13 Q. But you don't have any idea how long 14 before then? 15 A. Yeah, I -- I can't with specificity say it 16 was '09 or '0- -- you know, or '10 or -- I just can't. 17 I just don't recall. 18 Q. And who made the decision to allow you to 19 have access to this chargeback information? 20 A. I have no idea. 21 Q. Did Karen Harper make that decision? 22 A. Karen Harper didn't have the authority to 23 make that decision. 24 Q. So who would have had the authority then?</p>
<p style="text-align: right;">Page 227</p> <p>1 But the answer is -- and I understood when they 2 explained initially that if this gets out, all of our 3 competitors will know how much we sell to everyone, 4 and that's really confidential, and I understood why 5 it was confidential. At that time I didn't know that 6 we could glean so much information or we needed to 7 know or customer's customer. You have to understand 8 that. Initially I didn't know that, one, we could do 9 that or that it was, you know, acceptable in the -- in 10 the manufacturing process with all of the 11 manufacturers that they could go out and see not only 12 to whom they are selling but whom those customers are 13 selling to, so. 14 Q. But prior to 2011, the fact remains that 15 you and Karen Harper were not deemed to need to know 16 this information? 17 MR. O'CONNOR: Objection. 18 BY MR. KAWAMOTO: 19 Q. Correct? 20 A. No. I think we knew about it earlier and 21 I think we used it, and I think the first time that -- 22 nah, that's just -- one of the pharmacies -- one of 23 the distributors had an issue and I know that they 24 pulled some information for us and told us it was</p>	<p style="text-align: right;">Page 229</p> <p>1 A. I have no idea. 2 Q. Well, the people -- I mean, the people 3 ahead of you and Karen Harper would have been the vice 4 presidents, or I'm just trying to now understand 5 Mallinckrodt's corporate structure? 6 MR. O'CONNOR: Objection. 7 BY THE WITNESS: 8 A. I -- I literally don't know who possessed 9 the information or who was authorized to release the 10 information. That's -- I'm just telling you I don't 11 know. 12 BY MR. KAWAMOTO: 13 Q. And you have no i- -- you don't have any 14 recollection of when you found out about it, or do you 15 recall how you found out about it? 16 MR. O'CONNOR: Objection. 17 BY THE WITNESS: 18 A. I know at some point that we were able to 19 use some of that information. 20 BY MR. KAWAMOTO: 21 Q. But this could have been in 2005, this 22 could have been in 2007, this could have been in 2009, 23 you just don't know? 24 MR. O'CONNOR: Objection.</p>

<p style="text-align: right;">Page 230</p> <p>1 BY THE WITNESS:</p> <p>2 A. I just don't know.</p> <p>3 BY MR. KAWAMOTO:</p> <p>4 Q. If I wanted to find out the answer to</p> <p>5 this, who would I ask?</p> <p>6 A. You'd have to find out who controls the</p> <p>7 chargeback information.</p> <p>8 Q. And so in terms of your access to the</p> <p>9 chargeback information, did you have direct access or</p> <p>10 did you make a request of someone and they provided</p> <p>11 you with the data?</p> <p>12 A. Karen Harper gave me the information on a</p> <p>13 spreadsheet and said, These customers' customers are</p> <p>14 buying this, and so I had a spreadsheet that listed</p> <p>15 all of the names, okay, of those 30. So, who she</p> <p>16 talked to, where she got that information, but she</p> <p>17 provided it to me, and I was on a plane by myself to</p> <p>18 go down and find all of these pharmacies to see, you</p> <p>19 know, plus the additional help from the east side of</p> <p>20 Florida.</p> <p>21 Q. Now, you indicated at some point that</p> <p>22 Mallinckrodt started using chargeback data in its</p> <p>23 suspicious order monitoring program, right?</p> <p>24 MR. O'CONNOR: Objection.</p>	<p style="text-align: right;">Page 232</p> <p>1 A. In this instance.</p> <p>2 Q. Understood.</p> <p>3 Did the national account managers have</p> <p>4 access to this information via Karen Harper?</p> <p>5 A. You are asking me questions I have no --</p> <p>6 no clue as to who does. I just don't know.</p> <p>7 Q. So you've indicated that you do recall</p> <p>8 this August 2011 meeting. Do you have any specific</p> <p>9 memories of any other meetings with DEA, or is it this</p> <p>10 one and then you recalled the other one in St. Louis</p> <p>11 from I believe 2010?</p> <p>12 MR. O'CONNOR: Objection.</p> <p>13 BY THE WITNESS:</p> <p>14 A. I know that we had one where the plant</p> <p>15 manager, Karen Harper and I were summoned to DEA about</p> <p>16 some issue.</p> <p>17 BY MR. KAWAMOTO:</p> <p>18 Q. Do you recall the issue?</p> <p>19 A. No. I just remember we went.</p> <p>20 Q. Do you recall roughly when this occurred?</p> <p>21 A. I have no clue.</p> <p>22 Q. And the plant manager would have been who?</p> <p>23 A. His first name was Paul.</p> <p>24 Q. Okay. And I take if you don't recall the</p>
<p style="text-align: right;">Page 231</p> <p>1 BY THE WITNESS:</p> <p>2 A. (Nodding head.)</p> <p>3 BY MR. KAWAMOTO:</p> <p>4 Q. So at that point who had access to this</p> <p>5 information?</p> <p>6 A. Well, it would have been Karen and if she</p> <p>7 shared it with me, you know, the -- I'm just really</p> <p>8 not trying to be -- I just don't remember. It's just</p> <p>9 been too long ago to say it happened this time or this</p> <p>10 person was present. At my age I'm -- I'm just doing</p> <p>11 the best I can.</p> <p>12 Q. Oh, I understand that. But we're talking</p> <p>13 about highly sensitive information. And so you had</p> <p>14 access to it, Karen Harper had access to it, so --</p> <p>15 A. And I didn't have direct access. I</p> <p>16 shouldn't have.</p> <p>17 Q. But you didn't have direct access?</p> <p>18 A. No.</p> <p>19 Q. So Karen -- Karen Harper either had direct</p> <p>20 access or could get it from someone?</p> <p>21 A. Or she could ask for specific things that</p> <p>22 she wanted.</p> <p>23 Q. Okay. And she would provide that to you.</p> <p>24 Did the --</p>	<p style="text-align: right;">Page 233</p> <p>1 last name?</p> <p>2 A. No.</p> <p>3 Q. Okay.</p> <p>4 A. I was lucky to recall Paul.</p> <p>5 Q. Fair enough.</p> <p>6 But at some point you, Karen Harper and</p> <p>7 Paul were -- I assume DEA summoned you.</p> <p>8 Would they -- do you know if they summoned</p> <p>9 you to their St. Louis office or --</p> <p>10 MR. O'CONNOR: Objection.</p> <p>11 BY THE WITNESS:</p> <p>12 A. No. That was in DC.</p> <p>13 BY MR. KAWAMOTO:</p> <p>14 Q. Okay. So you were summoned to DC?</p> <p>15 A. Um-hum.</p> <p>16 Q. Okay. Do you recall if it had anything to</p> <p>17 do with diversion?</p> <p>18 A. I don't think so, but I don't recall what</p> <p>19 it was about. I mean, it wasn't an unpleasant</p> <p>20 meeting.</p> <p>21 Q. Would you describe the August 2011 meeting</p> <p>22 as an unpleasant one?</p> <p>23 MR. O'CONNOR: Objection.</p> <p>24 BY THE WITNESS:</p>

<p style="text-align: right;">Page 234</p> <p>1 A. Based on my background and former Federal 2 law enforcement experience, it was unpleasant to me, 3 but not to everyone there. 4 BY MR. KAWAMOTO: 5 Q. Okay. Why was it unpleasant to you? 6 A. They had -- they had diversion people from 7 other states, Detroit as I recall, St. Louis, and they 8 were being very stern in their presentation. They had 9 never helped us before, they had never approved any of 10 our programs, but they were being very stern with us, 11 and I took that as being unpleasant. 12 Q. And it's fair to say then that they were 13 very concerned, DEA was? 14 MR. O'CONNOR: Objection. 15 BY THE WITNESS: 16 A. That was my impression. 17 BY MR. KAWAMOTO: 18 Q. Now, you indicated that you took this as 19 unpleasant but other people might not have. Do you 20 have any -- do you have anyone in mind? I mean, do 21 you know if Karen also took this meeting as an 22 unpleasant one? 23 MR. O'CONNOR: Objection. 24 BY THE WITNESS:</p>	<p style="text-align: right;">Page 236</p> <p>1 fly first to St. Louis and then to Florida? 2 A. To St. Louis. We gathered the 3 information, it was given to me, and then I went to 4 Florida. 5 Q. Okay. So within 24 hours of this DEA 6 meeting, you were on a -- 48 hours you were on plane 7 going to -- 8 A. It was Friday, I believe, the meeting 9 occurred. 10 Q. Okay. 11 A. I could -- you could look up on the 12 calendar what day of the week it was, but it was the 13 following week when I left. 14 Q. Okay. Do you know what a 222 form is? 15 A. Vaguely. It's -- you transfer -- transfer 16 narcotics with it. You have to have a 222 that says 17 what the product is to be transferred with the 18 product. That's the best I can tell you. 19 Q. Yeah. 20 And so Mal- -- I'm just trying to 21 understand the mechanics. Mallinckrodt would receive 22 this form along with the order request from its 23 customer? 24 A. You are beyond me now. I don't know.</p>
<p style="text-align: right;">Page 235</p> <p>1 A. You would have to ask Karen. 2 BY MR. KAWAMOTO: 3 Q. Do you know if Karen was concerned about 4 this? 5 MR. O'CONNOR: Objection. 6 BY THE WITNESS: 7 A. I think we were both concerned. 8 BY MR. KAWAMOTO: 9 Q. And you were concerned enough to get on a 10 plane the next day, is that correct? 11 MR. O'CONNOR: Objection. 12 BY THE WITNESS: 13 A. No. 14 BY MR. KAWAMOTO: 15 Q. I'm sorry. 16 A. We left the night before. 17 Q. Yeah, you left earlier? 18 A. We left -- no. The earthquake occurred. 19 They closed down the airport for two-and-a-half, three 20 hours to make sure that all of the tanks, nothing had 21 cracked. They had all kinds of issues, but we 22 eventually flew out that night to go back to 23 St. Louis. 24 Q. And you flew to Florida from DC or did you</p>	<p style="text-align: right;">Page 237</p> <p>1 Q. Okay. 2 (WHEREUPON, a certain document was 3 marked Mallinckrodt-Ratliff 4 Deposition Exhibit No. 022, for 5 identification, as of 12/19/2018.) 6 BY MR. KAWAMOTO: 7 Q. So, directing your attention to the, I 8 guess the second page that says "Agenda," it says: 9 "Introduction - Bill Ratliff, Director" -- "Director 10 Security Tyco Healthcare." 11 Do you see that? 12 A. Yes. 13 Q. So did you present this PowerPoint? 14 A. No. 15 Q. Okay. Did you help -- 16 A. I started "Welcome to the meeting" and 17 introduced everybody and more than likely I left. I 18 had other responsibilities. 19 Q. So you weren't -- you weren't involved in 20 the preparation of this PowerPoint -- 21 A. No. 22 Q. -- to your recollection? 23 A. No. I'm not knowledgeable enough to 24 prepare this.</p>

<p style="text-align: right;">Page 238</p> <p>1 Q. And so if you count backwards, right</p> <p>2 before the slide that says "Almost Over," you've got</p> <p>3 this slide right here. So it is almost at the very</p> <p>4 end.</p> <p>5 A. Okay.</p> <p>6 Q. And so this is a presentation that --</p> <p>7 well, strike that.</p> <p>8 Do you see how it says: "Refer any phone</p> <p>9 calls to me concerning"?</p> <p>10 A. Say again.</p> <p>11 Q. The top line says: "Refer any phone calls</p> <p>12 to me concerning," and then it lists various items?</p> <p>13 A. I am on the wrong page here.</p> <p>14 Q. Okay. So "Almost Over," it is going to be</p> <p>15 the page right before.</p> <p>16 A. "Refer any phone calls"?</p> <p>17 Q. Yeah, "Refer any phone calls to me</p> <p>18 concerning."</p> <p>19 Do you know who the "me" is, is that --</p> <p>20 A. That would be Karen.</p> <p>21 Q. Okay.</p> <p>22 (WHEREUPON, a certain document was</p> <p>23 marked Mallinckrodt-Ratliff</p> <p>24 Deposition Exhibit No. 023, for</p>	<p style="text-align: right;">Page 240</p> <p>1 registration and you have a DEA 222, that wasn't -- or</p> <p>2 not alone adequate in determining whether an order is</p> <p>3 suspicious, that's -- if you had those, it would not</p> <p>4 be deemed suspicious, so I don't know if they mixed up</p> <p>5 their words or if Karen misspoke. That doesn't sound</p> <p>6 right.</p> <p>7 Q. But your understanding is that provided</p> <p>8 that the customer had a current DEA registration and</p> <p>9 it had a -- and it provided a 222 form, then its</p> <p>10 orders were not suspicious -- were I guess de facto</p> <p>11 not suspicious?</p> <p>12 MR. O'CONNOR: Objection.</p> <p>13 BY THE WITNESS:</p> <p>14 A. Well, there are a lot of other factors</p> <p>15 that go into that, so I'm not in a position to tell</p> <p>16 you that that's -- makes it not suspicious. I don't</p> <p>17 know that, so. You know, I know I was there at the</p> <p>18 presentation. I talked a little bit about security.</p> <p>19 And Karen talked about the rest of this because I'm</p> <p>20 not knowledgeable enough to really talk about it, so.</p> <p>21 I would ask her about that specific statement if it</p> <p>22 were me.</p> <p>23 BY MR. KAWAMOTO:</p> <p>24 Q. Okay. But your -- your understanding with</p>
<p style="text-align: right;">Page 239</p> <p>1 identification, as of 12/19/2018.)</p> <p>2 BY MR. KAWAMOTO:</p> <p>3 Q. So this is an e-mail from Karen Harper to</p> <p>4 you and others. It is dated June 6th, 2008, and it is</p> <p>5 419956.</p> <p>6 A. Okay.</p> <p>7 Q. If I could direct your attention to the</p> <p>8 highlighted portion of this e-mail.</p> <p>9 Can you please read that for me?</p> <p>10 A. "The group found it significant and</p> <p>11 noteworthy that confirmation of the customer's current</p> <p>12 DEA registration status and receipt of a DEA 222 form</p> <p>13 are not alone adequate in determining whether an order</p> <p>14 is suspicious."</p> <p>15 Q. Would you agree with that statement?</p> <p>16 A. If I could read it again, I'm --</p> <p>17 Q. Sure.</p> <p>18 A. Yeah, I don't know what it means.</p> <p>19 Q. Okay.</p> <p>20 A. It seems to be contradictory.</p> <p>21 Q. But you don't have any -- you don't have</p> <p>22 any understanding of what this statement is referring</p> <p>23 to or the requirement it is talking about?</p> <p>24 A. Well, normally if you have a DEA</p>	<p style="text-align: right;">Page 241</p> <p>1 respect to the DEA registration status and the 222</p> <p>2 form is that if you have those two items, then your</p> <p>3 order is -- you -- your order is -- is automatically</p> <p>4 not suspicious or it's not suspicious?</p> <p>5 A. No. Those things are necessary to process</p> <p>6 an order and then a lot of other things go into it,</p> <p>7 so.</p> <p>8 Q. So even if you have the registration</p> <p>9 status and a valid 222 form, that's not the end of the</p> <p>10 inquiry, is that your understanding?</p> <p>11 A. Correct, to the best of my knowledge.</p> <p>12 Q. So if I were to say -- if DEA were to</p> <p>13 contact me and say we think this order is suspicious</p> <p>14 and I were to tell them, No, I checked the</p> <p>15 registration status and I got a 222 form that I</p> <p>16 verified, that would not be adequate as a matter of</p> <p>17 compliance?</p> <p>18 MR. O'CONNOR: Objection.</p> <p>19 BY THE WITNESS:</p> <p>20 A. If DEA called and say thought -- they</p> <p>21 thought it was suspicious, it's suspicious. They are</p> <p>22 our regulator. So we would take their word as --</p> <p>23 unless we had additional information, but we would</p> <p>24 work with them to try to determine why they thought it</p>

Page 242

1 was suspicious.
2 Q. But it would not be proper to just rely
3 solely on the registration status and the 222 form in
4 determining whether or not to ship an order?
5 MR. O'CONNOR: Objection.
6 MS. DURFEE: Objection.
7 BY THE WITNESS:
8 A. That's my opinion, but I'm certainly not
9 an expert in this.
10 (WHEREUPON, a certain document was
11 marked Mallinckrodt-Ratliff
12 Deposition Exhibit No. 024, for
13 identification, as of 12/19/2018.)
14 BY THE WITNESS:
15 A. So I'm not named on this, so...
16 BY MR. KAWAMOTO:
17 Q. No.
18 So I wanted to direct your attention to
19 the middle e-mail first. It is from Jim Rausch to
20 Karen Harper, cc'ing George Saffold.
21 Do you know who Mr. Saffold is?
22 A. No.
23 Q. Okay. And then can you read that sentence
24 that I highlighted? And I understand you didn't

Page 243

1 receive this.
2 A. "I have not had any orders in the
3 classification of peculiar that has not been cleared
4 and explainable thus far. As we have discussed, it
5 takes time to get the information back from marketing
6 and sales, sometimes all day."
7 Q. Again, the next sentence is?
8 A. "Since I don't hold the orders up during
9 my due diligence, it's possible that the order could
10 ship."
11 Q. Okay. So, were you aware that Mr. Rausch
12 was not holding orders up while he was conducting his
13 due diligence on them?
14 MR. O'CONNOR: Objection.
15 BY THE WITNESS:
16 A. No.
17 BY MR. KAWAMOTO:
18 Q. Okay. If you had known that that was what
19 he was doing, would you have been concerned?
20 MR. O'CONNOR: Objection.
21 BY THE WITNESS:
22 A. It certainly should have been discussed
23 with -- or his boss.
24 BY MR. KAWAMOTO:

Page 244

1 Q. And his boss would -- who would Jim's boss
2 have been?
3 A. I have no clue. I just don't know. It
4 has been too many years.
5 Q. Okay. Fair enough.
6 All right. I'm sorry. Karen's -- Karen
7 Harper's e-mail at the very top, could you read the --
8 what she is saying, the highlighted sentence?
9 A. "Jim, We absolutely did have the
10 discussion previously and there is no disagreement
11 now - I merely wanted to confirm that we have not
12 shipped any suspicious orders (even if we do the
13 investigation after the shipment). The information is
14 being gathered for JoAnne and ultimately presentation
15 to Tim Wright about regulatory vulnerabilities. Thank
16 you and have a great day."
17 Q. Do you know who Tim Wright is?
18 A. I think he was the present at the time.
19 Q. And Karen is referencing a discussion, but
20 you weren't -- you weren't part of that discussion?
21 MR. O'CONNOR: Objection.
22 BY THE WITNESS:
23 A. No.
24 BY MR. KAWAMOTO:

Page 245

1 Q. And you don't have -- you don't have any
2 opinion on this practice as you sit here today?
3 A. I -- it's just been too long.
4 Q. Okay. Oh, I'm sorry. I just -- I just
5 have two more questions.
6 A. On that?
7 Q. Yes, on that e-mail, so if you can look at
8 it.
9 The top e-mail on the back page, so that
10 would be Bates number 264413, that's from Jim Rausch
11 to Karen Harper again.
12 A. Okay.
13 Q. Can you read that e-mail from Jim?
14 A. "Karen, yes, I run the checks every day as
15 I showed you. As we discussed, I do not hold any
16 orders while I do my research due to the time" -- "due
17 to the time constraints."
18 Q. Do you know what the reference to time
19 constraints means?
20 A. When the trucks arrive or when it's
21 shipped, I don't know.
22 Q. Okay. And Jim --
23 A. They don't ship out of headquarters. Jim
24 worked at headquarters, so if that helps.

<p style="text-align: right;">Page 246</p> <p>1 Q. And your understanding of -- or your 2 recollection of Jim's role is that he was reviewing 3 peculiar orders. 4 Is that accurate? 5 A. Apparently based on this from Karen. 6 Q. Okay. Do you know if he was the only one 7 that was running checks on peculiar orders? 8 MR. O'CONNOR: Objection. 9 BY THE WITNESS: 10 A. I have no idea. 11 THE WITNESS: Sorry. 12 MR. KAWAMOTO: Could we take a break? 13 MR. O'CONNOR: Sure. 14 MR. KAWAMOTO: Is that fine with you? 15 THE WITNESS: I'm good. 16 THE VIDEOGRAPHER: We are going off the record 17 at 3:44. 18 (WHEREUPON, a recess was had 19 from 3:44 to 4:00 p.m.) 20 THE VIDEOGRAPHER: We are back on the record at 21 4:00 p.m. 22 MR. KAWAMOTO: So here is another exhibit. 23 (WHEREUPON, a certain document was 24 marked Mallinckrodt-Ratliff</p>	<p style="text-align: right;">Page 248</p> <p>1 but normally they had books that they would present 2 and they would -- Karen would go through the books and 3 I would be there and we would look at certain things 4 and we would ask questions about how they identified 5 their customers and that's pretty much it. I mean, 6 there were -- we'd ask a number of questions, so. 7 Q. What was the information that was 8 contained in these books? 9 A. It was basically that -- in an attempt to 10 show they were in compliance with the -- with the 11 regulation requiring the -- they were preventing 12 diversion, so, it was basically their program. 13 Q. And the revision date is 1/04/2011. 14 Do you recall when you started conducting 15 these audits? 16 A. I don't. But I believe it was before 17 that, would be my guess. I shouldn't guess. I can't 18 be accurate to know exactly when we started, but... 19 Q. Do you have a rough sense of how far 20 before 2011 these started? 21 A. The first audit -- there were two audits 22 and they were both in Cincinnati. So if we could 23 detail that date, then I would know when it started. 24 Q. And do you recall who was being audited?</p>
<p style="text-align: right;">Page 247</p> <p>1 Deposition Exhibit No. 025, for 2 identification, as of 12/19/2018.) 3 BY MR. KAWAMOTO: 4 Q. So this is a document Bates numbered 5 307322. It's entitled "Global Controlled Substance 6 Compliance Procedure," and the subject is "Suspicious 7 Order Monitoring Customer Audit Program." 8 A. Okay. 9 Q. Mr. Ratliff, were you involved with this, 10 in the customer audit program? 11 A. Yes. 12 Q. And what was your role in it? 13 A. On occasion I assisted Karen Harper with 14 conducting audits of our distributors. 15 Q. And by "assisting," what do you mean by 16 that? 17 A. We would travel to that distributor 18 together or she would fly in and I would be there from 19 another area and we would then do the audits. 20 Q. And what did you look for when you were 21 conducting the audits? 22 A. We had to provide their book or however 23 they con -- they had their suspicious order monitoring 24 program, if it was in a box or if -- whatever it was,</p>	<p style="text-align: right;">Page 249</p> <p>1 A. Well, it was the Masters, maybe, and -- 2 and I don't remember the other name. 3 Q. And how were you identifying which 4 distributors to audit? 5 A. Karen identified them and I went along to 6 assist. 7 Q. Okay. And do you recall how often a 8 distributor was audited, were they put on a cycle or 9 was it based on some other metric? 10 MR. O'CONNOR: Objection. 11 BY THE WITNESS: 12 A. These were the first audits that I was 13 involved in, so if they conducted other audits, I 14 don't know that. 15 BY MR. KAWAMOTO: 16 Q. Do you recall any distributors that failed 17 their audits? 18 MR. O'CONNOR: Objection. 19 BY THE WITNESS: 20 A. I think Masters and the other one. There 21 were some issues that we needed to address, so. I 22 don't know that that's a pass/fail. 23 BY MR. KAWAMOTO: 24 Q. And do you see Point 5 on Page 307323?</p>

Page 250

1 A. Um-hum.
2 Q. It says: "In conjunction with Security,
3 notifies DEA in the event of adverse audit findings."
4 Do you recall doing that?
5 A. I wouldn't have done it. Karen Harper
6 would have done that.
7 Q. But do you have -- do you have -- well,
8 with respect to the -- with respect to the audits
9 where there were issues with the distributor, and I --
10 I believe you -- you think there were two of them that
11 you can recall, or is that number wrong?
12 MR. O'CONNOR: Objection.
13 BY THE WITNESS:
14 A. Well, those were the initial -- those were
15 the initial ones that I was involved in. There was
16 another one in Kentucky. I can't remember the name of
17 the company. Those may have been the only -- the only
18 three that I was involved in.
19 BY MR. KAWAMOTO:
20 Q. Now, you don't know if those results were
21 communicated -- were communicated to DEA?
22 MR. O'CONNOR: Objection.
23 BY MR. KAWAMOTO:
24 Q. Well, let me rephrase that.

Page 251

1 You weren't involved in communicating
2 those results to DEA?
3 A. Correct.
4 Q. Okay. Do you have any specific
5 recollection or knowledge of Karen Harper doing so?
6 A. Not a specific rec- -- recollection, I
7 don't.
8 Q. Okay.
9 (WHEREUPON, a certain document was
10 marked Mallinckrodt-Ratliff
11 Deposition Exhibit No. 026, for
12 identification, as of 12/19/2018.)
13 BY MR. KAWAMOTO:
14 Q. So this is a document entitled "Pharmacy
15 Information Sheet." It's Bates number is 570903.
16 A. Okay.
17 Q. Do you recognize this form?
18 A. Yes.
19 Q. What is it?
20 A. This is the form I've been speaking of
21 that we used. We put all kinds of information in here
22 to help us make a determination if it should be a
23 continuing -- continuing with -- I'm getting really
24 tired, just so you know.

Page 252

1 Q. Understood.
2 A. Okay. I'm old.
3 That they should remain a customer of our
4 customer. So we -- we put down a lot of information
5 in there.
6 Q. And so at the very bottom, do you see a
7 reference to "Suzanne Pea deactivated as customer on"
8 and then there is a blank.
9 Who was Suzanne Pea?
10 A. I don't have a clue.
11 Q. Now, at the very top it says: "If sales
12 of controlled substances restricted, effective date of
13 restriction: 10/5/11."
14 Do you see that?
15 A. Where are you?
16 Q. At the very top under "Current Status:
17 Sales of controlled substances restricted."
18 A. Okay.
19 Q. So as of 10/5/11, that's when the
20 restriction was imposed on Gulf Coast Medical
21 Pharmacy?
22 A. Okay.
23 Q. And then do you see that -- that the
24 information under Statistics?

Page 253

1 A. Yes.
2 Q. Can you review that?
3 A. Okay.
4 Q. And so the percentage of controlled
5 substances versus non-controlled substances was 90 to
6 10?
7 A. Correct.
8 Q. The top product by volume was oxy 30?
9 A. Correct.
10 Q. The volume of the oxy family was 3 million
11 tablets from 5/10 through 10/11 with approximately
12 225 -- 225,000 per month?
13 A. Yes.
14 Q. And the value of oxy 30 was 175,000 per
15 month?
16 A. Okay.
17 Q. And then it says cash sales versus
18 non-cash sales, 30 percent are in cash sales.
19 So would you find this -- this data to be
20 disturbing?
21 MR. O'CONNOR: Objection.
22 BY THE WITNESS:
23 A. Yes. I testified in court and these
24 people were prosecuted by DEA.

<p style="text-align: right;">Page 254</p> <p>1 BY MR. KAWAMOTO:</p> <p>2 Q. So this is pretty clearly a pill mill?</p> <p>3 MR. O'CONNOR: Objection.</p> <p>4 BY THE WITNESS:</p> <p>5 A. That was my opinion.</p> <p>6 BY MR. KAWAMOTO:</p> <p>7 Q. Okay. Now, you also have your notes,</p> <p>8 because you visited this -- this pharmacy on</p> <p>9 September 13th, 2011?</p> <p>10 A. I did.</p> <p>11 Q. Okay. And you -- as you noted, you</p> <p>12 testified against them.</p> <p>13 Now, under the status of Due Diligence, do</p> <p>14 you see that? It is on -- I'm sorry. It is on the</p> <p>15 front page.</p> <p>16 A. Front page. Okay.</p> <p>17 Q. It says: "Number of site visits and dates</p> <p>18 of each," and then it goes: "8/08, 4/09, 12/09,</p> <p>19 10/10, 2/11 and 9/11."</p> <p>20 Do you see that?</p> <p>21 A. I do.</p> <p>22 Q. Who was performing those visits?</p> <p>23 A. I don't remember specifically at this time</p> <p>24 because of the time that's past, but I believe that</p>	<p style="text-align: right;">Page 256</p> <p>1 on the distributor's part, was it not?</p> <p>2 MR. O'CONNOR: Objection.</p> <p>3 BY THE WITNESS:</p> <p>4 A. Yes.</p> <p>5 MR. KAWAMOTO: Okay. Actually, could we go off</p> <p>6 the record very quickly.</p> <p>7 THE VIDEOGRAPHER: We are going off the record</p> <p>8 at 4:11.</p> <p>9 (WHEREUPON, a recess was had</p> <p>10 from 4:11 to 4:18 p.m.)</p> <p>11 (WHEREUPON, a certain document was</p> <p>12 marked Mallinckrodt-Ratliff</p> <p>13 Deposition Exhibit No. 027, for</p> <p>14 identification, as of 12/19/2018.)</p> <p>15 THE VIDEOGRAPHER: We are back on the record at</p> <p>16 4:18.</p> <p>17 BY MR. KAWAMOTO:</p> <p>18 Q. So, sir, I've put another exhibit in front</p> <p>19 of you. Its Bates number is 571105, and it is another</p> <p>20 Pharmacy Information Sheet.</p> <p>21 A. Yes.</p> <p>22 Q. And the subject is this pharmacy is Lam's</p> <p>23 Pharmacy and it's in Las Vegas.</p> <p>24 Okay. Could you quickly review this</p>
<p style="text-align: right;">Page 255</p> <p>1 was their distributor or their security person, so.</p> <p>2 Q. So prior to you visiting this pill mill,</p> <p>3 it was visited five times by the security person for</p> <p>4 the distributor?</p> <p>5 A. It's just been too long to -- to be</p> <p>6 absolutely positive that that's the case, but I</p> <p>7 received the information from someone, so.</p> <p>8 Q. And that -- well, that -- that -- then</p> <p>9 that's what the data suggests, does it not?</p> <p>10 A. Yes.</p> <p>11 MR. O'CONNOR: Objection.</p> <p>12 BY MR. KAWAMOTO:</p> <p>13 Q. Okay. And yet this -- this pill mill was</p> <p>14 restricted on 10/5/2011.</p> <p>15 In your opinion, shouldn't this pill mill</p> <p>16 have been shut down earlier?</p> <p>17 MR. O'CONNOR: Objection.</p> <p>18 BY THE WITNESS:</p> <p>19 A. Should it have been shut down earlier?</p> <p>20 BY MR. KAWAMOTO:</p> <p>21 Q. Yes.</p> <p>22 A. They were in a building with a number of</p> <p>23 pain doctors, and I would say yes.</p> <p>24 Q. And so in your opinion this was a failure</p>	<p style="text-align: right;">Page 257</p> <p>1 sheet?</p> <p>2 A. Okay.</p> <p>3 Q. So, if you look at the statistics, you</p> <p>4 have the percentage of controlled -- controlled</p> <p>5 substances versus non-controlled substances of 60/40.</p> <p>6 A. Yes.</p> <p>7 Q. You have the volume of controlled</p> <p>8 substances as 400,000 tablets per month.</p> <p>9 A. Um-hum.</p> <p>10 Q. The top product is once again oxy 30.</p> <p>11 A. Um-hum.</p> <p>12 Q. The volume of the oxy family is 3 million</p> <p>13 tablets from 5/10 through 10/11, approximately 160,000</p> <p>14 per month, the volume of oxy 30 tablets ranges from</p> <p>15 100,000 to 120,000 per month, and then the percent of</p> <p>16 cash sales versus non-cash sales is slightly more than</p> <p>17 50 percent. And then in addition, apparently there</p> <p>18 was a recent indictment of a pharmacist, and then you</p> <p>19 also visited this site on 10/4/2011.</p> <p>20 A. Um-hum.</p> <p>21 Q. So in your opinion, is this a pill mill?</p> <p>22 MR. O'CONNOR: Objection.</p> <p>23 BY THE WITNESS:</p> <p>24 A. Yes.</p>

Page 258

1 BY MR. KAWAMOTO:
2 Q. Okay. Now, you'll note that under Due
3 Diligence you have site visit dates.
4 A. Um-hum.
5 Q. And it says: "Mone visited CA 1/09." And
6 there were a "Total of four visits by Mone, most
7 recent being 7/11," and yet this was shut down in
8 October of 2011.
9 Do you see that, sir?
10 MR. O'CONNOR: Objection.
11 BY THE WITNESS:
12 A. I do.
13 BY MR. KAWAMOTO:
14 Q. Is this another instance where this pill
15 mill should have been shut down earlier --
16 MR. O'CONNOR: Objection.
17 BY MR. KAWAMOTO:
18 Q. -- given the due diligence that was
19 purportedly being done?
20 A. Yes.
21 Q. Okay. Now, directing your attention to
22 the second page of this document, that's 571106.
23 A. Um-hum.
24 Q. Do you know why this was included in this

Page 259

1 file? It's an e-mail from Mr. Lohman, and I will -- I
2 will represent to you that this came out of your
3 custodial file.
4 A. Mine personally?
5 Q. Yes.
6 A. I was traveling with Mr. Lohman.
7 Q. Okay. And do you see the e-mail that
8 says: "Ned called in to check SOM system and protect
9 Lam's in pharmacist sting/raid 8-2010"?
10 A. I see it.
11 Q. Okay. And I believe Ned reference is a
12 reference to Ned Milenkovich, do you see that, because
13 it is a teleconference between Ted Milenkovich and
14 Donald Lohman?
15 MR. O'CONNOR: Objection.
16 BY THE WITNESS:
17 A. Okay.
18 BY MR. KAWAMOTO:
19 Q. So Ned called Mr. Lohman and he wanted to
20 check the SOM system and protect Lam's in the
21 pharmacist sting/raid.
22 Do you know what that means?
23 MR. O'CONNOR: Objection.
24 BY THE WITNESS:

Page 260

1 A. No.
2 BY MR. KAWAMOTO:
3 Q. Okay. If Lam -- if -- if Ned were the --
4 representing the distributor, because I believe Ned is
5 an attorney, do you know why the distributor would
6 want to protect Lam's?
7 MR. O'CONNOR: Objection.
8 BY THE WITNESS:
9 A. I think Lam's changed hands and that after
10 the indictment, according to what the individual told
11 me, that's just based on my memory of it, he said, You
12 know, our pharmacist was indicted and we are -- we've
13 changed everything, DEA has been in here, and so.
14 BY MR. KAWAMOTO:
15 Q. Okay. Now, do you see the -- the heading
16 that says "Message"?
17 A. Yes.
18 Q. It says: "No contractual relationship
19 with Lam's. Suggested they call DEA. Barb," I guess
20 Barb Boockholdt, "chief of regulatory section."
21 A. Okay.
22 Q. Do you know what's meant by "no
23 contractual relationship with Lam's"?
24 A. I don't.

Page 261

1 Q. Okay. What about the -- the statement
2 "purpose - data review," do you see that?
3 A. I do.
4 Q. "Asked for our help. I said no."
5 Do you know what that means?
6 A. I don't.
7 Q. Do you know if this was a request from
8 either Lam's or the distributor for access to
9 Mallinckrodt chargeback data?
10 MR. O'CONNOR: Objection.
11 BY THE WITNESS:
12 A. I don't remember ever seeing this
13 communication at all, and so I don't -- I don't know
14 the answer.
15 BY MR. KAWAMOTO:
16 Q. Okay. You can put that aside.
17 (WHEREUPON, a certain document was
18 marked Mallinckrodt-Ratliff
19 Deposition Exhibit No. 028, for
20 identification, as of 12/19/2018.)
21 BY MR. KAWAMOTO:
22 Q. So, actually, this may be a relatively
23 short question. Do you rec -- is this your
24 handwriting, sir?

<p style="text-align: right;">Page 262</p> <p>1 A. Sadly it is.</p> <p>2 Q. Okay.</p> <p>3 A. It has gotten worse, too, just so you...</p> <p>4 Q. Fair enough.</p> <p>5 Reviewing this, do you -- do you know what</p> <p>6 these notes refer to?</p> <p>7 A. I know I met with George Euson at one</p> <p>8 time. And a lot of this information came from him. I</p> <p>9 don't know what -- what is confusing to me, those</p> <p>10 other names.</p> <p>11 Q. Okay.</p> <p>12 A. But this was before he went down to</p> <p>13 Florida to do the investigation.</p> <p>14 Q. But as you sit here today, you don't know</p> <p>15 what these notes refer to?</p> <p>16 A. Well, they refer to that meeting with</p> <p>17 George.</p> <p>18 Q. Okay. And does this refresh your</p> <p>19 recollection as to what you discussed in that meeting?</p> <p>20 A. Well, I can read it all to you, but</p> <p>21 it's -- basically what he was telling me they were</p> <p>22 doing. He was --</p> <p>23 Q. And -- I'm sorry.</p> <p>24 A. He came over to discuss this with us and</p>	<p style="text-align: right;">Page 264</p> <p>1 It's a 1-6-4.</p> <p>2 Q. Yes. So I'm sorry. 164 pharmacies have</p> <p>3 been cut off?</p> <p>4 A. Yeah. That information was given to me,</p> <p>5 so.</p> <p>6 Q. Okay.</p> <p>7 A. I made a star by it because obviously -- I</p> <p>8 put a star by it because normally when I do that to me</p> <p>9 that is -- shows to me later that it was important.</p> <p>10 Q. And then at the very bottom of Page 472,</p> <p>11 do you see the reference to "298 accounts walked</p> <p>12 away"?</p> <p>13 A. Uh-huh.</p> <p>14 Q. Do you know what that means?</p> <p>15 A. I don't. I just -- let me have a little</p> <p>16 due diligence.</p> <p>17 I don't know the answer to that.</p> <p>18 Q. Okay. That's fine.</p> <p>19 So I have another PowerPoint that I would</p> <p>20 like you to look at. This was produced to us in</p> <p>21 native form, so I've manually put the Bates number on</p> <p>22 it. The Bates number is 2694677.</p> <p>23 (WHEREUPON, a certain document was</p> <p>24 marked Mallinckrodt-Ratliff</p>
<p style="text-align: right;">Page 263</p> <p>1 to explain to us that the owner had told him to go to</p> <p>2 Florida and look at all of these pharmacies and they</p> <p>3 weren't going to ship anything until -- until they</p> <p>4 made their determination if it was a legitimate</p> <p>5 pharmacy or not.</p> <p>6 Q. And this was the e-mail that we reviewed</p> <p>7 near the beginning of the deposition, right --</p> <p>8 MR. O'CONNOR: Objection.</p> <p>9 BY MR. KAWAMOTO:</p> <p>10 Q. -- regarding H.D. Smith and pain</p> <p>11 management clinics?</p> <p>12 MR. O'CONNOR: Objection.</p> <p>13 BY THE WITNESS:</p> <p>14 A. Okay. Yeah, I don't remember that</p> <p>15 exactly, but I take notes and then I write from the</p> <p>16 notes.</p> <p>17 BY MR. KAWAMOTO:</p> <p>18 Q. And then do you see at the end -- or</p> <p>19 towards the bottom of Page 386471?</p> <p>20 A. Yes.</p> <p>21 Q. That's: "106 pharmacies have been cut</p> <p>22 off." Is that -- does that mean that H.D. Smith had</p> <p>23 stopped doing business with 106 pharmacies?</p> <p>24 A. There is 164 pharmacies have been cut off.</p>	<p style="text-align: right;">Page 265</p> <p>1 Deposition Exhibit No. 029, for</p> <p>2 identification, as of 12/19/2018.)</p> <p>3 BY MR. KAWAMOTO:</p> <p>4 Q. And because this isn't numbered, I'll use</p> <p>5 the Elmo to sort of identify what I want to direct you</p> <p>6 to.</p> <p>7 So the first page is EXALGO Utilization by</p> <p>8 Julie Milford.</p> <p>9 Do you know who Julie Milford is?</p> <p>10 A. No clue.</p> <p>11 Q. Okay. And then if you turn into the</p> <p>12 PowerPoint, there is "National Use of Opioids, Heat</p> <p>13 Maps of Units Through Cash Transactions."</p> <p>14 A. Where are you?</p> <p>15 Q. I'm probably -- I'm around -- I'm on</p> <p>16 Page 6 of the PowerPoint.</p> <p>17 A. Okay.</p> <p>18 Q. Okay. So: "National Use of Opioids, Heat</p> <p>19 Maps of Units Through Cash Transactions."</p> <p>20 A. Okay.</p> <p>21 Q. And then the methodology is -- do you see</p> <p>22 the -- do you see the second bullet point?</p> <p>23 A. "Product basket," is that what you are</p> <p>24 asking?</p>

Page 266

1 Q. Yes.
2 "Product basket included therapies and
3 strengths known to be highly abused, as well as
4 EXALGO."
5 A. Okay.
6 Q. Do you know what -- what analysis is being
7 done or what analysis is being presented in this
8 PowerPoint?
9 A. No.
10 Q. Okay. Were you aware that anyone in
11 Mal -- at Mallinckrodt was developing heat maps of
12 units through cash transactions?
13 A. Okay.
14 Q. Now, crash transactions are a potential
15 indicator of diversion, are they not?
16 MR. O'CONNOR: Objection.
17 BY THE WITNESS:
18 A. You are saying these are cash? The last
19 two years... Yeah, I don't know. I don't know where
20 that information would come from even.
21 BY MR. KAWAMOTO:
22 Q. And then if you look on the second page of
23 the methodology, do you see the two bullet points:
24 "Calculated the per capita rate of cash Rx tablets for

Page 267

1 each three-digit zip code"?
2 Do you see that?
3 A. Yes.
4 Q. And then underneath that: "Coded per
5 capita rates into five different groupings to produce
6 heat maps."
7 A. Okay.
8 Q. Dark red is a "'Critical Spot' with 2 to 3
9 cash tablets per person."
10 Would this type of analysis have been
11 helpful in developing anti-diversion measures?
12 MR. O'CONNOR: Objection.
13 BY THE WITNESS:
14 A. I don't recall ever seeing it, but it's on
15 Covidien's -- you know, it was produced by someone
16 from Covidien apparently, so they were trying to -- to
17 make some sense of it, I guess. I mean, I just don't
18 remember.
19 Do you know when it was produced? Was I
20 even with the company?
21 BY MR. KAWAMOTO:
22 Q. I'll be honest, I -- I don't know that.
23 A. Yeah.
24 Q. It says "April 2011" and then "Patient

Page 268

1 counts increased considerably since 2012."
2 A. Yeah.
3 Q. So...
4 A. And the reason I say that is I have been
5 gone six-and-a-half years, as you've -- as I've noted
6 a number of times. I just don't remember seeing
7 anything even like this. And, you know, it's possible
8 that it was created while I was there, but I just
9 don't recall it, so.
10 Q. Now, you weren't aware of anyone doing
11 this type of analysis while you were at Mallinckrodt?
12 MR. O'CONNOR: Objection.
13 BY THE WITNESS:
14 A. Not personally.
15 BY MR. KAWAMOTO:
16 Q. So this is not something you recall Karen
17 Harper ever sharing with you?
18 A. No.
19 Q. Okay. Would this information have been
20 helpful to you as director of security?
21 MR. O'CONNOR: Objection.
22 BY THE WITNESS:
23 A. I would say, yes, it would be helpful to,
24 but I don't know -- the problem I'm having with this

Page 269

1 is I don't know if it's just our customers or if it's
2 from some national database that has, you know, EXALGO
3 patient account trends. I'm not -- did we manufacture
4 EXALGO? I don't remember.
5 BY MR. KAWAMOTO:
6 Q. Well, regardless --
7 A. So, IMS NPA --
8 Q. Oh, sorry.
9 A. -- IMS, a Marketing -- a Market Dynamics.
10 That's the source. IMS NPA, IMS NPA Market Dynamics.
11 So, without knowing who that is... IMS Xponent
12 Plantrak. I don't know where the information came
13 from, I don't know how I could accept -- how I could
14 determine how accurate it is without knowing or having
15 more information.
16 Q. And you are not familiar with IMS Xponent
17 Plantrak, are you?
18 A. No.
19 Q. But a database that tracked cash
20 transactions of prescription opioids, that information
21 would be potentially helpful?
22 MR. O'CONNOR: Objection.
23 BY MR. KAWAMOTO:
24 Q. Assuming its accurate?

<p style="text-align: right;">Page 270</p> <p>1 A. Right, and -- and assuming that it's our 2 customers. See, we don't know it's our customers. We 3 don't know based on the information provided if it's 4 all of the manufacturers or -- or where the 5 information came from. There is no way even looking 6 at it at this time to say that these are our customers 7 or how they would be able to divide that out and how 8 IMS Xponent Plantrak would be able to divide that out. 9 Q. So even if it weren't limited to just your 10 customers, it was national, so it was your customers 11 and others, would it knowing certain regions that 12 were -- that had a very high level of cash 13 transactions for opioids be helpful in terms of 14 targeting your own audit efforts? 15 MR. O'CONNOR: Objection. 16 BY THE WITNESS: 17 A. Oh, I think we knew a lot of this 18 information for our customers and that's what we were 19 focusing on, so. But I -- I just don't have enough 20 information to know where this came from. 21 BY MR. KAWAMOTO: 22 Q. But you had a sense for your customers 23 the -- the amount and the location of cash 24 transactions?</p>	<p style="text-align: right;">Page 272</p> <p>1 Q. Sure. It is on Bates number 290603. 2 A. Okay. 3 Q. So this is an e-mail from Victor Borelli 4 to Brenda Rehkop. 5 Do you know who Brenda was? 6 A. No. 7 Q. Okay. Do you know who Victor Borelli is? 8 A. He was one of our salespeople. 9 Q. Did you work with him? 10 A. No. 11 Q. Did you -- no. 12 So that e-mail above it -- well, I'm 13 sorry. 14 The e-mail from Victor indicates that they 15 are -- they are setting up a new account for Sunrise, 16 is that accurate? 17 A. Be more specific. Which one are you 18 looking at, the very first one? 19 Q. The very first one in the chain dated 20 May 20th, 2008, at 7:57 a.m. 21 A. Okay. "Who is going to be the customer 22 service manager for this new account and can I have 23 that person's phone, fax, e-mail, et cetera. I am 24 traveling down to the account and want to supply them</p>
<p style="text-align: right;">Page 271</p> <p>1 MR. O'CONNOR: Objection. 2 BY THE WITNESS: 3 A. I don't know that I could separate down to 4 cash transactions. Once we started sending those 5 forms out, the distributors had to fill out all of 6 that information. And so when we talked previously, 7 the distributor filled out all of the information and 8 then I took that information and used it in our audits 9 of those -- our customer's customer. 10 BY MR. KAWAMOTO: 11 Q. Okay. 12 (WHEREUPON, a certain document was 13 marked Mallinckrodt-Ratliff 14 Deposition Exhibit No. 030, for 15 identification, as of 12/19/2018.) 16 BY MR. KAWAMOTO: 17 Q. So this is an e-mail chain between you and 18 Karen Harper regarding Sunrise Wholesale, and it's 19 Bates No. 290601. 20 A. Okay. 21 Q. Okay. And if I could direct your 22 attention to -- let's start with the very back e-mail 23 on Page 290603. 24 A. Sorry. The back of --</p>	<p style="text-align: right;">Page 273</p> <p>1 with all of the proper information. Also, they will 2 buying -- be buying C2s as well. What address to 3 they," but it should be "do they send that to?" 4 Q. So this is -- this is a new account. 5 A. Okay. 6 Q. And then the e-mail above it is an e-mail 7 from Brenda to Victor Borelli along with Cathy -- 8 Cathy Stewart and Connie Gregory. 9 Do you see that? 10 A. I do. 11 Q. And the -- the paragraph, do you see the 12 paragraph: "The 222 forms total 195,000"? 13 A. Yes. 14 Q. Okay. So could you please read that? 15 A. "The 222 forms total 195,000. I have put 16 the last" -- "the latest and largest order on hold (it 17 is also waiting to be allocated) till I hear from you. 18 Were you expecting Sunrise to place such a large 19 order? And do they really want 2,520 bottles of 20 oxycodone HCL 30-milligram tabs USP, 100 count each?" 21 Q. So this is the initial order from Sunrise 22 to Mallinckrodt, and right off the bat they want 23 2,520 bottles of oxy 30, is that accurate? 24 MR. O'CONNOR: Objection.</p>

Page 274

1 BY THE WITNESS:
 2 A. Yes.
 3 BY MR. KAWAMOTO:
 4 Q. Okay. And then there is an e-mail from
 5 Cathy Stewart to you and Karen Harper. That's on the
 6 first page, 290601.
 7 A. Front page?
 8 Q. Front page, very top of the front page,
 9 29 -- 290601. I'm sorry. I'll put it up on the Elmo.
 10 A. It says, "From Bill Ratliff"?
 11 Q. Yes, exactly.
 12 A. To Harper?
 13 Q. Yep.
 14 And so can you read your e-mail?
 15 A. "Karen seems" -- "Karen, seems to be a lot
 16 of product for the first order especially in light of
 17 the new customer status and credit limit. Do you know
 18 if they completed the D&B?" which would be
 19 Dun & Bradstreet.
 20 Q. And what would the -- what would D&B be,
 21 or what -- what was that?
 22 A. It tells a lot about their -- their
 23 liability as a company, how long they've been in
 24 business, the amount of cash that they have. It's --

Page 275

1 there is a lot of information in a Dun & Bradstreet
 2 report.
 3 Q. And so it's essentially their -- the
 4 financial condition of the company, is that fair?
 5 A. That's correct.
 6 MR. O'CONNOR: Objection.
 7 BY MR. KAWAMOTO:
 8 Q. Okay. But given their status as a new
 9 customer and their credit limit, and actually, if you
 10 look down at the bottom of the page, do you see the
 11 credit limit is 35,000?
 12 A. Um-hum.
 13 Q. So in light of their status as a new
 14 customer and the credit limit of 35,000, you -- you --
 15 you believe -- or your impression is that this is a
 16 lot of product, is that fair?
 17 A. Yes, that's fair.
 18 Q. Okay. So would it be accurate to say that
 19 you had -- you felt that this order should be subject
 20 to some review?
 21 MR. O'CONNOR: Objection.
 22 BY THE WITNESS:
 23 A. Yes.
 24 THE WITNESS: I'm sorry.

Page 276

1 BY MR. KAWAMOTO:
 2 Q. Okay.
 3 Okay. So my apologies. This is an
 4 exhibit, but they are not stapled, so I'm going to try
 5 to keep them separated, but there are three copies
 6 right there.
 7 MR. O'CONNOR: Is there any chance you guys have
 8 another copy or are we down to three here?
 9 MR. KAWAMOTO: There are -- yes, there are
 10 three -- there are three copies.
 11 MR. O'CONNOR: Okay.
 12 (WHEREUPON, a certain document was
 13 marked Mallinckrodt-Ratliff
 14 Deposition Exhibit No. 031, for
 15 identification, as of 12/19/2018.)
 16 BY MR. KAWAMOTO:
 17 Q. And I want to -- what I want to focus is
 18 your attention on the very top e-mail, Mr. Ratliff.
 19 It is from Karen Harper to you.
 20 A. Okay.
 21 Q. Okay. So can you please read that?
 22 A. I can.
 23 "I have placed a call to Sue Marlatt
 24 (credit manager who is also working on our suspicious

Page 277

1 order monitoring team) to ask her for a better
 2 interpretation of the Dun & Bradstreet and gave her my
 3 cell number. Rhonda Hart has been dealing with this
 4 account and reports to Sue. Rhonda indicated their
 5 D&B results show an extremely small company. Sunrise
 6 has a two screen informational web page and a contact
 7 us e-mail screen. E-mail address is @Yahoo.com, so it
 8 doesn't look like a very big company there either.
 9 Web page says established in 2003."
 10 Q. So did this information do anything to
 11 allay your concerns with their order, their initial
 12 order?
 13 MR. O'CONNOR: Objection.
 14 BY THE WITNESS:
 15 A. To be honest, I don't know if it was
 16 filled or not at this time. I just don't know.
 17 BY MR. KAWAMOTO:
 18 Q. Okay. But in light of this information,
 19 you -- it's your opinion that this order should have
 20 been subject to additional scrutiny?
 21 MR. O'CONNOR: Objection.
 22 BY THE WITNESS:
 23 A. Yes.
 24 BY MR. KAWAMOTO:

<p style="text-align: right;">Page 278</p> <p>1 Q. Okay.</p> <p>2 (WHEREUPON, a certain document was</p> <p>3 marked Mallinckrodt-Ratliff</p> <p>4 Deposition Exhibit No. 032, for</p> <p>5 identification, as of 12/19/2018.)</p> <p>6 BY THE WITNESS:</p> <p>7 A. Okay.</p> <p>8 BY MR. KAWAMOTO:</p> <p>9 Q. Okay. So directing your attention to the</p> <p>10 front page of this e-mail -- oh, I'm sorry. This is</p> <p>11 an e-mail chain between you and Cathy Stewart, Susan</p> <p>12 Marlatt and Karen Harper, among others. Its Bates</p> <p>13 number is 290580.</p> <p>14 A. Okay.</p> <p>15 Q. And the e-mail from Susan Marlatt, do you</p> <p>16 see it says: "We have completed our check"?</p> <p>17 A. Um-hum.</p> <p>18 Q. And then your response is: "This should</p> <p>19 be your decision based on the credit checks. If they</p> <p>20 are qualified, Karen and I don't need to make the</p> <p>21 decision. This will become easier as we go. Have a</p> <p>22 good weekend."</p> <p>23 So what -- what are you saying in that</p> <p>24 e-mail?</p>	<p style="text-align: right;">Page 280</p> <p>1 A. Um-hum.</p> <p>2 Q. And how -- how does a credit check</p> <p>3 reassure you that this order isn't excessive for such</p> <p>4 a small institution?</p> <p>5 MR. O'CONNOR: Objection.</p> <p>6 BY THE WITNESS:</p> <p>7 A. Well, and there is -- there is certain</p> <p>8 things we can do, and so, I mean, we do -- in the</p> <p>9 normal course of business we do credit checks and --</p> <p>10 and just to see if the company is viable, how long it</p> <p>11 has been in business and so forth. There were no --</p> <p>12 nothing other than the amount was a flag at all. It</p> <p>13 just seemed it was a new customer and they were trying</p> <p>14 to establish an amount that they could start their</p> <p>15 distribution network with, so.</p> <p>16 Q. But it is a new customer asking for</p> <p>17 2,500 bottles of oxy 30, and that -- and oxy 30 is, as</p> <p>18 we've discussed is --</p> <p>19 A. Yeah.</p> <p>20 Q. -- one of Mallinckrodt's most heavily</p> <p>21 abused products --</p> <p>22 A. Yeah.</p> <p>23 Q. -- is that true?</p> <p>24 MR. O'CONNOR: Objection.</p>
<p style="text-align: right;">Page 279</p> <p>1 A. That the -- there was nothing negative in</p> <p>2 the credit checks to indicate that -- that the -- that</p> <p>3 there were -- there was any background that would</p> <p>4 prevent us from doing business with them based on what</p> <p>5 Dun & Bradstreet came back with, so.</p> <p>6 Q. But the credit check doesn't address the</p> <p>7 fact that their initial order, and they are an</p> <p>8 extremely small company and with a Yahoo e-mail</p> <p>9 address, was 2,500, correct?</p> <p>10 MR. O'CONNOR: Objection.</p> <p>11 BY MR. KAWAMOTO:</p> <p>12 Q. So shouldn't you and Karen have been the</p> <p>13 ones to sign off on that initial 2,500 order?</p> <p>14 A. I don't think so. It's a -- I mean, there</p> <p>15 are certain things that we do to ensure that they are</p> <p>16 creditworthy, that they are a legitimate company, and</p> <p>17 all of those things were done. So what they are</p> <p>18 saying is they -- they obviously broke the order up so</p> <p>19 they didn't go over their -- their credit limit.</p> <p>20 Q. But your initial reaction was that 2,500</p> <p>21 seems like an awfully large order for such a new</p> <p>22 customer with such a small credit limit, and you later</p> <p>23 learned that it is an extremely small company with an</p> <p>24 @Yahoo e-mail address?</p>	<p style="text-align: right;">Page 281</p> <p>1 BY MR. KAWAMOTO:</p> <p>2 Q. Okay. So at the very top, do you see</p> <p>3 that, can you please read your e-mail right up here?</p> <p>4 A. I said: "Sorry for not being more clear.</p> <p>5 This is a new customer that has cleared credit</p> <p>6 references. The salesman has not raised any issues of</p> <p>7 substance. Therefore, this should be approved in the</p> <p>8 normal course of business, not by Karen or me. If I</p> <p>9 have missed something, please let me know."</p> <p>10 Q. So is what you are saying that</p> <p>11 notwithstanding the fact that this order appears</p> <p>12 large, because the credit checks were clear and the</p> <p>13 salesman doesn't have any concerns, you know, there is</p> <p>14 nothing for you or Karen to approve? Am I</p> <p>15 interpreting that correctly?</p> <p>16 A. Yes.</p> <p>17 Q. Okay. Now, if the salesman had raised</p> <p>18 issues, then would that be a different matter?</p> <p>19 A. Absolutely. Then we wouldn't have shipped</p> <p>20 it at all.</p> <p>21 Q. Okay. Does the salesman have an incentive</p> <p>22 to let orders go through --</p> <p>23 MR. O'CONNOR: Objection.</p> <p>24 BY MR. KAWAMOTO:</p>

<p style="text-align: right;">Page 282</p> <p>1 Q. -- because of their compensation scheme?</p> <p>2 A. I don't know how they are compensated.</p> <p>3 Q. And what does a clear -- what does a clear</p> <p>4 credit reference tell you in terms of the risk of</p> <p>5 diversion? I mean, the clear -- I mean, credit</p> <p>6 references measure the -- a company's financial</p> <p>7 health, right?</p> <p>8 A. Yes.</p> <p>9 Q. And so if a company is profitable, that</p> <p>10 doesn't necessarily tell you that, you know, their</p> <p>11 orders aren't suspicious or their orders are proper,</p> <p>12 does it?</p> <p>13 A. There was nothing negative in the -- in</p> <p>14 the report at all to say they were late in paying or</p> <p>15 that they had had any issues at all. So,</p> <p>16 Dun & Bradstreet is a very prominent source for -- we</p> <p>17 used it in the FBI, so.</p> <p>18 Q. Well, sir, I mean, pill mills have the</p> <p>19 potential to be highly profitable, don't they?</p> <p>20 MR. O'CONNOR: Objection.</p> <p>21 BY THE WITNESS:</p> <p>22 A. At the time we didn't know it was a pill</p> <p>23 mill, so.</p> <p>24 (WHEREUPON, a certain document was</p>	<p style="text-align: right;">Page 284</p> <p>1 A. Apparently, yes.</p> <p>2 BY MR. KAWAMOTO:</p> <p>3 Q. Okay. And so you have Cathy Stewart</p> <p>4 telling you that the customer service reps -- well,</p> <p>5 strike that.</p> <p>6 If you need to, you can -- you can</p> <p>7 reference the prior e-mail, but one of the bases that</p> <p>8 you were provided or you indicated for the approval of</p> <p>9 the order was that the salesman had not raised any</p> <p>10 issues of substance.</p> <p>11 Do you recall that?</p> <p>12 A. Yes.</p> <p>13 Q. So here you have an e-mail from Cathy</p> <p>14 Stewart to you and Karen Harper --</p> <p>15 A. Um-hum.</p> <p>16 Q. -- indicating that the sales rep Victor is</p> <p>17 going to tell people anything they want to hear just</p> <p>18 so he can get the sales through?</p> <p>19 A. Um-hum.</p> <p>20 MR. O'CONNOR: Objection.</p> <p>21 BY MR. KAWAMOTO:</p> <p>22 Q. Didn't that concern you?</p> <p>23 A. This is after the fact that the order --</p> <p>24 the other is in --</p>
<p style="text-align: right;">Page 283</p> <p>1 marked Mallinckrodt-Ratliff</p> <p>2 Deposition Exhibit No. 033, for</p> <p>3 identification, as of 12/19/2018.)</p> <p>4 BY MR. KAWAMOTO:</p> <p>5 Q. So this is another e-mail chain dated</p> <p>6 5/22/2008 between Cathy -- and it's from Cathy Stewart</p> <p>7 to you and Karen Harper. And you can tell from the</p> <p>8 subject line that this relates to the new customer</p> <p>9 Sunrise Whole -- Wholesale, correct?</p> <p>10 A. Um-hum.</p> <p>11 Q. Okay. Can you please read the top e-mail</p> <p>12 that I just highlighted?</p> <p>13 A. I don't see it on the screen.</p> <p>14 Q. Oh, no, I'm sorry. My apologies.</p> <p>15 A. Okay. "FYI - the customer service reps</p> <p>16 all state that Victor will tell them anything they</p> <p>17 want to hear just so he can get the sale."</p> <p>18 Q. Okay. And Victor is Victor Borelli,</p> <p>19 correct?</p> <p>20 A. Correct.</p> <p>21 Q. And he is a sales -- he is the manager or</p> <p>22 the sales rep for this new customer, is he not?</p> <p>23 MR. O'CONNOR: Objection.</p> <p>24 BY THE WITNESS:</p>	<p style="text-align: right;">Page 285</p> <p>1 Q. Well --</p> <p>2 A. -- May 24th -- well, no, it's not. I know</p> <p>3 that Victor wasn't a very popular person, so.</p> <p>4 Q. Do you think he was an honest person?</p> <p>5 A. I don't know that.</p> <p>6 Q. Do you think he was reliable?</p> <p>7 MR. O'CONNOR: Objection.</p> <p>8 BY THE WITNESS:</p> <p>9 A. I don't know that either. I just know he</p> <p>10 wasn't very popular.</p> <p>11 BY MR. KAWAMOTO:</p> <p>12 Q. Do you know why he wasn't popular?</p> <p>13 A. No.</p> <p>14 Q. In light of this information from Cathy</p> <p>15 regarding Victor, did you or Karen do anything to try</p> <p>16 to verify, you know, Victor's assessment of this new</p> <p>17 customer?</p> <p>18 A. I think that's --</p> <p>19 MR. O'CONNOR: Objection.</p> <p>20 BY THE WITNESS:</p> <p>21 A. I think that's when they did the audit, or</p> <p>22 did they do the audit shortly thereafter?</p> <p>23 BY MR. KAWAMOTO:</p> <p>24 Q. I'll represent to you I don't believe that</p>

<p style="text-align: right;">Page 286</p> <p>1 they did audit in -- in the summer of 2008.</p> <p>2 A. Okay. I don't know that, so.</p> <p>3 Q. So to the best of your recollection,</p> <p>4 nothing was -- was done in response to this</p> <p>5 particular --</p> <p>6 A. No.</p> <p>7 Q. -- piece of information?</p> <p>8 A. I do know that they represented there was</p> <p>9 a DEA agent that was working with them to ensure they</p> <p>10 were in total compliance. And in talking to DEA after</p> <p>11 the fact they said, Well, he is not the most reliable</p> <p>12 person either. But there was no way for us to</p> <p>13 determine that earlier, so.</p> <p>14 Q. And so just so I'm clear, in terms of</p> <p>15 the -- the origination history for Sunrise</p> <p>16 Wholesale --</p> <p>17 A. Um-hum.</p> <p>18 Q. -- you have an extremely small company</p> <p>19 with a Yahoo e-mail address that contacts Mallinckrodt</p> <p>20 asking for 2500 bottles of oxy 30. The sales rep,</p> <p>21 Mr. Borelli, is someone that his colleagues indicated</p> <p>22 is unpopular. And, in fact, Cathy says, you know,</p> <p>23 "Victor will tell them anything they want to hear just</p> <p>24 so he can get the sale." And nevertheless, this --</p>	<p style="text-align: right;">Page 288</p> <p>1 Q. But you didn't audit them before shipping</p> <p>2 this order for 2,500 bottles of oxy 30?</p> <p>3 A. No.</p> <p>4 Q. Okay. Should you have?</p> <p>5 MR. O'CONNOR: Objection.</p> <p>6 BY THE WITNESS:</p> <p>7 A. Well, if you are saying is hindsight</p> <p>8 20/20, you know, maybe we should have -- should have</p> <p>9 at least looked at it, so, but we did what we thought</p> <p>10 was appropriate at the time.</p> <p>11 (WHEREUPON, a certain document was</p> <p>12 marked Mallinckrodt-Ratliff</p> <p>13 Deposition Exhibit No. 034, for</p> <p>14 identification, as of 12/19/2018.)</p> <p>15 BY MR. KAWAMOTO:</p> <p>16 Q. So, Mr. Ratliff, this is an e-mail from</p> <p>17 Mr. Harper -- I'm sorry -- Ms. Harper to you. It is</p> <p>18 dated November of 2008. And you'll see from the --</p> <p>19 the e-mail string that this, once again, is Sunrise</p> <p>20 Wholesale. So if I can direct your attention to the</p> <p>21 bottom e-mail that spans 307120 and 307121.</p> <p>22 A. Okay. I'm just trying to figure out,</p> <p>23 there is a from Karen to me, FYI.</p> <p>24 Q. Yes, understood.</p>
<p style="text-align: right;">Page 287</p> <p>1 this customer was accepted and this order was approved</p> <p>2 in the ordinary course.</p> <p>3 Is that correct, sir?</p> <p>4 MR. O'CONNOR: Objection.</p> <p>5 BY THE WITNESS:</p> <p>6 A. I was just looking at the order amount</p> <p>7 again.</p> <p>8 BY MR. KAWAMOTO:</p> <p>9 Q. Well, the order amount is at the bottom of</p> <p>10 3028219, so the e-mail we were just looking at from</p> <p>11 Cathy Stewart.</p> <p>12 A. 2,520 bottles. Okay. Yeah.</p> <p>13 Q. Doesn't this suggest a -- a breakdown in</p> <p>14 the review process?</p> <p>15 MR. O'CONNOR: Objection.</p> <p>16 BY MR. KAWAMOTO:</p> <p>17 Q. For either -- for both no clients and</p> <p>18 orders, sir?</p> <p>19 MR. O'CONNOR: Objection.</p> <p>20 BY THE WITNESS:</p> <p>21 A. It has been ten years ago. I know</p> <p>22 initially we did an audit and that they are no longer</p> <p>23 in business, so.</p> <p>24 BY MR. KAWAMOTO:</p>	<p style="text-align: right;">Page 289</p> <p>1 A. Okay.</p> <p>2 Q. She is forwarding you this e-mail chain.</p> <p>3 And actually, sir, if I can ask you to</p> <p>4 read the e-mail on the back page, which I've -- I've</p> <p>5 highlighted?</p> <p>6 A. "Just a quick FYI regarding Sunrise. As</p> <p>7 you know, they have been growing in sales each and</p> <p>8 every month and when I was visiting them this week,</p> <p>9 they introduced me to their new sales manager. He was</p> <p>10 Anda's No. 1 salesman and brings a wealth of knowledge</p> <p>11 and systems to Sunrise. This salesman is extremely</p> <p>12 tied to the Florida market and has been the cause of</p> <p>13 most of the growth (new customers, contacts" --</p> <p>14 "contacts, et cetera). In addition to the recently</p> <p>15 hired sales manager, they are adding five additional</p> <p>16 salespeople, as well as additional states to</p> <p>17 distribute product to. To make a long story short, I</p> <p>18 wanted to" -- "you to be aware of their growth and to</p> <p>19 supply you with some new monthly sales projections for</p> <p>20 this account. Beginning in January, can we raise our</p> <p>21 projections for Sunrise: Oxy 15-milligrams: 3,000</p> <p>22 bottles; oxy 30s: 12,000 bottles. Hope this" --</p> <p>23 Q. So the date of this -- I'm sorry, sir.</p> <p>24 A. I'm sorry. You wanted me to read more?</p>

<p style="text-align: right;">Page 290</p> <p>1 Q. The date of this e-mail is November, 2008,</p> <p>2 so this would be approximately five or six months</p> <p>3 after they first became a Mallinckrodt customer?</p> <p>4 A. Yes.</p> <p>5 Q. And they are increasing their oxy 30 order</p> <p>6 from 2,500 bottles to 12,000 bottles per month.</p> <p>7 Do you see that?</p> <p>8 A. I do.</p> <p>9 Q. Doesn't that increase -- shouldn't that</p> <p>10 increase cause some concern?</p> <p>11 A. That's easy to say now. I don't know that</p> <p>12 I knew that at the time.</p> <p>13 Q. Well, but, sir, at the time, this is what</p> <p>14 you did know, this is an extremely small company, they</p> <p>15 start off right off the bat asking for 2,520 bottles</p> <p>16 of OxyContin. The sales rep that's in charge of this</p> <p>17 account, you receive an e-mail that he will say</p> <p>18 anything to get his sales through. And then five or</p> <p>19 six months later he is sending another e-mail saying</p> <p>20 to everyone, They are going to increase their volume</p> <p>21 from 2,520 to 12,000 bottles and they are then going</p> <p>22 to add 3,000 bottles of oxy 15.</p> <p>23 Isn't this problematic, sir?</p> <p>24 MR. O'CONNOR: Objection.</p>	<p style="text-align: right;">Page 292</p> <p>1 Q. But what you knew back then, sir, because</p> <p>2 this is a -- I mean, well, you would agree this is a</p> <p>3 sub -- this is a massive increase in their order?</p> <p>4 A. Um-hum.</p> <p>5 Q. Correct?</p> <p>6 MR. O'CONNOR: Objection.</p> <p>7 BY MR. KAWAMOTO:</p> <p>8 Q. And it's being -- I mean, to say that the</p> <p>9 person providing you with this information,</p> <p>10 Mr. Borelli, you know, is someone that will say</p> <p>11 anything to get a sale, and so he is telling you that</p> <p>12 Sunrise is asking for 12,000 -- well, now 15,000</p> <p>13 bottles of oxy and the reason they are doing this is</p> <p>14 because they are going to -- they have hired new</p> <p>15 salespeople and they are going to look to additional</p> <p>16 states to distribute product to.</p> <p>17 Do you know if anything was done to</p> <p>18 actually ascertain whether in fact they were going to</p> <p>19 distribute products to additional states?</p> <p>20 MR. O'CONNOR: Objection.</p> <p>21 BY THE WITNESS:</p> <p>22 A. I don't know.</p> <p>23 BY MR. KAWAMOTO:</p> <p>24 Q. If you had known that all of this was</p>
<p style="text-align: right;">Page 291</p> <p>1 BY THE WITNESS:</p> <p>2 A. I'm just wondering when we did our audit.</p> <p>3 Do you have that information?</p> <p>4 BY MR. KAWAMOTO:</p> <p>5 Q. I believe it was in 2009.</p> <p>6 A. Okay. Early 2009 or --</p> <p>7 Q. Well, I think we'll -- I think we'll get</p> <p>8 to it, but it's -- let me see if I can find that</p> <p>9 information for you.</p> <p>10 I be -- I believe it is August of 2009.</p> <p>11 A. Okay. Six months after this, so.</p> <p>12 Q. Well, actually, sir, that would be nine --</p> <p>13 that would be nine months after this, because August</p> <p>14 of 2009, this is November of 2008.</p> <p>15 A. Okay.</p> <p>16 Q. Did -- did anyone do anything to try to</p> <p>17 verify Mr. Borelli's information about Sunrise?</p> <p>18 A. I don't know.</p> <p>19 Q. In your opinion, should something have</p> <p>20 been done to try to verify this information?</p> <p>21 MR. O'CONNOR: Objection.</p> <p>22 BY THE WITNESS:</p> <p>23 A. Based on what we know now, yes.</p> <p>24 BY MR. KAWAMOTO:</p>	<p style="text-align: right;">Page 293</p> <p>1 going to Florida, sir, would you have been concerned?</p> <p>2 MR. O'CONNOR: Objection.</p> <p>3 BY THE WITNESS:</p> <p>4 A. In -- and so, okay. Ten years ago, I'm</p> <p>5 not certain that this had exploded like it has in more</p> <p>6 recent times. So I don't know that that would have</p> <p>7 been as big an exception for us, so.</p> <p>8 BY MR. KAWAMOTO:</p> <p>9 Q. Okay. But suffice to say that based on</p> <p>10 this e-mail chain, this -- this increase -- this</p> <p>11 increase didn't draw any increased scrutiny?</p> <p>12 MR. O'CONNOR: Objection.</p> <p>13 BY MR. KAWAMOTO:</p> <p>14 Q. That you are aware of?</p> <p>15 A. I don't know that.</p> <p>16 Q. Well, sir, as you sit here today, I mean,</p> <p>17 I understand that you said hindsight is 20/20, but as</p> <p>18 you sit here today, do you think something should have</p> <p>19 been done to scrutinize this customer and this order?</p> <p>20 MR. O'CONNOR: Objection.</p> <p>21 BY THE WITNESS:</p> <p>22 A. As we sit here today, it's easy to -- to</p> <p>23 scrutinize or question our judgment, so yes.</p> <p>24 (WHEREUPON, a certain document was</p>

<p style="text-align: right;">Page 294</p> <p>1 marked Mallinckrodt-Ratliff 2 Deposition Exhibit No. 035, for 3 identification, as of 12/19/2018.) 4 BY MR. KAWAMOTO: 5 Q. Okay. So this is another long e-mail 6 chain, but I'm going to take it from the -- the back 7 going forward. So I'm going to start at Page 307207 8 and go up to 307203. 9 A. Okay. 10 Q. So, if you look at the e-mail on 11 Page 307207, it is an e-mail from Paul Kleissle to you 12 and Karen. And he says: "When you can, can you give 13 me a call regarding the oxy case?" 14 A. Right, but -- 15 Q. Do you know what the reference to the oxy 16 case is? 17 A. Well, based on the other e-mails, it is 18 going to be Sunrise. 19 Q. Okay. And then do you see the e-mail on 20 Page 307206, and I'll highlight it for you. 21 A. "The DEA Diversion Group Supervisor 22 recommended that we audit Sunrise as soon as possible. 23 Please let me know the best way to accomplish this. 24 Please give me a call to discuss."</p>	<p style="text-align: right;">Page 296</p> <p>1 Q. -- we can go back to it -- 2 A. They wanted to go up to that. 3 Q. -- they wanted to go up to it and there is 4 no indication that they weren't allowed to and, in 5 fact, isn't that what your sales department was 6 advocating? 7 A. Beginning in January, raise to 12,000 8 bottles, yeah. That's a lot. 9 Q. Okay. So for -- presumably for five 10 months or six months, because you got the call from 11 the DEA in July of 2009 -- I'm sorry -- in July 12 of 2009, you had been shipping them around 15,000 13 bottles of oxy? 14 MR. O'CONNOR: Objection. 15 BY THE WITNESS: 16 A. Okay. 17 BY MR. KAWAMOTO: 18 Q. Okay. 19 I'm sorry. Actually, if I could direct 20 your attention to the previous exhibit, so that -- is 21 that Exhibit 34 or 35? Okay. So 35. 22 It is John Adams e-mailing Cathy Stewart, 23 Victor Borelli and Karen Harper. He says: "For 24 suspicious order monitoring, this is a potential</p>
<p style="text-align: right;">Page 295</p> <p>1 Q. So DEA is telling that you need -- telling 2 you that you need to audit Sunrise as soon as 3 possible? 4 A. Yes. 5 Q. Is this an unusual call? 6 MR. O'CONNOR: Objection. 7 BY THE WITNESS: 8 A. We spoke with DEA a lot. I don't know 9 that I had ever been asked to go audit someone though, 10 so I will say it is unusual. 11 BY MR. KAWAMOTO: 12 Q. Okay. And this is -- as you saw from the 13 previous e-mail, this is when they were receiving 14 15,000 bottles of Mallinckrodt oxy product a month, 15 correct? 16 MR. O'CONNOR: Objection. 17 BY THE WITNESS: 18 A. I don't know exactly what they were 19 shipping them or if they approved the entire order. I 20 don't -- I mean... 21 BY MR. KAWAMOTO: 22 Q. Well, but, I mean, looking at the previous 23 e-mail, and we can -- 24 A. Okay.</p>	<p style="text-align: right;">Page 297</p> <p>1 increase on the horizon." 2 Do you -- do you know why he is conveying 3 that information in the context of suspicious order 4 monitoring? 5 A. You've lost me here. 6 Q. I'm sorry. 7 MR. O'CONNOR: I think there is no Exhibit 36, 8 as far as I know. 9 BY MR. KAWAMOTO: 10 Q. Oh, okay. That may be my mistake then. I 11 apologize. 12 Okay. So we are -- we are on 13 Exhibit 30- -- 14 A. 35. 15 Q. -- 35 and the previous e-mail -- e-mail is 16 Exhibit 34? 17 A. Correct. 18 Q. So looking back at Exhibit 34, this is the 19 one where you are learning that they are increasing 20 their oxy order? 21 A. Okay. 22 Q. At the very bottom of Page 307120, it 23 says: "For the suspicious order monitoring, this is a 24 potential increase on the horizon."</p>

Page 298

1 Do you know -- I mean, who is John Adams?
 2 A. I don't recall.
 3 Q. Okay. And why is -- but why is he telling
 4 you and Karen about this increase?
 5 A. At this time I don't remember.
 6 Q. I mean, as you sit here, you have no
 7 reason to believe that this order was either denied or
 8 subject to heightened scrutiny?
 9 MR. O'CONNOR: Objection.
 10 BY THE WITNESS:
 11 A. I have no way to know that.
 12 BY MR. KAWAMOTO:
 13 Q. Okay. So turning back now to Exhibit 35.
 14 A. Okay.
 15 Q. So the DEA is asking you to audit this
 16 company and this in your recollection is that this the
 17 first time that they are -- or this is the first time
 18 you recall them doing that?
 19 A. Yes.
 20 Q. Do you see the e-mail in the middle of the
 21 page on 307205?
 22 A. I do.
 23 Q. Okay. And it says: "Bill, I know that we
 24 don't want to make this audit 'a cast of thousands',

Page 299

1 and assume the scope of audit review will be at a
 2 fairly high" -- "a fairly high security and compliance
 3 level?"
 4 Do you know what Karen means by that?
 5 A. Not exactly.
 6 What -- what is your question?
 7 Q. Well, I'm asking about the scope of the
 8 audit being at a fairly high security and compliance
 9 level, and I guess my question is: Given what you
 10 know about this company, meaning it's an extremely
 11 small company, it's now asking for 15,000 bottles of
 12 oxy and the DEA has called you up and specifically
 13 said you should audit these, shouldn't your audit be a
 14 fairly detailed one?
 15 MR. O'CONNOR: Objection.
 16 BY THE WITNESS:
 17 A. Yes.
 18 BY MR. KAWAMOTO:
 19 Q. So why would it be a high security and
 20 compliance -- why would it be at a high level?
 21 MR. O'CONNOR: Objection.
 22 BY THE WITNESS:
 23 A. I really don't know what she is
 24 recommending here, other than not taking in 10 or 15

Page 300

1 people, not that we had that many people to do that,
 2 but...
 3 Q. So that's all for that exhibit.
 4 MR. KAWAMOTO: And so this I believe is now
 5 Exhibit 36. Okay.
 6 (WHEREUPON, a certain document was
 7 marked Mallinckrodt-Ratliff
 8 Deposition Exhibit No. 036, for
 9 identification, as of 12/19/2018.)
 10 BY MR. KAWAMOTO:
 11 Q. So I'd like to direct your attention to
 12 the e-mail at the very back, which would be spanning
 13 Pages 562328 to 562329.
 14 A. Okay.
 15 Q. Okay. So this bottom e-mail is from
 16 Dwayne Collins to you.
 17 And who is Dwayne Collins?
 18 A. He is a Morristown police officer --
 19 Q. And what --
 20 A. -- who worked in the HIDTA out of the
 21 Morristown resident agency under Kevin Keithly. HIDTA
 22 is a high intensity drug trafficking area. And they
 23 often are on loan to the FBI to help with
 24 investigations.

Page 301

1 Q. And what is he writing to tell you?
 2 A. He is writing to say that they have a
 3 large amount of 30-milligram oxycodone coming into his
 4 area and he is asking for my assistance.
 5 Q. And this oxy 30, it's a Mallinckrodt
 6 product, is it not, sir?
 7 A. Oxycodone 30 is, yes.
 8 Q. Okay. And then can -- could you please
 9 look at the e-mail above that, so at the e-mail at the
 10 top of the page, 562328.
 11 A. Yes.
 12 Q. So who is -- you were able to trace back
 13 this product, were you not?
 14 A. We were, through our system.
 15 Q. And that's a chargeback system?
 16 MR. O'CONNOR: Objection.
 17 BY THE WITNESS:
 18 A. I don't think so. Well, it may have been,
 19 but they -- the SKU on this, and the NDC number, that
 20 tells us where it was manufactured, and I don't know
 21 if it was through chargebacks we determined those
 22 bottles. I'm not sure it's with that specificity that
 23 we are able to track chargebacks.
 24 BY MR. KAWAMOTO:

<p style="text-align: right;">Page 302</p> <p>1 Q. Okay.</p> <p>2 A. We were able to determine where those</p> <p>3 shipments were -- went through our Hobart office, and</p> <p>4 this is just from memory.</p> <p>5 Q. I see. So you were --</p> <p>6 A. So they could identify them going to</p> <p>7 Sunrise.</p> <p>8 Q. So the distributor for this product was</p> <p>9 Sunrise Wholesale?</p> <p>10 A. That's where it was shipped to.</p> <p>11 Q. Okay. And this is, once again, the same</p> <p>12 company that asked for 15 -- or was receiving 15,000</p> <p>13 bottles of oxycodone starting in January of 2009,</p> <p>14 correct, sir?</p> <p>15 A. Okay.</p> <p>16 MR. O'CONNOR: Objection.</p> <p>17 MR. KAWAMOTO: Okay. Why don't we take a really</p> <p>18 quick break and then we'll come right back.</p> <p>19 THE VIDEOGRAPHER: We are going off the record</p> <p>20 at 5:16.</p> <p>21 (WHEREUPON, a recess was had</p> <p>22 from 5:16 to 5:21 p.m.)</p> <p>23 THE VIDEOGRAPHER: We are back on the record at</p> <p>24 5:21.</p>	<p style="text-align: right;">Page 304</p> <p>1 methadone 10-milligram; and 4 hydromorphone. All came</p> <p>2 from the customer we discussed except the</p> <p>3 hydromorphone."</p> <p>4 Q. Okay. And the customer is, I think we've</p> <p>5 established, is Sunrise, correct? And that -- that</p> <p>6 would be the e-mail that spans 562 and 327.</p> <p>7 A. Okay.</p> <p>8 Q. Okay. So if you see where I've</p> <p>9 highlighted.</p> <p>10 A. "The only shipment of this lot..." I</p> <p>11 don't know where that is.</p> <p>12 Q. It is at the very top of the page, 562328.</p> <p>13 So it's a --</p> <p>14 A. Okay.</p> <p>15 Q. So you've received a call from a -- from</p> <p>16 law enforcement in Tennessee?</p> <p>17 A. Um-hum.</p> <p>18 Q. And they've identified Mallinckrodt oxy 30</p> <p>19 in their jurisdiction?</p> <p>20 A. Um-hum.</p> <p>21 Q. And you've traced the -- the product back</p> <p>22 to Sunrise Wholesale. Is that accurate?</p> <p>23 A. Yes.</p> <p>24 Q. Okay. And then in addition, you</p>
<p style="text-align: right;">Page 303</p> <p>1 BY MR. KAWAMOTO:</p> <p>2 Q. Okay. And so this e-mail exchange is</p> <p>3 between you and Dwayne Collins of Morristown.</p> <p>4 And Morristown is in Tennessee, is it not,</p> <p>5 sir?</p> <p>6 A. I believe so.</p> <p>7 Q. So what we are seeing is an example of</p> <p>8 medication that is initially sent to Florida and then</p> <p>9 migrates to Tennessee, is that accurate?</p> <p>10 MR. O'CONNOR: Objection.</p> <p>11 BY THE WITNESS:</p> <p>12 A. I think that's accurate.</p> <p>13 BY MR. KAWAMOTO:</p> <p>14 Q. Okay. And then do you see the e-mail --</p> <p>15 well, let me highlight it for you. It is going to be</p> <p>16 on Page 562327.</p> <p>17 A. Okay.</p> <p>18 Q. And let me try to -- so can you -- can you</p> <p>19 read that e-mail, sir?</p> <p>20 A. Where it says "Dwayne"?</p> <p>21 Q. Yes, please.</p> <p>22 A. "Dwayne, the doctor we discussed ordered</p> <p>23 the following during the last 12 months: 78 bottles</p> <p>24 of oxy, 15-milligram; 204 oxy 30-milligram; 20</p>	<p style="text-align: right;">Page 305</p> <p>1 communicate again with the officer, Dwayne, and you</p> <p>2 tell him, "Dwayne, the doctor we discussed ordered the</p> <p>3 following during the last 12 months, all came from the</p> <p>4 customer we discussed except the hydromorphone."</p> <p>5 And so I just want to clarify that the</p> <p>6 customer you are referring to is Sunrise?</p> <p>7 A. Okay.</p> <p>8 Q. And you also have a reference to the</p> <p>9 doctor, so that means you -- you know, you know both</p> <p>10 the customer and the end user, is that accurate?</p> <p>11 MR. O'CONNOR: Objection.</p> <p>12 BY THE WITNESS:</p> <p>13 A. I don't know that we've named the doctor</p> <p>14 in here, have we?</p> <p>15 BY MR. KAWAMOTO:</p> <p>16 Q. Well, you state: "The doctor we</p> <p>17 discussed," so presumably you know who he is?</p> <p>18 A. Okay. I'll go with that.</p> <p>19 Q. The final thing I want to note is an</p> <p>20 e-mail in the middle of the page that's 562326.</p> <p>21 Do you see that?</p> <p>22 A. Yes.</p> <p>23 Q. Okay.</p> <p>24 A. "After discussions with his supervisor,</p>

<p style="text-align: right;">Page 306</p> <p>1 the DEA Diversion Group Supervisor recommended that we</p> <p>2 audit Sunrise distributors as soon as possible. The</p> <p>3 investigation in Eastern Tennessee" -- "Eastern</p> <p>4 Tennessee has substantially slowed because of</p> <p>5 infighting between the subjects. The audit has been</p> <p>6 scheduled for August 18th and 19th in Sunrise,</p> <p>7 Florida, which is close to Ft. Lauderdale. The team</p> <p>8 is being selected and it will be handled like a normal</p> <p>9 customer audit."</p> <p>10 Q. And so the reason I'm noting this is</p> <p>11 because that the audit is now scheduled for Sunrise?</p> <p>12 A. Um-hum.</p> <p>13 Q. It is August 18th and 19th?</p> <p>14 A. Um-hum.</p> <p>15 Q. And going into this audit you have the</p> <p>16 following information. You've got an extremely small</p> <p>17 company that is a relatively new Mallinckrodt customer</p> <p>18 that has increased its orders from 2,500 to 15,000,</p> <p>19 and the product that you are shipping, the oxy product</p> <p>20 that you are shipping to them has now appeared in</p> <p>21 Tennessee where it's the subject of law enforcement</p> <p>22 scrutiny.</p> <p>23 Is that all accurate?</p> <p>24 MR. O'CONNOR: Objection.</p>	<p style="text-align: right;">Page 308</p> <p>1 them as a normal customer?</p> <p>2 A. I didn't characterize them as a normal</p> <p>3 customer. That's the way they are going to conduct</p> <p>4 the audit.</p> <p>5 Q. Well --</p> <p>6 A. What would you suggest?</p> <p>7 Q. Well, I mean, I would -- I would have</p> <p>8 suggested shutting them down, but, you know, that's --</p> <p>9 A. Um-hum, okay.</p> <p>10 Q. -- that's between the two of us.</p> <p>11 MR. O'CONNOR: Object.</p> <p>12 BY MR. KAWAMOTO:</p> <p>13 Q. Okay.</p> <p>14 (WHEREUPON, a certain document was</p> <p>15 marked Mallinckrodt-Ratliff</p> <p>16 Deposition Exhibit No. 037, for</p> <p>17 identification, as of 12/19/2018.)</p> <p>18 BY MR. KAWAMOTO:</p> <p>19 Q. So this is an e-mail chain with an</p> <p>20 attachment. Its Bates number is 456333. The subject</p> <p>21 of this e-mail is "Sunrise Customer Chargebacks."</p> <p>22 Do you see that, sir?</p> <p>23 A. Yes.</p> <p>24 Q. Okay. And when you look at the chargeback</p>
<p style="text-align: right;">Page 307</p> <p>1 BY THE WITNESS:</p> <p>2 A. Yes.</p> <p>3 BY MR. KAWAMOTO:</p> <p>4 Q. Okay. And so for this audit, though, "The</p> <p>5 team is being selected and it will be handled like a</p> <p>6 normal customer audit."</p> <p>7 A. Um-hum.</p> <p>8 Q. What do you mean by "a normal customer</p> <p>9 audit"?</p> <p>10 A. Protocols. I mean, they go in and they do</p> <p>11 the regular audit. They -- they talk to them about</p> <p>12 their suspicious order monitoring program, who does</p> <p>13 that, and at the time I think they told them that they</p> <p>14 had a -- that's when they -- I think we knew before</p> <p>15 that about the DEA agent that assisted in identifying</p> <p>16 customers and -- and doing due diligence to ensure</p> <p>17 that they were operating correctly.</p> <p>18 Q. But based on the information available to</p> <p>19 you at this time, sir, I mean, they are not a normal</p> <p>20 customer, are they?</p> <p>21 MR. O'CONNOR: Objection.</p> <p>22 BY MR. KAWAMOTO:</p> <p>23 Q. Based on all of the information you have</p> <p>24 about Sunrise, I mean, how -- how can you characterize</p>	<p style="text-align: right;">Page 309</p> <p>1 data in the attachment --</p> <p>2 A. Okay.</p> <p>3 Q. -- it contains the DEA number, the ship to</p> <p>4 customer name, pricing contract, the SKU, product</p> <p>5 description, the pricing quantity and net sales.</p> <p>6 Do you see that, sir?</p> <p>7 A. Yes.</p> <p>8 Q. Okay. So this tells you who Sunrise</p> <p>9 customers are, doesn't it?</p> <p>10 MR. O'CONNOR: Objection.</p> <p>11 BY THE WITNESS:</p> <p>12 A. Yes.</p> <p>13 BY MR. KAWAMOTO:</p> <p>14 Q. And it also tells you the product that</p> <p>15 they are ordering is oxy 30?</p> <p>16 A. Correct.</p> <p>17 Q. And it also tells you the amount, the</p> <p>18 pricing quantities, is that what it is?</p> <p>19 A. Yes.</p> <p>20 MR. O'CONNOR: Objection.</p> <p>21 BY MR. KAWAMOTO:</p> <p>22 Q. Okay. And this is all information that</p> <p>23 you had available to you in advance of your audit, is</p> <p>24 that correct -- correct, sir?</p>

Page 310

1 A. I wasn't involved in the audit, so. The
 2 persons -- or Karen conducted the audit and so this
 3 would have been in her possession, so.
 4 (WHEREUPON, a certain document was
 5 marked Mallinckrodt-Ratliff
 6 Deposition Exhibit No. 038, for
 7 identification, as of 12/19/2018.)
 8 BY MR. KAWAMOTO:
 9 Q. So this is another e-mail exchange with an
 10 attachment.
 11 A. Yep.
 12 Q. Sunrise Chargeback Summary. The Bates
 13 number is 290041. And it is from Cathy Stewart to you
 14 and Karen, among others. And then at the top e-mail
 15 it says: "Cathy, Here's the other file....the doctor
 16 in question is in column CX."
 17 And if you look at the attachment, sir,
 18 which I believe starts on -- starts on Bates
 19 No. 290042, it appears to be a breakdown of the
 20 doctors along with the comparative amount or the
 21 relative amount that they are purchasing or obtaining
 22 from Sunrise.
 23 Is that accurate?
 24 MR. O'CONNOR: Objection.

Page 311

1 BY THE WITNESS:
 2 A. I don't know that I -- I don't know really
 3 what this says, just so you know, what the documents
 4 say. You are saying that they are -- I just want to
 5 be clear before I say yes or no.
 6 You are saying that this identifies the
 7 doctors, is that what you are saying?
 8 BY MR. KAWAMOTO:
 9 Q. Yes. This attachment.
 10 A. So all of these pages?
 11 Q. I believe so. If you look at row one, I
 12 believe those are the last names of doctors.
 13 A. Row one. I'm trying to find row one, so.
 14 Q. Well, I'm sorry. Let me help you out with
 15 that, okay. So if you look on the Elmo, I think those
 16 are doctors.
 17 A. So they would be B, C, D, E, is that what
 18 you are saying?
 19 Q. Yes.
 20 A. Okay. So let --
 21 Q. One doctor is in B, another doctor is in
 22 C, and another doctor is in D.
 23 A. Okay. I've got that.
 24 So you've identified those as doctors?

Page 312

1 Q. I believe so. You have doctors, you have
 2 the number of orders, you have the total quant --
 3 quantity and equivalent API.
 4 MR. O'CONNOR: Objection.
 5 BY MR. KAWAMOTO:
 6 Q. And you know the -- the measure for total
 7 quantity and equivalent APIs, is that essentially the
 8 number of pills?
 9 A. I'm still trying to figure out what the
 10 chart says.
 11 Q. Okay.
 12 A. What's all of the information at the
 13 bottom?
 14 Q. I think that is a comparative analysis of
 15 the API for the different doctors.
 16 A. Say that again.
 17 Q. I believe that on the assumption that the
 18 total quantity and equivalent API is the measure of
 19 essentially the pills that these doctors have been
 20 ordering, the chart is going to be the differing --
 21 the differing volumes of pills that each doctor has
 22 ordered. That's my reading of the chart.
 23 A. So you are saying one has purchased 10
 24 million pills?

Page 313

1 Q. I believe so. Where do you see that?
 2 A. Well, on the side where the numbers are,
 3 when you look at the chart, it is over 10 million.
 4 Q. Yes, I believe that means that they
 5 purchased 10 million in equivalent API.
 6 MR. O'CONNOR: Objection.
 7 BY THE WITNESS:
 8 A. So how does the chart below compare to the
 9 above, how do you separate that?
 10 BY MR. KAWAMOTO:
 11 Q. Well, I think the -- I think Beretsky, for
 12 example, you have got four orders for 702,000. I
 13 think that's his little block.
 14 A. Okay. Okay. I can read that, but what
 15 does this at the bottom mean?
 16 Q. I think that is a visual depiction of the
 17 total quantity and equivalent API that these doctors
 18 are obtaining.
 19 MR. O'CONNOR: Objection.
 20 BY MR. KAWAMOTO:
 21 Q. And I think if you look at Bates number --
 22 I believe if you can turn to page Bates No. 290048,
 23 sir, and it's got a -- it would be column CX.
 24 A. CX, okay.

<p style="text-align: right;">Page 314</p> <p>1 Q. So that's Schultz?</p> <p>2 A. Yes.</p> <p>3 Q. And do you see that there underneath it is</p> <p>4 one and 612,000?</p> <p>5 A. Okay.</p> <p>6 Q. So I believe that means one order for 612</p> <p>7 API?</p> <p>8 MR. O'CONNOR: Objection.</p> <p>9 BY MR. KAWAMOTO:</p> <p>10 Q. 612,000 API?</p> <p>11 A. Yeah. I don't know how to read the chart,</p> <p>12 so I'm going to have to go with -- I don't know what</p> <p>13 to say. I've never seen this before that I remember,</p> <p>14 and I don't really know what it's stating or how I</p> <p>15 should have been involved in this, so.</p> <p>16 Q. Well, but it does indicate for -- I mean,</p> <p>17 these are -- you would agree these are the customers'</p> <p>18 customers for Sunrise?</p> <p>19 MR. O'CONNOR: Objection.</p> <p>20 BY THE WITNESS:</p> <p>21 A. Okay. I -- okay. I -- if that's what you</p> <p>22 are saying, okay.</p> <p>23 BY MR. KAWAMOTO:</p> <p>24 Q. Well, isn't that a plausible</p>	<p style="text-align: right;">Page 316</p> <p>1 BY MR. KAWAMOTO:</p> <p>2 Q. Moving over to CW, do you see that column?</p> <p>3 A. I do.</p> <p>4 Q. It's Shook, right?</p> <p>5 A. Yes.</p> <p>6 Q. And do you see the volume -- or the volume</p> <p>7 of API?</p> <p>8 A. If that's what that means, API --</p> <p>9 Q. Okay. So what -- what is the volume</p> <p>10 indicated there?</p> <p>11 A. So you are saying it's API. I don't know</p> <p>12 that. It says "12,597,000."</p> <p>13 Q. Well, do you know what API means?</p> <p>14 A. Active pharmaceutical ingredient.</p> <p>15 Q. Okay. So is that essentially a measure of</p> <p>16 pills?</p> <p>17 MR. O'CONNOR: Objection.</p> <p>18 BY THE WITNESS:</p> <p>19 A. I'm trying to see on here where it</p> <p>20 specifies that that's API. I --</p> <p>21 BY MR. KAWAMOTO:</p> <p>22 Q. Well, fair enough.</p> <p>23 If you turn to the first page, that's</p> <p>24 going to be 209942.</p>
<p style="text-align: right;">Page 315</p> <p>1 interpretation of the e-mail on this chart? I mean --</p> <p>2 A. Well, it's plausible. I'm just saying</p> <p>3 that I don't know that to be a fact is what I'm</p> <p>4 saying.</p> <p>5 Q. Okay. But if you -- assuming this</p> <p>6 cover --</p> <p>7 A. Should we have known every one of these</p> <p>8 customers, did we run a thing at the time, so the</p> <p>9 answer is I don't know now, so.</p> <p>10 Q. So next to Schultz, do you see column CW?</p> <p>11 Well, actually, let me step back.</p> <p>12 So column CX is Schultz. Did you ever</p> <p>13 recall hearing about a Dr. Schultz?</p> <p>14 A. I lost the page now, so.</p> <p>15 Q. The page is 290048.</p> <p>16 A. Okay.</p> <p>17 Q. So column CX with Dr. Schultz.</p> <p>18 A. Um-hum.</p> <p>19 Q. Do you ever recall --</p> <p>20 A. This is ten years ago. No.</p> <p>21 Q. Okay. Would it surprise you to learn that</p> <p>22 Dr. Schultz is in prison?</p> <p>23 A. Good.</p> <p>24 MR. O'CONNOR: Objection.</p>	<p style="text-align: right;">Page 317</p> <p>1 Do you see that?</p> <p>2 A. Okay.</p> <p>3 Q. And do you see that notation? I'm sorry.</p> <p>4 It is a little blurry, but --</p> <p>5 A. Total quantity equivalent to API in column</p> <p>6 three.</p> <p>7 Q. Well, row three?</p> <p>8 A. Row three.</p> <p>9 So you are saying that corresponds with</p> <p>10 Schultz and Shook or --</p> <p>11 Q. Yes. So that --</p> <p>12 A. So the column then, again, would be --</p> <p>13 Q. The value for -- the value for row three</p> <p>14 for Shook is as you indicated --</p> <p>15 A. Okay.</p> <p>16 Q. -- 12 million?</p> <p>17 A. I'll go with that.</p> <p>18 Q. Okay.</p> <p>19 A. I understand.</p> <p>20 Q. So Shook is getting 12,597,000, you know,</p> <p>21 API or active pharmaceutical ingredients?</p> <p>22 A. Um-hum.</p> <p>23 Q. Doesn't that strike you as suspicious,</p> <p>24 sir?</p>

<p style="text-align: right;">Page 318</p> <p>1 A. That's a lot of pills.</p> <p>2 Q. Given that Mallinckrodt had access to this</p> <p>3 data, shouldn't they have investigated Mr. Shook?</p> <p>4 MR. O'CONNOR: Objection.</p> <p>5 BY THE WITNESS:</p> <p>6 A. Well, what you are saying is this is in</p> <p>7 '08 or '9. I don't know that we were using the</p> <p>8 chargeback system for that. I mean, I see that</p> <p>9 they've pulled this information and we did an audit,</p> <p>10 but I don't know that this information was available</p> <p>11 to me or was sent to me personally and said, You need</p> <p>12 to look at this. I know Pete Kleissle with DEA said</p> <p>13 you need to audit these people right away. So we went</p> <p>14 down to audit those people.</p> <p>15 BY MR. KAWAMOTO:</p> <p>16 Q. Well, regardless, certainly -- well,</p> <p>17 actually, sir, if you -- if you look at the e-mail on</p> <p>18 Page 290041 --</p> <p>19 A. Okay.</p> <p>20 Q. -- your -- your -- it was actually sent to</p> <p>21 you. It was sent to Karen Harper and Bill Ratliff.</p> <p>22 A. Um-hum.</p> <p>23 Q. So you received this information, sir?</p> <p>24 A. If this is properly marked, yes. And the</p>	<p style="text-align: right;">Page 320</p> <p>1 BY THE WITNESS:</p> <p>2 A. These just aren't stapled, is that</p> <p>3 correct?</p> <p>4 BY MR. KAWAMOTO:</p> <p>5 Q. Yes.</p> <p>6 MR. O'CONNOR: How many copies do we have?</p> <p>7 MR. KAWAMOTO: We just have two, one for you and</p> <p>8 one for the witness.</p> <p>9 BY MR. KAWAMOTO:</p> <p>10 Q. So, sir, this is a document Bates numbered</p> <p>11 307243. It is titled "Controlled Substance Compliance</p> <p>12 Suspicious Order Monitoring, Custom" -- "Customer</p> <p>13 Audit Checklist."</p> <p>14 A. Okay.</p> <p>15 Q. Do you see that, sir? Are you familiar</p> <p>16 with this form?</p> <p>17 A. I've seen this form. Not this particular</p> <p>18 one, but I've seen this form before.</p> <p>19 Q. And so this is the audit report for</p> <p>20 Sunrise Wholesale, is it not, sir?</p> <p>21 A. It appears, yes.</p> <p>22 Q. And this is the result of the audit that</p> <p>23 the DEA urged you to conduct immediately, correct?</p> <p>24 A. Yes.</p>
<p style="text-align: right;">Page 319</p> <p>1 answer is I just don't remember it, so.</p> <p>2 Q. Well, shouldn't -- as you sit here today,</p> <p>3 shouldn't you have taken a look at Dr. Shook --</p> <p>4 MR. O'CONNOR: Objection.</p> <p>5 BY MR. KAWAMOTO:</p> <p>6 Q. -- with his 12 million plus API?</p> <p>7 MR. O'CONNOR: Objection.</p> <p>8 BY THE WITNESS:</p> <p>9 A. I mean, that's reasonable.</p> <p>10 May I add something?</p> <p>11 BY MR. KAWAMOTO:</p> <p>12 Q. Yes, you can.</p> <p>13 A. I'm not certain we were looking at our</p> <p>14 customers' customers during that time, so.</p> <p>15 Q. But you certainly had the capability of</p> <p>16 looking at them had you chosen to do so?</p> <p>17 MR. O'CONNOR: Objection.</p> <p>18 BY MR. KAWAMOTO:</p> <p>19 Q. You got the chargeback reports?</p> <p>20 A. That -- that -- yeah, okay.</p> <p>21 (WHEREUPON, a certain document was</p> <p>22 marked Mallinckrodt-Ratliff</p> <p>23 Deposition Exhibit No. 039, for</p> <p>24 identification, as of 12/19/2018.)</p>	<p style="text-align: right;">Page 321</p> <p>1 Q. Okay. Is it fair to say that Sunrise</p> <p>2 passed its audit?</p> <p>3 MR. O'CONNOR: Objection.</p> <p>4 BY THE WITNESS:</p> <p>5 A. Are there any more pages, just these two?</p> <p>6 BY MR. KAWAMOTO:</p> <p>7 Q. That's -- that's all we have, sir.</p> <p>8 A. Okay. Well, "Does the subject company</p> <p>9 fill prescriptions issued by practitioners based</p> <p>10 solely on an online questionnaire without a medical</p> <p>11 examination...? Yes. Is the prescribing practitioner</p> <p>12 licensed to practice...? Yes. Is there any evidence</p> <p>13 the physician offers to sell controlled substances</p> <p>14 without a prescription? Yes. Does the physician</p> <p>15 charge reasonable prices? Yes."</p> <p>16 I mean, they were willing to fill it</p> <p>17 with -- we are missing some pages here. This says</p> <p>18 Page 3. There is nothing in between. This is not a</p> <p>19 complete audit.</p> <p>20 Q. No, I apologize. I think Page 2 may have</p> <p>21 been omitted from there, so why don't we...</p> <p>22 (WHEREUPON, the document was tendered</p> <p>23 to the witness.)</p> <p>24 BY THE WITNESS:</p>

Page 322

1 A. Okay. I'm still looking for the place
2 where it says they passed. Can you direct me to that
3 page?
4 BY MR. KAWAMOTO:
5 Q. Well, I believe this is what I have for
6 the audit. It is actually one, two --
7 A. Three pages.
8 Q. -- three pages.
9 Is your recollection -- is your
10 recollection that these -- these audits --
11 A. I don't recall.
12 Q. -- are more pages?
13 A. I don't recall. I wasn't on the audit. I
14 can't recall even reviewing the completed audit after
15 it was -- after it was completed. I recall talking to
16 Karen and they placed a lot of credence in the DEA
17 person that was assisting them with their -- their
18 business. So later we came to learn that he was not
19 as reputable as one would like, but we didn't know
20 that at the time when she did the audit, so.
21 Q. So your understanding or recollection,
22 though, is that Sunrise passed its audit?
23 A. I don't remember that. I don't know. I
24 mean, if they voluntarily gave up their -- their --

Page 323

1 their registration, that would tell me that there was
2 some -- some issues, so.
3 Q. Okay. Well, I'm going to -- this is
4 another exhibit. And what this is is this is an
5 excerpt of chargeback data that was produced to us.
6 A. Okay.
7 Q. And I've limited it to Sunrise.
8 (WHEREUPON, a certain document was
9 marked Mallinckrodt-Ratliff
10 Deposition Exhibit No. 040, for
11 identification, as of 12/19/2018.)
12 BY MR. KAWAMOTO:
13 Q. And there are three copies there.
14 A. Let's see if that's everything there. Oh,
15 here is another. Thank you.
16 Q. So the chargeback -- looking at Page 1 of
17 2, the chargeback system indicates that they received
18 in 2010, 21,368,000 sales in terms of government UOM.
19 So given that the audit was conducted in
20 2009 and they were receiving product in 2010, does
21 that indicate they passed?
22 MR. O'CONNOR: Objection.
23 BY THE WITNESS:
24 A. That would -- that would be logical.

Page 324

1 BY MR. KAWAMOTO:
2 Q. Okay. Now, this audit, does it -- does
3 it -- the audit pages that we have, does it indicate
4 any -- does it provide any explanation for how a
5 Mallinckrodt product that was shipped to Sunrise ended
6 up in Tennessee where it was in the possession of law
7 enforcement?
8 MR. O'CONNOR: Objection.
9 BY THE WITNESS:
10 A. Well, that's my memory that it was sold to
11 a doctor and the doctor was, in fact, the person who
12 was selling those tablets, so that's just from memory.
13 So it wasn't directly from Sunrise. It was to their
14 customer who was selling it to -- to a doctor. And
15 it's -- it's just from memory.
16 BY MR. KAWAMOTO:
17 Q. But Mallinckrodt knew who Sunrise
18 customers were and they knew -- and Mallinckrodt knew
19 the amount of oxy that customers were provided, isn't
20 that correct?
21 MR. O'CONNOR: Objection.
22 BY THE WITNESS:
23 A. That's correct.
24 BY MR. KAWAMOTO:

Page 325

1 Q. And so does this audit address the fact
2 that Dr. Shook is getting 12 million, 12 million plus
3 API from Sunrise?
4 A. I don't know that that was included. I --
5 I just don't know.
6 Q. Shouldn't it have?
7 MR. O'CONNOR: Objection.
8 BY THE WITNESS:
9 A. It is subjective. I don't know.
10 BY MR. KAWAMOTO:
11 Q. Looking at these totals and assuming that
12 this extrapolation from the -- the data that was
13 produced is accurate, for a three-year time span, do
14 you see how many pills were provided -- were sent to
15 Florida, that's going to be Total Sales Quantity
16 Government UOM?
17 A. I see those figures.
18 Q. And so what -- what figure is that?
19 A. At the bottom?
20 Q. Yes.
21 A. Total Sales Quantity Government UOM --
22 UOM, is that it or...?
23 Q. That's correct.
24 A. 49,348,900.

Page 326

1 Q. And then do you see Florida Percentage
 2 Sales Quantity Government UOM? And I will represent
 3 to you that my understanding is that's the percentage
 4 of their total sales that went to Florida.
 5 MR. O'CONNOR: Objection.
 6 BY THE WITNESS:
 7 A. 49,196,500.
 8 BY MR. KAWAMOTO:
 9 Q. Or 99.7 percent?
 10 MR. O'CONNOR: Objection.
 11 BY MR. KAWAMOTO:
 12 Q. Do you recall the e-mail where Victor
 13 Borelli said the justification for their increase in
 14 orders is because they were expanding to other states?
 15 Do you recall that, sir?
 16 A. I recall reading that, yes.
 17 Q. Okay. Does that appear accurate based on
 18 this chargeback data?
 19 MR. O'CONNOR: Objection.
 20 BY THE WITNESS:
 21 A. Based on the chargeback data, it would
 22 not.
 23 BY MR. KAWAMOTO:
 24 Q. So once -- so it appears that Victor was

Page 327

1 saying whatever he needed to do to make a sale, is
 2 that fair?
 3 MR. O'CONNOR: Objection.
 4 BY THE WITNESS:
 5 A. That's not for me to judge, so.
 6 BY MR. KAWAMOTO:
 7 Q. But that's what the data suggests, sir,
 8 isn't it?
 9 MR. O'CONNOR: Objection.
 10 BY MR. KAWAMOTO:
 11 Q. Sir, they shipped 99.7 percent of their
 12 product to Florida. That was 49 mil -- 49 million
 13 plus of UOM, which I assume had some relationship to
 14 pills, and they passed an audit. They passed
 15 Mallinckrodt's audit.
 16 Doesn't that suggest problems with your
 17 audit system?
 18 MR. O'CONNOR: Objection.
 19 BY THE WITNESS:
 20 A. So you have two different sheets. And so
 21 you are doing Oxycodone HCL 15-milligram tablets. So
 22 you are combining those for Florida?
 23 BY MR. KAWAMOTO:
 24 Q. Yes.

Page 328

1 A. So it's not all just oxy 30s. It's oxy
 2 15s and 30s?
 3 Q. Yes.
 4 A. Okay.
 5 Q. And they -- their order was for 3,000
 6 bottles of oxy 15 starting January of 2009, sir.
 7 Do you recall that?
 8 MR. O'CONNOR: Objection.
 9 BY THE WITNESS:
 10 A. Yes.
 11 BY MR. KAWAMOTO:
 12 Q. So my question is: We've now spent a fair
 13 amount of time looking in detail at Sunrise --
 14 A. Um-hum.
 15 Q. -- both how Mallinckrodt decided to do
 16 business with them and how Mallinckrodt responded when
 17 it started receiving information regarding them, and,
 18 you know, and the fact that Mallinckrodt did an audit
 19 of Sunrise and they presumably passed.
 20 So my question to you, sir, is doesn't
 21 this suggest a problem with Mallinckrodt's screening
 22 of its customers and its audit process?
 23 MR. O'CONNOR: Objection.
 24 BY THE WITNESS:

Page 329

1 A. You are talking about one distributor.
 2 BY MR. KAWAMOTO:
 3 Q. One distributor that sent 49 million pills
 4 to Florida over a three-year span, sir.
 5 A. Um-hum.
 6 MR. O'CONNOR: Same objection.
 7 BY MR. KAWAMOTO:
 8 Q. Doesn't that strike you as troubling?
 9 MR. O'CONNOR: Objection.
 10 BY THE WITNESS:
 11 A. Based on what we know today, yes.
 12 MR. KAWAMOTO: Okay. Why don't we take a quick
 13 break.
 14 THE VIDEOGRAPHER: Going off the record at 5:54.
 15 (WHEREUPON, a recess was had
 16 from 5:54 to 6:05 p.m.)
 17 THE VIDEOGRAPHER: We are back on the record at
 18 6:05.
 19 MR. O'CONNOR: And before we get started again,
 20 I just wanted to say, as the witness has mentioned, he
 21 is getting up there in years and he is physically
 22 getting tired, so we would appreciate anything that
 23 you can do and your colleague to -- to move along.
 24 MR. KAWAMOTO: Sure. Well, this is the last

<p style="text-align: right;">Page 330</p> <p>1 exhibit that I have, so. I mean, I can -- I can tell</p> <p>2 you that.</p> <p>3 MR. O'CONNOR: Yeah.</p> <p>4 (WHEREUPON, a certain document was</p> <p>5 marked Mallinckrodt-Ratliff</p> <p>6 Deposition Exhibit No. 041, for</p> <p>7 identification, as of 12/19/2018.)</p> <p>8 BY MR. KAWAMOTO:</p> <p>9 Q. So, Mr. Ratliff, and I appreciate that we</p> <p>10 have been going at this for a while, this is the last</p> <p>11 exhibit, and the document that I've handed you is the</p> <p>12 Administrative Memorandum of Agreement between the DEA</p> <p>13 and Mallinckrodt.</p> <p>14 Are you aware that Mallinckrodt has</p> <p>15 entered into a settlement with the Drug Enforcement</p> <p>16 Administration?</p> <p>17 A. When, when was this?</p> <p>18 Q. I believe if you check the back date, it</p> <p>19 was in 2017, July of 2017.</p> <p>20 A. No.</p> <p>21 Q. Okay.</p> <p>22 A. I've been retired since '12.</p> <p>23 Q. Okay. So if you turn to Page 2 of this</p> <p>24 agreement, do you see "Covered Conduct"?</p>	<p style="text-align: right;">Page 332</p> <p>1 Q. Okay. What about the second statement,</p> <p>2 "Detect and report to the DEA orders of unusual size</p> <p>3 and frequency"?</p> <p>4 A. I have been retired a long time. I don't</p> <p>5 know what that means, but...</p> <p>6 Q. Okay. Turning to Page 3, do you see</p> <p>7 paragraph (b)?</p> <p>8 A. What did you say?</p> <p>9 Q. Paragraph (b) on Page 3, it says: "With</p> <p>10 respect to the manufacture of controlled substances at</p> <p>11 Mallinckrodt's Hobart, New York facility."</p> <p>12 A. Are you saying (b)?</p> <p>13 Q. (b), (b) as in boy.</p> <p>14 A. (b), I'm sorry. I thought you said (e).</p> <p>15 Okay.</p> <p>16 Q. Okay. And do you see the paragraph</p> <p>17 underneath it that says: "Failure to take actual</p> <p>18 weights of controlled substances at all stages of the</p> <p>19 manufacturing process"?</p> <p>20 A. I do.</p> <p>21 Q. Were you aware of any concerns by the DEA</p> <p>22 regarding this topic?</p> <p>23 A. No.</p> <p>24 Q. Okay. Do you see Topic ii: "Use of a</p>
<p style="text-align: right;">Page 331</p> <p>1 A. Page 2?</p> <p>2 Q. Yes, Page 2.</p> <p>3 A. Okay.</p> <p>4 Q. And it is going to be Paragraph 3, Covered</p> <p>5 Conduct.</p> <p>6 A. Okay.</p> <p>7 Q. Okay. And then it's got subheading, do</p> <p>8 you see the little paragraph (a)?</p> <p>9 A. Um-hum.</p> <p>10 Q. And it says: "With respect to its</p> <p>11 distribution of oxycodone and hydrocodone products,</p> <p>12 Mallinckrodt's alleged failure to distribute these</p> <p>13 controlled substances in a manner authorized by its</p> <p>14 registration and Mallinckrodt's alleged failure to</p> <p>15 operate an effective suspicious order monitoring</p> <p>16 system and report suspicious orders to the DEA when</p> <p>17 discovered as required by and in violation of 21 CFR</p> <p>18 1301.74(b). The above is includes, but not limited</p> <p>19 to, Mallinckrodt's alleged failure to." And then the</p> <p>20 first, the little (i) is "conduct adequate due</p> <p>21 diligence of its customers."</p> <p>22 Do you have any knowledge of the factual</p> <p>23 basis for that statement?</p> <p>24 A. I don't.</p>	<p style="text-align: right;">Page 333</p> <p>1 'target' tablet weight for purposes of rec" -- "of</p> <p>2 reconciling batch records and determining the number</p> <p>3 of units of finished form manufactured even though the</p> <p>4 average weight of the tables in any specific batch</p> <p>5 sometimes deviated from the target weight"?</p> <p>6 Do you see that paragraph?</p> <p>7 A. I do.</p> <p>8 Q. Do you have -- were you aware of any</p> <p>9 concerns from the DEA regarding that topic?</p> <p>10 A. No.</p> <p>11 Q. Okay. What about Topic iii: "Commingling</p> <p>12 of dust collector waste and assignment of dust</p> <p>13 losses"?</p> <p>14 A. No.</p> <p>15 Q. Okay. What about Topic iv: "Failure to</p> <p>16 check-weigh controlled substances received into the</p> <p>17 facility"?</p> <p>18 A. No.</p> <p>19 Q. Okay. Topic v: "Failure to maintain</p> <p>20 accurate records of substances transferred from the</p> <p>21 manufacturing process to Mallinckrodt's analytical</p> <p>22 laboratories"?</p> <p>23 A. No.</p> <p>24 Q. You have no knowledge of that, okay.</p>

<p style="text-align: right;">Page 334</p> <p>1 What about any knowledge of Topic vi: 2 "Failure to include substances held in certain 3 vaults/storage as part of the biennial inventory?" 4 A. No. 5 Q. Okay. And I believe you testified 6 previously that you were not interviewed by the DEA or 7 DOJ in connection with this settlement agreement or 8 this Administrative Memorandum of Agreement? 9 A. Correct. 10 Q. Okay. So you have no knowledge of the 11 basis for this agreement? 12 A. No. I was retired many years and... 13 Q. Okay. 14 A. And I was not -- they had a security 15 manager in Hobart and so I really wasn't involved. 16 Q. Okay. So that concludes my -- my 17 examination. Thank you for your time, sir. 18 A. Sure. 19 MR. KAWAMOTO: Andrew, I would note that, as I 20 indicated to Jennifer Patina yesterday, we are 21 objecting to the late production of documents. I 22 believe it's 45 documents or 400 pages, and so we are 23 reserving our rights on that issue. 24 MR. O'CONNOR: Okay. I'll just state for the</p>	<p style="text-align: right;">Page 336</p> <p>1 minute? 2 MS. HERZFELD: Yeah, let's go off the record for 3 a minute. 4 THE VIDEOGRAPHER: We are going off the record 5 at 6:14. 6 (WHEREUPON, a recess was had 7 from 6:14 to 6:19 p.m.) 8 THE VIDEOGRAPHER: We are back on the record at 9 6:19. 10 BY MS. HERZFELD: 11 Q. Okay. Mr. Ratliff, we are back on the 12 record. And before we took a break and you had a 13 chance to speak with your counsel, you were saying you 14 were a bit tired, and I understand that we have been 15 here the whole day. 16 A. Sure. 17 Q. But this is probably my only opportunity 18 to examine you, so -- 19 A. That's fine. 20 Q. -- or to examine you at all. 21 So you -- you are fine going forward this 22 evening and that's not going to prevent -- 23 A. I am. 24 Q. -- you being able to give accurate and</p>
<p style="text-align: right;">Page 335</p> <p>1 record, you had them with plenty of time to review 45 2 documents, but I understand your objection. 3 MR. KAWAMOTO: Okay. 4 THE VIDEOGRAPHER: We are going off the record 5 at 6:10 p.m. 6 (WHEREUPON, a recess was had 7 from 6:10 to 6:13 p.m.) 8 THE VIDEOGRAPHER: We are back on the record at 9 6:13. 10 EXAMINATION 11 BY MS. HERZFELD: 12 Q. Okay. Mr. Ratliff, good evening. My name 13 is Tricia Herzfeld, and I'm an attorney representing 14 the Plaintiffs in Tennessee in the Tennessee State 15 litigation. 16 How are you doing this evening? 17 A. I'm tired. 18 Q. Yeah. I've offered to your attorneys that 19 we could reset this for tomorrow morning. 20 Are you fine going ahead now? 21 A. I'm willing to do it tomorrow. I mean, 22 I'm worn out. 23 Q. Do you want to take -- 24 MR. O'CONNOR: Can we go off the record for a</p>	<p style="text-align: right;">Page 337</p> <p>1 complete testimony today? 2 A. That's -- that's absolutely correct. 3 Q. Okay. Great. Fantastic. 4 MS. HERZFELD: I just want to lodge our 5 continuing objection to the late disclosure of 6 documents in this case and also continue with our 7 objection from the Tennessee State case that it's 8 under different -- different rules, same objections 9 we've made to every deposition. 10 MR. O'CONNOR: And we would repeat our response. 11 You had plenty of time to review the documents and we 12 are complying with all relevant rules and protocol. 13 MS. HERZFELD: Great. Okay. We'll move along. 14 BY MS. HERZFELD: 15 Q. Mr. Ratliff, have you ever been to 16 Tennessee? 17 A. I have. 18 Q. Okay. For business or for pleasure? 19 A. Both. 20 Q. Okay. And when have you been for 21 business? 22 A. We audited FedEx in -- in Memphis to see 23 how our packages were handled. 24 Q. Okay. Is that the only time for business?</p>

<p style="text-align: right;">Page 338</p> <p>1 A. I might have been there more than once to 2 the FedEx hub. I don't recall exactly when or the 3 dates. 4 Q. Did you ever go to anyplace other than the 5 FedEx in Memphis for business in Tennessee? 6 A. No. 7 Q. Okay. And then -- 8 A. To the best of my knowledge. 9 Q. Do you know roughly what year that audit 10 was of the FedEx in Memphis? 11 A. Not a clue. 12 Q. And how often have you gone for vacation, 13 pleasure? 14 A. I've been to Nashville. I drive through 15 there frequently because I live in Florida -- 16 Q. Okay. 17 A. -- and I have a home here, so we travel 18 through Tennessee often. 19 Q. Okay. And here is Indiana? 20 A. Here is Indiana. 21 Q. Okay. Great. 22 And have you ever been to upper East 23 Tennessee, the Appalachian portion of Tennessee? 24 A. I've traveled through there through</p>	<p style="text-align: right;">Page 340</p> <p>1 A. At this time I don't recall. 2 Q. Okay. And in that one dealing with 3 Morristown, that officer actually approached 4 Mallinckrodt, Mallinckrodt didn't approach the 5 officer, is that correct? 6 A. That's correct. 7 Q. Okay. And you mentioned the HIDTA. Do 8 you know what that is? 9 A. HIDTA? 10 Q. HIDTA, is that how you call it? 11 A. It is high intensity drug trafficking 12 area. 13 Q. Okay. And have you heard it called the 14 Appalachian high intensity drug trafficking area? 15 A. I have not. 16 Q. Do you know if there are certain drug -- 17 high drug trafficking areas across the country? 18 A. There are. 19 Q. Okay. And do you know how it is the DEA 20 makes those classifications? 21 MR. O'CONNOR: Objection. 22 BY THE WITNESS: 23 A. I'm not certain I understand your 24 question.</p>
<p style="text-align: right;">Page 339</p> <p>1 Knoxville, through Pigeon Forge. I've actually 2 vacationed in -- close to Pigeon Forge in a log cabin. 3 I've traveled through that area going to play golf 4 in -- in North Carolina. 5 Q. Okay. Have you ever made a report to 6 Tennessee law enforcement about any opioid diversion 7 or any suspected diversion? 8 A. No. 9 Q. Okay. Have you ever heard of anyone at 10 Mallinckrodt making, pardon me, a report to law 11 enforcement in Tennessee about suspected opioid 12 diversion? 13 A. Well, I might need to correct that. I 14 dealt with one of the officers there who was 15 associated with HIDTA, and I assisted him with an 16 investigation. We had located bottles that contained 17 identifying information that led it back to -- to one 18 of the distributors in Florida. 19 Q. Okay. And that was that Morristown e-mail 20 that you discussed earlier in your testimony today? 21 A. That's correct. 22 Q. Okay. And other than that investigation, 23 have you been involved in any other investigations 24 involving diverted opioids in Tennessee?</p>	<p style="text-align: right;">Page 341</p> <p>1 BY MS. HERZFELD: 2 Q. Sure. 3 Do you know how a particular area ends up 4 classified as a high intensity drug trafficking area 5 based on your law enforcement experience? 6 A. Well, normally those are associated with 7 the FBI. 8 Q. Okay. 9 A. So, if we have a drug problem in that area 10 we have assessed, then we collaborate with local law 11 enforcement, state and local, and bring them in 12 because of their specific expertise in those areas. A 13 lot of times the FBI wouldn't have the street 14 knowledge as officers would, so we bring them in to -- 15 to help with the investigations. 16 Q. Okay. So based on your training, 17 knowledge and experience in law enforcement, would you 18 consider counties that have been designated within a 19 particular high intensity drug trafficking area for 20 that to be a reliable indicator that there is drug 21 problems within those -- within those counties? 22 MR. O'CONNOR: Objection. 23 MS. DURFEE: Object to form. 24 BY THE WITNESS:</p>

<p style="text-align: right;">Page 342</p> <p>1 A. I think I would agree with that. Those 2 are all over the country, though. They are not just 3 in Tennessee. 4 BY MS. HERZFELD: 5 Q. Okay. Were you ever involved in -- or had 6 you ever reported anyone in Tennessee to a licensing 7 board? 8 A. Personally, no. 9 Q. Yes, sir. 10 Do you know if anybody at Mallinckrodt 11 has? 12 A. I don't know. 13 Q. Okay. Do you know -- know whether 14 Mallinckrodt looks at media reports to gain 15 information about pharmacies engaged in suspected 16 diversion? 17 A. I don't know that. 18 Q. Okay. Have you ever personally done that, 19 sir? 20 A. No. 21 Q. Okay. What about looking at media reports 22 to gain information about physicians suspected of 23 diversion? 24 A. Personally?</p>	<p style="text-align: right;">Page 344</p> <p>1 person? 2 A. That individual had been the special agent 3 in charge of the FBI in St. Louis and also in Miami, 4 Florida. Do I know his name, no. I can't recall it. 5 Q. Did you have -- 6 A. At one time I did know it, so. 7 Q. That's okay. 8 So you knew it at one point, you just 9 can't remember it as we sit here today? 10 A. Correct. 11 Q. Okay. And did you have any overlap at 12 all, the two of you? 13 A. We did, but I was actually -- they kept 14 delaying my retirement and I worked the last three 15 months from home, and he really didn't need any 16 overlap or training. 17 Q. Okay. And all your files, did you leave 18 those at Mallinckrodt? 19 A. Yes. 20 Q. So if he needed any information about 21 pharmacies or distributors that you suspected of 22 diversion, that would have been contained within 23 your -- your files? 24 A. Correct.</p>
<p style="text-align: right;">Page 343</p> <p>1 Q. Yes, sir. 2 A. No. 3 Q. Okay. Do you know if anyone else had that 4 responsibility at Mallinckrodt? 5 A. I know that we looked at doctors and we 6 had people that would do that, so. 7 Q. Do you know who that was? 8 A. I think Karen Harper would be involved in 9 that program and... 10 Q. Do you know of anybody else? 11 A. Not -- not immediately, no. 12 Q. Okay. 13 Okay. And did you ever review the 14 decisions of licensing boards about physicians or 15 pharmacies in doing your job at Mallinckrodt? 16 A. No. 17 Q. Okay. And you retired in 2012? 18 A. Correct. 19 Q. Okay. Was there someone who replaced you? 20 A. Yes. 21 Q. Okay. Who was that? 22 A. I have no idea. 23 Q. Okay. Do you know if there was a 24 transition plan in place to go from you to that</p>	<p style="text-align: right;">Page 345</p> <p>1 Q. Okay. And he would have had access to 2 those files, to your knowledge? 3 A. To the best of my knowledge. 4 Q. Okay. And you spoke a little before, I 5 just want to clarify this, because I'm not quite sure 6 I understood it, you -- I've got it down here, whether 7 a pharmacy -- you spoke about whether a pharmacy 8 should be continuing as a customer of your customer, 9 the distributor, and that you guys could block that. 10 MR. O'CONNOR: Objection. 11 BY MS. HERZFELD: 12 Q. Did I understand that correctly? 13 A. What we would do, we would recommend to 14 our -- the distributor, it was our distributor, one of 15 our customers, we could say, We are going to deny 16 chargebacks, and so that distributor normally would 17 then deny product to that particular end user, which 18 would be a pharmacy. 19 Q. Okay. And do you ever know of a time that 20 you recommended that the -- that the chargebacks be 21 denied and the distributor continued to -- to service 22 that -- that client? 23 A. No, because I got many, many, many calls 24 in the evening and during the day from pharmacies that</p>

<p>Page 346</p> <p>1 had been refused oxycodone or hydrocodone or our 2 products and they wanted -- their distributors told 3 them that it was my fault, that we did it, and I would 4 instruct them they needed to talk to their 5 distributor, show them what they were doing 6 differently, convince them that they were a -- a 7 trustworthy customer, and then they would come back 8 and try to convince us. 9 Q. Okay. And -- 10 A. I don't know that that ever happened. 11 MS. KVESELIS: Late objection. 12 BY THE WITNESS: 13 A. Okay. 14 BY MS. HERZFELD: 15 Q. Okay. Yeah, I'm going to go through some 16 documents with you, and hopefully we'll get through 17 them pretty quickly, okay. 18 A. Okay. 19 Q. I know it looks bad that there is so many 20 but that's because I brought five copies, so it is not 21 as bad as it looks. 22 A. That's fine. 23 Q. Okay. I'm going to hand you what we are 24 going to mark as -- I don't know what exhibit we are</p> <p>Page 347</p> <p>1 on -- what we've marked as Plaintiff's Exhibit 42 -- 2 or I guess Ratliff Exhibit 42. 3 (WHEREUPON, a certain document was 4 marked Mallinckrodt-Ratliff 5 Deposition Exhibit No. 042, for 6 identification, as of 12/19/2018.) 7 BY THE WITNESS: 8 A. Okay. 9 BY MS. HERZFELD: 10 Q. Okay. So my understanding from your 11 previous testimony is that after the August 23rd 12 meeting, 2011 meeting with the DEA, there were various 13 reports that were pulled on the top pharmacies within 14 Florida and then the top pharmacies outside of 15 Florida, is that correct? 16 MR. O'CONNOR: Objection. 17 BY THE WITNESS: 18 A. It would be the -- we went to the top 19 three distributors. 20 BY MS. HERZFELD: 21 Q. Okay. 22 A. And looked at their -- their top ten 23 customers that ordered product in Florida. 24 Q. Okay. And then based on that, there were</p>	<p>Page 348</p> <p>1 various charts that were created, is that correct? 2 A. Various charts, I'm not certain what that 3 means. I received that information based on those 4 three distributors. 5 Q. Okay. So if you'll turn with me to the 6 page that's marked MNK_TNSTA05224022, it's about 7 halfway through. It looks like this. 8 A. I have it. 9 Q. Do you recognize this document, sir? 10 A. I do. 11 Q. Okay. And what do you recognize it to be? 12 A. Well, this is the -- the pharmacies that 13 they identified. 14 Q. Okay. So that would be like the top 15 pharmacies nationwide? 16 A. In Florida, yes, where we were 17 concentrating initially. 18 Q. Okay. And then looking at starting on 19 this Page 4022, that ends in 4022, it looks like there 20 are a whole bunch much pharmacies on there that are 21 also not in Florida. 22 Do you see where I am referring? 23 A. I do. 24 Q. Okay. And so is it possible that this --</p> <p>Page 349</p> <p>1 this chart is, indeed, the -- the list of the top 2 pharmacies in all of the country? 3 MR. O'CONNOR: Objection. 4 BY THE WITNESS: 5 A. I recognize -- this is not the list that I 6 had, just so you know. 7 BY MS. HERZFELD: 8 Q. Okay. 9 A. So the list I had was very specific to 10 those three distributors. 11 Q. Okay. Maybe -- 12 A. And it was a much smaller list. It didn't 13 contain all of these -- 14 Q. Okay. So maybe -- 15 A. -- which -- 16 Q. I don't mean to interrupt you. Sorry. Go 17 ahead. 18 A. Well, we started in Florida and then we 19 started doing investigations in other parts of the 20 country. 21 Q. Okay. So looking at this page and then 22 kind of flipping through, it looks like there are 23 quite a few, if you'll take a moment, pharmacies that 24 are located in Tennessee. Specifically I'm looking at</p>
---	---

Page 350

1 15 lines down on that first page. It indicates Lowe's
2 Drugs in Maryville, Tennessee.
3 Do you see where I'm talking about? It is
4 right under that last little checkmark. Maybe my
5 highlighting will show you.
6 A. Okay.
7 Q. And then if you go down kind of midway
8 through the page, there is another one, Riggs Ten- --
9 Riggs Drug in Powell, Tennessee.
10 Do you see where I'm at there? Do you see
11 that, sir?
12 A. I haven't found it yet. I'm looking.
13 Q. Okay. If you look at the fourth kind
14 of -- there is like a dashed line on the side, it is
15 the second above that.
16 A. And what's the name?
17 Q. Riggs Drug.
18 A. I found that. Okay.
19 Q. In Powell, Tennessee.
20 A. Okay.
21 Q. And if you flip through for the various
22 other pages, and I won't spend the time going through
23 each one, I would submit to you that there are various
24 other pharmacies in Tennessee.

Page 351

1 A. Um-hum.
2 Q. Do you agree with me there?
3 A. Say again.
4 Q. That there are other pharmacies in
5 Tennessee on this list for top pharmacies in the
6 country, would you agree with that statement?
7 A. Well, are you saying there were two on
8 that front page?
9 Q. Um-hum.
10 A. And then on this page there are additional
11 ones, is that what you are saying?
12 Q. Yes, sir.
13 If you look at the fifth pharmacy?
14 A. Um-hum.
15 Q. -- LaFollette --
16 A. Yep.
17 Q. -- in Tennessee, do you see that one?
18 And then about the 10th or 11th, there is
19 another one, Macs Pharmacy, Knoxville.
20 Do you see that?
21 A. I do.
22 Q. Okay. So you would agree with me that
23 there are multiple Tennessees -- pharmacies on this
24 list of top pharmacies within the country?

Page 352

1 A. Right, but I don't know that I've ever
2 seen this list.
3 Q. Okay. But my question is you would agree
4 with me that they are identified in this?
5 A. Yes.
6 Q. Okay. Thank you, sir.
7 Okay. And then switching over to the
8 page that I think this might be more of what you were
9 thinking about, the very first page, the one marked
10 MNK_TNSTA05224016, the very first page.
11 A. Okay.
12 Q. Do you see it?
13 A. I do.
14 Q. Okay. And on this list do you recognize
15 what this chart is?
16 A. I don't recall it, so.
17 Q. Okay. Have you ever -- do you recall
18 seeing ever a chart that has on the various
19 distributors broken down by three-digit zip code?
20 A. No.
21 Q. Okay. And do you recall having these
22 reports run as being part of a diversion prevention
23 program?
24 MR. O'CONNOR: Objection.

Page 353

1 BY THE WITNESS:
2 A. I don't know when these were run, so.
3 BY MS. HERZFELD:
4 Q. Okay.
5 A. Do you know?
6 Q. I -- I don't have a date on this. Sorry.
7 A. Yeah, so, you have to remember I've been
8 retired six-and-a-half years, so.
9 Q. Sure. I understand.
10 A. I don't know if this was run before or I
11 just don't know the answer to that.
12 Q. I believe it was in your custodian file,
13 so I thought you might know.
14 You don't know?
15 A. In my custodian file?
16 Q. I believe so, sir, yes.
17 A. My personal custodian file?
18 Q. I believe so, yes, sir.
19 A. Well, I would probably disagree with that
20 because I don't think so.
21 Q. You don't think this is a document --
22 A. This was not -- this could have been in
23 the DEA compliance file which is not mine.
24 Q. Okay. So what you are saying is you don't

Page 354

1 recognize this and you didn't create it?

2 A. Correct.

3 Q. Okay. And you don't think you have ever

4 seen it before?

5 A. Correct.

6 Q. Okay. Well, then I guess we'll move on.

7 Do you have any idea who might have

8 created it?

9 A. I don't know. But I assure you this

10 wasn't in my file.

11 Q. Okay, sir.

12 Okay. Moving along then, do you know

13 specifically about there being an opioid problem in

14 Appalachia?

15 MR. O'CONNOR: Objection.

16 BY THE WITNESS:

17 A. I have seen news reports to that effect.

18 BY MS. HERZFELD:

19 Q. Okay. And have you seen those during your

20 time when you were employed at Mallinckrodt or since

21 you've left?

22 A. Since I've left.

23 Q. Okay. Were you aware of the opioid

24 problem in Appalachia at that time that you were

Page 355

1 employed at Mallinckrodt?

2 A. I think I know there were problems in West

3 Virginia, I think there were problems in other states,

4 but most of that, to my memory, was after I left

5 Mallinckrodt.

6 Q. Okay. Did you ever --

7 A. Actually left Covidien, Mallinckrodt being

8 one of the corporations.

9 Q. Okay. Did you ever -- other than your

10 conversation with the gentleman in Morristown, did you

11 know about there being an opioid problem in Tennessee?

12 MR. O'CONNOR: Objection.

13 BY THE WITNESS:

14 A. I don't know that I knew specifically that

15 they had an opioid problem. I knew that there was an

16 opioid problem in Florida, so.

17 BY MS. HERZFELD:

18 Q. Okay. Do you recall participating in the

19 auditing of ABC, a distributor named ABC?

20 A. AmerisourceBergen Corporation, yes.

21 Q. Yes, AmerisourceBergen -- no. ABC?

22 A. Now, is that a pharmacy?

23 Q. Oh, no. It is AmerisourceBergen, yes,

24 sir. ABC, yes.

Page 356

1 A. Okay.

2 Q. Do you recall being involved in that --

3 A. I do.

4 Q. -- audit?

5 Okay. Do you recall taking notes in --

6 during your participation in that audit, sir?

7 A. I would normally and usually take notes.

8 Q. You would usually?

9 A. Yes.

10 Q. Okay. And do you know what happened to

11 your notes?

12 A. I don't.

13 Q. Okay. I'm going to hand you what we will

14 mark as Exhibit 43.

15 (WHEREUPON, a certain document was

16 marked Mallinckrodt-Ratliff

17 Deposition Exhibit No. 043, for

18 identification, as of 12/19/2018.)

19 BY MS. HERZFELD:

20 Q. Do you recognize this document, sir?

21 A. Yes.

22 Q. Okay. And there is some handwritten notes

23 that are on this document. Is that your handwriting?

24 A. No.

Page 357

1 Q. Do you know whose it is?

2 A. No.

3 Q. Okay. Did you prepare this document

4 absent the handwriting?

5 A. The problem I'm having is I don't ever

6 recall going to Jabos Pharmacy, Jabos Pharmacy in

7 Newport, Tennessee. I have no memory of that at all.

8 Q. Okay. Well, let's just go through this

9 sheet for a second. So this --

10 A. Source of information, AmerisourceBergen.

11 What they do, just to be helpful, they provide this

12 information to us.

13 Q. Okay.

14 A. So this information would have come to us

15 from AmerisourceBergen.

16 Q. Okay.

17 A. So what's -- 10/17 of '11. Well, it says

18 I prepared the document. This document came from

19 AmerisourceBergen and was sent to us.

20 Q. Okay. So I want to make sure I

21 understand.

22 So this document is a Pharmacy Information

23 Sheet for Jabos Pharmacy in Newport, Tennessee, is

24 that correct?

<p style="text-align: right;">Page 358</p> <p>1 A. Correct.</p> <p>2 Q. And it is dated 10/17/11, is that correct?</p> <p>3 A. That's correct.</p> <p>4 Q. Okay. And you believe that the</p> <p>5 information contained within this worksheet came from</p> <p>6 AmerisourceBergen Health, is that correct?</p> <p>7 A. Well, it says: "Source of information:</p> <p>8 AmerisourceBergen Health."</p> <p>9 Q. And when it says: "Prepared by: B.</p> <p>10 Ratliff," is it possible you got that information from</p> <p>11 them and typed it up?</p> <p>12 Why would it say prepared by you?</p> <p>13 MR. O'CONNOR: Objection.</p> <p>14 BY THE WITNESS:</p> <p>15 A. I'm stumped because I don't...</p> <p>16 BY MS. HERZFELD:</p> <p>17 Q. Well, at the very least you would have</p> <p>18 been responsible for reviewing this sheet, is that</p> <p>19 correct, sir?</p> <p>20 MR. O'CONNOR: Objection.</p> <p>21 BY THE WITNESS:</p> <p>22 A. Okay. Let's go back to the handwriting.</p> <p>23 "Need to visit, leave on CB list." What I was saying</p> <p>24 in that list -- that is my writing.</p>	<p style="text-align: right;">Page 360</p> <p>1 Q. Okay.</p> <p>2 A. So -- so this is one of our Pharmacy</p> <p>3 Information Sheets that we had AmerisourceBergen fill</p> <p>4 out and give to us or at least the information. So</p> <p>5 it's possible that I -- I had it typed up, so.</p> <p>6 Q. Okay. Okay. So now that we've</p> <p>7 established that and that it is your handwriting on --</p> <p>8 let's go through it a little bit, if we could, okay.</p> <p>9 A. 10/17 of '11.</p> <p>10 Q. So here at the bottom it says --</p> <p>11 A. Okay.</p> <p>12 Q. -- "Karen Harper Notes."</p> <p>13 Do you know where "Karen Harper Notes"</p> <p>14 comes from? What does that mean?</p> <p>15 A. They came from Karen Harper.</p> <p>16 Q. Okay. And so she -- these are her notes</p> <p>17 inputted into this --</p> <p>18 A. Um-hum.</p> <p>19 Q. -- chart, is that correct, this sheet?</p> <p>20 A. We conducted the audit together.</p> <p>21 Q. Okay. So is this, perhaps, a summary of</p> <p>22 your notes and Karen Harper's notes?</p> <p>23 MR. O'CONNOR: Objection.</p> <p>24 BY THE WITNESS:</p>
<p style="text-align: right;">Page 359</p> <p>1 BY MS. HERZFELD:</p> <p>2 Q. That is your handwriting, sir, the</p> <p>3 handwriting?</p> <p>4 A. It is.</p> <p>5 Q. And what does it say?</p> <p>6 A. The note that I said, we would have taken</p> <p>7 these to -- or with us once we received them from</p> <p>8 AmerisourceBergen. And when I'm saying "Need" -- when</p> <p>9 I'm saying "Need to visit," they need to visit this</p> <p>10 based on what we read here or what I read.</p> <p>11 Q. Okay. When you said "take this sheet with</p> <p>12 us," take this sheet with us where?</p> <p>13 A. No. It was -- I was telling -- I was</p> <p>14 saying, leaving it on our list because they need to go</p> <p>15 visit this.</p> <p>16 Q. Okay. And so you --</p> <p>17 A. And so, "Karen Harper notes: Customer</p> <p>18 since... risk based..."</p> <p>19 We received a lot of this information, so,</p> <p>20 from them, and I'm -- it has just been so long ago.</p> <p>21 It says prepared by me, so I may have prepared it</p> <p>22 based on the information they provided to me. But the</p> <p>23 thing that's -- I was having difficulty with is I've</p> <p>24 never been to Newport, Tennessee.</p>	<p style="text-align: right;">Page 361</p> <p>1 A. It appears that these are Karen's notes.</p> <p>2 BY MS. HERZFELD:</p> <p>3 Q. Where it says "Karen Harper's Notes"?</p> <p>4 A. Yes.</p> <p>5 Q. Okay. So in Karen Harper's notes, it</p> <p>6 classifies Jabos Pharmacy or Jabos Pharmacy as:</p> <p>7 "Medium risk based on volume."</p> <p>8 Do you see where it says that? Do you see</p> <p>9 where it says: "Karen Harper's Notes"?</p> <p>10 A. I do.</p> <p>11 Q. Okay. And so --</p> <p>12 A. "Medium risk based on volume," okay.</p> <p>13 Q. Okay. And then it says: "No site visits</p> <p>14 from compliance."</p> <p>15 Do you know what that means?</p> <p>16 A. From AmerisourceBergen compliance.</p> <p>17 Q. So they had not visited --</p> <p>18 A. Right.</p> <p>19 Q. -- that pharmacy?</p> <p>20 A. And so the 29.4 percent controlled to</p> <p>21 non-controlled, that means that was a -- they had more</p> <p>22 non-controlled than controlled. So that's a low</p> <p>23 amount for a pharmacy, and I think that's why they</p> <p>24 were saying it was a medium risk.</p>

<p style="text-align: right;">Page 362</p> <p>1 Q. Okay. So you considered 29.4 percent</p> <p>2 controlled to non-controlled to be a low number?</p> <p>3 A. That's less than a third of what they</p> <p>4 purchase.</p> <p>5 Q. So that's considered a low number?</p> <p>6 A. Yes.</p> <p>7 Q. Okay. And then it says: "No site visits</p> <p>8 from compliance."</p> <p>9 Was that a problem?</p> <p>10 MR. O'CONNOR: Objection.</p> <p>11 BY THE WITNESS:</p> <p>12 A. We asked them to visit.</p> <p>13 BY MS. HERZFELD:</p> <p>14 Q. Before or after this report?</p> <p>15 A. I don't know.</p> <p>16 Q. Okay. And then it says: "Waiting for</p> <p>17 updated questionnaire and photographs. Other than</p> <p>18 numbers ABC has no issue with them, this customer has</p> <p>19 been difficult when it comes to responding to</p> <p>20 questionnaire."</p> <p>21 Do you know what that means, "difficult</p> <p>22 when it comes to responding to questionnaire"?</p> <p>23 MR. O'CONNOR: Objection.</p> <p>24 BY THE WITNESS:</p>	<p style="text-align: right;">Page 364</p> <p>1 Q. Okay.</p> <p>2 A. Cash sales versus non-cash sales reported</p> <p>3 by the pharmacy, 10 percent, that's low.</p> <p>4 Q. Okay. So do you know what it was about</p> <p>5 this pharmacy that would -- would have been a flag for</p> <p>6 Mallinckrodt to put on the chargeback restriction</p> <p>7 list?</p> <p>8 MR. O'CONNOR: Objection.</p> <p>9 BY THE WITNESS:</p> <p>10 A. Well, what we were doing is just based on</p> <p>11 the volume, we wanted more information from</p> <p>12 AmerisourceBergen about this customer.</p> <p>13 BY MS. HERZFELD:</p> <p>14 Q. Okay. And so the volume was inappropriate</p> <p>15 here?</p> <p>16 A. No.</p> <p>17 MR. O'CONNOR: Objection.</p> <p>18 BY THE WITNESS:</p> <p>19 A. I'm not saying it was inappropriate. I'm</p> <p>20 saying that we looked at it based on their other</p> <p>21 customers and this came up on our list to look at</p> <p>22 them.</p> <p>23 BY MS. HERZFELD:</p> <p>24 Q. Okay. And do you know what factor put it</p>
<p style="text-align: right;">Page 363</p> <p>1 A. Well, we are talking about ABC providing</p> <p>2 the information.</p> <p>3 BY MS. HERZFELD:</p> <p>4 Q. Okay. So when you say: "This customer</p> <p>5 has been difficult when it comes to responding to</p> <p>6 questionnaire," that means ABC has been difficult, not</p> <p>7 Jabos?</p> <p>8 A. Right.</p> <p>9 Q. Okay. And: "Other than numbers, ABC has</p> <p>10 no issue with them."</p> <p>11 What -- do you know what was concerning</p> <p>12 about the numbers, if you say 29.4 percent of</p> <p>13 controlled to non-controlled is low?</p> <p>14 MR. O'CONNOR: Objection.</p> <p>15 BY THE WITNESS:</p> <p>16 A. I'm just looking at the volume of</p> <p>17 oxycodone, 30-milligram tablets per month, 55,200.</p> <p>18 That's tablets.</p> <p>19 BY MS. HERZFELD:</p> <p>20 Q. Is that high, sir?</p> <p>21 MR. O'CONNOR: Objection.</p> <p>22 BY THE WITNESS:</p> <p>23 A. I don't know that.</p> <p>24 BY MS. HERZFELD:</p>	<p style="text-align: right;">Page 365</p> <p>1 on your list?</p> <p>2 A. No.</p> <p>3 Q. Okay. And then if you go, it says:</p> <p>4 "Late" -- pardon me -- "Latest Site Visit: Once per</p> <p>5 month by sales manager will be providing photos,</p> <p>6 difficult customer."</p> <p>7 Do you know what that means?</p> <p>8 A. No. I just know that we said, We want you</p> <p>9 to visit this pharmacy and we would like to have</p> <p>10 photo -- photographs and -- and a site visit, so</p> <p>11 that's basically all I know.</p> <p>12 Q. And it says: "Top prescribers</p> <p>13 identified?: Yes."</p> <p>14 Do you know who those top prescribers</p> <p>15 were?</p> <p>16 A. No.</p> <p>17 Q. Okay. And did you do anything to verify</p> <p>18 any of this information that was reported to you by</p> <p>19 AmerisourceBergen about Jabos Pharmacy on this sheet?</p> <p>20 A. No.</p> <p>21 Q. Okay. And do you know if</p> <p>22 AmerisourceBergen ever visited this pharmacy as you</p> <p>23 requested?</p> <p>24 A. Not at this point I don't know that.</p>

Page 366

1 Q. Okay. And do you know if the photographs
 2 were ever provided that you requested?
 3 A. I didn't know that either.
 4 Q. Okay. Sorry. I'm losing my voice a
 5 little bit.
 6 A. I am too. I think I can use more water.
 7 MR. O'CONNOR: Do you want some water?
 8 THE WITNESS: Yeah, please.
 9 BY MS. HERZFELD:
 10 Q. Okay. The next exhibit is 45, I believe.
 11 A. That one was 43.
 12 Q. Oh, then 44. Thank you for your help with
 13 that.
 14 (WHEREUPON, a certain document was
 15 marked Mallinckrodt-Ratliff
 16 Deposition Exhibit No. 044, for
 17 identification, as of 12/19/2018.)
 18 BY THE WITNESS:
 19 A. Thank you.
 20 BY MS. HERZFELD:
 21 Q. Hopefully we'll get through it a little
 22 quicker this time.
 23 Okay. Do you recognize this document,
 24 sir?

Page 367

1 A. I do.
 2 Q. Okay. And is this your handwriting at the
 3 top?
 4 A. It is.
 5 Q. Okay. And what does your handwriting say
 6 there?
 7 A. "Need to visit and report."
 8 Q. Okay. And this is a Pharmacy Information
 9 Sheet?
 10 A. It is.
 11 Q. And it is dated 10/11 -- 10/17/11, is that
 12 correct?
 13 A. Correct.
 14 Q. It says it was prepared by you and the
 15 source of information was AmerisourceBergen, is that
 16 correct?
 17 A. Correct.
 18 Q. Okay. And it says the pharmacy name here
 19 is Rippetoe, Inc. in Morristown, Tennessee.
 20 Is that correct?
 21 A. That's correct.
 22 Q. Okay. And if you take a second to look
 23 over this sheet, my first question is: Did you
 24 receive all of this information from

Page 368

1 AmerisourceBergen?
 2 A. Yes.
 3 Q. Okay. And did you do anything
 4 independently, did Mallinckrodt to your knowledge do
 5 anything independently to verify the information
 6 contained within this sheet?
 7 MR. O'CONNOR: Objection.
 8 BY THE WITNESS:
 9 A. No.
 10 BY MS. HERZFELD:
 11 Q. I'm sorry, sir?
 12 A. No.
 13 Q. Okay. And so if you'll take a look with
 14 me down on where it says "Karen Harper Notes"?
 15 A. Um-hum.
 16 Q. "Customer since 03/04, medium risk based
 17 on volume. Have requested an updated questionnaire.
 18 No visits by Compliance."
 19 Did I read that correctly?
 20 A. Correct.
 21 Q. "Don't have photographs in the file. They
 22 are coming."
 23 Do you know if the photographs ever came?
 24 A. I don't.

Page 369

1 Q. "This customer is in Tennessee market and
 2 'always on the radar.'"
 3 Do you know why they were always on the
 4 radar?
 5 A. I do not know.
 6 Q. Do you know what that means?
 7 A. I don't.
 8 Q. Do you know if they ended up on your
 9 chargeback list, your no charge -- no chargeback list?
 10 A. I don't know that.
 11 MR. O'CONNOR: Objection.
 12 BY MS. HERZFELD:
 13 Q. Okay. Do you know after this report if
 14 Mallinckrodt continued shipping to AmerisourceBergen
 15 and AmerisourceBergen shipped to Rippetoe?
 16 MR. O'CONNOR: Objection.
 17 BY THE WITNESS:
 18 A. I don't know that either.
 19 BY MS. HERZFELD:
 20 Q. Okay.
 21 A. There is nothing on this that would
 22 indicate -- if they are medium risk, we wouldn't deny
 23 them through the chargeback system.
 24 Q. Okay. And so when it says: "Need to

Page 370

1 visit and report," what did you mean by that?
2 A. We are saying that AmerisourceBergen needs
3 to visit and report to us.
4 Q. Report to you the findings of their visit?
5 A. Yeah, sure, and the photos and...
6 Q. Okay. Exhibit 45.
7 (WHEREUPON, a certain document was
8 marked Mallinckrodt-Ratliff
9 Deposition Exhibit No. 045, for
10 identification, as of 12/19/2018.)
11 BY MS. HERZFELD:
12 Q. Okay. Sir, have you seen this document
13 before?
14 A. Yes.
15 Q. Okay. And it is a Pharmacy Information
16 Sheet, is that correct?
17 A. Correct.
18 Q. Okay. And it is dated 10/17/11, is that
19 correct?
20 A. All of these have been dated the same
21 date.
22 Q. Okay. And this one also says to be
23 prepared by you based on information from
24 AmerisourceBergen, is that correct?

Page 371

1 A. Correct. That's correct.
2 Q. Okay. And the pharmacy in this one is
3 East Tennessee Discount Drug in Strawberry Plains,
4 Tennessee.
5 Am I correct on that?
6 A. Yes.
7 Q. Okay. And this is your handwritten notes
8 on the -- on the document?
9 A. The ones on the upper left are. "To be
10 visited in the process of being scheduled," that's not
11 my writing.
12 Q. Do you know whose writing it is?
13 A. No.
14 Q. Do you recognize it?
15 A. I don't.
16 Q. Okay. And so that hand writing on the
17 left-hand side, what does that say?
18 A. "Leave on no CB list, problem" is what I
19 said.
20 Q. Do you know what the problem was with this
21 pharmacy, sir?
22 A. It appears there was a spike in oxy
23 purchases. It said they were supplying to a clinic in
24 Nashville, Tennessee. "'Back to Wellness' driven out

Page 372

1 of Knoxville."
2 Q. Okay. And how did you get that
3 information, sir?
4 A. We would have received it from
5 AmerisourceBergen.
6 Q. Okay. And did you do anything to
7 independently verify the information that was given to
8 you from AmerisourceBergen?
9 A. We asked them to -- to visit the pharmacy.
10 Q. Okay. And do you know if they did?
11 A. I don't know.
12 Q. Okay. And do you know what the
13 significant red flags were about this particular
14 pharmacy?
15 A. (Witness reading to himself.)
16 Well, the ABC Pharmacy in Las Vegas, red
17 flag, flag, that was a totally different issue, so.
18 That got on there by mistake. That's not yours, the
19 pharmacy in Las Vegas.
20 Q. Okay. So that doesn't have anything to do
21 with this pharmacy?
22 A. No.
23 Q. Okay. So it says: "Significant red flags
24 about East Tennessee Discount Drug...RED FLAG RED

Page 373

1 FLAG," in all caps.
2 Do you know what the significance --
3 A. "Significant red flags about East
4 Tennessee Drug" -- "Discount Drug..."
5 45,900 tablets would be a lot of -- that's
6 the overall oxycodone family. 32,500 of 30s is not
7 particularly high. The percentage of oxycodone sales,
8 30-milligram tablets versus all oxycodone SKUs,
9 70 percent, that is high.
10 Q. Okay. And so is that the reason that this
11 was identified as high risk by the wholesaler, would
12 that be your understanding?
13 MR. O'CONNOR: Objection.
14 BY THE WITNESS:
15 A. To the best of my knowledge. It has just
16 been a long time.
17 BY MS. HERZFELD:
18 Q. Okay. And would you agree with me, sir,
19 that suspect pharmacies can indicate suspect
20 physicians in the area?
21 MR. O'CONNOR: Objection.
22 BY THE WITNESS:
23 A. I think that's an assumption, but it's a
24 reasonable assumption, so.

<p style="text-align: right;">Page 374</p> <p>1 BY MS. HERZFELD:</p> <p>2 Q. Do you know who Ed Hazewski is?</p> <p>3 A. It has been a long time.</p> <p>4 Q. Does the name ring a bell to you at all?</p> <p>5 A. It rings a bell, but I'm not certain who</p> <p>6 he is.</p> <p>7 (WHEREUPON, a certain document was</p> <p>8 marked Mallinckrodt-Ratliff</p> <p>9 Deposition Exhibit No. 046, for</p> <p>10 identification, as of 12/19/2018.)</p> <p>11 BY MS. HERZFELD:</p> <p>12 Q. I'm going to hand you what is the next</p> <p>13 exhibit which I believe is No. 46. I'll submit to you</p> <p>14 that it is yet another Pharmacy Information Sheet.</p> <p>15 A. Okay. Thank you.</p> <p>16 Q. Take a look at it for a second.</p> <p>17 Do you know who would receive these</p> <p>18 pharmacy information sheets at Mallinckrodt?</p> <p>19 A. Karen Harper would have maintained them.</p> <p>20 Is there more than --</p> <p>21 Q. Would they have been provided to you at</p> <p>22 some point during your -- in your job</p> <p>23 responsibilities?</p> <p>24 A. It would have been provided by me to</p>	<p style="text-align: right;">Page 376</p> <p>1 So let's just take a look at it for a second.</p> <p>2 A. Okay.</p> <p>3 Q. On -- it's, again, it's another</p> <p>4 information pharmacy sheet for East Tennessee Discount</p> <p>5 Drug in Strawberry Plains, Tennessee, the one we just</p> <p>6 talked about before. Yes, sir?</p> <p>7 A. Okay.</p> <p>8 Q. I'm looking down here all of the way at</p> <p>9 the bottom, and it says: "Top prescribers identified?</p> <p>10 Yes."</p> <p>11 Do you know who those top prescribers</p> <p>12 were?</p> <p>13 A. I'm saying I don't know that I ever saw</p> <p>14 this, so there is no way I would know that.</p> <p>15 Q. Okay.</p> <p>16 A. Ed Hazewski, I believe, is their security</p> <p>17 director or security manager for AmerisourceBergen.</p> <p>18 Q. Okay.</p> <p>19 A. I'm not absolutely positive about that,</p> <p>20 but --</p> <p>21 Q. Okay. So then this says --</p> <p>22 A. -- that's what comes to mind.</p> <p>23 Q. Okay. And then at the bottom, it says:</p> <p>24 "Visited on 1/18/2012. Pharmacy is located in a</p>
<p style="text-align: right;">Page 375</p> <p>1 Karen. She maintained the files.</p> <p>2 Q. Okay. So you would have seen them and</p> <p>3 they would have crossed your desk?</p> <p>4 A. Yes.</p> <p>5 Q. Okay. So, sir, this appears to be a</p> <p>6 Pharmacy Information Sheet dated 2/26/2012 prepared by</p> <p>7 Ed Hazewski with the source of information being</p> <p>8 AmerisourceBergen?</p> <p>9 A. Um-hum.</p> <p>10 Q. Did I say all of that correctly?</p> <p>11 A. You did.</p> <p>12 Q. Okay. And do you believe that this one</p> <p>13 also would have crossed your desk in the regular</p> <p>14 course of business?</p> <p>15 A. I don't recall it and my name isn't on it</p> <p>16 and nor do I have any notes on it. And this is 2/26</p> <p>17 of '12. That was the time I was transitioning out of</p> <p>18 Mallinckrodt, going back home to Indiana, working my</p> <p>19 final days, so there is a strong chance I never saw</p> <p>20 this.</p> <p>21 Q. Okay. And if you didn't see it, who would</p> <p>22 have been responsible for seeing it?</p> <p>23 A. It would have gone to Karen Harper.</p> <p>24 Q. It would have gone to Karen Harper, okay.</p>	<p style="text-align: right;">Page 377</p> <p>1 supermarket. Spoke personally to the owner/PIC,"</p> <p>2 which I'm guessing is person in charge, "who is well</p> <p>3 aware of the," O-X, "OX issue in Tennessee. Customer</p> <p>4 is being held to strict threshold."</p> <p>5 A. Yeah, that would be a pharmacy --</p> <p>6 MR. O'CONNOR: Objection.</p> <p>7 BY THE WITNESS:</p> <p>8 A. -- pharmacist in charge.</p> <p>9 BY MS. HERZFELD:</p> <p>10 Q. Oh, pharmacist in charge is --</p> <p>11 A. PIC is.</p> <p>12 Q. Okay. And do you know anything about this</p> <p>13 conversation that was had with the pharmacist in</p> <p>14 charge about the oxy issue in Tennessee?</p> <p>15 A. No, because I don't think I've ever seen</p> <p>16 this.</p> <p>17 Q. Very good, sir.</p> <p>18 Okay. I'm going to hand you what we'll</p> <p>19 mark as exhibit --</p> <p>20 A. 47.</p> <p>21 Q. -- 47. Thank you.</p> <p>22 (WHEREUPON, a certain document was</p> <p>23 marked Mallinckrodt-Ratliff</p> <p>24 Deposition Exhibit No. 047, for</p>

<p style="text-align: right;">Page 378</p> <p>1 identification, as of 12/19/2018.)</p> <p>2 BY MS. HERZFELD:</p> <p>3 Q. If you'll take a look at the first page,</p> <p>4 sir, it appears to be an e-mail from Karen Harper to</p> <p>5 Christine Inman.</p> <p>6 Do you know who Christine Inman is?</p> <p>7 A. Not right offhand.</p> <p>8 Q. Okay. And I'll cut through some of it</p> <p>9 here. You are not copied -- you are not copied on</p> <p>10 this exact e-mail, but looking at the attachment --</p> <p>11 A. Um-hum.</p> <p>12 Q. -- it says: "ABC Visit Notes 10/17/2011."</p> <p>13 Have you seen those before?</p> <p>14 A. I would have been involved in that audit,</p> <p>15 I believe. So...</p> <p>16 Q. I'll submit to you that your name shows up</p> <p>17 on the metadata for this document, just to kind of</p> <p>18 push things along a little bit here.</p> <p>19 A. Okay.</p> <p>20 Q. So you were involved in the audit of ABC</p> <p>21 on 10/17/2011, is that correct?</p> <p>22 A. I believe so, yes.</p> <p>23 Q. Okay. And so looking through these notes</p> <p>24 for a second here, on Page 2, if you'll flip with me</p>	<p style="text-align: right;">Page 380</p> <p>1 Q. Sure.</p> <p>2 It says, at the top of that document:</p> <p>3 "ABC has not necessarily made the decision to visit</p> <p>4 based upon the Top 40."</p> <p>5 Do you know what that refers to?</p> <p>6 A. Not -- not really.</p> <p>7 Q. Okay. Do you know if you created this</p> <p>8 document?</p> <p>9 A. No, I didn't.</p> <p>10 Q. Okay. Do you know if Karen Harper created</p> <p>11 this document?</p> <p>12 A. It's reasonable.</p> <p>13 Q. Okay. Who else was on -- at the audit</p> <p>14 besides you and Karen Harper?</p> <p>15 A. Just the two of us.</p> <p>16 Q. Okay. So if it's notes that were created</p> <p>17 by Karen Harper, do you find her notes to be generally</p> <p>18 reliable?</p> <p>19 MR. O'CONNOR: Objection.</p> <p>20 BY THE WITNESS:</p> <p>21 A. Yes.</p> <p>22 BY MS. HERZFELD:</p> <p>23 Q. Do you have any reason to doubt the</p> <p>24 veracity of notes that she has taken at the audit?</p>
<p style="text-align: right;">Page 379</p> <p>1 to the second page of this audit.</p> <p>2 A. Okay.</p> <p>3 Q. The very first sentence says: "Some of</p> <p>4 the Top 40 predate due diligence, ABC requested that</p> <p>5 the account manager update the questionnaire in</p> <p>6 advance of the Mallinckrodt visit."</p> <p>7 Do you know if that occurred?</p> <p>8 A. Eventually we talked to management at ABC</p> <p>9 to ensure that they understood our needs, and</p> <p>10 eventually, it's my understanding, that they provided</p> <p>11 all of the necessary documents, but I can't say that</p> <p>12 unequivocally.</p> <p>13 Q. Okay. So you don't know if the</p> <p>14 questionnaire itself was updated per your request --</p> <p>15 per ABC's request?</p> <p>16 MR. O'CONNOR: Objection.</p> <p>17 BY THE WITNESS:</p> <p>18 A. I just don't recall.</p> <p>19 BY MS. HERZFELD:</p> <p>20 Q. Okay. And then it says: "ABC has not</p> <p>21 necessarily made the decision to visit based upon Top</p> <p>22 40."</p> <p>23 Do you know what that refers to?</p> <p>24 A. Tell me your question again.</p>	<p style="text-align: right;">Page 381</p> <p>1 A. No.</p> <p>2 Q. Okay.</p> <p>3 Okay. On -- do you know at that audit if</p> <p>4 Mallinckrodt required copies of AmerisourceBergen's</p> <p>5 suspicious order monitoring procedures?</p> <p>6 A. I know we reviewed them at some point.</p> <p>7 Excuse me.</p> <p>8 Q. Okay. You reviewed them. Did you ever</p> <p>9 get copies?</p> <p>10 A. I don't recall.</p> <p>11 Q. Okay.</p> <p>12 MS. HERZFELD: Okay. I'm having a really hard</p> <p>13 time with this microphone today. My apologies.</p> <p>14 BY MS. HERZFELD:</p> <p>15 Q. Okay. I'm going to mark -- hand you what</p> <p>16 we will mark as the next sequential exhibit. No. 48?</p> <p>17 A. Correct.</p> <p>18 Q. Yes.</p> <p>19 (WHEREUPON, a certain document was</p> <p>20 marked Mallinckrodt-Ratliff</p> <p>21 Deposition Exhibit No. 048, for</p> <p>22 identification, as of 12/19/2018.)</p> <p>23 BY MS. HERZFELD:</p> <p>24 Q. Do you recognize this document, sir?</p>

<p style="text-align: right;">Page 382</p> <p>1 A. Let me look at it. 2 Okay. I recognize it. 3 Q. Okay. What do you recognize it to be? 4 A. An audit report. 5 Q. Okay. And is the audit report for 6 AmerisourceBergen? 7 A. It is. 8 Q. Okay. And this audit report was completed 9 2/1/12 according to this document, is that correct? 10 A. Yes. 11 Q. Okay. And did you have input into this 12 document? 13 A. I would have, yes. 14 Q. Okay. So going with me to the second 15 page of this document, if you look down to Section 2, 16 and we are going to look at some of the bolded answers 17 here. 18 A. Okay. 19 Q. Okay. On Page 2 -- 20 A. I see it. 21 Q. -- it says: "Does the distributor visit 22 the customer's facility to assess clientele, check for 23 out-of-state license plates, long lines, et cetera?" 24 The answer is: "ABC Compliance performance some</p>	<p style="text-align: right;">Page 384</p> <p>1 A. Say that one more time, please. 2 BY MS. HERZFELD: 3 Q. I'll back it up. 4 In your previous testimony about things 5 that can be indicative of diversion at various 6 pharmacies -- 7 A. Um-hum. 8 Q. -- you talked about different factors 9 that -- 10 A. Okay. 11 Q. -- could be indicative of diversion, is 12 that correct? 13 A. Okay. Yes. 14 Q. Okay. And one of those was long lines? 15 MR. O'CONNOR: Objection. 16 BY THE WITNESS: 17 A. Correct. 18 BY MS. HERZFELD: 19 Q. One of those was out-of-state tags in the 20 parking lot? 21 MR. O'CONNOR: Objection. 22 BY THE WITNESS: 23 A. Correct. 24 BY MS. HERZFELD:</p>
<p style="text-align: right;">Page 383</p> <p>1 pharmacy on-site inspections. ABC Sales calls on some 2 pharmacies. Not all pharmacies are visited by ABC." 3 And then it's blank, the "yes" or "no" beside it. 4 Do you know why it's blank? 5 A. I don't. 6 Q. Okay. Is that something that's supposed 7 to be checked off there? 8 MR. O'CONNOR: Objection. 9 BY THE WITNESS: 10 A. Well, I think it's because they do visit 11 some, they don't visit all, so it is not really yes or 12 no, so. 13 BY MS. HERZFELD: 14 Q. Okay. 15 A. That's why the information was typed in 16 the box and this is something Karen would have done. 17 Q. Okay. So it says here, though, they are 18 supposed to visit at the customer's facility to assess 19 the clientele, check the out-of-state license plates 20 and long lines. 21 That's to check for signs of diversion, is 22 that correct? 23 MR. O'CONNOR: Objection. 24 BY THE WITNESS:</p>	<p style="text-align: right;">Page 385</p> <p>1 Q. Okay. And was one of those kind of 2 looking at the clientele, you talked about, you know, 3 old people or young people, people in the parking lot, 4 is that generally what you testified to earlier? 5 MR. O'CONNOR: Objection. 6 BY THE WITNESS: 7 A. Correct. 8 BY MS. HERZFELD: 9 Q. Okay. And so when you are looking at this 10 question here, it says: "Does the distributor visit 11 the customer's facility to assess clientele, check for 12 out-of-state license plates, long lines, et cetera," 13 that's essentially a question asking for signs of 14 diversion, is that correct? 15 MR. O'CONNOR: Objection. 16 BY THE WITNESS: 17 A. Correct. 18 BY MS. HERZFELD: 19 Q. Okay. And here it says that: "ABC 20 Compliance performs some pharmacy on-site inspections" 21 but "not all pharmacies are visited," so they are not 22 looking for diversion at all pharmacies that are on 23 their clientele list according to this answer, is that 24 correct?</p>

<p style="text-align: right;">Page 386</p> <p>1 MR. O'CONNOR: Objection.</p> <p>2 BY THE WITNESS:</p> <p>3 A. It is a reasonable assumption.</p> <p>4 BY MS. HERZFELD:</p> <p>5 Q. Okay. And it is not marked off "yes" or</p> <p>6 "no" on this audit checklist, is that correct?</p> <p>7 A. It appears not.</p> <p>8 Q. Okay. Then the next question says: "Does</p> <p>9 the distributor have an established procedure for</p> <p>10 reporting suspicious orders to the DEA before</p> <p>11 shipment?" And the answer is: "ABC indicated that</p> <p>12 they have written SOM procedures and provided</p> <p>13 Mallinckrodt a listing of those procedure titles."</p> <p>14 Do you know why it is only the titles were</p> <p>15 provided to Mallinckrodt?</p> <p>16 A. From memory, they said that they were</p> <p>17 confidential.</p> <p>18 Q. Okay. And so did you -- to your</p> <p>19 knowledge, you never got a copy of those because they</p> <p>20 were confidential?</p> <p>21 A. They said they were confidential, so they</p> <p>22 didn't provide us a copy.</p> <p>23 Q. Okay. So how do you know they were --</p> <p>24 they were adequate if you didn't see a copy?</p>	<p style="text-align: right;">Page 388</p> <p>1 Q. Okay. On -- do you know what that means?</p> <p>2 A. There is -- there is more than one way to</p> <p>3 track it. We would prefer if they did it in dosage</p> <p>4 units.</p> <p>5 Q. Okay. And why is that?</p> <p>6 A. Well, because it is easier for us to read.</p> <p>7 Q. Okay.</p> <p>8 A. So this is not the only company that did</p> <p>9 it this way, the only distributor.</p> <p>10 Q. Okay.</p> <p>11 Okay. If you will switch -- if you'll go</p> <p>12 with me to the one that's marked Page 4 of 8, flip two</p> <p>13 pages.</p> <p>14 Under Section 5 at the very bottom, it</p> <p>15 says "Additional Comments."</p> <p>16 A. Okay.</p> <p>17 Q. Okay. Under Additional Comments, it says:</p> <p>18 "ABC metrics on pharmacy purchases including the</p> <p>19 following data points are tracked in dollars," dollar</p> <p>20 sign, "purchased versus dosage units. ABC compliance</p> <p>21 director performs conversion from dollars purchased to</p> <p>22 dosage units 'on the fly.'"</p> <p>23 Did I read that correctly?</p> <p>24 A. You did.</p>
<p style="text-align: right;">Page 387</p> <p>1 A. Well, they had copied the numbers and so</p> <p>2 forth and it appeared that it was in sequence and</p> <p>3 would have been with the titles, we saw those. We</p> <p>4 just didn't see the procedures themselves.</p> <p>5 Q. Okay. So you had to make an assumption</p> <p>6 based on the titles that they were adequate?</p> <p>7 MR. O'CONNOR: Objection.</p> <p>8 BY THE WITNESS:</p> <p>9 A. Yes.</p> <p>10 BY MS. HERZFELD:</p> <p>11 Q. Okay.</p> <p>12 Okay. And then also looking at Page 2, it</p> <p>13 says, towards the bottom there, the next kind of</p> <p>14 bolded answer, it says: "Does the distributor track</p> <p>15 changes in pharmacy buying patterns?"</p> <p>16 Do you see where it says that?</p> <p>17 A. I do.</p> <p>18 Q. Okay. And then it says: "ABC tracks</p> <p>19 purchasing patterns in terms of dollars and is</p> <p>20 converted to dosage unit as needed," and then it</p> <p>21 checks off "Yes."</p> <p>22 A. Um-hum.</p> <p>23 Q. Did I read that correctly?</p> <p>24 A. Yes.</p>	<p style="text-align: right;">Page 389</p> <p>1 Q. Okay. And was that of concern to -- to</p> <p>2 Mallinckrodt?</p> <p>3 MR. O'CONNOR: Objection.</p> <p>4 BY THE WITNESS:</p> <p>5 A. It is one way to do it. We would prefer</p> <p>6 if they did it in dosage units. It would make it much</p> <p>7 simpler for us.</p> <p>8 BY MS. HERZFELD:</p> <p>9 Q. I'm going to stop for a second because I</p> <p>10 don't think I actually finished reading that sentence.</p> <p>11 If you will a flip with me to the next</p> <p>12 page, so we'll go "on the fly as requested.</p> <p>13 Mallinckrodt auditors suggested that ABC consider</p> <p>14 implementing dosage unit measurements for the purposes</p> <p>15 of," suspicious order monitoring, "SOM."</p> <p>16 A. Yeah.</p> <p>17 Q. Did I read that correctly?</p> <p>18 A. That is correct.</p> <p>19 Q. Okay. So your preference was that it</p> <p>20 would be do in -- done in dosage unit measurements?</p> <p>21 A. Um-hum.</p> <p>22 Q. But ABC did it according to dollars?</p> <p>23 MR. O'CONNOR: Objection.</p> <p>24 BY MS. HERZFELD:</p>

<p style="text-align: right;">Page 390</p> <p>1 Q. Yes, sir? Is that a yes?</p> <p>2 A. Would we prefer it in dosage units?</p> <p>3 Q. Yes, sir.</p> <p>4 A. Absolutely.</p> <p>5 Q. Okay. And that's because it is easier to</p> <p>6 track suspicious orders that way, is that correct?</p> <p>7 MR. O'CONNOR: Objection.</p> <p>8 BY THE WITNESS:</p> <p>9 A. Correct.</p> <p>10 BY MS. HERZFELD:</p> <p>11 Q. Okay. And do you know if they ever</p> <p>12 changed the way they did it?</p> <p>13 A. I don't know.</p> <p>14 Q. Okay. Do you know what they meant by "on</p> <p>15 the fly"?</p> <p>16 A. If needed he would do it, because it's on</p> <p>17 the fly.</p> <p>18 Q. So it wasn't done regularly, just if</p> <p>19 somebody requested it?</p> <p>20 A. That's my memory of it.</p> <p>21 Q. Okay. Great.</p> <p>22 Okay. Switching back to Page 3 of 8.</p> <p>23 A. Back to 3 of 8?</p> <p>24 Q. Yes, sir. Section 3.</p>	<p style="text-align: right;">Page 392</p> <p>1 MR. O'CONNOR: Objection.</p> <p>2 BY THE WITNESS:</p> <p>3 A. That's an assumption.</p> <p>4 BY MS. HERZFELD:</p> <p>5 Q. Okay. So it's possible, yes, sir?</p> <p>6 A. It's possible.</p> <p>7 Q. Okay.</p> <p>8 Okay. And then if you'll go down to</p> <p>9 Section No. 4, the second question.</p> <p>10 A. Um-hum.</p> <p>11 Q. "That the physician complies with the laws</p> <p>12 in every state in which controlled substances are sold</p> <p>13 or shipped?" Answer: "ABC checks discipline history</p> <p>14 for top dispensing physicians when they obtain that</p> <p>15 information from pharmacies, but such information is</p> <p>16 not gathered for all pharmacies."</p> <p>17 Did I read that correctly?</p> <p>18 A. You did.</p> <p>19 Q. Okay. So it looks like only top</p> <p>20 prescribing physicians get their discipline history</p> <p>21 checked from that.</p> <p>22 Was that concerning to you in the audit?</p> <p>23 MR. O'CONNOR: Objection.</p> <p>24 BY THE WITNESS:</p>
<p style="text-align: right;">Page 391</p> <p>1 A. Section 3. Okay.</p> <p>2 Q. Go to the one that's the first bolded one,</p> <p>3 that's probably the easiest way to get there.</p> <p>4 "Does the distribute" -- "Does the</p> <p>5 distributor audit pharmacy customers and review Rx</p> <p>6 data to check for patterns of excessive prescribing by</p> <p>7 physicians?" The answer is: "ABC audits some but not</p> <p>8 all pharmacies to screen for excessive prescribing by</p> <p>9 physicians." And then "yes" or "no" is not checked.</p> <p>10 Did I read that correctly, sir?</p> <p>11 A. You did.</p> <p>12 Q. Okay. So if AmerisourceBergen is not</p> <p>13 checking all pharmacies for excessive prescribing by</p> <p>14 physicians, it wouldn't be seeing if people were -- if</p> <p>15 pharmacies were filling excessive prescriptions by</p> <p>16 particular physicians, is that correct?</p> <p>17 MR. O'CONNOR: Objection.</p> <p>18 BY THE WITNESS:</p> <p>19 A. If they didn't do all.</p> <p>20 BY MS. HERZFELD:</p> <p>21 Q. So there could be some pill mills that</p> <p>22 were writing prescriptions filled by some of those</p> <p>23 pharmacies and they wouldn't be caught, is that</p> <p>24 correct?</p>	<p style="text-align: right;">Page 393</p> <p>1 A. Yes.</p> <p>2 BY MS. HERZFELD:</p> <p>3 Q. Okay. And it's marked "no" in the check</p> <p>4 box, is that correct?</p> <p>5 A. That's correct.</p> <p>6 Q. Okay. And what do the yes or noes</p> <p>7 indicate here?</p> <p>8 A. We ask questions to see how robust their</p> <p>9 sus- -- suspicious order monitoring program is.</p> <p>10 Q. Okay.</p> <p>11 A. So we've developed this, Karen did, to</p> <p>12 cover a lot of those questions that would help us</p> <p>13 better assess, give us more information to make a</p> <p>14 determination.</p> <p>15 Q. Okay. And then switching back to Page 6</p> <p>16 of 8, if you go halfway down the page, it says: "ABC</p> <p>17 Non-Florida Top Dispensing Oxy 30 Pharmacies: Twenty</p> <p>18 Pharmacies Reviewed With ABC Previous Quarterly</p> <p>19 Meeting."</p> <p>20 And then it says: "ABC was not prepared</p> <p>21 with any updated statistical information to re-review</p> <p>22 the 20 non-Florida pharmacies discussed in the</p> <p>23 previous quarterly meeting 10/17/11."</p> <p>24 Did I read that correctly?</p>

<p style="text-align: right;">Page 394</p> <p>1 A. You did.</p> <p>2 Q. Okay. And were you concerned that they</p> <p>3 were not prepared with updated statistical information</p> <p>4 since your last audit?</p> <p>5 MR. O'CONNOR: Objection.</p> <p>6 BY THE WITNESS:</p> <p>7 A. Concerned enough to contact their</p> <p>8 management to determine what they knew about their</p> <p>9 process and what they were going to do to meet our</p> <p>10 requirements.</p> <p>11 BY MS. HERZFELD:</p> <p>12 Q. Okay. And is there a memo or something</p> <p>13 somewhere that reflects that conversation with</p> <p>14 management?</p> <p>15 A. Our attorneys were the responsible parties</p> <p>16 that made the contact. We were in the room, but we</p> <p>17 didn't speak and I don't know if there was a document.</p> <p>18 We were assured at that time that they were unaware</p> <p>19 that they weren't being as compliant as they should</p> <p>20 and they would take care of the situation, so.</p> <p>21 Q. Okay. And do you know if any of those</p> <p>22 things were updated that were requested to be updated?</p> <p>23 A. I don't know that.</p> <p>24 Q. Okay. So finishing off just that</p>	<p style="text-align: right;">Page 396</p> <p>1 and Mallinckrodt agrees with ABC's decision based on</p> <p>2 ABC's surveillance results and the pharmacist's</p> <p>3 conversation in which the pharmacist was behaving</p> <p>4 erratically and emotionally crying."</p> <p>5 Do you know what happened -- oh, sorry.</p> <p>6 I'll finish that.</p> <p>7 "When ABC discussed current oxy diversion</p> <p>8 trends."</p> <p>9 Were you involved at all in that</p> <p>10 conversation with the pharmacist?</p> <p>11 A. No.</p> <p>12 Q. Okay. Was it reported to you what was</p> <p>13 said and kind of what was your understanding of it?</p> <p>14 MR. O'CONNOR: Objection.</p> <p>15 BY THE WITNESS:</p> <p>16 A. That's -- it's in the notes here. That's</p> <p>17 what I note.</p> <p>18 BY MS. HERZFELD:</p> <p>19 Q. That's it. Okay.</p> <p>20 And so do you know what the current oxy</p> <p>21 diversion trends are that's referred to here?</p> <p>22 A. I don't.</p> <p>23 Q. Okay.</p> <p>24 Okay. Then the next one on the list is</p>
<p style="text-align: right;">Page 395</p> <p>1 sentence: "ABC Compliance Director committed to</p> <p>2 updating the pharmacy information sheets and providing</p> <p>3 information for Mallinckrodt for further review."</p> <p>4 Was that after the conversation with the</p> <p>5 lawyers?</p> <p>6 A. I don't recall exactly when that occurred,</p> <p>7 the conversation with attorneys. This was when I was</p> <p>8 phasing out of the company.</p> <p>9 Q. Okay.</p> <p>10 A. And I just -- I don't know.</p> <p>11 Q. Okay.</p> <p>12 Okay. And then looking at Page 6, it</p> <p>13 talks about some specific pharmacies that were of</p> <p>14 concern for that were mentioned in this report. The</p> <p>15 first one is Munsey Pharmacy in Tennessee.</p> <p>16 Do you see where I am at, on Page 6 of 8?</p> <p>17 A. Where in the page, it is a big page? Oh,</p> <p>18 Munsey down at the bottom.</p> <p>19 Q. Yeah, do you see it?</p> <p>20 A. Okay. ABC 11/30.</p> <p>21 Q. Okay. So here it says: "ABC provided</p> <p>22 Mallinckrodt information 11/30/11 that ABC had</p> <p>23 discontinued selling controlled drugs to this</p> <p>24 pharmacy. Mallinckrodt discussed this account with Ed</p>	<p style="text-align: right;">Page 397</p> <p>1 Jabos Pharmacy, which we talked about a little bit</p> <p>2 earlier.</p> <p>3 A. Um-hum.</p> <p>4 Q. I'm looking at where it says Jabos, it</p> <p>5 says: "ABC previously provided Mallinckrodt</p> <p>6 (11/30/11) that ABC had discontinued selling</p> <p>7 controlled drugs to this company."</p> <p>8 Did I read that correctly?</p> <p>9 A. To this pharmacy.</p> <p>10 Q. Oh, sorry. "To this pharmacy."</p> <p>11 A. Yes.</p> <p>12 Q. Okay. "However, ABC stated in the meeting</p> <p>13 with Mallinckrodt 2/1/12 that they've reconsidered</p> <p>14 their decision and are continuing business with</p> <p>15 Jabos."</p> <p>16 Did I read that correctly?</p> <p>17 A. You did.</p> <p>18 Q. "Mallinckrodt expressed concerns about</p> <p>19 this decision when ABC indicated that a customer who</p> <p>20 exited Jabos during ABC's surveillance of the Jabos</p> <p>21 parking lot attempted to sell oxycodone 30-milligram</p> <p>22 tablets to the ABC investigator. ABC indicates they</p> <p>23 have fired the ABC sales rep who formerly called on</p> <p>24 Jabos because ABC determined that the sales rep was</p>

<p style="text-align: right;">Page 398</p> <p>1 incorrectly representing Jabos Pharmacy business and 2 asking ABC to increase Jabos controlled substance 3 purchasing limits." 4 Did I read that correctly? 5 A. You did. 6 Q. Okay. And do you know any other 7 information than what's contained in this paragraph 8 about what happened at Jabos? 9 A. No, but I -- I remember distinctly him 10 talking about the customer coming out and trying to 11 sell their security person some drugs, so. 12 Q. Okay. And that's something that would 13 indicate diversion, is it not? 14 A. Absolutely. 15 Q. Okay. And do you know if ABC reconsidered 16 their decision and decided to continue their business 17 with Jabos? 18 A. I don't know that. 19 Q. Okay. But it indicates in this paragraph 20 that that's what they were considering, is that right? 21 A. That's what it says. 22 Q. Okay. And do you know if Mallinckrodt 23 took any action -- action to stop having -- stop 24 having their product go from ABC to Jabos?</p>	<p style="text-align: right;">Page 400</p> <p>1 about in Tennessee? 2 A. Yes. 3 Q. Okay. And to your knowledge, Mallinckrodt 4 didn't personally conduct any site visits to those 5 pharmacies in Tennessee, is that correct? 6 MR. O'CONNOR: Objection. 7 BY THE WITNESS: 8 A. Some audits were conducted by the person 9 who took my position once I left. 10 BY MS. HERZFELD: 11 Q. Okay. 12 A. I don't know if he conducted any in 13 Tennessee or not. That's a possibility. 14 Q. Okay. So to clarify my question then, 15 during your tenure -- 16 A. No. 17 Q. -- you don't know of any site visits that 18 were done in Tennessee on behalf of Mallinckrodt? 19 A. Correct. 20 Q. Okay. Do you agree that there are some 21 signs of diversion that can only be detected through a 22 site visit? 23 MR. O'CONNOR: Objection. 24 BY THE WITNESS:</p>
<p style="text-align: right;">Page 399</p> <p>1 MR. O'CONNOR: Objection. 2 BY THE WITNESS: 3 A. I don't know that. 4 BY MS. HERZFELD: 5 Q. Okay. And do you know if Mallinckrodt 6 products continued to ship to Jabos Pharmacy in 7 Tennessee? 8 MR. O'CONNOR: Objection. 9 BY THE WITNESS: 10 A. I don't know that. 11 BY MS. HERZFELD: 12 Q. Okay. Do you know if Jabos at this time, 13 the two -- 2/1/12, do you know if Jabos was put on a 14 chargeback restriction list? 15 A. I don't know that. 16 Q. Okay. 17 Okay. You can set that document down, 18 sir. 19 A. Okay. 20 Q. Okay. So you personally didn't conduct 21 any site visits of these pharmacies, is that correct, 22 sir? 23 A. That's correct. 24 Q. Okay. And the ones we've just talked</p>	<p style="text-align: right;">Page 401</p> <p>1 A. Yes. 2 BY MS. HERZFELD: 3 Q. Okay. Like long lines? 4 A. Correct. 5 Q. Customers engaging in drug seeking 6 behaviors, like trying to sell oxy in the parking lot? 7 A. Yes. 8 Q. Okay. Cars full of pharmacy customers? 9 A. Yes. 10 Q. Okay. Cars in the parking lot with 11 license plates from other states or far away counties? 12 A. Yes. 13 Q. Okay. Pharmacies with minimal or no 14 front-end merchandise? 15 A. Yes. 16 Q. Pharmacies with little or no walk-in 17 business? 18 A. Yes. 19 Q. Evidence of illicit drug use around the 20 facility? 21 A. Yes. 22 Q. Okay. Mailing materials or other evidence 23 of operation of an internet pharmacy? 24 A. I don't know that. What are you saying?</p>

Page 402

1 Q. If you show up and it looks like it's just
2 like a computer and there are some pamphlets there
3 because it's an address for nothing but an internet
4 pharmacy?
5 A. Yeah, I don't -- I've never encountered an
6 internet pharmacy.
7 Q. Okay. Primarily cash transactions, is
8 that something you could see with a site visit?
9 A. That's information that would be furnished
10 by the pharmacy.
11 Q. Okay.
12 A. There is no way by a site visit that we
13 would see if it was cash or -- or other.
14 Q. Okay. What about if there was only one
15 employee that was responsible for the order,
16 monitoring and invoicing of products, is that
17 something you could determine at a site visit?
18 A. Not necessarily.
19 Q. Okay. What about photographs, is there a
20 way to obtain photographs if you haven't done a site
21 visit?
22 A. Are you asking about if we did the site
23 visit or if we required the distributor to do the site
24 visit?

Page 403

1 Q. Well, I guess I'm asking, site visits
2 would provide the best opportunity for photographs of
3 a particular site, is that correct?
4 A. We always requested photographs from the
5 distributors.
6 Q. Okay. It sounds like the distributors
7 didn't always give them to you, is that right?
8 A. Correct.
9 Q. Okay. Did you sometimes look up
10 pharmacies on things like Google Maps or Google --
11 Google Earth back in 2012? I don't even know if it
12 existed.
13 A. I don't know if it was in 2012, but we did
14 that on occasion.
15 Q. Okay. And would that be sufficient to
16 satisfy the photographs element of what it is you
17 required?
18 MR. O'CONNOR: Objection.
19 BY THE WITNESS:
20 A. No. It was done not for that purpose.
21 BY MS. HERZFELD:
22 Q. Okay.
23 A. We were trying to determine if a building
24 existed or an address existed and where it was in

Page 404

1 location to other businesses, was it a prominent
2 location or in an isolated location.
3 Q. Okay. And did you do anything to verify
4 that AmerisourceBergen's information that they gave
5 you about those Tennessee pharmacies was accurate?
6 A. Personally?
7 Q. Yes, sir.
8 A. No.
9 Q. Do you know if anyone within Mallinckrodt
10 did?
11 A. Not while I was there. I don't know.
12 Q. Okay.
13 When you were looking for potential
14 diversion at pharmacies, was one of the things that
15 you would take into -- into account is whether
16 multiple distributors were providing oxycodone to one
17 pharmacy?
18 A. There is no way we would know that.
19 Q. Okay. So how would you not know that?
20 A. Because we don't have access to other
21 manufacturers' records.
22 Q. I'm sorry. I must not have asked the
23 question very well. I apologize.
24 So I guess what I'm trying to figure out

Page 405

1 is if you had multiple customers, it's possible that
2 AmerisourceBergen and McKesson could have both been
3 shipping Mallinckrodt oxycodone to Jabos Pharmacy, for
4 example, is that correct?
5 MS. KVESELIS: Object to the form.
6 BY THE WITNESS:
7 A. I don't know. I really don't. I mean,
8 if -- so if we had -- yeah, I just don't know that.
9 BY MS. HERZFELD:
10 Q. Okay. I'm going to show you a document
11 that's been listed in your custodian file, and maybe
12 we can see each other on the same page on this, okay.
13 We'll mark this as Exhibit 49.
14 (WHEREUPON, a certain document was
15 marked Mallinckrodt-Ratliff
16 Deposition Exhibit No. 049, for
17 identification, as of 12/19/2018.)
18 BY MS. HERZFELD:
19 Q. Take a minute and look at it.
20 A. "Custodian Bill Ratliff," who -- who put
21 that on there?
22 Q. Oh, I think that's probably my notes.
23 A. On the front, it says: "ABC Top 40 and
24 Multi Dist Tab, Custodian: Bill Ratliff."

<p style="text-align: right;">Page 406</p> <p>1 (WHEREUPON, there was a short 2 interruption.) 3 BY THE WITNESS: 4 A. Okay. These were mine. 5 BY MS. HERZFELD: 6 Q. That's probably my note on the front just 7 to know what it is. 8 Okay. So if you look with me, sir, for 9 the second page here, it says at the top: 10 "AmerisourceBergen All Other States 30-milligram 11 2011," year to date, "YTD." 12 Did I read that correctly? 13 A. Well, let me look at this again because I 14 was -- 15 MR. O'CONNOR: Which page? 16 MS. HERZFELD: The second page. Well, the 17 second graph page. This one. 18 MR. O'CONNOR: So the third page of the packet. 19 MS. HERZFELD: Third page of the packet. 20 BY THE WITNESS: 21 A. Right, I remember this page. 22 BY MS. HERZFELD: 23 Q. So you remember the first page with the 24 yellow highlighting on it?</p>	<p style="text-align: right;">Page 408</p> <p>1 again, Jabos Pharmacy, do you see it, in Newport, 2 Tennessee? 3 A. I do. 4 Q. Okay. And that one also says "Multi Dist" 5 all of the way to the right? 6 A. Um-hum. 7 Q. Okay. And I'm sorry. It says at the top, 8 right there, "Sales Quantity Government UOM," that 9 stands for unit of measure? 10 A. I don't know. 11 MR. O'CONNOR: Objection. 12 BY MS. HERZFELD: 13 Q. Do you know what a unit of measure is, a 14 government unit of measure? 15 A. No. 16 Q. Okay. And then going down four more from 17 Jabos Pharmacy, it says: "East Tennessee Discount 18 Drugs, Strawberry Plains, Tennessee." 19 Do you see where I'm at? 20 A. Um-hum. 21 Q. And then that one doesn't say Multi Dist? 22 A. Um-hum. 23 Q. So from looking at this, the ones that say 24 "Multi Dist," does that mean they have multiple</p>
<p style="text-align: right;">Page 407</p> <p>1 A. Yes. 2 Q. Okay. And that says "Florida" at the top? 3 A. Right. 4 Q. Okay. So switch to the next page with me. 5 A. I don't remember this at all. 6 Q. Okay. What does the second one say? It 7 says: "All Other States 30-milligram," is that 8 correct? 9 A. Yes. 10 Q. Okay. So looking through that list, 11 the -- the second -- the second pharmacy there is 12 Rippetoe, Inc. -- 13 A. Um-hum. 14 Q. -- in Morristown, Tennessee. 15 Did I read that correctly? 16 A. You did. 17 Q. Okay. And then if you look all of the way 18 over to the right, it's in that little blue box, it 19 says "Multi Dist." 20 Does that stand for multiple distributors? 21 A. That would be my opinion about it, yes. 22 Q. Okay. And then looking down midway 23 through this chart, one, two, three, four, five, six, 24 seven, eight, nine, the ninth one down is, there we go</p>	<p style="text-align: right;">Page 409</p> <p>1 distributors that were distributing to them? 2 A. I still have a problem with who put on the 3 front of this "Custodian Bill Ratliff." 4 Q. Sir, all I'm doing is telling you it was 5 presented to us as being in your custodian file. 6 A. Because I don't recall these other two 7 pages. 8 Q. Okay, sir. 9 A. I just -- you know, the one page I do 10 recall. 11 Q. Okay. 12 A. Because I had that for the two other -- 13 these were all Florida. So somebody added this to it, 14 and I don't know who the source is of that. 15 Q. Okay. 16 A. Or that I should know about this. 17 Q. So did you only look at the top 18 distributors for Florida? 19 A. Yes. 20 MR. O'CONNOR: Objection. 21 BY MS. HERZFELD: 22 Q. Did -- did you look at the top 23 distributors outside of Florida? 24 A. Well, not originally, so. I mean, there</p>

Page 410

1 may have been a time that they started looking at
2 those, but we literally concentrated on Florida
3 initially. And you have to remember then shortly
4 after the first of the year, I was transitioning out
5 of the company, so. When you are asking did we do it,
6 I didn't do it.
7 Q. Okay. Okay. Okay. Then you can set that
8 one aside.
9 A. Okay.
10 Q. Okay. You also participated in reviewing
11 McKesson's top pharmacies, is that correct?
12 A. Correct.
13 Q. And McKesson had only one pharmacy listed
14 in Tennessee, Bradley Drug Company. Do you recall
15 that?
16 A. No.
17 MS. KVESELIS: Object to form.
18 BY MS. HERZFELD:
19 Q. Okay. Do you ever recall hearing about
20 Bradley Drug Company in Nashville?
21 A. I did -- I did Florida.
22 Q. You only did Florida?
23 A. Yes.
24 Q. Okay. I'm going to hand you what we are

Page 411

1 going to mark as Exhibit 50.
2 (WHEREUPON, a certain document was
3 marked Mallinckrodt-Ratliff
4 Deposition Exhibit No. 050, for
5 identification, as of 12/19/2018.)
6 BY MS. HERZFELD:
7 Q. Okay. Sir, this appears to be an e-mail
8 that was sent from you to Donald Walker, December 5th,
9 2011?
10 A. Okay.
11 Q. Is that correct?
12 A. Yes.
13 Q. Okay. And it copies Donald Lohman and
14 Karen Harper.
15 Who was Donald Walker?
16 A. He was the vice president in charge of --
17 I don't know his exact title, but he was with
18 McKesson.
19 Q. Okay. And Donald Lohman?
20 A. He is sitting right there.
21 Q. Do you know who that is?
22 Oh, there he is. Hello.
23 Okay. So in this e-mail, it says: "Don,
24 as you may recall, the original list presented to

Page 412

1 McKesson contained 20 pharmacies in and 20 out of the
2 State of Florida. 15 of the pharmacies out of the
3 State of Florida were handled by Michael Oriente
4 leaving five that we have not addressed. They are as
5 follows." And the last one on that list is: "Bradley
6 Drug Company, Tennessee."
7 Did I read that correctly?
8 A. You did.
9 Q. Okay. "It would be helpful if we could
10 identify the persons that handle those pharmacies," et
11 cetera, et cetera. "Thanksgiving," et cetera.
12 Did I read that correctly?
13 MR. O'CONNOR: Objection.
14 BY MS. HERZFELD:
15 Q. Okay. And then switching to the second
16 page, it appears to be an e-mail from Don Walker to
17 you, 12/12/2011, Additional Pharmacies.
18 "Bill, attached is the documentation for
19 all of the remaining pharmacies with the exception of
20 Laabs," and then there is an attachment to that
21 e-mail.
22 MR. O'CONNOR: Counsel, the Bates numbers are
23 not consecutive here. Are you suggesting that
24 these --

Page 413

1 MS. HERZFELD: Oh, you know what, I think
2 somebody probably put them together. We can label
3 them as separate exhibits, if you prefer.
4 MR. O'CONNOR: Yeah, I think so, so to be clear,
5 are you saying that Bates number ending in 282 is
6 Exhibit 50?
7 MS. HERZFELD: 50. And let's do the ones ending
8 4116 and 4117 as 51. My apologies for that.
9 (WHEREUPON, a certain document was
10 marked Mallinckrodt-Ratliff
11 Deposition Exhibit No. 051, for
12 identification, as of 12/19/2018.)
13 BY MS. HERZFELD:
14 Q. Okay. So now looking at document 51, it
15 appears to be an e-mail from Don Walker to you, is
16 that correct?
17 A. Yes.
18 Q. Okay. And do you have any reason to think
19 that this wasn't sent to you?
20 A. No.
21 Q. Okay. And so it talks about additional
22 pharmacies on 12/12/2011.
23 A. Um-hum.
24 Q. And then there is an attachment which is

<p style="text-align: right;">Page 414</p> <p>1 the second page. 2 Will you take a look at that for me, 3 please? 4 A. Yes. 5 Q. Okay. And do you know what this document 6 is? 7 A. It's our form that we would give the -- 8 the companies to fill out to give us the information. 9 Q. So it looks like it's a version of the 10 pharmacy information sheets we were going over 11 earlier? 12 A. Yes. 13 Q. Okay. And the pharmacy name on this one 14 is Bradley Drug Company in Nashville, Tennessee, is 15 that correct? 16 A. Correct, yes. 17 Q. Okay. So going through this -- 18 A. It says: "Active/sales of controlled 19 substances restricted." 20 Q. Yes, sir. 21 Okay. So it says in that e-mail, if 22 you'll flip back, in that first paragraph -- 23 A. Um-hum. 24 Q. -- "Bill, attached is the documentation</p>	<p style="text-align: right;">Page 416</p> <p>1 Q. Okay. And it says: "If so, background 2 checks? Pogue had reprimand for unprofessional 3 conduct in 9/9 for injecting multiple patients with 4 HGH for pain. Cochran, Yarzagaray, Scott and Rhodes 5 are clear." 6 Did I read that correctly? 7 A. You did. 8 Q. Okay. And this form came attached to this 9 e-mail on 12/12/2011, is that correct? 10 A. Correct. 11 Q. Okay. Did you do anything to verify the 12 information that was contained within this worksheet? 13 A. No. 14 Q. Okay. And did you yourself fill out this 15 worksheet, the Pharmacy Information Sheet? 16 A. No. 17 Q. Okay. The information was given to you by 18 the distributor? 19 A. Yes. 20 Q. Okay. In this case that would be 21 McKesson, is that right? 22 A. Correct. 23 Q. Okay. I'm going to hand you what we'll 24 mark as Exhibit 52.</p>
<p style="text-align: right;">Page 415</p> <p>1 for all remaining pharmacies with the exception of 2 Laabs. We ceased all controls to Laabs in October 3 after action taken by DEA and FBI. The one I have 4 directed some additional work on is Bradley given the 5 prescribing physicians." 6 Do you know what he meant by "given the 7 prescribing physicians"? 8 MS. KVESELIS: Object to the form. 9 BY THE WITNESS: 10 A. I don't know. 11 BY MS. HERZFELD: 12 Q. You don't know what he was referring to? 13 A. No. 14 Q. Okay. So looking at the Pharmacy 15 Information Sheet then on the second page -- 16 A. Okay. 17 Q. -- it says: "Top prescribers identified: 18 As of 10/25/2011," at the bottom of the page. 19 Do you see where I am at? 20 A. Yes. 21 Q. Okay. It says "James Pogue, RT Cochran, 22 Junior, Luis Yarzagaray, Cindy Scott, and Michael 23 Rhodes," is that correct? 24 A. Yes.</p>	<p style="text-align: right;">Page 417</p> <p>1 (WHEREUPON, a certain document was 2 marked Mallinckrodt-Ratliff 3 Deposition Exhibit No. 052, for 4 identification, as of 12/19/2018.) 5 BY MS. HERZFELD: 6 Q. Do you recognize this document as a 7 Pharmacy Information Sheet for Bradley Drug Company, 8 sir? 9 A. Yes. 10 Q. Okay. And it is dated 3/20/2012, is that 11 correct? 12 A. Correct. 13 Q. It says it is prepared by Bill Mahoney. 14 Do you know who that is? 15 A. No. 16 Q. Okay. Do you know whose handwriting this 17 is on the document? 18 A. It's mine. 19 Q. Okay. Could you read it for me, please? 20 A. And I wrote at the top, "Bill Mahoney," I 21 wrote "3/22/12, blister packing for" -- 22 Q. I thought it might be nursing? 23 A. -- "nursing homes, 15,000 square feet, 24 near the hospital district near Vanderbilt," and then</p>

<p>Page 418</p> <p>1 it says, "Comfortable." 2 Q. Okay. Do you know what you meant by your 3 notes there? 4 A. That was the location, I believe. 5 Q. Where did you obtain information about 6 where that pharmacy was located? 7 A. Well, from Bill Mahoney. It appears that 8 I talked to him on 3/20/2012. 9 Q. Okay. And Bill Mahoney, did he work for 10 McKesson? 11 A. That's an assumption. I -- I don't really 12 remember at this point. 13 Q. Okay. Did you do anything to verify that 14 information about it being near Vanderbilt or near the 15 hospital district? 16 A. No. 17 Q. Okay. In fact, sir, it is not near 18 Vanderbilt or the hospital district. 19 A. Say again. 20 Q. It is not near Vanderbilt or the hospital 21 district. Has anyone told you that? 22 MR. O'CONNOR: Objection. 23 BY THE WITNESS: 24 A. If he said -- I mean, I wrote down what he</p>	<p>Page 420</p> <p>1 saw -- if you were doing a site visit and you saw that 2 it was surrounded by check cashing places and liquor 3 stores and pawn shops and things of -- of that nature 4 in a high crime area -- 5 MR. O'CONNOR: Objection. 6 BY MS. HERZFELD: 7 Q. -- would that be indicative of you that 8 you might need to look a little bit closer for 9 diversion at that pharmacy? 10 MR. O'CONNOR: Objection. 11 BY THE WITNESS: 12 A. Possibly. 13 At that point I was dealing with McKesson 14 and they were being very -- they had hired a new 15 person to -- to help develop a program and they did 16 everything that we had asked them to do, so no longer 17 filling except for long-term patients. They are more 18 careful, Pogue is allegedly. "All clear except for 19 Pogue." So that was also a note that he told me at 20 the time, so. 21 Q. Okay. So based on your notes here and 22 your conversation with Mr. Mahoney, you felt 23 comfortable -- 24 A. Based on what he told me, yes.</p>
<p>Page 419</p> <p>1 told me. 2 BY MS. HERZFELD: 3 Q. Okay. But you didn't do anything else to 4 verify that? 5 A. I didn't. 6 Q. Okay. Would one of the things that you 7 were looking for for a pharmacy that may be 8 potentially engaged in diversion the area in which 9 it's located? 10 MR. O'CONNOR: Objection. 11 BY THE WITNESS: 12 A. Occasionally that will tell us something, 13 but it also tells us why they would be using a lot of 14 our product, be it they are near a hospital or -- or 15 an area where there are a lot of doctors and so forth. 16 BY MS. HERZFELD: 17 Q. Okay. But if it wasn't and it was a high 18 crime area, for example, is that something that could 19 be indicative of diversion? 20 MR. O'CONNOR: Objection. 21 BY THE WITNESS: 22 A. It could be, but not necessarily. 23 BY MS. HERZFELD: 24 Q. What if you went to that pharmacy and you</p>	<p>Page 421</p> <p>1 Q. -- continuing to allow Mallinckrodt 2 products to go through McKesson to Bradley Drug, is 3 that correct? 4 MR. O'CONNOR: Objection. 5 MS. KVESELIS: Object to the form. 6 BY THE WITNESS: 7 A. Yes. 8 BY MS. HERZFELD: 9 Q. Okay. Did you do anything independently 10 to verify the information that was provided to you on 11 this sheet by McKesson? 12 A. I did not. 13 Q. Did anyone at Mallinckrodt look at IMS 14 data for any of these physicians? 15 MR. O'CONNOR: Objection. 16 BY MS. HERZFELD: 17 Q. Or I'm sorry. For the area? 18 MR. O'CONNOR: Objection. 19 BY THE WITNESS: 20 A. So you are saying where this is located? 21 BY MS. HERZFELD: 22 Q. Yes, sir. 23 A. Not to my knowledge. 24 Q. Okay.</p>

<p style="text-align: right;">Page 422</p> <p>1 A. I'm not certain that I was -- I think I 2 was already in Indiana when this occurred, so. 3 Q. Okay. Do you know why Bradley Drug 4 Company was placed on a chargeback restriction list? 5 MR. O'CONNOR: Objection. 6 BY THE WITNESS: 7 A. I don't. 8 BY MS. HERZFELD: 9 Q. Okay. Or if it ever was? 10 A. I don't know that. 11 Q. Okay. This should go pretty quickly now. 12 When it said in the previous exhibit that 13 Pogue had been disciplined in 2009 for use of HGH 14 treatment for pain, do you know what the circumstances 15 were of that discipline? 16 A. No. 17 Q. Did Mallinckrodt do any additional 18 research to find out more information about that 19 disciplinary infraction? 20 A. They basically put the information there 21 as why he was disciplined in 2009. He supplied HGH in 22 treatment of pain. 23 Q. Okay. And do you know if Dr. Pogue is 24 prescribing now?</p>	<p style="text-align: right;">Page 424</p> <p>1 MR. O'CONNOR: Objection. 2 BY THE WITNESS: 3 A. It would have been -- it would have been 4 interesting to know. 5 MS. HERZFELD: Okay. We'll mark the next 6 exhibit 54. 7 THE WITNESS: 53. 8 MS. HERZFELD: 53. 9 (WHEREUPON, a certain document was 10 marked Mallinckrodt-Ratliff 11 Deposition Exhibit No. 053, for 12 identification, as of 12/19/2018.) 13 BY MS. HERZFELD: 14 Q. If you'd take a look at this document, 15 sir, I'll submit to you that it's a copy of the 16 Consent Order by the Tennessee Department of Health. 17 Again, Dr. Michael Rhodes. If you'd take a look at 18 the back page, it is dated July 21st of 2009. 19 Have you ever seen this document before, 20 sir? 21 A. I have not. 22 Q. Okay. And you weren't aware of this 23 previous disciplinary history of Dr. Rhodes? 24 A. I was not.</p>
<p style="text-align: right;">Page 423</p> <p>1 A. I don't know that. 2 Q. Okay. Do you know if Dr. Pogue still has 3 a medical license or prescribes -- a license to 4 prescribe? 5 A. I have no idea. 6 Q. Okay. 7 Okay. What about Robert Cochran, do you 8 know if Robert Cochran is still able? 9 A. I have no idea. 10 Q. Okay. What about Michael Rhodes, if 11 Michael Rhodes had -- 12 A. I have no idea. 13 Q. -- if he had been reprimanded for 14 prescribing controlled substances without documenting 15 appropriate medical histories or performing adequate 16 physical examinations back in 2009, is that 17 information you would have wanted to have known? 18 A. Yes. 19 MR. O'CONNOR: Objection. 20 THE WITNESS: Sorry. 21 BY MS. HERZFELD: 22 Q. Okay. Is an order like that in a 23 physician's file something that could be indicative of 24 diversion?</p>	<p style="text-align: right;">Page 425</p> <p>1 Q. And what about Cindy Scott, the nurse we 2 discussed earlier, do you know if she still has a 3 license to prescribe? 4 MR. O'CONNOR: Objection. 5 BY THE WITNESS: 6 A. I have no idea. 7 BY MS. HERZFELD: 8 Q. Okay. 9 Okay. You testified earlier that you have 10 some familiarity with chargeback data in your -- in 11 the context of your job at Mallinckrodt, is that 12 correct? 13 A. No. I have very little information. 14 Q. Okay. 15 A. I am still totally confused by it. 16 Q. Okay. Did you review chargeback data 17 regularly as part of your job? 18 A. No. 19 Q. I'll come back to that in one second. 20 Do you recall on any discussion about a 21 Food City in Tennessee from your time at Mallinckrodt? 22 MR. O'CONNOR: Objection. 23 BY THE WITNESS: 24 A. I don't -- I don't recall.</p>

<p style="text-align: right;">Page 426</p> <p>1 BY MS. HERZFELD:</p> <p>2 Q. I'm going to show you what we will mark as</p> <p>3 54.</p> <p>4 (WHEREUPON, a certain document was</p> <p>5 marked Mallinckrodt-Ratliff</p> <p>6 Deposition Exhibit No. 054, for</p> <p>7 identification, as of 12/19/2018.)</p> <p>8 BY MS. HERZFELD:</p> <p>9 Q. No. 54, ignore this top page if it makes</p> <p>10 you nervous. As I'm handing this to you, I will</p> <p>11 submit to you that this was not in your custodian</p> <p>12 file. It was in a general file.</p> <p>13 A. Okay.</p> <p>14 Q. But my question is, take a look at it, the</p> <p>15 file name on this document was: "May 2012 Top Oxy 30</p> <p>16 Pharmacies." If you look down, they are classified by</p> <p>17 state.</p> <p>18 A. Um-hum.</p> <p>19 Q. And if you look at the second page and you</p> <p>20 get to where it says "Tennessee," if you'll take a</p> <p>21 look with me there, sir, it should be on the last</p> <p>22 page.</p> <p>23 Do you see where I am at?</p> <p>24 A. I have never seen it before.</p>	<p style="text-align: right;">Page 428</p> <p>1 restricting that Food City in Tennessee?</p> <p>2 MR. O'CONNOR: Objection.</p> <p>3 BY THE WITNESS:</p> <p>4 A. Well, the only thing I would tell you is,</p> <p>5 I was no longer with the company. I was already</p> <p>6 retired.</p> <p>7 BY MS. HERZFELD:</p> <p>8 Q. Okay. Well, it looks like some of this</p> <p>9 data is back from June 2011, and it says you</p> <p>10 recommended restricting it.</p> <p>11 A. Okay.</p> <p>12 Q. So do you have any memory why you would</p> <p>13 have recommended restricting that pharmacy?</p> <p>14 A. If it's the one that says Masters?</p> <p>15 Q. Yes, sir.</p> <p>16 A. That would be one of the audits that we</p> <p>17 did that we discussed at great length.</p> <p>18 Q. Okay.</p> <p>19 A. So that would probably --</p> <p>20 Q. And do you know --</p> <p>21 A. -- as I say, I can't recall it, but that</p> <p>22 would certainly be a reason.</p> <p>23 Q. Okay. And do you know if that pharmacy</p> <p>24 was ever restricted?</p>
<p style="text-align: right;">Page 427</p> <p>1 Q. That's okay.</p> <p>2 So down on Tennessee, there is a couple of</p> <p>3 different ones that are highlighted yellow. Do you</p> <p>4 see where I am at?</p> <p>5 A. I see them.</p> <p>6 Q. Okay. And there are two that are Food</p> <p>7 City, Chapman Highway and Seymour, Tennessee?</p> <p>8 A. I see that.</p> <p>9 Q. So one is AmerisourceBergen and the other</p> <p>10 is DBS Trading, Inc. Masters Pharmacy.</p> <p>11 Do you see that?</p> <p>12 A. I do.</p> <p>13 Q. Okay. And then there are some notes all</p> <p>14 of the way to the right there. One of the notes says</p> <p>15 "PIS."</p> <p>16 Do you know what PIS means?</p> <p>17 A. I don't know.</p> <p>18 Q. Okay. And then the next note says: "B.</p> <p>19 Ratliff," I'm assuming that's you --</p> <p>20 A. Yes.</p> <p>21 Q. -- "recommends restricting" --</p> <p>22 A. Okay.</p> <p>23 Q. -- that Food City.</p> <p>24 Do you know why you would have recommended</p>	<p style="text-align: right;">Page 429</p> <p>1 A. I don't know that.</p> <p>2 Q. Okay.</p> <p>3 A. This says: "Date Created: 7/17. Date</p> <p>4 Last Modified: 7/19." I'm just saying I was retired,</p> <p>5 so.</p> <p>6 Q. Understood, sir.</p> <p>7 A. Okay.</p> <p>8 Q. Okay.</p> <p>9 Okay. Almost, almost done.</p> <p>10 A. Okay.</p> <p>11 Q. Okay. I'm going to hand you two sets of</p> <p>12 chargeback data, and we'll see if we can work through</p> <p>13 it together, okay. Number -- the first one first, the</p> <p>14 second one second. 55, Exhibit 55.</p> <p>15 (WHEREUPON, a certain document was</p> <p>16 marked Mallinckrodt-Ratliff</p> <p>17 Deposition Exhibit No. 055, for</p> <p>18 identification, as of 12/19/2018.)</p> <p>19 BY MS. HERZFELD:</p> <p>20 Q. Okay. If you'll take a look with me, I'll</p> <p>21 represent to you that we put chargeback data for</p> <p>22 Tennessee. This is only Tennessee on this chart.</p> <p>23 A. Okay.</p> <p>24 Q. So I'm not expecting you to have seen it</p>

Page 430

1 before, okay?
2 A. Okay.
3 Q. OKAY. So looking at this, the number one
4 for chargeback says: "Bradley Drug Company."
5 Do you see where it says that?
6 A. Brad -- are you saying Bradley Drug
7 Company?
8 Q. Um-hum, where it says No. 3, Bradley Drug
9 Company --
10 A. I see that.
11 Q. -- Charlotte Avenue.
12 And then some of this stuff here is in red
13 and it looks like their total oxy 15 --
14 A. Uh-huh.
15 Q. -- shipment for, it says the past
16 12 months --
17 A. Yeah.
18 Q. -- through June 2012 is 87,400.
19 Do you know what that is, units?
20 A. I was retired, I believe, at this time.
21 Q. I believe this covers a year's worth back
22 through July of 2011.
23 Were you still employed in July 2011?
24 A. I was in '11, yes.

Page 431

1 Q. Okay. So I'm looking at those numbers
2 there, 87,400 is -- do you see that?
3 A. Okay.
4 Q. Do you know if that's tablets or bottles?
5 A. I don't know.
6 Q. Okay.
7 A. And part of it is when I was retired, so.
8 Q. Correct. I understand that.
9 Part of it was when you were there and
10 part of it was when you were not?
11 A. Correct.
12 Q. Okay.
13 And then looking down, the one that
14 said -- next to No. 5, it says Rippetoe, Inc.?
15 A. Yes.
16 Q. Morristown, Tennessee?
17 A. I see it.
18 Q. And if you look all of the way over to the
19 end, it says 59,200 units, whatever those are, right,
20 for 12 months.
21 Do you see where I am at?
22 A. I do see that.
23 Q. Okay. And does that seem like a high
24 number to you?

Page 432

1 MR. O'CONNOR: Objection.
2 BY THE WITNESS:
3 A. Well, the thing I don't know is, is this
4 all of the products they purchased from us, is it one
5 particular product they purchased from us? It's --
6 you know, normally when you say 59,200, if they are
7 purchasing multiple products from us, that's a low
8 number.
9 BY MS. HERZFELD:
10 Q. Okay.
11 A. If it's a -- and especially when you are
12 looking at the length of time, so it's a full year,
13 you'd have to give me more information to be able
14 to -- to substantiate what you are saying because I
15 can't based on what I see here.
16 Q. Okay. I'll try to give you some
17 information.
18 So if you look at the top of this sheet,
19 it says "Oxy 15," so it looks like it is for that
20 product.
21 Do you see at the very top?
22 A. Tennessee only -- or oxy 15s and 30s
23 through June 20- -- okay. So that's --
24 Q. This sheet says --

Page 433

1 A. -- both of the --
2 Q. -- oxy 15, do you see?
3 A. What's that?
4 Q. This sheet says: "Sheet: Oxy 15"?
5 A. Doesn't it say and 30s through June --
6 Q. I think that's the file name because the
7 next one I'm going to show you is oxy 30. I have
8 another one. So, look, see where it says at the
9 top --
10 A. Uh-huh.
11 Q. -- "Tennessee oxy 15 and 30 through
12 June 2012," and it says, "Path:/suspicious order
13 monitoring/distributor information, Sheet:", the sheet
14 here --
15 A. Oh.
16 Q. -- "oxy 15 Tennessee?"
17 Do you see that?
18 A. Okay.
19 Q. Okay. So it appears that this is the
20 chargeback data for oxy 15s from pharmacies in
21 Tennessee, is that correct?
22 MR. O'CONNOR: Objection.
23 BY THE WITNESS:
24 A. Based on what you are telling me because I

Page 434

1 didn't deal with this information.
2 BY MS. HERZFELD:
3 Q. I understand. If you'll just be patient
4 with me, too, because it took me kind of a minute.
5 Okay. So looking at that and knowing that
6 it's oxy 15 and the number for the Rippetoe Pharmacy
7 in Morristown, Tennessee is 59,200, if I told you --
8 well, first, did you ever take into consideration the
9 population of any particular areas when evaluating
10 potential suspicious orders?
11 MR. O'CONNOR: Objection.
12 BY THE WITNESS:
13 A. Personally, I -- I don't recall taking in
14 the population, so.
15 BY MS. HERZFELD:
16 Q. Okay. And do you know if anyone at
17 Mallinckrodt did?
18 MR. O'CONNOR: Objection.
19 BY THE WITNESS:
20 A. So, are you asking do we know the
21 population of Morristown, Tennessee?
22 BY MS. HERZFELD:
23 Q. No, no. I'm just asking if you know if
24 anybody considered the populations where particular

Page 435

1 pharmacies were located in looking for suspicious
2 orders?
3 MR. O'CONNOR: Objection.
4 BY THE WITNESS:
5 A. That's not the way we -- we did things.
6 We -- we had distributors there to do it. We
7 identified their major purchasers there, our
8 customers' customers, and we did look at those people.
9 So, did we look at the size of the town, I don't know
10 that we did that, so.
11 BY MS. HERZFELD:
12 Q. Okay. You don't specifically recall doing
13 it?
14 A. Correct.
15 Q. Okay. So back to the Rippetoe Pharmacy
16 here in Morristown, Tennessee, it has like the third
17 highest number for this time period for the oxy 15s at
18 59,200.
19 Did you know that the population of
20 Morristown, Tennessee is 29,137 during that year?
21 MR. O'CONNOR: Objection.
22 BY THE WITNESS:
23 A. No.
24 BY MS. HERZFELD:

Page 436

1 Q. Okay. So if the population of a town
2 where a pharmacy is located is 29,137 people, yet the
3 number of oxy's are 59,200 being supplied by
4 Mallinckrodt, does that seem high to you?
5 MR. O'CONNOR: Objection.
6 BY THE WITNESS:
7 A. There is no way I'd know. Is this the
8 only pharmacy in town? I don't know that.
9 BY MS. HERZFELD:
10 Q. Does that matter?
11 A. If it's the only pharmacy in town, it
12 might.
13 Q. Okay.
14 A. I mean, are they supplying the hospital,
15 are they supplying, you know, multiple doctors, how
16 many -- you know, I just don't know. What's the aging
17 population of that area? I don't know that, so.
18 Q. Okay. So would that information cause you
19 to do a deeper inquiry, do you think it should have
20 flagged an inquiry?
21 MR. O'CONNOR: Objection.
22 BY THE WITNESS:
23 A. I just don't know that.
24 BY MS. HERZFELD:

Page 437

1 Q. Okay.
2 Okay. Let's go then to the next one, the
3 one next to No. 10 is Jabos Pharmacy, the one we've
4 talked about before, in Newport, Tennessee.
5 Have you ever been to Newport, Tennessee,
6 sir?
7 A. Not to my knowledge.
8 Q. Okay. And that one appears to have 42,000
9 units of oxy 15.
10 A. Um-hum.
11 Q. Do you know what the population is of
12 Newport, Tennessee?
13 A. I have no idea.
14 Q. Okay. If I told you that the population
15 of Newport, Tennessee -- well, that Newport,
16 Tennessee, first off, is in Cocke County, which is
17 very rural, do you know that?
18 MR. O'CONNOR: Objection.
19 BY THE WITNESS:
20 A. There is no way I would know that. I have
21 never been there, so.
22 BY MS. HERZFELD:
23 Q. Okay. So if I tell you that Newport,
24 Tennessee has a population of 6,833 people as of the

Page 438

1 2010 census, would that at all impact your opinion of
 2 whether 42,000 units of oxy 15s at the Jabos Pharmacy
 3 in Newport, Tennessee was concerning?
 4 MR. O'CONNOR: Objection.
 5 BY THE WITNESS:
 6 A. So, didn't they all -- already cancel
 7 Jabos?
 8 BY MS. HERZFELD:
 9 Q. I'm just asking, sir, if that's a flag for
 10 you?
 11 MR. O'CONNOR: Objection.
 12 BY THE WITNESS:
 13 A. It is and it may be why they were
 14 cancelled. I don't know.
 15 BY MS. HERZFELD:
 16 Q. Okay. Do you know that that's why they
 17 were cancelled?
 18 A. I don't know that.
 19 Q. Okay. So --
 20 A. I'm saying it's -- that seems based on the
 21 population of 6,000, I mean, so.
 22 Q. It seems high?
 23 MR. O'CONNOR: Objection.
 24 BY THE WITNESS:

Page 439

1 A. I mean, it seems high, yeah.
 2 BY MS. HERZFELD:
 3 Q. Okay. So could that be an indicator of --
 4 of a diversion to you?
 5 MR. O'CONNOR: Objection.
 6 BY THE WITNESS:
 7 A. I don't know that and I can't speculate,
 8 so.
 9 BY MS. HERZFELD:
 10 Q. Okay. So if you've got one pharmacy in a
 11 tiny rural town that's supplying 42,000 15 oxys --
 12 42,000 oxy 15s for a population in that town of 6,833,
 13 do you think that could indicate that there is a pill
 14 mill?
 15 MR. O'CONNOR: Objection.
 16 BY THE WITNESS:
 17 A. I don't know that, but are they supplying
 18 the whole county? I mean, you'd have to understand
 19 that counties sometimes have larger populations than a
 20 town, so.
 21 BY MS. HERZFELD:
 22 Q. Do you think that that's information that
 23 should have been inquired into when you see these
 24 numbers?

Page 440

1 A. Well, we --
 2 MR. O'CONNOR: Objection.
 3 BY THE WITNESS:
 4 A. -- we inquired into Jabos when we were at
 5 McKesson -- or not McKesson, but AmerisourceBergen,
 6 so.
 7 BY MS. HERZFELD:
 8 Q. But you didn't know the population of
 9 Newport, so that wasn't something that was taken into
 10 consideration, was it?
 11 A. No.
 12 Q. Okay. So moving on to the next one,
 13 you've got No. 21, East Tennessee Discount Drug in
 14 Strawberry Plains, Tennessee.
 15 Do you see where we are at?
 16 A. I do.
 17 Q. Okay. And over there it says
 18 24,900 units --
 19 A. Okay.
 20 Q. -- of oxy 15 --
 21 A. Okay.
 22 Q. -- for the year from East Tennessee
 23 Discount Drug.
 24 Do you see where I am at?

Page 441

1 A. I do see it.
 2 Q. Okay. And do you know what the population
 3 is of Strawberry Plains, Tennessee?
 4 A. I don't.
 5 Q. Okay. If I told you that the population
 6 of Strawberry Plains is 4,667 people, do you think it
 7 should have merited some inquiry that there are 24,900
 8 oxy 15s going into that pharmacy?
 9 MR. O'CONNOR: Objection.
 10 BY THE WITNESS:
 11 A. By AmerisourceBergen, yes.
 12 BY MS. HERZFELD:
 13 Q. Okay. But not by Mallinckrodt?
 14 MR. O'CONNOR: Objection.
 15 BY THE WITNESS:
 16 A. Not necessarily. We take the information
 17 that they provide us initially to try to make a
 18 determination if they are -- if they are doing due
 19 diligence.
 20 BY MS. HERZFELD:
 21 Q. Okay.
 22 A. And we -- we're -- we met with them more
 23 than once, so.
 24 Q. Okay. So going over these three

Page 442

1 pharmacies that we just talked about, Rippetoe, Jabos
2 and East Tennessee Discount Drug, do you think based
3 on population and the number of oxy 15s going into
4 those areas that there should have been some red flags
5 for diversion inquired into?
6 MR. O'CONNOR: Objection.
7 BY THE WITNESS:
8 A. Are you saying by -- by Mallinckrodt?
9 BY MS. HERZFELD:
10 Q. Let's start with by the distributors.
11 MR. O'CONNOR: Objection.
12 BY THE WITNESS:
13 A. By the distributors, yes.
14 Q. Okay.
15 A. I mean, that's their job to have a program
16 to prevent diversion. If they are selling that many
17 tablets into a tiny little town, it may be that's why
18 they were slow in getting us the information. I don't
19 know.
20 Q. Okay, sir. But you don't think that was
21 the responsibility of Mallinckrodt?
22 MR. O'CONNOR: Objection.
23 BY THE WITNESS:
24 A. There was a time when they were saying

Page 443

1 "know your customer's customer" to us, not initially,
2 so there are a lot of customers' customers, so.
3 Q. Okay. And if at that point you had known
4 your customer's customer, would that have been a red
5 flag for you for diversion for East Tennessee Discount
6 Drug?
7 MR. O'CONNOR: Objection.
8 BY THE WITNESS:
9 A. We would have liked to have had additional
10 information.
11 BY MS. HERZFELD:
12 Q. Okay. But to your knowledge, nobody
13 considered the population factor, is that correct?
14 MR. O'CONNOR: Objection.
15 BY THE WITNESS:
16 A. Correct.
17 BY MS. HERZFELD:
18 Q. Okay. And the same for Jabos Pharmacy?
19 MR. O'CONNOR: Same objection.
20 BY THE WITNESS:
21 A. Did we talk about how many people were in
22 Newport?
23 BY MS. HERZFELD:
24 Q. Yes, we did, sir.

Page 444

1 A. How many?
2 Q. 6,833.
3 A. Yeah, okay.
4 Yeah, that's -- again, we don't know how
5 many pharmacies are there. We don't know if they are
6 supplying the whole county. You know, I...
7 Q. But you would have liked answers to those
8 questions?
9 A. Yeah, it would have been nice.
10 Q. Okay. To your knowledge, nobody -- nobody
11 inquired as to those questions, is that right?
12 A. To the best of my knowledge.
13 Q. Okay. If you'll give me just one moment.
14 Okay. Last one and then we are done.
15 No. 57?
16 A. 56.
17 Q. 56. Gosh, I'm always off on this.
18 (WHEREUPON, a certain document was
19 marked Mallinckrodt-Ratliff
20 Deposition Exhibit No. 056, for
21 identification, as of 12/19/2018.)
22 BY MS. HERZFELD:
23 Q. Okay. I'll submit to you that this is the
24 same document except this one the sheet says "oxy 30."

Page 445

1 Do you see that at the top?
2 A. I do.
3 Q. Okay. So all of that information we just
4 went through, let's go through it again, but not quite
5 as long.
6 No. 5 there talks about Rippetoe Pharmacy
7 in Morristown. Do you see where I am at?
8 A. I do.
9 Q. Okay. And it says there that there are
10 224,100 units of oxy 30 from Tennessee during that
11 time, is that correct?
12 A. It is.
13 Q. Okay. And Bradley Drug had 212,700 units
14 of oxy 30?
15 A. So, that -- you are saying that's for a
16 whole year?
17 Q. Yes, sir.
18 A. So --
19 Q. Yes.
20 A. So divide it up 12 months, it would be --
21 and the number of pills in a bottle, I know you -- it
22 seems excessive when you just look at the number, but
23 that's for 12 months.
24 Q. Okay. So let's look at No. 9, Jabos

<p style="text-align: right;">Page 446</p> <p>1 Pharmacy in Newport. 2 A. Okay. 3 Q. 160,800, and we just talked about the 4 population of Jabos. Should that have been concerning 5 to Mallinckrodt? 6 MR. O'CONNOR: Objection. 7 BY THE WITNESS: 8 A. For an entire year? 9 BY MS. HERZFELD: 10 Q. Yes, sir. 11 The population -- 12 A. I'm not -- 13 Q. -- of Newport we just discussed was 6,833 14 people? 15 A. Right, right. 16 MR. O'CONNOR: Objection. 17 BY MS. HERZFELD: 18 Q. Did that merit further inquiry for 19 potential diversion, sir? 20 MR. O'CONNOR: Objection. 21 BY THE WITNESS: 22 A. For a whole year for 160,000 tablets, not 23 necessarily. 24 BY MS. HERZFELD:</p>	<p style="text-align: right;">Page 448</p> <p>1 or a lot of customers that buy a lot more than that, 2 and if it's for a whole year, it doesn't seem unusual 3 to us, so what you are saying is it's a little tiny 4 town and you should have known that. Well, if you 5 look at it for a whole year, it doesn't seem nearly as 6 large as what you are saying, so. 7 Q. Don't you think somebody should ask those 8 questions, though? 9 MR. O'CONNOR: Objection. 10 BY MS. HERZFELD: 11 Q. You said all of these questions, how many 12 elderly people, how big is the county -- 13 A. Yeah. 14 Q. -- how many hospitals, don't you think 15 somebody should have asked those questions? 16 MR. O'CONNOR: Objection. 17 BY THE WITNESS: 18 A. The distributor should have asked that. 19 BY MS. HERZFELD: 20 Q. Okay. But not Mallinckrodt? 21 MR. O'CONNOR: Objection. 22 BY THE WITNESS: 23 A. We look at this number and it's not that 24 large. Had we looked behind and said, Okay. Let's</p>
<p style="text-align: right;">Page 447</p> <p>1 Q. Not for a town with a population of 6,833 2 people? 3 A. Well, I didn't know the population, but 4 you need to tell me population of the county. 5 Q. Okay, sir. 6 A. Because not everybody lives in the city. 7 Q. Okay. Sir, if I tell you Cocke County is 8 very rural, does that make a difference? 9 MR. O'CONNOR: Objection. 10 BY THE WITNESS: 11 A. Do you know how many people live there in 12 the county? 13 BY MS. HERZFELD: 14 Q. No, I'm not going to tell you that right. 15 A. Do you know how many people are elderly? 16 Or do they say -- 17 Q. No, but I can Google it. 18 A. But do you understand what I'm saying? 19 Q. I do. 20 A. There are a lot of reasons people would 21 take material. I'm not discounting the fact that 22 maybe some of it was diverted by doctors or 23 unscrupulous people, but what I'm saying is, if you 24 look at that for a whole year, we have a lot of people</p>	<p style="text-align: right;">Page 449</p> <p>1 just figure out for this one customer, you have to 2 remember there are -- our distributors have thousands 3 of customers, okay. 4 BY MS. HERZFELD: 5 Q. Yes, sir. 6 A. And so we have to go through every one of 7 them and determine the size of the town and then 8 divide out how much they got for a whole year and how 9 many people live in the county, how many are elderly 10 and how -- you know, I know what you are saying, but 11 it's not nearly as big a red flag as you are making it 12 to be, in our -- in my opinion. In your opinion, you 13 are doing an admirable job, but what I'm saying is, 14 that's not a lot of tablets for a year. 15 Q. Okay. The question -- my question, sir, 16 is you said that the question should have been asked 17 by the distributor and my question is actually pretty 18 simple. It is should those questions have been asked 19 by Mallinckrodt? 20 MR. O'CONNOR: Objection. 21 BY THE WITNESS: 22 A. Based on the number, I don't think so. 23 BY MS. HERZFELD: 24 Q. Okay. And what about Strawberry Plains,</p>

<p style="text-align: right;">Page 450</p> <p>1 if we look here at East Tennessee Discount Drug, No. 2 12, it says Strawberry Plains had a 115,600 oxy 3 30 units -- 4 A. Okay. 5 Q. -- sent during that year to that pharmacy? 6 A. I'm sorry. How many. 7 Q. 115,600. 8 A. Okay, I've got that. 9 Q. Strawberry Plains, as we discussed, had a 10 population of 4,667 -- 11 A. Okay. 12 Q. -- people during that year. 13 Do you think that that number could have 14 been indicative of diversion in Strawberry Plains? 15 A. For a -- for a year -- 16 MR. O'CONNOR: Objection. 17 BY THE WITNESS: 18 A. -- it's a -- if you divide it by 12, it's 19 not a great number. 20 BY MS. HERZFELD: 21 Q. I bet you it is a great number to the 22 people of Strawberry Plains? 23 MR. O'CONNOR: Objection. 24 BY THE WITNESS:</p>	<p style="text-align: right;">Page 452</p> <p>1 constantly, Well, we have all of these old people. 2 Well, one, the old people, do they not take 5s or 15s. 3 Why does everybody take 30s, so. 4 Q. To your knowledge -- 5 A. Folks, that's a legitimate question. 6 Q. Okay. And to your knowledge, those 7 questions weren't asked of these pharmacies in 8 Tennessee? 9 MR. O'CONNOR: Objection. 10 BY THE WITNESS: 11 A. To the best of my knowledge, I don't know. 12 MS. HERZFELD: Okay. If you'll give me just a 13 moment, just take a break real quick. 14 THE VIDEOGRAPHER: We are going off the record 15 at 8:10. 16 (WHEREUPON, a recess was had 17 from 8:10 to 8:16 p.m.) 18 THE VIDEOGRAPHER: We are back on the record at 19 8:16. 20 MS. HERZFELD: Okay. Mr. Ratliff, I appreciate 21 your time this evening. I don't have any more 22 questions for you. 23 THE WITNESS: Thank you. 24 MS. HERZFELD: Thank you.</p>
<p style="text-align: right;">Page 451</p> <p>1 A. Well, I'm certain it is. I don't discount 2 that at all. But what I'm saying is, if you look at 3 that as a manufacturer, to me those are things that 4 the -- the distributor should note. 5 BY MS. HERZFELD: 6 Q. Okay. So it could -- 7 A. And they should say -- and maybe they 8 should say, This is a rural area and there are only so 9 many people, but there are a lot of factors that they 10 look at or should look at when they are selling to 11 some of those areas. 12 Q. Okay. So you think that that's a 13 potential sign of diversion that should have been 14 looked into by the distributor? 15 MR. O'CONNOR: Objection. 16 BY THE WITNESS: 17 A. They are the ones that are supposed to do 18 the on-site visits. They should know if it's a town 19 of 4,000. They should be able to tell us when we 20 inquire, you know, how -- you know, how big a town it 21 is or what, you know, what their -- their aging 22 population is or things like that. I don't know that 23 we've asked that. We did that in Florida now, asking 24 what the aging population is, because the excuse was</p>	<p style="text-align: right;">Page 453</p> <p>1 MR. KAWAMOTO: So, Andrew, for your cross, do 2 you want me to change places with you or do you want 3 me just to sit there and object? 4 MR. O'CONNOR: I'm happy for you to sit there. 5 I think it will be literally two minutes. 6 MR. KAWAMOTO: Okay. 7 EXAMINATION 8 BY MR. O'CONNOR: 9 Q. Mr. Ratliff, I'm going to show you Exhibit 10 No. 16 which you looked at earlier today. 11 Do you recall reviewing this document this 12 afternoon? 13 A. Yes. 14 Q. Okay. I'm going to direct your attention 15 to the second page, and near the bottom of that 16 document, earlier today Mr. Kawamoto had you read from 17 a section of the document beginning with "within that 18 session"? 19 A. Yes. 20 Q. And I believe you testified that you 21 understood the sentences that follow to be related to 22 the "know your customer's customer" concept, is that 23 fair? 24 A. Yes. Fair.</p>

<p style="text-align: right;">Page 454</p> <p>1 Q. Okay. Are you aware of any instance 2 before this e-mail in which you had heard about any 3 obligation whatsoever to know your customer's 4 customer? 5 MR. KAWAMOTO: Counsel, what's the date of the 6 e-mail? I don't have the exhibit. 7 MR. O'CONNOR: It is July 21st, 2010. 8 BY THE WITNESS: 9 A. I don't recall that, but it -- it's not 10 part of the statute. It's -- at all, "know your 11 customer's customer." That's something that the DEA 12 came up with to -- to assist us or cause us to go 13 deeper and do a deeper dive, but it's not part of the 14 statute. 15 BY MR. O'CONNOR: 16 Q. And before July 21st, 2010, had DEA to the 17 best of your recollection ever communicated to 18 Mallinckrodt that it should know its customer's 19 customer? 20 MR. KAWAMOTO: Objection. 21 BY THE WITNESS: 22 A. It's been a long time ago. I -- I don't 23 recall that, so. 24 BY MR. O'CONNOR:</p>	<p style="text-align: right;">Page 456</p> <p>1 Howard Davis as a consultant. 2 Do you see that? 3 A. I do. 4 Q. Do you recall testifying earlier today 5 that you had hoped that Howard Davis had expertise 6 that he could lend to the company? 7 A. Correct. 8 Q. In actuality, do you have a view about 9 whether Howard Davis had expertise that was useful to 10 the company on the issue of suspicious order 11 monitoring? 12 MR. KAWAMOTO: Objection. 13 BY THE WITNESS: 14 A. It was my belief that he didn't have any 15 additional information that would assist us. 16 BY MR. O'CONNOR: 17 Q. What was your opinion about his level of 18 expertise on the subject of suspicious order 19 monitoring? 20 A. He asked -- he asked us a lot of the 21 questions about what we would be doing or what we 22 should be doing. 23 Q. Did he know the answers? 24 A. He was asking us to -- to try to school</p>
<p style="text-align: right;">Page 455</p> <p>1 Q. Do you recall any instance in which DEA 2 communicated that Mallinckrodt should know its 3 customer's customer before July 21st, 2010? 4 MR. KAWAMOTO: Objection. 5 BY THE WITNESS: 6 A. I don't recall. 7 MR. O'CONNOR: What's the objection? 8 MR. KAWAMOTO: Again, it's been asked and 9 answered. 10 MR. O'CONNOR: How about the first objection? 11 MR. KAWAMOTO: I believe he has already 12 testified on this. 13 MR. O'CONNOR: Okay. All right. 14 BY MR. O'CONNOR: 15 Q. Exhibit No. 20. 16 A. Should we put these back in order? 17 Q. Don't worry about it. 18 A. Okay. 19 Q. All right. Mr. Ratliff, earlier today you 20 reviewed this document marked as Exhibit 20. Do you 21 recall that? 22 A. I do recall that. 23 Q. Can you direct your attention to the 24 bottom paragraph on the second page where it mentions</p>	<p style="text-align: right;">Page 457</p> <p>1 himself on that information. 2 Q. Thank you. 3 A. He didn't have, in my opinion, any 4 knowledge about this -- the program or as it was 5 evolving. Now, he had retired, so I don't know that 6 they had the know your customer's customer 7 recommendations at that time, so. 8 MR. O'CONNOR: Thank you, Mr. Ratliff. That's 9 all I have. 10 MR. KAWAMOTO: Can I take a quick break to see 11 if I want to recross? How much time did you use? 12 MR. O'CONNOR: What's that? 13 MR. KAWAMOTO: How much time did you use? 14 THE VIDEOGRAPHER: We are going off the record 15 at 8:21. 16 (WHEREUPON, a recess was had 17 from 8:21 to 8:23 p.m.) 18 THE VIDEOGRAPHER: We are back on the record at 19 8:23. 20 MR. KAWAMOTO: Okay. I would like to mark this 21 as whatever the latest exhibit is. 22 THE WITNESS: 57. 23 MR. KAWAMOTO: Yeah. 24 (WHEREUPON, a certain document was</p>

<p style="text-align: right;">Page 458</p> <p>1 marked Mallinckrodt-Ratliff</p> <p>2 Deposition Exhibit No. 057, for</p> <p>3 identification, as of 12/19/2018.)</p> <p>4 MR. O'CONNOR: Do you have copies of this?</p> <p>5 MR. KAWAMOTO: Yes, it should be underneath</p> <p>6 there.</p> <p>7 FURTHER EXAMINATION</p> <p>8 BY MR. KAWAMOTO:</p> <p>9 Q. Mr. Ratliff, I've handed you an</p> <p>10 exhibit marked 269399. It's a memo to Karen Harper</p> <p>11 from Howard Davis.</p> <p>12 Do you recall receiving this memo?</p> <p>13 A. I'm certain that I saw it at the time.</p> <p>14 Q. Okay. And do you -- do you recall</p> <p>15 reviewing it?</p> <p>16 A. I don't recall specifically because of the</p> <p>17 length of time. It's been eight plus -- eight plus</p> <p>18 years, so.</p> <p>19 Q. Okay. So directing your attention to the</p> <p>20 bottom paragraph, this is by way of example, do you</p> <p>21 see the bottom paragraph of the memo?</p> <p>22 A. I do.</p> <p>23 Q. It starts with "an order." Could you</p> <p>24 please read that?</p>	<p style="text-align: right;">Page 460</p> <p>1 already knew everything in this, that paragraph. So</p> <p>2 what he is doing is trying to be formal by saying, Oh,</p> <p>3 if you did this, this would happen, but the answer is,</p> <p>4 we were already doing this.</p> <p>5 Q. And so, sir, your testimony is that if an</p> <p>6 order was three times the -- if an order was three</p> <p>7 times the prior historical average, Mallinckrodt would</p> <p>8 not have shipped that, is that correct?</p> <p>9 A. That's correct, yeah.</p> <p>10 Q. Okay. And if they did ship that, that</p> <p>11 would have been improper?</p> <p>12 MR. O'CONNOR: Objection.</p> <p>13 BY THE WITNESS:</p> <p>14 A. I would say yes.</p> <p>15 BY MR. KAWAMOTO:</p> <p>16 Q. Okay. Can you please read the second</p> <p>17 paragraph -- the first paragraph at the very top?</p> <p>18 A. "Numeric formulas do not identify</p> <p>19 circumstances that might be indicative of a diversion,</p> <p>20 such as ordering larger quantities of a limited</p> <p>21 variety regularly that would otherwise not be viewed</p> <p>22 as suspicious (like ordering controlled substance" --</p> <p>23 "substances with few, if any, other drugs or products</p> <p>24 whether controlled or non-controlled); ordering highly</p>
<p style="text-align: right;">Page 459</p> <p>1 A. "An order must not be processed and filled</p> <p>2 if it is either suspicious or excessive. The existing</p> <p>3 SOP excels to meet this requirement through a specific</p> <p>4 evaluation process. However, the numeric formula is</p> <p>5 problematic. For example, should an occasion arise</p> <p>6 where an order is three times over the historical</p> <p>7 average for that customer and an item or a situation</p> <p>8 where the order meets but not does not exceed the</p> <p>9 [REDACTED] criteria, it would theoretically be filled</p> <p>10 through normal processing without further question.</p> <p>11 In doing so in certain cases, as noted in recent</p> <p>12 immediate suspensions of other large DEA registrants,</p> <p>13 which are all a matter of public record, Mallinckrodt</p> <p>14 would be unnecessarily exposing itself to a potential</p> <p>15 liability. The fundamental basis of the immediate</p> <p>16 suspensions in question were suspicious order</p> <p>17 monitoring deficiencies."</p> <p>18 Q. So do you agree with that paragraph?</p> <p>19 MR. O'CONNOR: Objection.</p> <p>20 BY THE WITNESS:</p> <p>21 A. I do agree in that we would have</p> <p>22 already -- we wouldn't send it out if it was three</p> <p>23 times, though, what they had been ordering. I mean,</p> <p>24 that's a simplistic view of that. You know, we</p>	<p style="text-align: right;">Page 461</p> <p>1 abused controlled substances in limited quantities</p> <p>2 disproportionate to other products or even ordering</p> <p>3 them" -- "ordering the same controlled substances from</p> <p>4 multiple suppliers."</p> <p>5 Q. Okay. Thank you, sir.</p> <p>6 I take it you don't have any disagreement</p> <p>7 with that statement, do you?</p> <p>8 MR. O'CONNOR: Objection.</p> <p>9 BY THE WITNESS:</p> <p>10 A. Part of our form asks controlled to</p> <p>11 non-controlleds. So we should be able to pick up the</p> <p>12 fact if they say the majority of their business is oxy</p> <p>13 30s, then that's a red flag. And we already had that</p> <p>14 in a form.</p> <p>15 BY MR. KAWAMOTO:</p> <p>16 Q. So essentially your criticism of this memo</p> <p>17 is that you were already doing everything that the</p> <p>18 memo called for, is that correct?</p> <p>19 A. Pretty much.</p> <p>20 Q. And if you were not doing that, then that</p> <p>21 means that you -- you would -- that would not be</p> <p>22 proper, correct?</p> <p>23 MR. O'CONNOR: Objection.</p> <p>24 BY THE WITNESS:</p>

<p style="text-align: right;">Page 462</p> <p>1 A. No, I'm not saying that. I'm saying we 2 were doing almost -- almost everything that he came up 3 with, and that was already in our files and already in 4 our procedures, that's what I'm saying. 5 BY MR. KAWAMOTO: 6 Q. Okay. And can you identify anything he 7 has come up with that you weren't doing? 8 A. Do you want me to read the whole thing? 9 Because I'm saying right now we were already asking 10 those questions in our file, in our -- 11 Q. And to the degree that you were shipping 12 orders that violated these general criteria that he is 13 laying out here, that would not have been proper, 14 that's all I'm trying to get at? 15 MR. O'CONNOR: Objection. 16 BY THE WITNESS: 17 A. I'm saying we weren't shipping out orders 18 that he is pointing out would -- these are 19 hypothetical situations that he is pointing out. They 20 are not actual situations. They are hypothetical. 21 MR. O'CONNOR: Counsel, you have about -- you 22 have about ten seconds. 23 MR. KAWAMOTO: Okay. Nothing further. Thank 24 you.</p>	<p style="text-align: right;">Page 464</p> <p>1 REPORTER'S CERTIFICATE 2 3 I, JULIANA F. ZAJICEK, C.S.R. No. 84-2604, 4 a Certified Shorthand Reporter, do hereby certify: 5 That previous to the commencement of the 6 examination of the witness herein, the witness was 7 duly sworn to testify the whole truth concerning the 8 matters herein; 9 That the foregoing deposition transcript 10 was reported stenographically by me, was thereafter 11 reduced to typewriting under my personal direction and 12 constitutes a true record of the testimony given and 13 the proceedings had; 14 That the said deposition was taken before 15 me at the time and place specified; 16 That I am not a relative or employee or 17 attorney or counsel, nor a relative or employee of 18 such attorney or counsel for any of the parties 19 hereto, nor interested directly or indirectly in the 20 outcome of this action. 21 IN WITNESS WHEREOF, I do hereunto set my 22 hand on this 24th day of December, 2018. 23 24 JULIANA F. ZAJICEK, Certified Reporter</p>
<p style="text-align: right;">Page 463</p> <p>1 THE WITNESS: Thank you. 2 THE VIDEOGRAPHER: We are going off the record 3 at 8:28. 4 (Time Noted: 8:28 p.m.) 5 FURTHER DEPONENT SAITH NAUGHT. 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p>	<p style="text-align: right;">Page 465</p> <p>1 DEPOSITION ERRATA SHEET 2 3 4 Case Caption: In Re: National Prescription 5 Opiate Litigation 6 7 DECLARATION UNDER PENALTY OF PERJURY 8 9 I declare under penalty of perjury that I 10 have read the entire transcript of my Deposition taken 11 in the captioned matter or the same has been read to 12 me, and the same is true and accurate, save and except 13 for changes and/or corrections, if any, as indicated 14 by me on the DEPOSITION ERRATA SHEET hereof, with the 15 understanding that I offer these changes as if still 16 under oath. 17 18 WILLIAM RATLIFF 19 20 SUBSCRIBED AND SWORN TO 21 before me this day 22 of , A.D. 20__. 23 24 Notary Public</p>

Page 466

1 DEPOSITION ERRATA SHEET
2 Page No.____ Line No.____ Change to:_____
3 _____
4 Reason for change:_____
5 Page No.____ Line No.____ Change to:_____
6 _____
7 Reason for change:_____
8 Page No.____ Line No.____ Change to:_____
9 _____
10 Reason for change:_____
11 Page No.____ Line No.____ Change to:_____
12 _____
13 Reason for change:_____
14 Page No.____ Line No.____ Change to:_____
15 _____
16 Reason for change:_____
17 Page No.____ Line No.____ Change to:_____
18 _____
19 Reason for change:_____
20 Page No.____ Line No.____ Change to:_____
21 _____
22 Reason for change:_____
23 SIGNATURE:_____ DATE:_____
24 WILLIAM RATLIFF

Page 467

1 DEPOSITION ERRATA SHEET
2 Page No.____ Line No.____ Change to:_____
3 _____
4 Reason for change:_____
5 Page No.____ Line No.____ Change to:_____
6 _____
7 Reason for change:_____
8 Page No.____ Line No.____ Change to:_____
9 _____
10 Reason for change:_____
11 Page No.____ Line No.____ Change to:_____
12 _____
13 Reason for change:_____
14 Page No.____ Line No.____ Change to:_____
15 _____
16 Reason for change:_____
17 Page No.____ Line No.____ Change to:_____
18 _____
19 Reason for change:_____
20 Page No.____ Line No.____ Change to:_____
21 _____
22 Reason for change:_____
23 SIGNATURE:_____ DATE:_____
24 WILLIAM RATLIFF